#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.Phrase_borders|value


#Text=The Mann-Whitney U test was used to determine gender difference of clinical scores or integer based values .
1-1	0-3	The	9	
1-2	4-16	Mann-Whitney	_	
1-3	17-18	U	_	
1-4	19-23	test	1	
1-5	24-27	was	8	
1-6	28-32	used	_	
1-7	33-35	to	_	
1-8	36-45	determine	1	
1-9	46-52	gender	2	
1-10	53-63	difference	_	
1-11	64-66	of	_	
1-12	67-75	clinical	_	
1-13	76-82	scores	1	
1-14	83-85	or	2	
1-15	86-93	integer	_	
1-16	94-99	based	_	
1-17	100-106	values	_	
1-18	107-108	.	1	

#Text=This trial ( { " type":"clinical-trial","attrs":{"text":"NCT02370667","term_id":"NCT02370667"}}NCT02370667 ) was conducted at McMaster University in Hamilton , ON , Canada and was approved by the Hamilton Integrated Research Ethics Board ( # 15–021 ) where all participants provided written informed consent .
2-1	109-113	This	9	
2-2	114-119	trial	1	
2-3	120-121	(	5	
2-4	122-123	{	_	
2-5	124-125	"	_	
2-6	126-130	type	_	
2-7	130-131	"	_	
2-8	131-132	:	_	
2-9	132-133	"	_	
2-10	133-147	clinical-trial	_	
2-11	147-148	"	_	
2-12	148-149	,	_	
2-13	149-150	"	_	
2-14	150-155	attrs	_	
2-15	155-156	"	_	
2-16	156-157	:	_	
2-17	157-158	{	_	
2-18	158-159	"	_	
2-19	159-163	text	_	
2-20	163-164	"	_	
2-21	164-165	:	_	
2-22	165-166	"	_	
2-23	166-177	NCT02370667	_	
2-24	177-178	"	_	
2-25	178-179	,	_	
2-26	179-180	"	_	
2-27	180-187	term_id	_	
2-28	187-188	"	_	
2-29	188-189	:	_	
2-30	189-190	"	_	
2-31	190-201	NCT02370667	_	
2-32	201-202	"	_	
2-33	202-203	}	_	
2-34	203-204	}	_	
2-35	204-215	NCT02370667	_	
2-36	216-217	)	1	
2-37	218-221	was	8	
2-38	222-231	conducted	_	
2-39	232-234	at	1	
2-40	235-243	McMaster	2	
2-41	244-254	University	_	
2-42	255-257	in	_	
2-43	258-266	Hamilton	_	
2-44	267-268	,	_	
2-45	269-271	ON	_	
2-46	272-273	,	_	
2-47	274-280	Canada	1	
2-48	281-284	and	3	
2-49	285-288	was	_	
2-50	289-297	approved	_	
2-51	298-300	by	1	
2-52	301-304	the	2	
2-53	305-313	Hamilton	_	
2-54	314-324	Integrated	_	
2-55	325-333	Research	_	
2-56	334-340	Ethics	_	
2-57	341-346	Board	1	
2-58	347-348	(	5	
2-59	349-350	#	_	
2-60	351-353	15	_	
2-61	353-354	–	_	
2-62	354-357	021	_	
2-63	358-359	)	1	
2-64	360-365	where	6	
2-65	366-369	all	9	
2-66	370-382	participants	1	
2-67	383-391	provided	3	
2-68	392-399	written	2	
2-69	400-408	informed	_	
2-70	409-416	consent	_	
2-71	417-418	.	1	

#Text=Females who were pregnant or nursing were ineligible to participate .
3-1	419-426	Females	9	
3-2	427-430	who	6	
3-3	431-435	were	7	
3-4	436-444	pregnant	_	
3-5	445-447	or	_	
3-6	448-455	nursing	1	
3-7	456-460	were	8	
3-8	461-471	ineligible	_	
3-9	472-474	to	_	
3-10	475-486	participate	_	
3-11	487-488	.	1	

#Text=A pilot study was performed at each site to test logistics : 30 patients were enrolled at the AEOC in Oslo , 10 patients at each of the other sites .
4-1	489-490	A	9	
4-2	491-496	pilot	_	
4-3	497-502	study	1	
4-4	503-506	was	8	
4-5	507-516	performed	_	
4-6	517-519	at	1	
4-7	520-524	each	2	
4-8	525-529	site	1	
4-9	530-532	to	3	
4-10	533-537	test	1	
4-11	538-547	logistics	2	
4-12	548-549	:	6	
4-13	550-552	30	2	
4-14	553-561	patients	1	
4-15	562-566	were	3	
4-16	567-575	enrolled	_	
4-17	576-578	at	1	
4-18	579-582	the	2	
4-19	583-587	AEOC	_	
4-20	588-590	in	_	
4-21	591-595	Oslo	_	
4-22	596-597	,	1	
4-23	598-600	10	2	
4-24	601-609	patients	1	
4-25	610-612	at	2	
4-26	613-617	each	_	
4-27	618-620	of	_	
4-28	621-624	the	_	
4-29	625-630	other	_	
4-30	631-636	sites	_	
4-31	637-638	.	1	

#Text=Because each subject received both products ( 1 in each NLF ) , statistical comparisons were made using paired data .
5-1	639-646	Because	6	
5-2	647-651	each	9	
5-3	652-659	subject	1	
5-4	660-668	received	3	
5-5	669-673	both	2	
5-6	674-682	products	1	
5-7	683-684	(	5	
5-8	685-686	1	_	
5-9	687-689	in	_	
5-10	690-694	each	_	
5-11	695-698	NLF	_	
5-12	699-700	)	_	
5-13	701-702	,	1	
5-14	703-714	statistical	9	
5-15	715-726	comparisons	1	
5-16	727-731	were	3	
5-17	732-736	made	_	
5-18	737-742	using	1	
5-19	743-749	paired	2	
5-20	750-754	data	_	
5-21	755-756	.	1	

#Text=The trial was conducted in compliance with the International Conference on Harmonisation guidelines for good clinical practice ( GCP ) and the Declaration of Helsinki .
6-1	757-760	The	9	
6-2	761-766	trial	1	
6-3	767-770	was	8	
6-4	771-780	conducted	_	
6-5	781-783	in	_	
6-6	784-794	compliance	_	
6-7	795-799	with	1	
6-8	800-803	the	2	
6-9	804-817	International	_	
6-10	818-828	Conference	_	
6-11	829-831	on	_	
6-12	832-845	Harmonisation	_	
6-13	846-856	guidelines	_	
6-14	857-860	for	_	
6-15	861-865	good	_	
6-16	866-874	clinical	_	
6-17	875-883	practice	1	
6-18	884-885	(	5	
6-19	886-889	GCP	_	
6-20	890-891	)	1	
6-21	892-895	and	2	
6-22	896-899	the	_	
6-23	900-911	Declaration	_	
6-24	912-914	of	_	
6-25	915-923	Helsinki	_	
6-26	924-925	.	1	

#Text=Body temperature at the visit was ≤38 ° C if temperature was measured rectally or ear/aural ≤37.5 ° C if measured orally or ≤37.3 ° C if measured axillary .
7-1	926-930	Body	9	
7-2	931-942	temperature	1	
7-3	943-945	at	2	
7-4	946-949	the	_	
7-5	950-955	visit	1	
7-6	956-959	was	8	
7-7	960-961	≤	2	
7-8	961-963	38	_	
7-9	964-965	°	_	
7-10	966-967	C	1	
7-11	968-970	if	6	
7-12	971-982	temperature	9	
7-13	983-986	was	3	
7-14	987-995	measured	_	
7-15	996-1004	rectally	1	
7-16	1005-1007	or	2	
7-17	1008-1011	ear	_	
7-18	1011-1012	/	_	
7-19	1012-1017	aural	_	
7-20	1018-1019	≤	_	
7-21	1019-1023	37.5	_	
7-22	1024-1025	°	_	
7-23	1026-1027	C	1	
7-24	1028-1030	if	6	
7-25	1031-1039	measured	3	
7-26	1040-1046	orally	1	
7-27	1047-1049	or	2	
7-28	1050-1051	≤	_	
7-29	1051-1055	37.3	_	
7-30	1056-1057	°	_	
7-31	1058-1059	C	1	
7-32	1060-1062	if	6	
7-33	1063-1071	measured	2	
7-34	1072-1080	axillary	_	
7-35	1081-1082	.	1	

#Text=Careful attention was given to ideal alignment of the leg throughout the exercises .
8-1	1083-1090	Careful	9	
8-2	1091-1100	attention	1	
8-3	1101-1104	was	8	
8-4	1105-1110	given	_	
8-5	1111-1113	to	1	
8-6	1114-1119	ideal	2	
8-7	1120-1129	alignment	_	
8-8	1130-1132	of	_	
8-9	1133-1136	the	_	
8-10	1137-1140	leg	1	
8-11	1141-1151	throughout	2	
8-12	1152-1155	the	_	
8-13	1156-1165	exercises	_	
8-14	1166-1167	.	1	

#Text=Blood samples for phospholipid analyses were taken in serum collection tubes ( BD SST Vacutainer ) at admission ( 0 h ) , three hours after first dosage of antibiotics ( 3 h ) , in the morning of day one after 12–24 h ( Day 1 ) , and in the morning of day 2 after 36–48 h ( Day 2 ) .
9-1	1168-1173	Blood	9	
9-2	1174-1181	samples	_	
9-3	1182-1185	for	_	
9-4	1186-1198	phospholipid	_	
9-5	1199-1207	analyses	1	
9-6	1208-1212	were	8	
9-7	1213-1218	taken	_	
9-8	1219-1221	in	1	
9-9	1222-1227	serum	2	
9-10	1228-1238	collection	_	
9-11	1239-1244	tubes	1	
9-12	1245-1246	(	5	
9-13	1247-1249	BD	_	
9-14	1250-1253	SST	_	
9-15	1254-1264	Vacutainer	_	
9-16	1265-1266	)	1	
9-17	1267-1269	at	2	
9-18	1270-1279	admission	1	
9-19	1280-1281	(	5	
9-20	1282-1283	0	_	
9-21	1284-1285	h	_	
9-22	1286-1287	)	_	
9-23	1288-1289	,	1	
9-24	1290-1295	three	2	
9-25	1296-1301	hours	_	
9-26	1302-1307	after	_	
9-27	1308-1313	first	_	
9-28	1314-1320	dosage	_	
9-29	1321-1323	of	_	
9-30	1324-1335	antibiotics	1	
9-31	1336-1337	(	5	
9-32	1338-1339	3	_	
9-33	1340-1341	h	_	
9-34	1342-1343	)	_	
9-35	1344-1345	,	1	
9-36	1346-1348	in	2	
9-37	1349-1352	the	_	
9-38	1353-1360	morning	_	
9-39	1361-1363	of	_	
9-40	1364-1367	day	_	
9-41	1368-1371	one	_	
9-42	1372-1377	after	_	
9-43	1378-1380	12	_	
9-44	1380-1381	–	_	
9-45	1381-1383	24	_	
9-46	1384-1385	h	1	
9-47	1386-1387	(	5	
9-48	1388-1391	Day	_	
9-49	1392-1393	1	_	
9-50	1394-1395	)	_	
9-51	1396-1397	,	1	
9-52	1398-1401	and	2	
9-53	1402-1404	in	_	
9-54	1405-1408	the	_	
9-55	1409-1416	morning	_	
9-56	1417-1419	of	_	
9-57	1420-1423	day	_	
9-58	1424-1425	2	_	
9-59	1426-1431	after	_	
9-60	1432-1434	36	_	
9-61	1434-1435	–	_	
9-62	1435-1437	48	_	
9-63	1438-1439	h	1	
9-64	1440-1441	(	5	
9-65	1442-1445	Day	_	
9-66	1446-1447	2	_	
9-67	1448-1449	)	_	
9-68	1450-1451	.	1	

#Text=The study was a double-blind , randomized , parallel group , multicenter non-inferiority trial .
10-1	1452-1455	The	9	
10-2	1456-1461	study	_	
10-3	1462-1465	was	1	
10-4	1466-1467	a	2	
10-5	1468-1480	double-blind	_	
10-6	1481-1482	,	_	
10-7	1483-1493	randomized	_	
10-8	1494-1495	,	_	
10-9	1496-1504	parallel	_	
10-10	1505-1510	group	_	
10-11	1511-1512	,	_	
10-12	1513-1524	multicenter	_	
10-13	1525-1540	non-inferiority	_	
10-14	1541-1546	trial	_	
10-15	1547-1548	.	1	

#Text=Perfusion imaging had to be performed at the trial-site hospital in which endovascular therapy was planned .
11-1	1549-1558	Perfusion	9	
11-2	1559-1566	imaging	1	
11-3	1567-1570	had	8	
11-4	1571-1573	to	_	
11-5	1574-1576	be	_	
11-6	1577-1586	performed	_	
11-7	1587-1589	at	1	
11-8	1590-1593	the	2	
11-9	1594-1604	trial-site	_	
11-10	1605-1613	hospital	1	
11-11	1614-1616	in	6	
11-12	1617-1622	which	1	
11-13	1623-1635	endovascular	9	
11-14	1636-1643	therapy	1	
11-15	1644-1647	was	3	
11-16	1648-1655	planned	_	
11-17	1656-1657	.	1	

#Text=Participants were instructed to practice Tai Chi at home for at least 20 minutes per day .
12-1	1658-1670	Participants	9	
12-2	1671-1675	were	8	
12-3	1676-1686	instructed	_	
12-4	1687-1689	to	_	
12-5	1690-1698	practice	1	
12-6	1699-1702	Tai	2	
12-7	1703-1706	Chi	1	
12-8	1707-1709	at	2	
12-9	1710-1714	home	1	
12-10	1715-1718	for	2	
12-11	1719-1721	at	_	
12-12	1722-1727	least	_	
12-13	1728-1730	20	_	
12-14	1731-1738	minutes	_	
12-15	1739-1742	per	_	
12-16	1743-1746	day	_	
12-17	1747-1748	.	1	

#Text=Other effectiveness end points and safety parameters were analyzed descriptively .
13-1	1749-1754	Other	9	
13-2	1755-1768	effectiveness	_	
13-3	1769-1772	end	_	
13-4	1773-1779	points	_	
13-5	1780-1783	and	_	
13-6	1784-1790	safety	_	
13-7	1791-1801	parameters	1	
13-8	1802-1806	were	8	
13-9	1807-1815	analyzed	_	
13-10	1816-1829	descriptively	_	
13-11	1830-1831	.	1	

#Text=VAS data were analyzed using a two-way analysis of variance ( ANOVA ) followed by Bonferroni post hoc test using GraphPad Prism ( GraphPad Software Inc. , San Diego , CA , USA ) .
14-1	1832-1835	VAS	9	
14-2	1836-1840	data	1	
14-3	1841-1845	were	8	
14-4	1846-1854	analyzed	_	
14-5	1855-1860	using	1	
14-6	1861-1862	a	2	
14-7	1863-1870	two-way	_	
14-8	1871-1879	analysis	_	
14-9	1880-1882	of	_	
14-10	1883-1891	variance	1	
14-11	1892-1893	(	5	
14-12	1894-1899	ANOVA	_	
14-13	1900-1901	)	1	
14-14	1902-1910	followed	3	
14-15	1911-1913	by	1	
14-16	1914-1924	Bonferroni	2	
14-17	1925-1929	post	_	
14-18	1930-1933	hoc	_	
14-19	1934-1938	test	1	
14-20	1939-1944	using	3	
14-21	1945-1953	GraphPad	2	
14-22	1954-1959	Prism	1	
14-23	1960-1961	(	5	
14-24	1962-1970	GraphPad	_	
14-25	1971-1979	Software	_	
14-26	1980-1983	Inc	_	
14-27	1983-1984	.	_	
14-28	1985-1986	,	_	
14-29	1987-1990	San	_	
14-30	1991-1996	Diego	_	
14-31	1997-1998	,	_	
14-32	1999-2001	CA	_	
14-33	2002-2003	,	_	
14-34	2004-2007	USA	_	
14-35	2008-2009	)	_	
14-36	2010-2011	.	1	

#Text=Mild limitation was regarded as LEFS scores between 51 and 65 , and those between 30 and 50 were moderate [ 24 ] .
15-1	2012-2016	Mild	9	
15-2	2017-2027	limitation	1	
15-3	2028-2031	was	8	
15-4	2032-2040	regarded	_	
15-5	2041-2043	as	1	
15-6	2044-2048	LEFS	2	
15-7	2049-2055	scores	_	
15-8	2056-2063	between	_	
15-9	2064-2066	51	_	
15-10	2067-2070	and	_	
15-11	2071-2073	65	_	
15-12	2074-2075	,	1	
15-13	2076-2079	and	2	
15-14	2080-2085	those	_	
15-15	2086-2093	between	_	
15-16	2094-2096	30	_	
15-17	2097-2100	and	_	
15-18	2101-2103	50	1	
15-19	2104-2108	were	3	
15-20	2109-2117	moderate	2	
15-21	2118-2119	[	5	
15-22	2120-2122	24	_	
15-23	2123-2124	]	_	
15-24	2125-2126	.	1	

#Text=The ADL and SR subscales are 17-item and 5-item tools respectively ; where higher scores indicate better function .
16-1	2127-2130	The	9	
16-2	2131-2134	ADL	_	
16-3	2135-2138	and	_	
16-4	2139-2141	SR	_	
16-5	2142-2151	subscales	1	
16-6	2152-2155	are	8	
16-7	2156-2158	17	2	
16-8	2158-2159	-	_	
16-9	2159-2163	item	_	
16-10	2164-2167	and	_	
16-11	2168-2169	5	_	
16-12	2169-2170	-	_	
16-13	2170-2174	item	_	
16-14	2175-2180	tools	_	
16-15	2181-2193	respectively	1	
16-16	2194-2195	;	6	
16-17	2196-2201	where	1	
16-18	2202-2208	higher	9	
16-19	2209-2215	scores	1	
16-20	2216-2224	indicate	3	
16-21	2225-2231	better	2	
16-22	2232-2240	function	_	
16-23	2241-2242	.	1	

#Text=Neither the research nurse/doctor nor the patient knew which active substance was given , thus resulting in blinding for both the nurse/doctor and patient .
17-1	2243-2250	Neither	6	
17-2	2251-2254	the	9	
17-3	2255-2263	research	_	
17-4	2264-2269	nurse	_	
17-5	2269-2270	/	_	
17-6	2270-2276	doctor	1	
17-7	2277-2280	nor	6	
17-8	2281-2284	the	9	
17-9	2285-2292	patient	1	
17-10	2293-2297	knew	8	
17-11	2298-2303	which	6	
17-12	2304-2310	active	9	
17-13	2311-2320	substance	1	
17-14	2321-2324	was	3	
17-15	2325-2330	given	_	
17-16	2331-2332	,	1	
17-17	2333-2337	thus	6	
17-18	2338-2347	resulting	3	
17-19	2348-2350	in	1	
17-20	2351-2359	blinding	2	
17-21	2360-2363	for	_	
17-22	2364-2368	both	_	
17-23	2369-2372	the	_	
17-24	2373-2378	nurse	_	
17-25	2378-2379	/	_	
17-26	2379-2385	doctor	_	
17-27	2386-2389	and	_	
17-28	2390-2397	patient	_	
17-29	2398-2399	.	1	

#Text=The study was conducted and analyzed according to the protocol ( S1 Protocol ) and the statistical analysis plan ( SAP ) ( S1 Appendix ) .
18-1	2400-2403	The	9	
18-2	2404-2409	study	1	
18-3	2410-2413	was	8	
18-4	2414-2423	conducted	_	
18-5	2424-2427	and	_	
18-6	2428-2436	analyzed	_	
18-7	2437-2446	according	_	
18-8	2447-2449	to	1	
18-9	2450-2453	the	2	
18-10	2454-2462	protocol	1	
18-11	2463-2464	(	5	
18-12	2465-2467	S1	_	
18-13	2468-2476	Protocol	_	
18-14	2477-2478	)	1	
18-15	2479-2482	and	2	
18-16	2483-2486	the	_	
18-17	2487-2498	statistical	_	
18-18	2499-2507	analysis	_	
18-19	2508-2512	plan	1	
18-20	2513-2514	(	5	
18-21	2515-2518	SAP	_	
18-22	2519-2520	)	1	
18-23	2521-2522	(	5	
18-24	2523-2525	S1	_	
18-25	2526-2534	Appendix	_	
18-26	2535-2536	)	_	
18-27	2537-2538	.	1	

#Text=Subjects received initial treatment according to the randomization schedule and , if judged necessary by the TI , an optional touch-up treatment could be administered 30 days later .
19-1	2539-2547	Subjects	9	
19-2	2548-2556	received	8	
19-3	2557-2564	initial	2	
19-4	2565-2574	treatment	1	
19-5	2575-2584	according	2	
19-6	2585-2587	to	_	
19-7	2588-2591	the	_	
19-8	2592-2605	randomization	_	
19-9	2606-2614	schedule	1	
19-10	2615-2618	and	6	
19-11	2619-2620	,	_	
19-12	2621-2623	if	1	
19-13	2624-2630	judged	3	
19-14	2631-2640	necessary	7	
19-15	2641-2643	by	2	
19-16	2644-2647	the	_	
19-17	2648-2650	TI	_	
19-18	2651-2652	,	1	
19-19	2653-2655	an	9	
19-20	2656-2664	optional	_	
19-21	2665-2673	touch-up	_	
19-22	2674-2683	treatment	1	
19-23	2684-2689	could	3	
19-24	2690-2692	be	_	
19-25	2693-2705	administered	1	
19-26	2706-2708	30	2	
19-27	2709-2713	days	_	
19-28	2714-2719	later	_	
19-29	2720-2721	.	1	

#Text=In both YE and TE , participants were asked to exercise at an intensity of seven out of ten on the Borg Perceived Exertion Scale [ 25 ] .
20-1	2722-2724	In	2	
20-2	2725-2729	both	_	
20-3	2730-2732	YE	_	
20-4	2733-2736	and	_	
20-5	2737-2739	TE	_	
20-6	2740-2741	,	1	
20-7	2742-2754	participants	9	
20-8	2755-2759	were	8	
20-9	2760-2765	asked	_	
20-10	2766-2768	to	_	
20-11	2769-2777	exercise	_	
20-12	2778-2780	at	1	
20-13	2781-2783	an	2	
20-14	2784-2793	intensity	_	
20-15	2794-2796	of	_	
20-16	2797-2802	seven	_	
20-17	2803-2806	out	_	
20-18	2807-2809	of	_	
20-19	2810-2813	ten	_	
20-20	2814-2816	on	_	
20-21	2817-2820	the	_	
20-22	2821-2825	Borg	_	
20-23	2826-2835	Perceived	_	
20-24	2836-2844	Exertion	_	
20-25	2845-2850	Scale	1	
20-26	2851-2852	[	5	
20-27	2853-2855	25	_	
20-28	2856-2857	]	_	
20-29	2858-2859	.	1	

#Text=Subjects were considered to be a failure at the TOC visit if the subject had received the prescribed dosing regimen during the first 72 hours of study , did not meet any other indeterminate criteria and 1 of the following conditions were met : An antibiotic was prescribed for AOM ; or a surgical procedure was performed for AOM on or before the last day of the visit window ; or there was evidence of fullness or bulging of the tympanic membrane ; or perforation of tympanic membrane ; or the subject had unsatisfactory resolution of signs and symptoms of AOM according to the investigator .
21-1	2860-2868	Subjects	9	
21-2	2869-2873	were	8	
21-3	2874-2884	considered	_	
21-4	2885-2887	to	_	
21-5	2888-2890	be	1	
21-6	2891-2892	a	2	
21-7	2893-2900	failure	1	
21-8	2901-2903	at	2	
21-9	2904-2907	the	_	
21-10	2908-2911	TOC	_	
21-11	2912-2917	visit	1	
21-12	2918-2920	if	6	
21-13	2921-2924	the	9	
21-14	2925-2932	subject	1	
21-15	2933-2936	had	3	
21-16	2937-2945	received	1	
21-17	2946-2949	the	2	
21-18	2950-2960	prescribed	_	
21-19	2961-2967	dosing	_	
21-20	2968-2975	regimen	1	
21-21	2976-2982	during	2	
21-22	2983-2986	the	_	
21-23	2987-2992	first	_	
21-24	2993-2995	72	_	
21-25	2996-3001	hours	_	
21-26	3002-3004	of	_	
21-27	3005-3010	study	_	
21-28	3011-3012	,	1	
21-29	3013-3016	did	3	
21-30	3017-3020	not	_	
21-31	3021-3025	meet	1	
21-32	3026-3029	any	2	
21-33	3030-3035	other	_	
21-34	3036-3049	indeterminate	_	
21-35	3050-3058	criteria	1	
21-36	3059-3062	and	2	
21-37	3063-3064	1	_	
21-38	3065-3067	of	_	
21-39	3068-3071	the	_	
21-40	3072-3081	following	_	
21-41	3082-3092	conditions	1	
21-42	3093-3097	were	3	
21-43	3098-3101	met	1	
21-44	3102-3103	:	6	
21-45	3104-3106	An	9	
21-46	3107-3117	antibiotic	1	
21-47	3118-3121	was	3	
21-48	3122-3132	prescribed	_	
21-49	3133-3136	for	1	
21-50	3137-3140	AOM	2	
21-51	3141-3142	;	6	
21-52	3143-3145	or	9	
21-53	3146-3147	a	_	
21-54	3148-3156	surgical	_	
21-55	3157-3166	procedure	1	
21-56	3167-3170	was	3	
21-57	3171-3180	performed	_	
21-58	3181-3184	for	1	
21-59	3185-3188	AOM	2	
21-60	3189-3191	on	2	
21-61	3192-3194	or	_	
21-62	3195-3201	before	_	
21-63	3202-3205	the	_	
21-64	3206-3210	last	_	
21-65	3211-3214	day	_	
21-66	3215-3217	of	_	
21-67	3218-3221	the	_	
21-68	3222-3227	visit	_	
21-69	3228-3234	window	1	
21-70	3235-3236	;	6	
21-71	3237-3239	or	3	
21-72	3240-3245	there	_	
21-73	3246-3249	was	1	
21-74	3250-3258	evidence	2	
21-75	3259-3261	of	_	
21-76	3262-3270	fullness	_	
21-77	3271-3273	or	_	
21-78	3274-3281	bulging	_	
21-79	3282-3284	of	_	
21-80	3285-3288	the	_	
21-81	3289-3297	tympanic	_	
21-82	3298-3306	membrane	1	
21-83	3307-3308	;	6	
21-84	3309-3311	or	2	
21-85	3312-3323	perforation	_	
21-86	3324-3326	of	_	
21-87	3327-3335	tympanic	_	
21-88	3336-3344	membrane	1	
21-89	3345-3346	;	6	
21-90	3347-3349	or	9	
21-91	3350-3353	the	_	
21-92	3354-3361	subject	1	
21-93	3362-3365	had	3	
21-94	3366-3380	unsatisfactory	2	
21-95	3381-3391	resolution	_	
21-96	3392-3394	of	_	
21-97	3395-3400	signs	_	
21-98	3401-3404	and	_	
21-99	3405-3413	symptoms	_	
21-100	3414-3416	of	_	
21-101	3417-3420	AOM	1	
21-102	3421-3430	according	6	
21-103	3431-3433	to	1	
21-104	3434-3437	the	2	
21-105	3438-3450	investigator	_	
21-106	3451-3452	.	1	

#Text=The protocol specified that standard medical therapy , based on current American Heart Association guidelines , would be administered to patients in both groups of the trial.
22-1	3453-3456	The	9	
22-2	3457-3465	protocol	1	
22-3	3466-3475	specified	8	
22-4	3476-3480	that	2	
22-5	3481-3489	standard	_	
22-6	3490-3497	medical	_	
22-7	3498-3505	therapy	_	
22-8	3506-3507	,	1	
22-9	3508-3513	based	3	
22-10	3514-3516	on	1	
22-11	3517-3524	current	2	
22-12	3525-3533	American	_	
22-13	3534-3539	Heart	_	
22-14	3540-3551	Association	_	
22-15	3552-3562	guidelines	_	
22-16	3563-3564	,	1	
22-17	3565-3570	would	3	
22-18	3571-3573	be	_	
22-19	3574-3586	administered	_	
22-20	3587-3589	to	3	
22-21	3590-3598	patients	2	
22-22	3599-3601	in	2	
22-23	3602-3606	both	_	
22-24	3607-3613	groups	_	
22-25	3614-3616	of	_	
22-26	3617-3620	the	_	
22-27	3621-3626	trial	_	
22-28	3626-3627	.	1	

#Text=Patients with an APACHE II score of 15 or more were excluded because the risk of mortality in these patients was deemed too high — that is , disease severity or comorbidity , or both , presented a strict contraindication to surgery .
23-1	3628-3636	Patients	9	
23-2	3637-3641	with	_	
23-3	3642-3644	an	_	
23-4	3645-3651	APACHE	_	
23-5	3652-3654	II	_	
23-6	3655-3660	score	_	
23-7	3661-3663	of	_	
23-8	3664-3666	15	_	
23-9	3667-3669	or	_	
23-10	3670-3674	more	1	
23-11	3675-3679	were	8	
23-12	3680-3688	excluded	1	
23-13	3689-3696	because	6	
23-14	3697-3700	the	9	
23-15	3701-3705	risk	_	
23-16	3706-3708	of	_	
23-17	3709-3718	mortality	_	
23-18	3719-3721	in	_	
23-19	3722-3727	these	_	
23-20	3728-3736	patients	1	
23-21	3737-3740	was	3	
23-22	3741-3747	deemed	1	
23-23	3748-3751	too	7	
23-24	3752-3756	high	1	
23-25	3757-3758	—	6	
23-26	3759-3763	that	_	
23-27	3764-3766	is	_	
23-28	3767-3768	,	1	
23-29	3769-3776	disease	9	
23-30	3777-3785	severity	_	
23-31	3786-3788	or	_	
23-32	3789-3800	comorbidity	_	
23-33	3801-3802	,	_	
23-34	3803-3805	or	_	
23-35	3806-3810	both	_	
23-36	3811-3812	,	1	
23-37	3813-3822	presented	3	
23-38	3823-3824	a	2	
23-39	3825-3831	strict	_	
23-40	3832-3848	contraindication	_	
23-41	3849-3851	to	_	
23-42	3852-3859	surgery	_	
23-43	3860-3861	.	1	

#Text=Linear mixed modelling ( LMM ) was used to estimate the effect of sampling time points and other factors on the levels of phospholipids , cytokines , and autotaxin .
24-1	3862-3868	Linear	9	
24-2	3869-3874	mixed	_	
24-3	3875-3884	modelling	1	
24-4	3885-3886	(	5	
24-5	3887-3890	LMM	_	
24-6	3891-3892	)	1	
24-7	3893-3896	was	8	
24-8	3897-3901	used	_	
24-9	3902-3904	to	_	
24-10	3905-3913	estimate	1	
24-11	3914-3917	the	2	
24-12	3918-3924	effect	_	
24-13	3925-3927	of	_	
24-14	3928-3936	sampling	_	
24-15	3937-3941	time	_	
24-16	3942-3948	points	_	
24-17	3949-3952	and	_	
24-18	3953-3958	other	_	
24-19	3959-3966	factors	_	
24-20	3967-3969	on	_	
24-21	3970-3973	the	_	
24-22	3974-3980	levels	_	
24-23	3981-3983	of	_	
24-24	3984-3997	phospholipids	_	
24-25	3998-3999	,	_	
24-26	4000-4009	cytokines	_	
24-27	4010-4011	,	_	
24-28	4012-4015	and	_	
24-29	4016-4025	autotaxin	_	
24-30	4026-4027	.	1	

#Text=The DSMB also reviewed unblinded safety data of patients during the course of the study .
25-1	4028-4031	The	9	
25-2	4032-4036	DSMB	1	
25-3	4037-4041	also	8	
25-4	4042-4050	reviewed	1	
25-5	4051-4060	unblinded	2	
25-6	4061-4067	safety	_	
25-7	4068-4072	data	_	
25-8	4073-4075	of	_	
25-9	4076-4084	patients	1	
25-10	4085-4091	during	2	
25-11	4092-4095	the	_	
25-12	4096-4102	course	_	
25-13	4103-4105	of	_	
25-14	4106-4109	the	_	
25-15	4110-4115	study	_	
25-16	4116-4117	.	1	

#Text=Ability to give written consent was assessed by the study nurse or study doctor .
26-1	4118-4125	Ability	9	
26-2	4126-4128	to	_	
26-3	4129-4133	give	_	
26-4	4134-4141	written	_	
26-5	4142-4149	consent	1	
26-6	4150-4153	was	8	
26-7	4154-4162	assessed	_	
26-8	4163-4165	by	1	
26-9	4166-4169	the	2	
26-10	4170-4175	study	_	
26-11	4176-4181	nurse	_	
26-12	4182-4184	or	_	
26-13	4185-4190	study	_	
26-14	4191-4197	doctor	_	
26-15	4198-4199	.	1	

#Text=Symptoms of otalgia , irritability , anorexia , and fever were assessed at diagnosis and test-of-cure ( TOC ) .
27-1	4200-4208	Symptoms	9	
27-2	4209-4211	of	_	
27-3	4212-4219	otalgia	_	
27-4	4220-4221	,	_	
27-5	4222-4234	irritability	_	
27-6	4235-4236	,	_	
27-7	4237-4245	anorexia	_	
27-8	4246-4247	,	_	
27-9	4248-4251	and	_	
27-10	4252-4257	fever	1	
27-11	4258-4262	were	8	
27-12	4263-4271	assessed	_	
27-13	4272-4274	at	1	
27-14	4275-4284	diagnosis	2	
27-15	4285-4288	and	_	
27-16	4289-4301	test-of-cure	1	
27-17	4302-4303	(	5	
27-18	4304-4307	TOC	_	
27-19	4308-4309	)	_	
27-20	4310-4311	.	1	

#Text=Preliminary analyses examined the association of missingness with baseline predictors and longitudinal outcomes .
28-1	4312-4323	Preliminary	9	
28-2	4324-4332	analyses	1	
28-3	4333-4341	examined	8	
28-4	4342-4345	the	2	
28-5	4346-4357	association	_	
28-6	4358-4360	of	_	
28-7	4361-4372	missingness	_	
28-8	4373-4377	with	_	
28-9	4378-4386	baseline	_	
28-10	4387-4397	predictors	_	
28-11	4398-4401	and	_	
28-12	4402-4414	longitudinal	_	
28-13	4415-4423	outcomes	_	
28-14	4424-4425	.	1	

#Text=We did not make any major changes to the protocol after these pilots ; only 2 exclusion criteria were added ( Crohn 's disease and ulcerative colitis ) .
29-1	4426-4428	We	8	
29-2	4429-4432	did	_	
29-3	4433-4436	not	_	
29-4	4437-4441	make	1	
29-5	4442-4445	any	2	
29-6	4446-4451	major	_	
29-7	4452-4459	changes	_	
29-8	4460-4462	to	_	
29-9	4463-4466	the	_	
29-10	4467-4475	protocol	1	
29-11	4476-4481	after	2	
29-12	4482-4487	these	_	
29-13	4488-4494	pilots	1	
29-14	4495-4496	;	6	
29-15	4497-4501	only	9	
29-16	4502-4503	2	_	
29-17	4504-4513	exclusion	_	
29-18	4514-4522	criteria	1	
29-19	4523-4527	were	3	
29-20	4528-4533	added	1	
29-21	4534-4535	(	5	
29-22	4536-4541	Crohn	_	
29-23	4542-4543	'	_	
29-24	4543-4544	s	_	
29-25	4545-4552	disease	_	
29-26	4553-4556	and	_	
29-27	4557-4567	ulcerative	_	
29-28	4568-4575	colitis	_	
29-29	4576-4577	)	_	
29-30	4578-4579	.	1	

#Text=In case of immediate need for unblinding , sealed , opaque envelopes for each study number were kept at each study site .
30-1	4580-4582	In	2	
30-2	4583-4587	case	_	
30-3	4588-4590	of	_	
30-4	4591-4600	immediate	_	
30-5	4601-4605	need	_	
30-6	4606-4609	for	_	
30-7	4610-4620	unblinding	_	
30-8	4621-4622	,	1	
30-9	4623-4629	sealed	9	
30-10	4630-4631	,	_	
30-11	4632-4638	opaque	_	
30-12	4639-4648	envelopes	_	
30-13	4649-4652	for	_	
30-14	4653-4657	each	_	
30-15	4658-4663	study	_	
30-16	4664-4670	number	1	
30-17	4671-4675	were	8	
30-18	4676-4680	kept	_	
30-19	4681-4683	at	1	
30-20	4684-4688	each	2	
30-21	4689-4694	study	_	
30-22	4695-4699	site	_	
30-23	4700-4701	.	1	

#Text=They used gelatin capsules where red iron oxide was used for color and titanium oxide as an opacifier .
31-1	4702-4706	They	8	
31-2	4707-4711	used	1	
31-3	4712-4719	gelatin	2	
31-4	4720-4728	capsules	1	
31-5	4729-4734	where	6	
31-6	4735-4738	red	9	
31-7	4739-4743	iron	_	
31-8	4744-4749	oxide	1	
31-9	4750-4753	was	3	
31-10	4754-4758	used	_	
31-11	4759-4762	for	1	
31-12	4763-4768	color	2	
31-13	4769-4772	and	_	
31-14	4773-4781	titanium	_	
31-15	4782-4787	oxide	1	
31-16	4788-4790	as	2	
31-17	4791-4793	an	_	
31-18	4794-4803	opacifier	_	
31-19	4804-4805	.	1	

#Text=Assignment to the respective calibration standard was done by the length of the FA side chain .
32-1	4806-4816	Assignment	9	
32-2	4817-4819	to	_	
32-3	4820-4823	the	_	
32-4	4824-4834	respective	_	
32-5	4835-4846	calibration	_	
32-6	4847-4855	standard	1	
32-7	4856-4859	was	8	
32-8	4860-4864	done	_	
32-9	4865-4867	by	1	
32-10	4868-4871	the	2	
32-11	4872-4878	length	_	
32-12	4879-4881	of	_	
32-13	4882-4885	the	_	
32-14	4886-4888	FA	_	
32-15	4889-4893	side	_	
32-16	4894-4899	chain	_	
32-17	4900-4901	.	1	

#Text=Each AOM research site used an independent computer-generated random number table to allocate subjects .
33-1	4902-4906	Each	9	
33-2	4907-4910	AOM	_	
33-3	4911-4919	research	_	
33-4	4920-4924	site	1	
33-5	4925-4929	used	8	
33-6	4930-4932	an	2	
33-7	4933-4944	independent	_	
33-8	4945-4963	computer-generated	_	
33-9	4964-4970	random	_	
33-10	4971-4977	number	_	
33-11	4978-4983	table	1	
33-12	4984-4986	to	3	
33-13	4987-4995	allocate	1	
33-14	4996-5004	subjects	2	
33-15	5005-5006	.	1	

#Text=If more than 10 patients within the first 100 patients included were hospitalized , this would be a cause for unblinding of the hospitalized patients .
34-1	5007-5009	If	6	
34-2	5010-5014	more	9	
34-3	5015-5019	than	_	
34-4	5020-5022	10	_	
34-5	5023-5031	patients	_	
34-6	5032-5038	within	_	
34-7	5039-5042	the	_	
34-8	5043-5048	first	_	
34-9	5049-5052	100	_	
34-10	5053-5061	patients	_	
34-11	5062-5070	included	1	
34-12	5071-5075	were	3	
34-13	5076-5088	hospitalized	_	
34-14	5089-5090	,	1	
34-15	5091-5095	this	8	
34-16	5096-5101	would	_	
34-17	5102-5104	be	1	
34-18	5105-5106	a	2	
34-19	5107-5112	cause	_	
34-20	5113-5116	for	_	
34-21	5117-5127	unblinding	_	
34-22	5128-5130	of	_	
34-23	5131-5134	the	_	
34-24	5135-5147	hospitalized	_	
34-25	5148-5156	patients	_	
34-26	5157-5158	.	1	

#Text=This tool avoids ceiling effects in high functioning samples and has superior sensitivity and discriminant validity than KOOS subscales [ 34 ] .
35-1	5159-5163	This	9	
35-2	5164-5168	tool	1	
35-3	5169-5175	avoids	8	
35-4	5176-5183	ceiling	2	
35-5	5184-5191	effects	1	
35-6	5192-5194	in	2	
35-7	5195-5199	high	_	
35-8	5200-5211	functioning	_	
35-9	5212-5219	samples	1	
35-10	5220-5223	and	3	
35-11	5224-5227	has	1	
35-12	5228-5236	superior	2	
35-13	5237-5248	sensitivity	_	
35-14	5249-5252	and	_	
35-15	5253-5265	discriminant	_	
35-16	5266-5274	validity	1	
35-17	5275-5279	than	6	
35-18	5280-5284	KOOS	2	
35-19	5285-5294	subscales	1	
35-20	5295-5296	[	5	
35-21	5297-5299	34	_	
35-22	5300-5301	]	_	
35-23	5302-5303	.	1	

#Text=Facial digital photography was performed before and at 60 minutes after each treatment .
36-1	5304-5310	Facial	9	
36-2	5311-5318	digital	_	
36-3	5319-5330	photography	1	
36-4	5331-5334	was	8	
36-5	5335-5344	performed	_	
36-6	5345-5351	before	_	
36-7	5352-5355	and	_	
36-8	5356-5358	at	1	
36-9	5359-5361	60	2	
36-10	5362-5369	minutes	_	
36-11	5370-5375	after	_	
36-12	5376-5380	each	_	
36-13	5381-5390	treatment	_	
36-14	5391-5392	.	1	

#Text=We enrolled persons aged 40 years or older who met American College of Rheumatology criteria for symptomatic knee osteoarthritis and had radiographic evidence of tibiofemoral or patellofemoral osteoarthritis ( defined as the presence of a definite osteophyte in the tibiofemoral compartment and/or the patellofemoral compartment , as assessed on standing anterior – posterior and lateral or sunrise views ) ( 18 ) .
37-1	5393-5395	We	8	
37-2	5396-5404	enrolled	1	
37-3	5405-5412	persons	2	
37-4	5413-5417	aged	_	
37-5	5418-5420	40	_	
37-6	5421-5426	years	_	
37-7	5427-5429	or	_	
37-8	5430-5435	older	_	
37-9	5436-5439	who	_	
37-10	5440-5443	met	_	
37-11	5444-5452	American	_	
37-12	5453-5460	College	_	
37-13	5461-5463	of	_	
37-14	5464-5476	Rheumatology	_	
37-15	5477-5485	criteria	_	
37-16	5486-5489	for	_	
37-17	5490-5501	symptomatic	_	
37-18	5502-5506	knee	_	
37-19	5507-5521	osteoarthritis	1	
37-20	5522-5525	and	3	
37-21	5526-5529	had	1	
37-22	5530-5542	radiographic	2	
37-23	5543-5551	evidence	_	
37-24	5552-5554	of	_	
37-25	5555-5567	tibiofemoral	_	
37-26	5568-5570	or	_	
37-27	5571-5585	patellofemoral	_	
37-28	5586-5600	osteoarthritis	1	
37-29	5601-5602	(	5	
37-30	5603-5610	defined	_	
37-31	5611-5613	as	_	
37-32	5614-5617	the	_	
37-33	5618-5626	presence	_	
37-34	5627-5629	of	_	
37-35	5630-5631	a	_	
37-36	5632-5640	definite	_	
37-37	5641-5651	osteophyte	_	
37-38	5652-5654	in	_	
37-39	5655-5658	the	_	
37-40	5659-5671	tibiofemoral	_	
37-41	5672-5683	compartment	_	
37-42	5684-5687	and	_	
37-43	5687-5688	/	_	
37-44	5688-5690	or	_	
37-45	5691-5694	the	_	
37-46	5695-5709	patellofemoral	_	
37-47	5710-5721	compartment	_	
37-48	5722-5723	,	_	
37-49	5724-5726	as	_	
37-50	5727-5735	assessed	_	
37-51	5736-5738	on	_	
37-52	5739-5747	standing	_	
37-53	5748-5756	anterior	_	
37-54	5757-5758	–	_	
37-55	5759-5768	posterior	_	
37-56	5769-5772	and	_	
37-57	5773-5780	lateral	_	
37-58	5781-5783	or	_	
37-59	5784-5791	sunrise	_	
37-60	5792-5797	views	_	
37-61	5798-5799	)	1	
37-62	5800-5801	(	5	
37-63	5802-5804	18	_	
37-64	5805-5806	)	_	
37-65	5807-5808	.	1	

#Text=Boxplots were used to summarize location and variability of the sample of measurements .
38-1	5809-5817	Boxplots	9	
38-2	5818-5822	were	8	
38-3	5823-5827	used	_	
38-4	5828-5830	to	_	
38-5	5831-5840	summarize	1	
38-6	5841-5849	location	2	
38-7	5850-5853	and	_	
38-8	5854-5865	variability	_	
38-9	5866-5868	of	_	
38-10	5869-5872	the	_	
38-11	5873-5879	sample	_	
38-12	5880-5882	of	_	
38-13	5883-5895	measurements	_	
38-14	5896-5897	.	1	

#Text=Eligible patients were randomized 1:1 to receive either trimodulin ( 5 % protein solution ; BT086 ; Biotest AG , Dreieich , Germany ) or an equal volume of human albumin as placebo ( 1 % protein solution ) , both as intravenous infusion .
39-1	5898-5906	Eligible	9	
39-2	5907-5915	patients	1	
39-3	5916-5920	were	8	
39-4	5921-5931	randomized	_	
39-5	5932-5933	1	_	
39-6	5933-5934	:	_	
39-7	5934-5935	1	_	
39-8	5936-5938	to	_	
39-9	5939-5946	receive	1	
39-10	5947-5953	either	6	
39-11	5954-5964	trimodulin	2	
39-12	5965-5966	(	5	
39-13	5967-5968	5	_	
39-14	5969-5970	%	_	
39-15	5971-5978	protein	_	
39-16	5979-5987	solution	_	
39-17	5988-5989	;	_	
39-18	5990-5995	BT086	_	
39-19	5996-5997	;	_	
39-20	5998-6005	Biotest	_	
39-21	6006-6008	AG	_	
39-22	6009-6010	,	_	
39-23	6011-6019	Dreieich	_	
39-24	6020-6021	,	_	
39-25	6022-6029	Germany	_	
39-26	6030-6031	)	1	
39-27	6032-6034	or	2	
39-28	6035-6037	an	_	
39-29	6038-6043	equal	_	
39-30	6044-6050	volume	_	
39-31	6051-6053	of	_	
39-32	6054-6059	human	_	
39-33	6060-6067	albumin	_	
39-34	6068-6070	as	_	
39-35	6071-6078	placebo	1	
39-36	6079-6080	(	5	
39-37	6081-6082	1	_	
39-38	6083-6084	%	_	
39-39	6085-6092	protein	_	
39-40	6093-6101	solution	_	
39-41	6102-6103	)	_	
39-42	6104-6105	,	1	
39-43	6106-6110	both	2	
39-44	6111-6113	as	_	
39-45	6114-6125	intravenous	_	
39-46	6126-6134	infusion	_	
39-47	6135-6136	.	1	

#Text=Before study initiation , the principal investigator ( C.W. ) and the Tai Chi master ( R.R. , who was also 1 of the 3 instructors ) reviewed the concepts of knee osteoarthritis and trained the other instructors ( 17 , 21 ) .
40-1	6137-6143	Before	2	
40-2	6144-6149	study	_	
40-3	6150-6160	initiation	_	
40-4	6161-6162	,	1	
40-5	6163-6166	the	2	
40-6	6167-6176	principal	_	
40-7	6177-6189	investigator	1	
40-8	6190-6191	(	5	
40-9	6192-6195	C.W	_	
40-10	6195-6196	.	_	
40-11	6197-6198	)	1	
40-12	6199-6202	and	2	
40-13	6203-6206	the	_	
40-14	6207-6210	Tai	_	
40-15	6211-6214	Chi	_	
40-16	6215-6221	master	1	
40-17	6222-6223	(	5	
40-18	6224-6227	R.R	_	
40-19	6227-6228	.	_	
40-20	6229-6230	,	_	
40-21	6231-6234	who	_	
40-22	6235-6238	was	_	
40-23	6239-6243	also	_	
40-24	6244-6245	1	_	
40-25	6246-6248	of	_	
40-26	6249-6252	the	_	
40-27	6253-6254	3	_	
40-28	6255-6266	instructors	_	
40-29	6267-6268	)	1	
40-30	6269-6277	reviewed	8	
40-31	6278-6281	the	2	
40-32	6282-6290	concepts	_	
40-33	6291-6293	of	_	
40-34	6294-6298	knee	_	
40-35	6299-6313	osteoarthritis	1	
40-36	6314-6317	and	3	
40-37	6318-6325	trained	1	
40-38	6326-6329	the	2	
40-39	6330-6335	other	_	
40-40	6336-6347	instructors	1	
40-41	6348-6349	(	5	
40-42	6350-6352	17	_	
40-43	6353-6354	,	_	
40-44	6355-6357	21	_	
40-45	6358-6359	)	_	
40-46	6360-6361	.	1	

#Text=Statistical analyses were performed using Stata version 14.1 .
41-1	6362-6373	Statistical	9	
41-2	6374-6382	analyses	1	
41-3	6383-6387	were	8	
41-4	6388-6397	performed	_	
41-5	6398-6403	using	1	
41-6	6404-6409	Stata	2	
41-7	6410-6417	version	_	
41-8	6418-6422	14.1	_	
41-9	6423-6424	.	1	

#Text=We also explored several types of interactions .
42-1	6425-6427	We	8	
42-2	6428-6432	also	_	
42-3	6433-6441	explored	1	
42-4	6442-6449	several	2	
42-5	6450-6455	types	_	
42-6	6456-6458	of	_	
42-7	6459-6471	interactions	_	
42-8	6472-6473	.	1	

#Text=Clinical microbiology diagnostics were performed using culture methods , and a previously described qPCR panel for respiratory pathogens which was developed at the maximum possible extent according to the guidelines on minimum information for publication of qPCR experiments ( MIQE ) [ 13 ] .
43-1	6474-6482	Clinical	9	
43-2	6483-6495	microbiology	_	
43-3	6496-6507	diagnostics	1	
43-4	6508-6512	were	8	
43-5	6513-6522	performed	_	
43-6	6523-6528	using	1	
43-7	6529-6536	culture	2	
43-8	6537-6544	methods	_	
43-9	6545-6546	,	1	
43-10	6547-6550	and	2	
43-11	6551-6552	a	_	
43-12	6553-6563	previously	_	
43-13	6564-6573	described	_	
43-14	6574-6578	qPCR	_	
43-15	6579-6584	panel	_	
43-16	6585-6588	for	_	
43-17	6589-6600	respiratory	_	
43-18	6601-6610	pathogens	1	
43-19	6611-6616	which	6	
43-20	6617-6620	was	3	
43-21	6621-6630	developed	_	
43-22	6631-6633	at	1	
43-23	6634-6637	the	2	
43-24	6638-6645	maximum	_	
43-25	6646-6654	possible	_	
43-26	6655-6661	extent	2	
43-27	6662-6671	according	2	
43-28	6672-6674	to	_	
43-29	6675-6678	the	_	
43-30	6679-6689	guidelines	_	
43-31	6690-6692	on	_	
43-32	6693-6700	minimum	_	
43-33	6701-6712	information	_	
43-34	6713-6716	for	_	
43-35	6717-6728	publication	_	
43-36	6729-6731	of	_	
43-37	6732-6736	qPCR	_	
43-38	6737-6748	experiments	1	
43-39	6749-6750	(	5	
43-40	6751-6755	MIQE	_	
43-41	6756-6757	)	1	
43-42	6758-6759	[	5	
43-43	6760-6762	13	_	
43-44	6763-6764	]	_	
43-45	6765-6766	.	1	

#Text=We developed a standardized classical Yang style Tai Chi protocol for knee osteoarthritis that was based on the literature ( 13 ) .
44-1	6767-6769	We	8	
44-2	6770-6779	developed	1	
44-3	6780-6781	a	2	
44-4	6782-6794	standardized	_	
44-5	6795-6804	classical	_	
44-6	6805-6809	Yang	_	
44-7	6810-6815	style	_	
44-8	6816-6819	Tai	_	
44-9	6820-6823	Chi	_	
44-10	6824-6832	protocol	_	
44-11	6833-6836	for	_	
44-12	6837-6841	knee	_	
44-13	6842-6856	osteoarthritis	1	
44-14	6857-6861	that	6	
44-15	6862-6865	was	3	
44-16	6866-6871	based	_	
44-17	6872-6874	on	1	
44-18	6875-6878	the	2	
44-19	6879-6889	literature	1	
44-20	6890-6891	(	5	
44-21	6892-6894	13	_	
44-22	6895-6896	)	_	
44-23	6897-6898	.	1	

#Text=A research nurse/doctor contacted the patients for a telephone follow-up after 14 and 28 days .
45-1	6899-6900	A	9	
45-2	6901-6909	research	_	
45-3	6910-6915	nurse	_	
45-4	6915-6916	/	_	
45-5	6916-6922	doctor	1	
45-6	6923-6932	contacted	8	
45-7	6933-6936	the	2	
45-8	6937-6945	patients	1	
45-9	6946-6949	for	2	
45-10	6950-6951	a	_	
45-11	6952-6961	telephone	_	
45-12	6962-6971	follow-up	1	
45-13	6972-6977	after	2	
45-14	6978-6980	14	_	
45-15	6981-6984	and	_	
45-16	6985-6987	28	_	
45-17	6988-6992	days	_	
45-18	6993-6994	.	1	

#Text=The CHOCOLATE study was designed as a multicentre , randomised controlled , superiority trial , and the protocol has been previously described.
46-1	6995-6998	The	2	
46-2	6999-7008	CHOCOLATE	_	
46-3	7009-7014	study	1	
46-4	7015-7018	was	8	
46-5	7019-7027	designed	_	
46-6	7028-7030	as	1	
46-7	7031-7032	a	2	
46-8	7033-7044	multicentre	_	
46-9	7045-7046	,	_	
46-10	7047-7057	randomised	_	
46-11	7058-7068	controlled	_	
46-12	7069-7070	,	_	
46-13	7071-7082	superiority	_	
46-14	7083-7088	trial	_	
46-15	7089-7090	,	1	
46-16	7091-7094	and	9	
46-17	7095-7098	the	_	
46-18	7099-7107	protocol	1	
46-19	7108-7111	has	3	
46-20	7112-7116	been	_	
46-21	7117-7127	previously	_	
46-22	7128-7137	described	_	
46-23	7137-7138	.	1	

#Text=We obtained informed consent before baseline assessments for eligibility .
47-1	7139-7141	We	8	
47-2	7142-7150	obtained	1	
47-3	7151-7159	informed	2	
47-4	7160-7167	consent	1	
47-5	7168-7174	before	2	
47-6	7175-7183	baseline	_	
47-7	7184-7195	assessments	_	
47-8	7196-7199	for	_	
47-9	7200-7211	eligibility	_	
47-10	7212-7213	.	1	

#Text=Clinical response was defined as either 1 ) improvement of at least 50 % in pain or function and an absolute change of at least 20 points on a scale of 0 to 100 in the WOMAC pain or function subscores , or 2 ) at least 2 of the following criteria : improvement of at least 20 % and an absolute change greater than 10 points on a scale of 0 to 100 in the WOMAC pain score , improvement of at least 20 % and an absolute change greater than 10 points on a scale of 0 to 100 in the WOMAC function score , or improvement of at least 20 % in the Patient Global Assessment score and an absolute change greater than 10 points on a scale of 0 to 100 .
48-1	7214-7222	Clinical	9	
48-2	7223-7231	response	1	
48-3	7232-7235	was	8	
48-4	7236-7243	defined	_	
48-5	7244-7246	as	1	
48-6	7247-7253	either	6	
48-7	7254-7255	1	_	
48-8	7256-7257	)	1	
48-9	7258-7269	improvement	2	
48-10	7270-7272	of	_	
48-11	7273-7275	at	_	
48-12	7276-7281	least	_	
48-13	7282-7284	50	_	
48-14	7285-7286	%	_	
48-15	7287-7289	in	_	
48-16	7290-7294	pain	_	
48-17	7295-7297	or	_	
48-18	7298-7306	function	1	
48-19	7307-7310	and	2	
48-20	7311-7313	an	_	
48-21	7314-7322	absolute	_	
48-22	7323-7329	change	_	
48-23	7330-7332	of	_	
48-24	7333-7335	at	_	
48-25	7336-7341	least	_	
48-26	7342-7344	20	_	
48-27	7345-7351	points	_	
48-28	7352-7354	on	_	
48-29	7355-7356	a	_	
48-30	7357-7362	scale	_	
48-31	7363-7365	of	_	
48-32	7366-7367	0	_	
48-33	7368-7370	to	_	
48-34	7371-7374	100	_	
48-35	7375-7377	in	_	
48-36	7378-7381	the	_	
48-37	7382-7387	WOMAC	_	
48-38	7388-7392	pain	_	
48-39	7393-7395	or	_	
48-40	7396-7404	function	_	
48-41	7405-7414	subscores	_	
48-42	7415-7416	,	1	
48-43	7417-7419	or	6	
48-44	7420-7421	2	_	
48-45	7422-7423	)	1	
48-46	7424-7426	at	2	
48-47	7427-7432	least	_	
48-48	7433-7434	2	_	
48-49	7435-7437	of	_	
48-50	7438-7441	the	_	
48-51	7442-7451	following	_	
48-52	7452-7460	criteria	1	
48-53	7461-7462	:	6	
48-54	7463-7474	improvement	2	
48-55	7475-7477	of	_	
48-56	7478-7480	at	_	
48-57	7481-7486	least	_	
48-58	7487-7489	20	_	
48-59	7490-7491	%	_	
48-60	7492-7495	and	_	
48-61	7496-7498	an	_	
48-62	7499-7507	absolute	_	
48-63	7508-7514	change	_	
48-64	7515-7522	greater	_	
48-65	7523-7527	than	_	
48-66	7528-7530	10	_	
48-67	7531-7537	points	_	
48-68	7538-7540	on	_	
48-69	7541-7542	a	_	
48-70	7543-7548	scale	_	
48-71	7549-7551	of	_	
48-72	7552-7553	0	_	
48-73	7554-7556	to	_	
48-74	7557-7560	100	_	
48-75	7561-7563	in	_	
48-76	7564-7567	the	_	
48-77	7568-7573	WOMAC	_	
48-78	7574-7578	pain	_	
48-79	7579-7584	score	_	
48-80	7585-7586	,	1	
48-81	7587-7598	improvement	2	
48-82	7599-7601	of	_	
48-83	7602-7604	at	_	
48-84	7605-7610	least	_	
48-85	7611-7613	20	_	
48-86	7614-7615	%	_	
48-87	7616-7619	and	_	
48-88	7620-7622	an	_	
48-89	7623-7631	absolute	_	
48-90	7632-7638	change	_	
48-91	7639-7646	greater	_	
48-92	7647-7651	than	_	
48-93	7652-7654	10	_	
48-94	7655-7661	points	_	
48-95	7662-7664	on	_	
48-96	7665-7666	a	_	
48-97	7667-7672	scale	_	
48-98	7673-7675	of	_	
48-99	7676-7677	0	_	
48-100	7678-7680	to	_	
48-101	7681-7684	100	_	
48-102	7685-7687	in	_	
48-103	7688-7691	the	_	
48-104	7692-7697	WOMAC	_	
48-105	7698-7706	function	_	
48-106	7707-7712	score	_	
48-107	7713-7714	,	1	
48-108	7715-7717	or	2	
48-109	7718-7729	improvement	_	
48-110	7730-7732	of	_	
48-111	7733-7735	at	_	
48-112	7736-7741	least	_	
48-113	7742-7744	20	_	
48-114	7745-7746	%	_	
48-115	7747-7749	in	_	
48-116	7750-7753	the	_	
48-117	7754-7761	Patient	_	
48-118	7762-7768	Global	_	
48-119	7769-7779	Assessment	_	
48-120	7780-7785	score	_	
48-121	7786-7789	and	_	
48-122	7790-7792	an	_	
48-123	7793-7801	absolute	_	
48-124	7802-7808	change	_	
48-125	7809-7816	greater	_	
48-126	7817-7821	than	_	
48-127	7822-7824	10	_	
48-128	7825-7831	points	_	
48-129	7832-7834	on	_	
48-130	7835-7836	a	_	
48-131	7837-7842	scale	_	
48-132	7843-7845	of	_	
48-133	7846-7847	0	_	
48-134	7848-7850	to	_	
48-135	7851-7854	100	_	
48-136	7855-7856	.	1	

#Text=After the first of two interim analyses , the sample size was adjusted to 160 patients [ 18 ] .
49-1	7857-7862	After	2	
49-2	7863-7866	the	_	
49-3	7867-7872	first	_	
49-4	7873-7875	of	_	
49-5	7876-7879	two	_	
49-6	7880-7887	interim	_	
49-7	7888-7896	analyses	_	
49-8	7897-7898	,	1	
49-9	7899-7902	the	9	
49-10	7903-7909	sample	_	
49-11	7910-7914	size	1	
49-12	7915-7918	was	8	
49-13	7919-7927	adjusted	_	
49-14	7928-7930	to	1	
49-15	7931-7934	160	2	
49-16	7935-7943	patients	1	
49-17	7944-7945	[	5	
49-18	7946-7948	18	_	
49-19	7949-7950	]	_	
49-20	7951-7952	.	1	

#Text=A certain experience to undertake this procedure was not required , as percutaneous catheter drainage is reported to be a relatively easy procedure , performed by any radiologist in the Netherlands .
50-1	7953-7954	A	9	
50-2	7955-7962	certain	_	
50-3	7963-7973	experience	1	
50-4	7974-7976	to	3	
50-5	7977-7986	undertake	1	
50-6	7987-7991	this	2	
50-7	7992-8001	procedure	1	
50-8	8002-8005	was	8	
50-9	8006-8009	not	_	
50-10	8010-8018	required	_	
50-11	8019-8020	,	1	
50-12	8021-8023	as	2	
50-13	8024-8036	percutaneous	_	
50-14	8037-8045	catheter	_	
50-15	8046-8054	drainage	1	
50-16	8055-8057	is	3	
50-17	8058-8066	reported	_	
50-18	8067-8069	to	_	
50-19	8070-8072	be	1	
50-20	8073-8074	a	2	
50-21	8075-8085	relatively	_	
50-22	8086-8090	easy	_	
50-23	8091-8100	procedure	_	
50-24	8101-8102	,	1	
50-25	8103-8112	performed	3	
50-26	8113-8115	by	1	
50-27	8116-8119	any	2	
50-28	8120-8131	radiologist	1	
50-29	8132-8134	in	2	
50-30	8135-8138	the	_	
50-31	8139-8150	Netherlands	_	
50-32	8151-8152	.	1	

#Text=Potential participants were excluded if they were assessed as having severe psychiatric illness , dementia , severe drug addiction , or inability to communicate in the official language of the country .
51-1	8153-8162	Potential	9	
51-2	8163-8175	participants	1	
51-3	8176-8180	were	8	
51-4	8181-8189	excluded	1	
51-5	8190-8192	if	6	
51-6	8193-8197	they	3	
51-7	8198-8202	were	_	
51-8	8203-8211	assessed	_	
51-9	8212-8214	as	_	
51-10	8215-8221	having	1	
51-11	8222-8228	severe	2	
51-12	8229-8240	psychiatric	_	
51-13	8241-8248	illness	_	
51-14	8249-8250	,	1	
51-15	8251-8259	dementia	2	
51-16	8260-8261	,	1	
51-17	8262-8268	severe	2	
51-18	8269-8273	drug	_	
51-19	8274-8283	addiction	_	
51-20	8284-8285	,	1	
51-21	8286-8288	or	2	
51-22	8289-8298	inability	_	
51-23	8299-8301	to	_	
51-24	8302-8313	communicate	_	
51-25	8314-8316	in	_	
51-26	8317-8320	the	_	
51-27	8321-8329	official	_	
51-28	8330-8338	language	_	
51-29	8339-8341	of	_	
51-30	8342-8345	the	_	
51-31	8346-8353	country	_	
51-32	8354-8355	.	1	

#Text=Participants received group allocation information in an opaque envelope .
52-1	8356-8368	Participants	9	
52-2	8369-8377	received	8	
52-3	8378-8383	group	2	
52-4	8384-8394	allocation	_	
52-5	8395-8406	information	1	
52-6	8407-8409	in	2	
52-7	8410-8412	an	_	
52-8	8413-8419	opaque	_	
52-9	8420-8428	envelope	_	
52-10	8429-8430	.	1	

#Text=Pathogen detection was performed according to local standards , with sputum and blood cultures being the most frequently analyzed , followed by smear and bronchoalveolar lavage .
53-1	8431-8439	Pathogen	9	
53-2	8440-8449	detection	1	
53-3	8450-8453	was	8	
53-4	8454-8463	performed	_	
53-5	8464-8473	according	_	
53-6	8474-8476	to	1	
53-7	8477-8482	local	2	
53-8	8483-8492	standards	_	
53-9	8493-8494	,	1	
53-10	8495-8499	with	2	
53-11	8500-8506	sputum	_	
53-12	8507-8510	and	_	
53-13	8511-8516	blood	_	
53-14	8517-8525	cultures	1	
53-15	8526-8531	being	3	
53-16	8532-8535	the	_	
53-17	8536-8540	most	_	
53-18	8541-8551	frequently	_	
53-19	8552-8560	analyzed	_	
53-20	8561-8562	,	1	
53-21	8563-8571	followed	3	
53-22	8572-8574	by	1	
53-23	8575-8580	smear	2	
53-24	8581-8584	and	2	
53-25	8585-8600	bronchoalveolar	_	
53-26	8601-8607	lavage	_	
53-27	8608-8609	.	1	

#Text=Inclusion criteria were dysuria combined with either increased urinary frequency or urinary urgency or both , with or without visible hematuria .
54-1	8610-8619	Inclusion	9	
54-2	8620-8628	criteria	1	
54-3	8629-8633	were	8	
54-4	8634-8641	dysuria	2	
54-5	8642-8650	combined	_	
54-6	8651-8655	with	_	
54-7	8656-8662	either	_	
54-8	8663-8672	increased	_	
54-9	8673-8680	urinary	_	
54-10	8681-8690	frequency	_	
54-11	8691-8693	or	_	
54-12	8694-8701	urinary	_	
54-13	8702-8709	urgency	_	
54-14	8710-8712	or	_	
54-15	8713-8717	both	_	
54-16	8718-8719	,	_	
54-17	8720-8724	with	_	
54-18	8725-8727	or	_	
54-19	8728-8735	without	_	
54-20	8736-8743	visible	_	
54-21	8744-8753	hematuria	_	
54-22	8754-8755	.	1	

#Text=Women presenting with symptoms of an uncomplicated UTI were consecutively screened for eligibility by a doctor or a study nurse using a questionnaire ( S1 Fig ) .
55-1	8756-8761	Women	9	
55-2	8762-8772	presenting	3	
55-3	8773-8777	with	2	
55-4	8778-8786	symptoms	_	
55-5	8787-8789	of	_	
55-6	8790-8792	an	_	
55-7	8793-8806	uncomplicated	_	
55-8	8807-8810	UTI	1	
55-9	8811-8815	were	8	
55-10	8816-8829	consecutively	_	
55-11	8830-8838	screened	_	
55-12	8839-8842	for	1	
55-13	8843-8854	eligibility	2	
55-14	8855-8857	by	2	
55-15	8858-8859	a	_	
55-16	8860-8866	doctor	_	
55-17	8867-8869	or	_	
55-18	8870-8871	a	_	
55-19	8872-8877	study	_	
55-20	8878-8883	nurse	1	
55-21	8884-8889	using	3	
55-22	8890-8891	a	2	
55-23	8892-8905	questionnaire	1	
55-24	8906-8907	(	5	
55-25	8908-8910	S1	_	
55-26	8911-8914	Fig	_	
55-27	8915-8916	)	_	
55-28	8917-8918	.	1	

#Text=Patients were randomly assigned to either Tai Chi ( 2 times per week for 12 weeks ) or physical therapy in a clinical setting ( 2 times per week for 6 weeks , followed by 6 weeks of rigorously monitored home exercise ) .
56-1	8919-8927	Patients	9	
56-2	8928-8932	were	8	
56-3	8933-8941	randomly	_	
56-4	8942-8950	assigned	_	
56-5	8951-8953	to	1	
56-6	8954-8960	either	6	
56-7	8961-8964	Tai	2	
56-8	8965-8968	Chi	1	
56-9	8969-8970	(	5	
56-10	8971-8972	2	_	
56-11	8973-8978	times	_	
56-12	8979-8982	per	_	
56-13	8983-8987	week	_	
56-14	8988-8991	for	_	
56-15	8992-8994	12	_	
56-16	8995-9000	weeks	_	
56-17	9001-9002	)	1	
56-18	9003-9005	or	2	
56-19	9006-9014	physical	_	
56-20	9015-9022	therapy	1	
56-21	9023-9025	in	2	
56-22	9026-9027	a	_	
56-23	9028-9036	clinical	_	
56-24	9037-9044	setting	1	
56-25	9045-9046	(	5	
56-26	9047-9048	2	_	
56-27	9049-9054	times	_	
56-28	9055-9058	per	_	
56-29	9059-9063	week	_	
56-30	9064-9067	for	_	
56-31	9068-9069	6	_	
56-32	9070-9075	weeks	_	
56-33	9076-9077	,	_	
56-34	9078-9086	followed	_	
56-35	9087-9089	by	_	
56-36	9090-9091	6	_	
56-37	9092-9097	weeks	_	
56-38	9098-9100	of	_	
56-39	9101-9111	rigorously	_	
56-40	9112-9121	monitored	_	
56-41	9122-9126	home	_	
56-42	9127-9135	exercise	_	
56-43	9136-9137	)	_	
56-44	9138-9139	.	1	

#Text=Local clinicians performed data collection using case record forms .
57-1	9140-9145	Local	9	
57-2	9146-9156	clinicians	1	
57-3	9157-9166	performed	8	
57-4	9167-9171	data	2	
57-5	9172-9182	collection	1	
57-6	9183-9188	using	3	
57-7	9189-9193	case	2	
57-8	9194-9200	record	_	
57-9	9201-9206	forms	_	
57-10	9207-9208	.	1	

#Text=We will report other secondary outcomes , such as muscle strength and power and Patient-Reported Outcomes Measurement Information System measures , in separate articles .
58-1	9209-9211	We	8	
58-2	9212-9216	will	_	
58-3	9217-9223	report	1	
58-4	9224-9229	other	2	
58-5	9230-9239	secondary	_	
58-6	9240-9248	outcomes	_	
58-7	9249-9250	,	_	
58-8	9251-9255	such	_	
58-9	9256-9258	as	_	
58-10	9259-9265	muscle	_	
58-11	9266-9274	strength	_	
58-12	9275-9278	and	_	
58-13	9279-9284	power	_	
58-14	9285-9288	and	_	
58-15	9289-9305	Patient-Reported	_	
58-16	9306-9314	Outcomes	_	
58-17	9315-9326	Measurement	_	
58-18	9327-9338	Information	_	
58-19	9339-9345	System	_	
58-20	9346-9354	measures	_	
58-21	9355-9356	,	1	
58-22	9357-9359	in	2	
58-23	9360-9368	separate	_	
58-24	9369-9377	articles	_	
58-25	9378-9379	.	1	

#Text=We recruited 3 experienced Tai Chi instructors from the greater Boston area .
59-1	9380-9382	We	8	
59-2	9383-9392	recruited	1	
59-3	9393-9394	3	2	
59-4	9395-9406	experienced	_	
59-5	9407-9410	Tai	_	
59-6	9411-9414	Chi	_	
59-7	9415-9426	instructors	1	
59-8	9427-9431	from	2	
59-9	9432-9435	the	_	
59-10	9436-9443	greater	_	
59-11	9444-9450	Boston	_	
59-12	9451-9455	area	_	
59-13	9456-9457	.	1	

#Text=All study personnel were trained in GCP .
60-1	9458-9461	All	9	
60-2	9462-9467	study	_	
60-3	9468-9477	personnel	1	
60-4	9478-9482	were	8	
60-5	9483-9490	trained	1	
60-6	9491-9493	in	2	
60-7	9494-9497	GCP	_	
60-8	9498-9499	.	1	

#Text=The pathologists gave a judgment according to the following ranges : ( 1 ) 1–30 %   =   poor improvement , ( 2 ) 30–60 %   =   moderate improvement , and ( 3 ) 60–100 %   =   good improvement .
61-1	9500-9503	The	9	
61-2	9504-9516	pathologists	1	
61-3	9517-9521	gave	8	
61-4	9522-9523	a	2	
61-5	9524-9532	judgment	_	
61-6	9533-9542	according	_	
61-7	9543-9545	to	_	
61-8	9546-9549	the	_	
61-9	9550-9559	following	_	
61-10	9560-9566	ranges	2	
61-11	9567-9568	:	6	
61-12	9569-9570	(	5	
61-13	9571-9572	1	_	
61-14	9573-9574	)	1	
61-15	9575-9576	1	2	
61-16	9576-9577	–	_	
61-17	9577-9579	30	_	
61-18	9580-9581	%	_	
61-19	9584-9585	=	_	
61-20	9588-9592	poor	_	
61-21	9593-9604	improvement	_	
61-22	9605-9606	,	1	
61-23	9607-9608	(	5	
61-24	9609-9610	2	_	
61-25	9611-9612	)	1	
61-26	9613-9615	30	2	
61-27	9615-9616	–	_	
61-28	9616-9618	60	_	
61-29	9619-9620	%	_	
61-30	9623-9624	=	_	
61-31	9627-9635	moderate	_	
61-32	9636-9647	improvement	_	
61-33	9648-9649	,	1	
61-34	9650-9653	and	6	
61-35	9654-9655	(	5	
61-36	9656-9657	3	_	
61-37	9658-9659	)	1	
61-38	9660-9662	60	2	
61-39	9662-9663	–	_	
61-40	9663-9666	100	_	
61-41	9667-9668	%	_	
61-42	9671-9672	=	_	
61-43	9675-9679	good	_	
61-44	9680-9691	improvement	_	
61-45	9692-9693	.	1	

#Text=We did notice that Gagyor et al. had more cases of pyelonephritis in the ibuprofen group , but because the rate was only 2.1 % and the study was not powered to detect significant differences for pyelonephritis , we did not consider this to be a reason for early termination of our trial .
62-1	9694-9696	We	8	
62-2	9697-9700	did	_	
62-3	9701-9707	notice	1	
62-4	9708-9712	that	6	
62-5	9713-9719	Gagyor	9	
62-6	9720-9722	et	_	
62-7	9723-9725	al	_	
62-8	9725-9726	.	1	
62-9	9727-9730	had	3	
62-10	9731-9735	more	2	
62-11	9736-9741	cases	_	
62-12	9742-9744	of	_	
62-13	9745-9759	pyelonephritis	1	
62-14	9760-9762	in	2	
62-15	9763-9766	the	_	
62-16	9767-9776	ibuprofen	_	
62-17	9777-9782	group	_	
62-18	9783-9784	,	1	
62-19	9785-9788	but	6	
62-20	9789-9796	because	6	
62-21	9797-9800	the	9	
62-22	9801-9805	rate	1	
62-23	9806-9809	was	3	
62-24	9810-9814	only	2	
62-25	9815-9818	2.1	_	
62-26	9819-9820	%	1	
62-27	9821-9824	and	9	
62-28	9825-9828	the	_	
62-29	9829-9834	study	1	
62-30	9835-9838	was	3	
62-31	9839-9842	not	_	
62-32	9843-9850	powered	_	
62-33	9851-9853	to	_	
62-34	9854-9860	detect	1	
62-35	9861-9872	significant	2	
62-36	9873-9884	differences	_	
62-37	9885-9888	for	_	
62-38	9889-9903	pyelonephritis	_	
62-39	9904-9905	,	1	
62-40	9906-9908	we	3	
62-41	9909-9912	did	_	
62-42	9913-9916	not	_	
62-43	9917-9925	consider	_	
62-44	9926-9930	this	_	
62-45	9931-9933	to	_	
62-46	9934-9936	be	1	
62-47	9937-9938	a	2	
62-48	9939-9945	reason	_	
62-49	9946-9949	for	_	
62-50	9950-9955	early	_	
62-51	9956-9967	termination	_	
62-52	9968-9970	of	_	
62-53	9971-9974	our	_	
62-54	9975-9980	trial	_	
62-55	9981-9982	.	1	

#Text=We defined serious adverse events as those that were fatal , life-threatening , permanently disabling , or severely incapacitating or that required or prolonged inpatient hospitalization .
63-1	9983-9985	We	8	
63-2	9986-9993	defined	1	
63-3	9994-10001	serious	2	
63-4	10002-10009	adverse	_	
63-5	10010-10016	events	1	
63-6	10017-10019	as	6	
63-7	10020-10025	those	_	
63-8	10026-10030	that	1	
63-9	10031-10035	were	3	
63-10	10036-10041	fatal	7	
63-11	10042-10043	,	_	
63-12	10044-10060	life-threatening	_	
63-13	10061-10062	,	_	
63-14	10063-10074	permanently	_	
63-15	10075-10084	disabling	_	
63-16	10085-10086	,	_	
63-17	10087-10089	or	_	
63-18	10090-10098	severely	_	
63-19	10099-10113	incapacitating	1	
63-20	10114-10116	or	6	
63-21	10117-10121	that	1	
63-22	10122-10130	required	3	
63-23	10131-10133	or	_	
63-24	10134-10143	prolonged	1	
63-25	10144-10153	inpatient	2	
63-26	10154-10169	hospitalization	_	
63-27	10170-10171	.	1	

#Text=Estimates of the volume of the ischemic core and penumbral regions from CT perfusion or MRI diffusion and perfusion scans were calculated with the use of RAPID software ( iSchemaView ) , an automated image postprocessing system .
64-1	10172-10181	Estimates	9	
64-2	10182-10184	of	_	
64-3	10185-10188	the	_	
64-4	10189-10195	volume	_	
64-5	10196-10198	of	_	
64-6	10199-10202	the	_	
64-7	10203-10211	ischemic	_	
64-8	10212-10216	core	1	
64-9	10217-10220	and	9	
64-10	10221-10230	penumbral	_	
64-11	10231-10238	regions	_	
64-12	10239-10243	from	_	
64-13	10244-10246	CT	_	
64-14	10247-10256	perfusion	_	
64-15	10257-10259	or	_	
64-16	10260-10263	MRI	_	
64-17	10264-10273	diffusion	_	
64-18	10274-10277	and	_	
64-19	10278-10287	perfusion	_	
64-20	10288-10293	scans	1	
64-21	10294-10298	were	8	
64-22	10299-10309	calculated	1	
64-23	10310-10314	with	2	
64-24	10315-10318	the	_	
64-25	10319-10322	use	_	
64-26	10323-10325	of	_	
64-27	10326-10331	RAPID	_	
64-28	10332-10340	software	1	
64-29	10341-10342	(	5	
64-30	10343-10354	iSchemaView	_	
64-31	10355-10356	)	_	
64-32	10357-10358	,	1	
64-33	10359-10361	an	2	
64-34	10362-10371	automated	_	
64-35	10372-10377	image	_	
64-36	10378-10392	postprocessing	_	
64-37	10393-10399	system	_	
64-38	10400-10401	.	1	

#Text=The trial was monitored by an NIH-appointed independent data and safety monitoring board .
65-1	10402-10405	The	9	
65-2	10406-10411	trial	1	
65-3	10412-10415	was	8	
65-4	10416-10425	monitored	_	
65-5	10426-10428	by	1	
65-6	10429-10431	an	2	
65-7	10432-10445	NIH-appointed	_	
65-8	10446-10457	independent	_	
65-9	10458-10462	data	_	
65-10	10463-10466	and	_	
65-11	10467-10473	safety	_	
65-12	10474-10484	monitoring	_	
65-13	10485-10490	board	_	
65-14	10491-10492	.	1	

#Text=Session attendance and program adherence was monitored .
66-1	10493-10500	Session	9	
66-2	10501-10511	attendance	_	
66-3	10512-10515	and	_	
66-4	10516-10523	program	_	
66-5	10524-10533	adherence	1	
66-6	10534-10537	was	8	
66-7	10538-10547	monitored	_	
66-8	10548-10549	.	1	

#Text=The primary outcomes were pain , self-reported physical function and mobility performance .
67-1	10550-10553	The	9	
67-2	10554-10561	primary	_	
67-3	10562-10570	outcomes	1	
67-4	10571-10575	were	8	
67-5	10576-10580	pain	2	
67-6	10581-10582	,	_	
67-7	10583-10596	self-reported	_	
67-8	10597-10605	physical	_	
67-9	10606-10614	function	_	
67-10	10615-10618	and	_	
67-11	10619-10627	mobility	_	
67-12	10628-10639	performance	_	
67-13	10640-10641	.	1	

#Text=Mortality was followed up until day 28 in discharged patients .
68-1	10642-10651	Mortality	9	
68-2	10652-10655	was	8	
68-3	10656-10664	followed	_	
68-4	10665-10667	up	_	
68-5	10668-10673	until	1	
68-6	10674-10677	day	2	
68-7	10678-10680	28	1	
68-8	10681-10683	in	2	
68-9	10684-10694	discharged	_	
68-10	10695-10703	patients	_	
68-11	10704-10705	.	1	

#Text=VFDs were set to “ 0 ” if the patient died before day   28 or required IMV for   ≥   28   days [ 21 ] .
69-1	10706-10710	VFDs	9	
69-2	10711-10715	were	8	
69-3	10716-10719	set	_	
69-4	10720-10722	to	1	
69-5	10723-10724	“	2	
69-6	10725-10726	0	_	
69-7	10727-10728	”	1	
69-8	10729-10731	if	6	
69-9	10732-10735	the	9	
69-10	10736-10743	patient	1	
69-11	10744-10748	died	3	
69-12	10749-10755	before	2	
69-13	10756-10759	day	_	
69-14	10760-10761	 	_	
69-15	10762-10764	28	1	
69-16	10765-10767	or	3	
69-17	10768-10776	required	1	
69-18	10777-10780	IMV	2	
69-19	10781-10784	for	_	
69-20	10787-10788	≥	_	
69-21	10791-10793	28	_	
69-22	10794-10795	 	_	
69-23	10796-10800	days	1	
69-24	10801-10802	[	5	
69-25	10803-10805	21	_	
69-26	10806-10807	]	_	
69-27	10808-10809	.	1	

#Text=Apparatus settings were recorded for each participant at baseline and replicated during follow-up for consistency .
70-1	10810-10819	Apparatus	9	
70-2	10820-10828	settings	1	
70-3	10829-10833	were	8	
70-4	10834-10842	recorded	_	
70-5	10843-10846	for	1	
70-6	10847-10851	each	2	
70-7	10852-10863	participant	1	
70-8	10864-10866	at	2	
70-9	10867-10875	baseline	1	
70-10	10876-10879	and	3	
70-11	10880-10890	replicated	1	
70-12	10891-10897	during	2	
70-13	10898-10907	follow-up	1	
70-14	10908-10911	for	2	
70-15	10912-10923	consistency	_	
70-16	10924-10925	.	1	

#Text=This study was funded by the National Center for Complementary and Integrative Health .
71-1	10926-10930	This	9	
71-2	10931-10936	study	1	
71-3	10937-10940	was	8	
71-4	10941-10947	funded	_	
71-5	10948-10950	by	1	
71-6	10951-10954	the	2	
71-7	10955-10963	National	_	
71-8	10964-10970	Center	_	
71-9	10971-10974	for	_	
71-10	10975-10988	Complementary	_	
71-11	10989-10992	and	_	
71-12	10993-11004	Integrative	_	
71-13	11005-11011	Health	_	
71-14	11012-11013	.	1	

#Text=We tracked reasons for missed sessions and asked participants to complete daily logs indicating duration of practice .
72-1	11014-11016	We	8	
72-2	11017-11024	tracked	1	
72-3	11025-11032	reasons	2	
72-4	11033-11036	for	_	
72-5	11037-11043	missed	_	
72-6	11044-11052	sessions	1	
72-7	11053-11056	and	3	
72-8	11057-11062	asked	1	
72-9	11063-11075	participants	2	
72-10	11076-11078	to	3	
72-11	11079-11087	complete	1	
72-12	11088-11093	daily	2	
72-13	11094-11098	logs	_	
72-14	11099-11109	indicating	_	
72-15	11110-11118	duration	_	
72-16	11119-11121	of	_	
72-17	11122-11130	practice	_	
72-18	11131-11132	.	1	

#Text=We used a 5-week design as we hypothesized that this timecourse was necessary to allow long-lasting protection of the mucosa from gastric acid and promote the repair of histological lesions .
73-1	11133-11135	We	8	
73-2	11136-11140	used	1	
73-3	11141-11142	a	2	
73-4	11143-11144	5	_	
73-5	11144-11145	-	_	
73-6	11145-11149	week	_	
73-7	11150-11156	design	1	
73-8	11157-11159	as	6	
73-9	11160-11162	we	3	
73-10	11163-11175	hypothesized	1	
73-11	11176-11180	that	6	
73-12	11181-11185	this	9	
73-13	11186-11196	timecourse	1	
73-14	11197-11200	was	3	
73-15	11201-11210	necessary	7	
73-16	11211-11213	to	3	
73-17	11214-11219	allow	1	
73-18	11220-11232	long-lasting	2	
73-19	11233-11243	protection	_	
73-20	11244-11246	of	_	
73-21	11247-11250	the	_	
73-22	11251-11257	mucosa	_	
73-23	11258-11262	from	_	
73-24	11263-11270	gastric	_	
73-25	11271-11275	acid	1	
73-26	11276-11279	and	3	
73-27	11280-11287	promote	1	
73-28	11288-11291	the	2	
73-29	11292-11298	repair	_	
73-30	11299-11301	of	_	
73-31	11302-11314	histological	_	
73-32	11315-11322	lesions	_	
73-33	11323-11324	.	1	

#Text=Continuous endpoints were analyzed using linear mixed models with patient-specific random intercept and treatment , time ( randomization to day of assessment ) , treatment – time interaction , baseline value , and randomization stratum as fixed factors .
74-1	11325-11335	Continuous	2	
74-2	11336-11345	endpoints	1	
74-3	11346-11350	were	3	
74-4	11351-11359	analyzed	_	
74-5	11360-11365	using	1	
74-6	11366-11372	linear	2	
74-7	11373-11378	mixed	_	
74-8	11379-11385	models	_	
74-9	11386-11390	with	_	
74-10	11391-11407	patient-specific	_	
74-11	11408-11414	random	_	
74-12	11415-11424	intercept	_	
74-13	11425-11428	and	_	
74-14	11429-11438	treatment	_	
74-15	11439-11440	,	1	
74-16	11441-11445	time	2	
74-17	11446-11447	(	5	
74-18	11448-11461	randomization	_	
74-19	11462-11464	to	_	
74-20	11465-11468	day	_	
74-21	11469-11471	of	_	
74-22	11472-11482	assessment	_	
74-23	11483-11484	)	_	
74-24	11485-11486	,	1	
74-25	11487-11496	treatment	2	
74-26	11497-11498	–	_	
74-27	11499-11503	time	_	
74-28	11504-11515	interaction	_	
74-29	11516-11517	,	_	
74-30	11518-11526	baseline	_	
74-31	11527-11532	value	_	
74-32	11533-11534	,	_	
74-33	11535-11538	and	_	
74-34	11539-11552	randomization	_	
74-35	11553-11560	stratum	_	
74-36	11561-11563	as	_	
74-37	11564-11569	fixed	_	
74-38	11570-11577	factors	_	
74-39	11578-11579	.	1	

#Text=Participants were recruited through multimodal strategies , including print advertisements , online media , a booth at a senior exposition , and a clinical patient database .
75-1	11580-11592	Participants	9	
75-2	11593-11597	were	8	
75-3	11598-11607	recruited	_	
75-4	11608-11615	through	1	
75-5	11616-11626	multimodal	2	
75-6	11627-11637	strategies	_	
75-7	11638-11639	,	1	
75-8	11640-11649	including	3	
75-9	11650-11655	print	2	
75-10	11656-11670	advertisements	_	
75-11	11671-11672	,	_	
75-12	11673-11679	online	_	
75-13	11680-11685	media	_	
75-14	11686-11687	,	_	
75-15	11688-11689	a	_	
75-16	11690-11695	booth	_	
75-17	11696-11698	at	_	
75-18	11699-11700	a	_	
75-19	11701-11707	senior	_	
75-20	11708-11718	exposition	_	
75-21	11719-11720	,	_	
75-22	11721-11724	and	_	
75-23	11725-11726	a	_	
75-24	11727-11735	clinical	_	
75-25	11736-11743	patient	_	
75-26	11744-11752	database	_	
75-27	11753-11754	.	1	

#Text=Safety data were monitored throughout the trial by a certified monitor in each country .
76-1	11755-11761	Safety	9	
76-2	11762-11766	data	1	
76-3	11767-11771	were	8	
76-4	11772-11781	monitored	_	
76-5	11782-11792	throughout	1	
76-6	11793-11796	the	2	
76-7	11797-11802	trial	1	
76-8	11803-11805	by	2	
76-9	11806-11807	a	_	
76-10	11808-11817	certified	_	
76-11	11818-11825	monitor	1	
76-12	11826-11828	in	2	
76-13	11829-11833	each	_	
76-14	11834-11841	country	_	
76-15	11842-11843	.	1	

#Text=TOF-MS analysis was performed in positive mode after electrospray ionization .
77-1	11844-11850	TOF-MS	9	
77-2	11851-11859	analysis	1	
77-3	11860-11863	was	8	
77-4	11864-11873	performed	_	
77-5	11874-11876	in	1	
77-6	11877-11885	positive	2	
77-7	11886-11890	mode	1	
77-8	11891-11896	after	2	
77-9	11897-11909	electrospray	_	
77-10	11910-11920	ionization	_	
77-11	11921-11922	.	1	

#Text=Participants who were lost to follow-up after completing the intervention had worse outcomes than those who remained in the study , thus invalidating the missing-completely-at-random assumption required for complete-case analysis .
78-1	11923-11935	Participants	9	
78-2	11936-11939	who	6	
78-3	11940-11944	were	3	
78-4	11945-11949	lost	_	
78-5	11950-11952	to	_	
78-6	11953-11962	follow-up	_	
78-7	11963-11968	after	_	
78-8	11969-11979	completing	1	
78-9	11980-11983	the	2	
78-10	11984-11996	intervention	1	
78-11	11997-12000	had	8	
78-12	12001-12006	worse	2	
78-13	12007-12015	outcomes	1	
78-14	12016-12020	than	6	
78-15	12021-12026	those	3	
78-16	12027-12030	who	_	
78-17	12031-12039	remained	1	
78-18	12040-12042	in	2	
78-19	12043-12046	the	_	
78-20	12047-12052	study	_	
78-21	12053-12054	,	1	
78-22	12055-12059	thus	6	
78-23	12060-12072	invalidating	3	
78-24	12073-12076	the	2	
78-25	12077-12105	missing-completely-at-random	_	
78-26	12106-12116	assumption	1	
78-27	12117-12125	required	3	
78-28	12126-12129	for	2	
78-29	12130-12143	complete-case	_	
78-30	12144-12152	analysis	_	
78-31	12153-12154	.	1	

#Text=Pseudorandom numbers were generated in advance by the statistician ( C.S. ) using the R statistical package ( 20 ) .
79-1	12155-12167	Pseudorandom	9	
79-2	12168-12175	numbers	1	
79-3	12176-12180	were	8	
79-4	12181-12190	generated	_	
79-5	12191-12193	in	_	
79-6	12194-12201	advance	_	
79-7	12202-12204	by	1	
79-8	12205-12208	the	2	
79-9	12209-12221	statistician	1	
79-10	12222-12223	(	5	
79-11	12224-12227	C.S	_	
79-12	12227-12228	.	_	
79-13	12229-12230	)	1	
79-14	12231-12236	using	3	
79-15	12237-12240	the	2	
79-16	12241-12242	R	_	
79-17	12243-12254	statistical	_	
79-18	12255-12262	package	1	
79-19	12263-12264	(	2	
79-20	12265-12267	20	_	
79-21	12268-12269	)	_	
79-22	12270-12271	.	1	

#Text=Patients received a single dose of preoperative antibiotic prophylaxis according to the local hospital protocol .
80-1	12272-12280	Patients	9	
80-2	12281-12289	received	8	
80-3	12290-12291	a	2	
80-4	12292-12298	single	_	
80-5	12299-12303	dose	_	
80-6	12304-12306	of	_	
80-7	12307-12319	preoperative	_	
80-8	12320-12330	antibiotic	_	
80-9	12331-12342	prophylaxis	1	
80-10	12343-12352	according	2	
80-11	12353-12355	to	_	
80-12	12356-12359	the	_	
80-13	12360-12365	local	_	
80-14	12366-12374	hospital	_	
80-15	12375-12383	protocol	_	
80-16	12384-12385	.	1	

#Text=This design allowed for assessment of instructor-level effects .
81-1	12386-12390	This	9	
81-2	12391-12397	design	1	
81-3	12398-12405	allowed	8	
81-4	12406-12409	for	2	
81-5	12410-12420	assessment	_	
81-6	12421-12423	of	_	
81-7	12424-12440	instructor-level	_	
81-8	12441-12448	effects	_	
81-9	12449-12450	.	1	

#Text=Neurointerventionalists were preapproved to participate on the basis of training and experience .
82-1	12451-12474	Neurointerventionalists	9	
82-2	12475-12479	were	8	
82-3	12480-12491	preapproved	_	
82-4	12492-12494	to	_	
82-5	12495-12506	participate	1	
82-6	12507-12509	on	2	
82-7	12510-12513	the	_	
82-8	12514-12519	basis	_	
82-9	12520-12522	of	_	
82-10	12523-12531	training	_	
82-11	12532-12535	and	_	
82-12	12536-12546	experience	_	
82-13	12547-12548	.	1	

#Text=We monitored study participants for adverse events during each encounter .
83-1	12549-12551	We	8	
83-2	12552-12561	monitored	1	
83-3	12562-12567	study	2	
83-4	12568-12580	participants	1	
83-5	12581-12584	for	2	
83-6	12585-12592	adverse	_	
83-7	12593-12599	events	_	
83-8	12600-12606	during	_	
83-9	12607-12611	each	_	
83-10	12612-12621	encounter	_	
83-11	12622-12623	.	1	

#Text=The authors are solely responsible for the content of the manuscript and the decision to submit it for publication .
84-1	12624-12627	The	9	
84-2	12628-12635	authors	1	
84-3	12636-12639	are	8	
84-4	12640-12646	solely	7	
84-5	12647-12658	responsible	_	
84-6	12659-12662	for	1	
84-7	12663-12666	the	2	
84-8	12667-12674	content	_	
84-9	12675-12677	of	_	
84-10	12678-12681	the	_	
84-11	12682-12692	manuscript	1	
84-12	12693-12696	and	2	
84-13	12697-12700	the	_	
84-14	12701-12709	decision	_	
84-15	12710-12712	to	_	
84-16	12713-12719	submit	_	
84-17	12720-12722	it	_	
84-18	12723-12726	for	_	
84-19	12727-12738	publication	_	
84-20	12739-12740	.	1	

#Text=We planned for this trial to use an adaptive enrichment design.
85-1	12741-12743	We	8	
85-2	12744-12751	planned	_	
85-3	12752-12755	for	1	
85-4	12756-12760	this	2	
85-5	12761-12766	trial	1	
85-6	12767-12769	to	3	
85-7	12770-12773	use	1	
85-8	12774-12776	an	2	
85-9	12777-12785	adaptive	_	
85-10	12786-12796	enrichment	_	
85-11	12797-12803	design	_	
85-12	12803-12804	.	1	

#Text=The alternative hypothesis was that ibuprofen would be non-inferior regarding the proportion of patients feeling cured after 4 days by at most 10 % .
86-1	12805-12808	The	9	
86-2	12809-12820	alternative	_	
86-3	12821-12831	hypothesis	1	
86-4	12832-12835	was	8	
86-5	12836-12840	that	6	
86-6	12841-12850	ibuprofen	9	
86-7	12851-12856	would	3	
86-8	12857-12859	be	1	
86-9	12860-12872	non-inferior	7	
86-10	12873-12882	regarding	3	
86-11	12883-12886	the	2	
86-12	12887-12897	proportion	_	
86-13	12898-12900	of	_	
86-14	12901-12909	patients	_	
86-15	12910-12917	feeling	_	
86-16	12918-12923	cured	_	
86-17	12924-12929	after	_	
86-18	12930-12931	4	_	
86-19	12932-12936	days	_	
86-20	12937-12939	by	_	
86-21	12940-12942	at	_	
86-22	12943-12947	most	_	
86-23	12948-12950	10	_	
86-24	12951-12952	%	_	
86-25	12953-12954	.	1	

#Text=The coprimary effectiveness end points were the difference in mean improvement from baseline in EI-assessed NLFSS scores for VYC-17.5L versus control at Month 6 , and the observed responder rate for VYC-17.5L at Month 6 , defined as the proportion of subjects with at least a 1-point improvement from baseline on the NLFSS .
87-1	12955-12958	The	9	
87-2	12959-12968	coprimary	_	
87-3	12969-12982	effectiveness	_	
87-4	12983-12986	end	_	
87-5	12987-12993	points	1	
87-6	12994-12998	were	8	
87-7	12999-13002	the	2	
87-8	13003-13013	difference	_	
87-9	13014-13016	in	_	
87-10	13017-13021	mean	_	
87-11	13022-13033	improvement	_	
87-12	13034-13038	from	_	
87-13	13039-13047	baseline	_	
87-14	13048-13050	in	_	
87-15	13051-13062	EI-assessed	_	
87-16	13063-13068	NLFSS	_	
87-17	13069-13075	scores	_	
87-18	13076-13079	for	_	
87-19	13080-13083	VYC	_	
87-20	13083-13084	-	_	
87-21	13084-13089	17.5L	_	
87-22	13090-13096	versus	_	
87-23	13097-13104	control	_	
87-24	13105-13107	at	_	
87-25	13108-13113	Month	_	
87-26	13114-13115	6	_	
87-27	13116-13117	,	1	
87-28	13118-13121	and	2	
87-29	13122-13125	the	_	
87-30	13126-13134	observed	_	
87-31	13135-13144	responder	_	
87-32	13145-13149	rate	_	
87-33	13150-13153	for	_	
87-34	13154-13157	VYC	_	
87-35	13157-13158	-	_	
87-36	13158-13163	17.5L	_	
87-37	13164-13166	at	_	
87-38	13167-13172	Month	_	
87-39	13173-13174	6	_	
87-40	13175-13176	,	1	
87-41	13177-13184	defined	3	
87-42	13185-13187	as	1	
87-43	13188-13191	the	2	
87-44	13192-13202	proportion	_	
87-45	13203-13205	of	_	
87-46	13206-13214	subjects	_	
87-47	13215-13219	with	_	
87-48	13220-13222	at	_	
87-49	13223-13228	least	_	
87-50	13229-13230	a	_	
87-51	13231-13232	1	_	
87-52	13232-13233	-	_	
87-53	13233-13238	point	_	
87-54	13239-13250	improvement	_	
87-55	13251-13255	from	_	
87-56	13256-13264	baseline	_	
87-57	13265-13267	on	_	
87-58	13268-13271	the	_	
87-59	13272-13277	NLFSS	_	
87-60	13278-13279	.	1	

#Text=We used 2-sided tests at a significance level of 0.05 for all primary efficacy and interaction analyses .
88-1	13280-13282	We	8	
88-2	13283-13287	used	1	
88-3	13288-13289	2	2	
88-4	13289-13290	-	_	
88-5	13290-13295	sided	_	
88-6	13296-13301	tests	1	
88-7	13302-13304	at	2	
88-8	13305-13306	a	_	
88-9	13307-13319	significance	_	
88-10	13320-13325	level	_	
88-11	13326-13328	of	_	
88-12	13329-13333	0.05	1	
88-13	13334-13337	for	2	
88-14	13338-13341	all	_	
88-15	13342-13349	primary	_	
88-16	13350-13358	efficacy	_	
88-17	13359-13362	and	_	
88-18	13363-13374	interaction	_	
88-19	13375-13383	analyses	_	
88-20	13384-13385	.	1	

#Text=Randomization was stratified according to age , core infarct volume , time from symptom onset to enrollment , baseline score on the National Institutes of Health Stroke Scale ( NIHSS ; range , 0 to 42 , with higher scores indicating a greater deficit ) , and trial site .
89-1	13386-13399	Randomization	9	
89-2	13400-13403	was	8	
89-3	13404-13414	stratified	_	
89-4	13415-13424	according	_	
89-5	13425-13427	to	1	
89-6	13428-13431	age	2	
89-7	13432-13433	,	_	
89-8	13434-13438	core	_	
89-9	13439-13446	infarct	_	
89-10	13447-13453	volume	_	
89-11	13454-13455	,	_	
89-12	13456-13460	time	_	
89-13	13461-13465	from	_	
89-14	13466-13473	symptom	_	
89-15	13474-13479	onset	_	
89-16	13480-13482	to	_	
89-17	13483-13493	enrollment	_	
89-18	13494-13495	,	_	
89-19	13496-13504	baseline	_	
89-20	13505-13510	score	_	
89-21	13511-13513	on	_	
89-22	13514-13517	the	_	
89-23	13518-13526	National	_	
89-24	13527-13537	Institutes	_	
89-25	13538-13540	of	_	
89-26	13541-13547	Health	_	
89-27	13548-13554	Stroke	_	
89-28	13555-13560	Scale	_	
89-29	13561-13562	(	5	
89-30	13563-13568	NIHSS	_	
89-31	13569-13570	;	_	
89-32	13571-13576	range	_	
89-33	13577-13578	,	_	
89-34	13579-13580	0	_	
89-35	13581-13583	to	_	
89-36	13584-13586	42	_	
89-37	13587-13588	,	_	
89-38	13589-13593	with	_	
89-39	13594-13600	higher	_	
89-40	13601-13607	scores	_	
89-41	13608-13618	indicating	_	
89-42	13619-13620	a	_	
89-43	13621-13628	greater	_	
89-44	13629-13636	deficit	_	
89-45	13637-13638	)	1	
89-46	13639-13640	,	_	
89-47	13641-13644	and	_	
89-48	13645-13650	trial	_	
89-49	13651-13655	site	_	
89-50	13656-13657	.	1	

#Text=LPC 16:0 was used for LPCs with > 14 and < 17 carbons in the FA side chains .
90-1	13658-13661	LPC	9	
90-2	13662-13664	16	_	
90-3	13664-13665	:	_	
90-4	13665-13666	0	1	
90-5	13667-13670	was	8	
90-6	13671-13675	used	_	
90-7	13676-13679	for	1	
90-8	13680-13684	LPCs	2	
90-9	13685-13689	with	_	
90-10	13690-13691	>	_	
90-11	13692-13694	14	_	
90-12	13695-13698	and	_	
90-13	13699-13700	<	_	
90-14	13701-13703	17	_	
90-15	13704-13711	carbons	_	
90-16	13712-13714	in	_	
90-17	13715-13718	the	_	
90-18	13719-13721	FA	_	
90-19	13722-13726	side	_	
90-20	13727-13733	chains	_	
90-21	13734-13735	.	1	

#Text=Multiple primary outcomes were selected to ensure that both self-reported and performance-based measurements were included , since these outcomes reflect unique elements of OA disease [ 27–29 ] .
91-1	13736-13744	Multiple	9	
91-2	13745-13752	primary	_	
91-3	13753-13761	outcomes	1	
91-4	13762-13766	were	8	
91-5	13767-13775	selected	_	
91-6	13776-13778	to	_	
91-7	13779-13785	ensure	1	
91-8	13786-13790	that	6	
91-9	13791-13795	both	9	
91-10	13796-13809	self-reported	_	
91-11	13810-13813	and	_	
91-12	13814-13831	performance-based	_	
91-13	13832-13844	measurements	1	
91-14	13845-13849	were	3	
91-15	13850-13858	included	_	
91-16	13859-13860	,	1	
91-17	13861-13866	since	6	
91-18	13867-13872	these	9	
91-19	13873-13881	outcomes	1	
91-20	13882-13889	reflect	3	
91-21	13890-13896	unique	2	
91-22	13897-13905	elements	_	
91-23	13906-13908	of	_	
91-24	13909-13911	OA	_	
91-25	13912-13919	disease	1	
91-26	13920-13921	[	5	
91-27	13922-13924	27	_	
91-28	13924-13925	–	_	
91-29	13925-13927	29	_	
91-30	13928-13929	]	_	
91-31	13930-13931	.	1	

#Text=The supplementary appendix provides details on cost calculation .
92-1	13932-13935	The	9	
92-2	13936-13949	supplementary	_	
92-3	13950-13958	appendix	1	
92-4	13959-13967	provides	8	
92-5	13968-13975	details	2	
92-6	13976-13978	on	_	
92-7	13979-13983	cost	_	
92-8	13984-13995	calculation	_	
92-9	13996-13997	.	1	

#Text=We did not impute missing outcomes for continuous and time to event endpoints .
93-1	13998-14000	We	8	
93-2	14001-14004	did	_	
93-3	14005-14008	not	_	
93-4	14009-14015	impute	1	
93-5	14016-14023	missing	2	
93-6	14024-14032	outcomes	_	
93-7	14033-14036	for	_	
93-8	14037-14047	continuous	_	
93-9	14048-14051	and	_	
93-10	14052-14056	time	_	
93-11	14057-14059	to	_	
93-12	14060-14065	event	_	
93-13	14066-14075	endpoints	_	
93-14	14076-14077	.	1	

#Text=All outcomes were measured before and immediately after the 12-week intervention and led by the same blinded assessor .
94-1	14078-14081	All	9	
94-2	14082-14090	outcomes	1	
94-3	14091-14095	were	8	
94-4	14096-14104	measured	_	
94-5	14105-14111	before	_	
94-6	14112-14115	and	_	
94-7	14116-14127	immediately	_	
94-8	14128-14133	after	1	
94-9	14134-14137	the	2	
94-10	14138-14140	12	_	
94-11	14140-14141	-	_	
94-12	14141-14145	week	_	
94-13	14146-14158	intervention	1	
94-14	14159-14162	and	3	
94-15	14163-14166	led	_	
94-16	14167-14169	by	1	
94-17	14170-14173	the	_	
94-18	14174-14178	same	2	
94-19	14179-14186	blinded	_	
94-20	14187-14195	assessor	_	
94-21	14196-14197	.	1	

#Text=Quality control ( QC ) samples were prepared from a pool of sera .
95-1	14198-14205	Quality	9	
95-2	14206-14213	control	_	
95-3	14214-14215	(	5	
95-4	14216-14218	QC	_	
95-5	14219-14220	)	1	
95-6	14221-14228	samples	1	
95-7	14229-14233	were	8	
95-8	14234-14242	prepared	_	
95-9	14243-14247	from	1	
95-10	14248-14249	a	2	
95-11	14250-14254	pool	_	
95-12	14255-14257	of	_	
95-13	14258-14262	sera	_	
95-14	14263-14264	.	1	

#Text=The protocol was approved by the institutional review board of each participating centre .
96-1	14265-14268	The	9	
96-2	14269-14277	protocol	1	
96-3	14278-14281	was	8	
96-4	14282-14290	approved	_	
96-5	14291-14293	by	1	
96-6	14294-14297	the	2	
96-7	14298-14311	institutional	_	
96-8	14312-14318	review	_	
96-9	14319-14324	board	_	
96-10	14325-14327	of	_	
96-11	14328-14332	each	_	
96-12	14333-14346	participating	_	
96-13	14347-14353	centre	_	
96-14	14354-14355	.	1	

#Text=Additionally , to evaluate clinical significance , outcomes were interpreted relative to the minimal clinically important differences ( MCID ) and patient acceptable symptoms states ( PASS ) .
97-1	14356-14368	Additionally	6	
97-2	14369-14370	,	1	
97-3	14371-14373	to	3	
97-4	14374-14382	evaluate	1	
97-5	14383-14391	clinical	2	
97-6	14392-14404	significance	_	
97-7	14405-14406	,	1	
97-8	14407-14415	outcomes	9	
97-9	14416-14420	were	8	
97-10	14421-14432	interpreted	_	
97-11	14433-14441	relative	_	
97-12	14442-14444	to	1	
97-13	14445-14448	the	2	
97-14	14449-14456	minimal	_	
97-15	14457-14467	clinically	_	
97-16	14468-14477	important	_	
97-17	14478-14489	differences	1	
97-18	14490-14491	(	5	
97-19	14492-14496	MCID	_	
97-20	14497-14498	)	1	
97-21	14499-14502	and	2	
97-22	14503-14510	patient	_	
97-23	14511-14521	acceptable	_	
97-24	14522-14530	symptoms	_	
97-25	14531-14537	states	1	
97-26	14538-14539	(	5	
97-27	14540-14544	PASS	_	
97-28	14545-14546	)	_	
97-29	14547-14548	.	1	

#Text=If a patient experienced getting worse or not getting better , she was instructed to contact either the study doctor for advice or the study site for a second medical consultation .
98-1	14549-14551	If	6	
98-2	14552-14553	a	9	
98-3	14554-14561	patient	1	
98-4	14562-14573	experienced	3	
98-5	14574-14581	getting	1	
98-6	14582-14587	worse	7	
98-7	14588-14590	or	_	
98-8	14591-14594	not	_	
98-9	14595-14602	getting	_	
98-10	14603-14609	better	_	
98-11	14610-14611	,	1	
98-12	14612-14615	she	8	
98-13	14616-14619	was	_	
98-14	14620-14630	instructed	_	
98-15	14631-14633	to	_	
98-16	14634-14641	contact	1	
98-17	14642-14648	either	6	
98-18	14649-14652	the	2	
98-19	14653-14658	study	_	
98-20	14659-14665	doctor	1	
98-21	14666-14669	for	2	
98-22	14670-14676	advice	1	
98-23	14677-14679	or	2	
98-24	14680-14683	the	_	
98-25	14684-14689	study	_	
98-26	14690-14694	site	1	
98-27	14695-14698	for	2	
98-28	14699-14700	a	_	
98-29	14701-14707	second	_	
98-30	14708-14715	medical	_	
98-31	14716-14728	consultation	_	
98-32	14729-14730	.	1	

#Text=Patients who received prolonged non-steroidal anti-inflammatory drug therapy in the year preceding this study were also excluded .
99-1	14731-14739	Patients	9	
99-2	14740-14743	who	6	
99-3	14744-14752	received	3	
99-4	14753-14762	prolonged	2	
99-5	14763-14776	non-steroidal	_	
99-6	14777-14794	anti-inflammatory	_	
99-7	14795-14799	drug	_	
99-8	14800-14807	therapy	1	
99-9	14808-14810	in	2	
99-10	14811-14814	the	_	
99-11	14815-14819	year	_	
99-12	14820-14829	preceding	_	
99-13	14830-14834	this	_	
99-14	14835-14840	study	1	
99-15	14841-14845	were	8	
99-16	14846-14850	also	_	
99-17	14851-14859	excluded	_	
99-18	14860-14861	.	1	

#Text=Before enrollment , the supervising physical therapist ( M.I. ) trained the 3 physical therapists .
100-1	14862-14868	Before	2	
100-2	14869-14879	enrollment	_	
100-3	14880-14881	,	1	
100-4	14882-14885	the	9	
100-5	14886-14897	supervising	_	
100-6	14898-14906	physical	_	
100-7	14907-14916	therapist	1	
100-8	14917-14918	(	5	
100-9	14919-14922	M.I	_	
100-10	14922-14923	.	_	
100-11	14924-14925	)	1	
100-12	14926-14933	trained	8	
100-13	14934-14937	the	2	
100-14	14938-14939	3	_	
100-15	14940-14948	physical	_	
100-16	14949-14959	therapists	_	
100-17	14960-14961	.	1	

#Text=Calibration curves for the quantification of LPC species were produced , see the S1 Fig.
101-1	14962-14973	Calibration	9	
101-2	14974-14980	curves	_	
101-3	14981-14984	for	_	
101-4	14985-14988	the	_	
101-5	14989-15003	quantification	_	
101-6	15004-15006	of	_	
101-7	15007-15010	LPC	_	
101-8	15011-15018	species	1	
101-9	15019-15023	were	8	
101-10	15024-15032	produced	_	
101-11	15033-15034	,	1	
101-12	15035-15038	see	3	
101-13	15039-15042	the	2	
101-14	15043-15045	S1	_	
101-15	15046-15049	Fig	_	
101-16	15049-15050	.	1	

#Text=The calibration was done using duplicates at 0 , 0.5 , 1.0 , 5.0 , 10 , 50 , 100 , 200 , and 300 μM ( only for LPC 16:0 ) .
102-1	15051-15054	The	9	
102-2	15055-15066	calibration	1	
102-3	15067-15070	was	8	
102-4	15071-15075	done	_	
102-5	15076-15081	using	1	
102-6	15082-15092	duplicates	2	
102-7	15093-15095	at	2	
102-8	15096-15097	0	_	
102-9	15098-15099	,	_	
102-10	15100-15103	0.5	_	
102-11	15104-15105	,	_	
102-12	15106-15109	1.0	_	
102-13	15110-15111	,	_	
102-14	15112-15115	5.0	_	
102-15	15116-15117	,	_	
102-16	15118-15120	10	_	
102-17	15121-15122	,	_	
102-18	15123-15125	50	_	
102-19	15126-15127	,	_	
102-20	15128-15131	100	_	
102-21	15132-15133	,	_	
102-22	15134-15137	200	_	
102-23	15138-15139	,	_	
102-24	15140-15143	and	_	
102-25	15144-15147	300	_	
102-26	15148-15150	μM	1	
102-27	15151-15152	(	5	
102-28	15153-15157	only	_	
102-29	15158-15161	for	_	
102-30	15162-15165	LPC	_	
102-31	15166-15168	16	_	
102-32	15168-15169	:	_	
102-33	15169-15170	0	_	
102-34	15171-15172	)	_	
102-35	15173-15174	.	1	

#Text=All outcomes are similar to outcomes chosen in previous studies demonstrating efficacy of antibiotic treatment for uncomplicated UTI [ 12,14,21 ] .
103-1	15175-15178	All	9	
103-2	15179-15187	outcomes	1	
103-3	15188-15191	are	8	
103-4	15192-15199	similar	_	
103-5	15200-15202	to	1	
103-6	15203-15211	outcomes	2	
103-7	15212-15218	chosen	_	
103-8	15219-15221	in	_	
103-9	15222-15230	previous	_	
103-10	15231-15238	studies	1	
103-11	15239-15252	demonstrating	3	
103-12	15253-15261	efficacy	2	
103-13	15262-15264	of	_	
103-14	15265-15275	antibiotic	_	
103-15	15276-15285	treatment	_	
103-16	15286-15289	for	_	
103-17	15290-15303	uncomplicated	_	
103-18	15304-15307	UTI	1	
103-19	15308-15309	[	5	
103-20	15310-15318	12,14,21	_	
103-21	15319-15320	]	_	
103-22	15321-15322	.	1	

#Text=The primary and secondary dichotomous endpoints were analyzed using logistic regression ( single measurement ) or mixed effects logistic regression ( repeated measurements ) with treatment as a fixed effect , adjusted for randomization stratum ( center in Norway , country otherwise ) .
104-1	15323-15326	The	9	
104-2	15327-15334	primary	_	
104-3	15335-15338	and	_	
104-4	15339-15348	secondary	_	
104-5	15349-15360	dichotomous	_	
104-6	15361-15370	endpoints	1	
104-7	15371-15375	were	8	
104-8	15376-15384	analyzed	_	
104-9	15385-15390	using	1	
104-10	15391-15399	logistic	2	
104-11	15400-15410	regression	1	
104-12	15411-15412	(	5	
104-13	15413-15419	single	_	
104-14	15420-15431	measurement	_	
104-15	15432-15433	)	1	
104-16	15434-15436	or	2	
104-17	15437-15442	mixed	_	
104-18	15443-15450	effects	_	
104-19	15451-15459	logistic	_	
104-20	15460-15470	regression	1	
104-21	15471-15472	(	5	
104-22	15473-15481	repeated	_	
104-23	15482-15494	measurements	_	
104-24	15495-15496	)	1	
104-25	15497-15501	with	2	
104-26	15502-15511	treatment	_	
104-27	15512-15514	as	_	
104-28	15515-15516	a	_	
104-29	15517-15522	fixed	_	
104-30	15523-15529	effect	_	
104-31	15530-15531	,	1	
104-32	15532-15540	adjusted	3	
104-33	15541-15544	for	1	
104-34	15545-15558	randomization	2	
104-35	15559-15566	stratum	1	
104-36	15567-15568	(	5	
104-37	15569-15575	center	_	
104-38	15576-15578	in	_	
104-39	15579-15585	Norway	_	
104-40	15586-15587	,	_	
104-41	15588-15595	country	_	
104-42	15596-15605	otherwise	_	
104-43	15606-15607	)	_	
104-44	15608-15609	.	1	

#Text=This study was designed to test Tai Chi for noninferiority and then for superiority if noninferiority was established with regard to the primary outcome ( change in WOMAC pain score at 12 weeks ) .
105-1	15610-15614	This	9	
105-2	15615-15620	study	1	
105-3	15621-15624	was	8	
105-4	15625-15633	designed	_	
105-5	15634-15636	to	_	
105-6	15637-15641	test	1	
105-7	15642-15645	Tai	2	
105-8	15646-15649	Chi	_	
105-9	15650-15653	for	_	
105-10	15654-15668	noninferiority	_	
105-11	15669-15672	and	_	
105-12	15673-15677	then	_	
105-13	15678-15681	for	_	
105-14	15682-15693	superiority	1	
105-15	15694-15696	if	6	
105-16	15697-15711	noninferiority	9	
105-17	15712-15715	was	3	
105-18	15716-15727	established	_	
105-19	15728-15732	with	_	
105-20	15733-15739	regard	_	
105-21	15740-15742	to	1	
105-22	15743-15746	the	2	
105-23	15747-15754	primary	_	
105-24	15755-15762	outcome	1	
105-25	15763-15764	(	5	
105-26	15765-15771	change	_	
105-27	15772-15774	in	_	
105-28	15775-15780	WOMAC	_	
105-29	15781-15785	pain	_	
105-30	15786-15791	score	_	
105-31	15792-15794	at	_	
105-32	15795-15797	12	_	
105-33	15798-15803	weeks	_	
105-34	15804-15805	)	_	
105-35	15806-15807	.	1	

#Text=The study was conducted from January 2003-May 2005 with the four validated otoscopists completing the symptom scoring instruments ( JC , SB , JH and MP ) .
106-1	15808-15811	The	9	
106-2	15812-15817	study	1	
106-3	15818-15821	was	8	
106-4	15822-15831	conducted	_	
106-5	15832-15836	from	1	
106-6	15837-15844	January	2	
106-7	15845-15849	2003	_	
106-8	15849-15850	-	_	
106-9	15850-15853	May	_	
106-10	15854-15858	2005	1	
106-11	15859-15863	with	2	
106-12	15864-15867	the	_	
106-13	15868-15872	four	_	
106-14	15873-15882	validated	_	
106-15	15883-15894	otoscopists	_	
106-16	15895-15905	completing	_	
106-17	15906-15909	the	_	
106-18	15910-15917	symptom	_	
106-19	15918-15925	scoring	_	
106-20	15926-15937	instruments	1	
106-21	15938-15939	(	5	
106-22	15940-15942	JC	_	
106-23	15943-15944	,	_	
106-24	15945-15947	SB	_	
106-25	15948-15949	,	_	
106-26	15950-15952	JH	_	
106-27	15953-15956	and	_	
106-28	15957-15959	MP	_	
106-29	15960-15961	)	_	
106-30	15962-15963	.	1	

#Text=They received a kit labeled with a study number ; the kits were retrieved in chronological order from a locked facility at each study site .
107-1	15964-15968	They	8	
107-2	15969-15977	received	1	
107-3	15978-15979	a	2	
107-4	15980-15983	kit	1	
107-5	15984-15991	labeled	3	
107-6	15992-15996	with	2	
107-7	15997-15998	a	_	
107-8	15999-16004	study	_	
107-9	16005-16011	number	1	
107-10	16012-16013	;	6	
107-11	16014-16017	the	9	
107-12	16018-16022	kits	1	
107-13	16023-16027	were	3	
107-14	16028-16037	retrieved	_	
107-15	16038-16040	in	1	
107-16	16041-16054	chronological	2	
107-17	16055-16060	order	1	
107-18	16061-16065	from	2	
107-19	16066-16067	a	_	
107-20	16068-16074	locked	_	
107-21	16075-16083	facility	_	
107-22	16084-16086	at	_	
107-23	16087-16091	each	_	
107-24	16092-16097	study	_	
107-25	16098-16102	site	_	
107-26	16103-16104	.	1	

#Text=Exercises included all major muscle groups of the lower extremity .
108-1	16105-16114	Exercises	9	
108-2	16115-16123	included	8	
108-3	16124-16127	all	2	
108-4	16128-16133	major	_	
108-5	16134-16140	muscle	_	
108-6	16141-16147	groups	_	
108-7	16148-16150	of	_	
108-8	16151-16154	the	_	
108-9	16155-16160	lower	_	
108-10	16161-16170	extremity	_	
108-11	16171-16172	.	1	

#Text=The accuracy and CV for LPC concentration standards were calculated after normalization to the IS .
109-1	16173-16176	The	9	
109-2	16177-16185	accuracy	_	
109-3	16186-16189	and	_	
109-4	16190-16192	CV	_	
109-5	16193-16196	for	_	
109-6	16197-16200	LPC	_	
109-7	16201-16214	concentration	_	
109-8	16215-16224	standards	1	
109-9	16225-16229	were	8	
109-10	16230-16240	calculated	_	
109-11	16241-16246	after	1	
109-12	16247-16260	normalization	2	
109-13	16261-16263	to	_	
109-14	16264-16267	the	_	
109-15	16268-16270	IS	_	
109-16	16271-16272	.	1	

#Text=All participants were required to have a score of 40 or greater on at least 1 of the 5 questions in the Western Ontario and McMaster Universities Osteoarthritis Index ( WOMAC ) pain subscale ( range of 0 to 100 , with higher scores indicating greater pain ) at baseline .
110-1	16273-16276	All	9	
110-2	16277-16289	participants	1	
110-3	16290-16294	were	8	
110-4	16295-16303	required	_	
110-5	16304-16306	to	_	
110-6	16307-16311	have	1	
110-7	16312-16313	a	2	
110-8	16314-16319	score	2	
110-9	16320-16322	of	_	
110-10	16323-16325	40	_	
110-11	16326-16328	or	_	
110-12	16329-16336	greater	_	
110-13	16337-16339	on	_	
110-14	16340-16342	at	_	
110-15	16343-16348	least	_	
110-16	16349-16350	1	_	
110-17	16351-16353	of	_	
110-18	16354-16357	the	_	
110-19	16358-16359	5	_	
110-20	16360-16369	questions	_	
110-21	16370-16372	in	_	
110-22	16373-16376	the	_	
110-23	16377-16384	Western	_	
110-24	16385-16392	Ontario	_	
110-25	16393-16396	and	_	
110-26	16397-16405	McMaster	_	
110-27	16406-16418	Universities	_	
110-28	16419-16433	Osteoarthritis	_	
110-29	16434-16439	Index	1	
110-30	16440-16441	(	5	
110-31	16442-16447	WOMAC	_	
110-32	16448-16449	)	1	
110-33	16450-16454	pain	2	
110-34	16455-16463	subscale	1	
110-35	16464-16465	(	5	
110-36	16466-16471	range	_	
110-37	16472-16474	of	_	
110-38	16475-16476	0	_	
110-39	16477-16479	to	_	
110-40	16480-16483	100	_	
110-41	16484-16485	,	_	
110-42	16486-16490	with	_	
110-43	16491-16497	higher	_	
110-44	16498-16504	scores	_	
110-45	16505-16515	indicating	_	
110-46	16516-16523	greater	_	
110-47	16524-16528	pain	_	
110-48	16529-16530	)	1	
110-49	16531-16533	at	2	
110-50	16534-16542	baseline	_	
110-51	16543-16544	.	1	

#Text=Otoscopic examination of the tympanic membrane was rated as improved by the investigator at the visit , with no evidence of fullness or bulging of the tympanic membrane ; presence of middle ear effusion was acceptable .
111-1	16545-16554	Otoscopic	9	
111-2	16555-16566	examination	_	
111-3	16567-16569	of	_	
111-4	16570-16573	the	_	
111-5	16574-16582	tympanic	_	
111-6	16583-16591	membrane	1	
111-7	16592-16595	was	8	
111-8	16596-16601	rated	_	
111-9	16602-16604	as	1	
111-10	16605-16613	improved	7	
111-11	16614-16616	by	2	
111-12	16617-16620	the	_	
111-13	16621-16633	investigator	1	
111-14	16634-16636	at	2	
111-15	16637-16640	the	_	
111-16	16641-16646	visit	_	
111-17	16647-16648	,	1	
111-18	16649-16653	with	2	
111-19	16654-16656	no	_	
111-20	16657-16665	evidence	_	
111-21	16666-16668	of	_	
111-22	16669-16677	fullness	_	
111-23	16678-16680	or	_	
111-24	16681-16688	bulging	_	
111-25	16689-16691	of	_	
111-26	16692-16695	the	_	
111-27	16696-16704	tympanic	_	
111-28	16705-16713	membrane	1	
111-29	16714-16715	;	6	
111-30	16716-16724	presence	9	
111-31	16725-16727	of	_	
111-32	16728-16734	middle	_	
111-33	16735-16738	ear	_	
111-34	16739-16747	effusion	1	
111-35	16748-16751	was	8	
111-36	16752-16762	acceptable	7	
111-37	16763-16764	.	1	

#Text=Adult subjects ( aged ≥18 years ) with 2 fully visible NLFs were eligible if they had severity scores of 2 ( moderate ) for both NLFs or scores of 3 ( severe ) for both NLFs on the validated , 5-point photonumeric NLF Severity Scale ( NLFSS ) as assessed by the EI , and agreed to refrain from treatment with other antiwrinkle/volumizing agents in facial regions below the orbital rim for the study duration .
112-1	16765-16770	Adult	9	
112-2	16771-16779	subjects	1	
112-3	16780-16781	(	5	
112-4	16782-16786	aged	_	
112-5	16787-16788	≥	_	
112-6	16788-16790	18	_	
112-7	16791-16796	years	_	
112-8	16797-16798	)	1	
112-9	16799-16803	with	2	
112-10	16804-16805	2	_	
112-11	16806-16811	fully	_	
112-12	16812-16819	visible	_	
112-13	16820-16824	NLFs	1	
112-14	16825-16829	were	8	
112-15	16830-16838	eligible	7	
112-16	16839-16841	if	6	
112-17	16842-16846	they	3	
112-18	16847-16850	had	1	
112-19	16851-16859	severity	2	
112-20	16860-16866	scores	_	
112-21	16867-16869	of	_	
112-22	16870-16871	2	1	
112-23	16872-16873	(	5	
112-24	16874-16882	moderate	_	
112-25	16883-16884	)	1	
112-26	16885-16888	for	2	
112-27	16889-16893	both	_	
112-28	16894-16898	NLFs	_	
112-29	16899-16901	or	_	
112-30	16902-16908	scores	_	
112-31	16909-16911	of	_	
112-32	16912-16913	3	1	
112-33	16914-16915	(	5	
112-34	16916-16922	severe	_	
112-35	16923-16924	)	1	
112-36	16925-16928	for	2	
112-37	16929-16933	both	_	
112-38	16934-16938	NLFs	_	
112-39	16939-16941	on	_	
112-40	16942-16945	the	_	
112-41	16946-16955	validated	_	
112-42	16956-16957	,	_	
112-43	16958-16959	5	_	
112-44	16959-16960	-	_	
112-45	16960-16965	point	_	
112-46	16966-16978	photonumeric	_	
112-47	16979-16982	NLF	_	
112-48	16983-16991	Severity	_	
112-49	16992-16997	Scale	1	
112-50	16998-16999	(	5	
112-51	17000-17005	NLFSS	_	
112-52	17006-17007	)	1	
112-53	17008-17010	as	3	
112-54	17011-17019	assessed	_	
112-55	17020-17022	by	1	
112-56	17023-17026	the	2	
112-57	17027-17029	EI	_	
112-58	17030-17031	,	1	
112-59	17032-17035	and	3	
112-60	17036-17042	agreed	_	
112-61	17043-17045	to	_	
112-62	17046-17053	refrain	_	
112-63	17054-17058	from	1	
112-64	17059-17068	treatment	2	
112-65	17069-17073	with	_	
112-66	17074-17079	other	_	
112-67	17080-17091	antiwrinkle	_	
112-68	17091-17092	/	_	
112-69	17092-17102	volumizing	_	
112-70	17103-17109	agents	_	
112-71	17110-17112	in	_	
112-72	17113-17119	facial	_	
112-73	17120-17127	regions	_	
112-74	17128-17133	below	_	
112-75	17134-17137	the	_	
112-76	17138-17145	orbital	_	
112-77	17146-17149	rim	1	
112-78	17150-17153	for	2	
112-79	17154-17157	the	_	
112-80	17158-17163	study	_	
112-81	17164-17172	duration	_	
112-82	17173-17174	.	1	

#Text=Paired ( two-tailed ) t-tests between pre and post intervention group means were also calculated to detect within-group differences .
113-1	17175-17181	Paired	7	
113-2	17182-17183	(	5	
113-3	17184-17194	two-tailed	_	
113-4	17195-17196	)	1	
113-5	17197-17204	t-tests	9	
113-6	17205-17212	between	_	
113-7	17213-17216	pre	_	
113-8	17217-17220	and	_	
113-9	17221-17225	post	_	
113-10	17226-17238	intervention	_	
113-11	17239-17244	group	_	
113-12	17245-17250	means	1	
113-13	17251-17255	were	8	
113-14	17256-17260	also	_	
113-15	17261-17271	calculated	_	
113-16	17272-17274	to	_	
113-17	17275-17281	detect	1	
113-18	17282-17294	within-group	2	
113-19	17295-17306	differences	_	
113-20	17307-17308	.	1	

#Text=Patients were assigned a unique randomization number generated by Accovion GmbH ( Eschborn , Germany ; now Clinipace Worldwide , Morrisville , North Carolina , USA ) using Rando ® and recorded by the investigator .
114-1	17309-17317	Patients	9	
114-2	17318-17322	were	8	
114-3	17323-17331	assigned	1	
114-4	17332-17333	a	2	
114-5	17334-17340	unique	_	
114-6	17341-17354	randomization	_	
114-7	17355-17361	number	1	
114-8	17362-17371	generated	3	
114-9	17372-17374	by	1	
114-10	17375-17383	Accovion	2	
114-11	17384-17388	GmbH	1	
114-12	17389-17390	(	5	
114-13	17391-17399	Eschborn	_	
114-14	17400-17401	,	_	
114-15	17402-17409	Germany	_	
114-16	17410-17411	;	_	
114-17	17412-17415	now	_	
114-18	17416-17425	Clinipace	_	
114-19	17426-17435	Worldwide	_	
114-20	17436-17437	,	_	
114-21	17438-17449	Morrisville	_	
114-22	17450-17451	,	_	
114-23	17452-17457	North	_	
114-24	17458-17466	Carolina	_	
114-25	17467-17468	,	_	
114-26	17469-17472	USA	_	
114-27	17473-17474	)	1	
114-28	17475-17480	using	3	
114-29	17481-17486	Rando	2	
114-30	17487-17488	®	1	
114-31	17489-17492	and	3	
114-32	17493-17501	recorded	_	
114-33	17502-17504	by	1	
114-34	17505-17508	the	2	
114-35	17509-17521	investigator	_	
114-36	17522-17523	.	1	

#Text=Study-specific guidance on IMV , weaning procedures based on the concept of lung-protective ventilation , and on antibiotic treatment according to the Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of CAP in adults was provided to minimize potential differences among sites and countries [ 18 , 20 ] .
115-1	17524-17538	Study-specific	9	
115-2	17539-17547	guidance	_	
115-3	17548-17550	on	_	
115-4	17551-17554	IMV	_	
115-5	17555-17556	,	_	
115-6	17557-17564	weaning	_	
115-7	17565-17575	procedures	_	
115-8	17576-17581	based	_	
115-9	17582-17584	on	_	
115-10	17585-17588	the	_	
115-11	17589-17596	concept	_	
115-12	17597-17599	of	_	
115-13	17600-17615	lung-protective	_	
115-14	17616-17627	ventilation	_	
115-15	17628-17629	,	1	
115-16	17630-17633	and	9	
115-17	17634-17636	on	_	
115-18	17637-17647	antibiotic	_	
115-19	17648-17657	treatment	_	
115-20	17658-17667	according	_	
115-21	17668-17670	to	_	
115-22	17671-17674	the	_	
115-23	17675-17685	Infectious	_	
115-24	17686-17694	Diseases	_	
115-25	17695-17702	Society	_	
115-26	17703-17705	of	_	
115-27	17706-17713	America	_	
115-28	17713-17714	/	_	
115-29	17714-17722	American	_	
115-30	17723-17731	Thoracic	_	
115-31	17732-17739	Society	_	
115-32	17740-17749	consensus	_	
115-33	17750-17760	guidelines	_	
115-34	17761-17763	on	_	
115-35	17764-17767	the	_	
115-36	17768-17778	management	_	
115-37	17779-17781	of	_	
115-38	17782-17785	CAP	_	
115-39	17786-17788	in	_	
115-40	17789-17795	adults	1	
115-41	17796-17799	was	8	
115-42	17800-17808	provided	_	
115-43	17809-17811	to	_	
115-44	17812-17820	minimize	1	
115-45	17821-17830	potential	2	
115-46	17831-17842	differences	_	
115-47	17843-17848	among	_	
115-48	17849-17854	sites	_	
115-49	17855-17858	and	_	
115-50	17859-17868	countries	1	
115-51	17869-17870	[	5	
115-52	17871-17873	18	_	
115-53	17874-17875	,	_	
115-54	17876-17878	20	_	
115-55	17879-17880	]	_	
115-56	17881-17882	.	1	

#Text=In the following example , SM 42:1:2 , the number 2 stands for two hydroxyl groups .
116-1	17883-17885	In	2	
116-2	17886-17889	the	_	
116-3	17890-17899	following	_	
116-4	17900-17907	example	1	
116-5	17908-17909	,	2	
116-6	17910-17912	SM	_	
116-7	17913-17915	42	_	
116-8	17915-17916	:	_	
116-9	17916-17917	1	_	
116-10	17917-17918	:	_	
116-11	17918-17919	2	_	
116-12	17920-17921	,	1	
116-13	17922-17925	the	9	
116-14	17926-17932	number	_	
116-15	17933-17934	2	1	
116-16	17935-17941	stands	8	
116-17	17942-17945	for	1	
116-18	17946-17949	two	2	
116-19	17950-17958	hydroxyl	_	
116-20	17959-17965	groups	_	
116-21	17966-17967	.	1	

#Text=If we did not have information from the diary , we used the number of days until cure reported by the patient during the telephone follow-up .
117-1	17968-17970	If	6	
117-2	17971-17973	we	3	
117-3	17974-17977	did	_	
117-4	17978-17981	not	_	
117-5	17982-17986	have	1	
117-6	17987-17998	information	2	
117-7	17999-18003	from	_	
117-8	18004-18007	the	_	
117-9	18008-18013	diary	_	
117-10	18014-18015	,	1	
117-11	18016-18018	we	8	
117-12	18019-18023	used	1	
117-13	18024-18027	the	2	
117-14	18028-18034	number	_	
117-15	18035-18037	of	_	
117-16	18038-18042	days	_	
117-17	18043-18048	until	_	
117-18	18049-18053	cure	1	
117-19	18054-18062	reported	3	
117-20	18063-18065	by	1	
117-21	18066-18069	the	2	
117-22	18070-18077	patient	1	
117-23	18078-18084	during	2	
117-24	18085-18088	the	_	
117-25	18089-18098	telephone	_	
117-26	18099-18108	follow-up	_	
117-27	18109-18110	.	1	

#Text=Antibiotic treatment was amox/clav HD ( dose 80 mg/Kg/day amoxicillin divided twice daily ) or cefdinir ( dose 14 mg/Kg/day divided twice daily ) .
118-1	18111-18121	Antibiotic	9	
118-2	18122-18131	treatment	1	
118-3	18132-18135	was	8	
118-4	18136-18140	amox	2	
118-5	18140-18141	/	_	
118-6	18141-18145	clav	_	
118-7	18146-18148	HD	1	
118-8	18149-18150	(	5	
118-9	18151-18155	dose	_	
118-10	18156-18158	80	_	
118-11	18159-18161	mg	_	
118-12	18161-18162	/	_	
118-13	18162-18164	Kg	_	
118-14	18164-18165	/	_	
118-15	18165-18168	day	_	
118-16	18169-18180	amoxicillin	_	
118-17	18181-18188	divided	_	
118-18	18189-18194	twice	_	
118-19	18195-18200	daily	_	
118-20	18201-18202	)	1	
118-21	18203-18205	or	2	
118-22	18206-18214	cefdinir	1	
118-23	18215-18216	(	5	
118-24	18217-18221	dose	_	
118-25	18222-18224	14	_	
118-26	18225-18227	mg	_	
118-27	18227-18228	/	_	
118-28	18228-18230	Kg	_	
118-29	18230-18231	/	_	
118-30	18231-18234	day	_	
118-31	18235-18242	divided	_	
118-32	18243-18248	twice	_	
118-33	18249-18254	daily	_	
118-34	18255-18256	)	_	
118-35	18257-18258	.	1	

#Text=The correction algorithm was constructed using the data obtained for the calibration curves of LPC 16:0 , 18:1 , 17:0 , and 12:0 .
119-1	18259-18262	The	9	
119-2	18263-18273	correction	_	
119-3	18274-18283	algorithm	1	
119-4	18284-18287	was	8	
119-5	18288-18299	constructed	_	
119-6	18300-18305	using	1	
119-7	18306-18309	the	2	
119-8	18310-18314	data	_	
119-9	18315-18323	obtained	_	
119-10	18324-18327	for	_	
119-11	18328-18331	the	_	
119-12	18332-18343	calibration	_	
119-13	18344-18350	curves	_	
119-14	18351-18353	of	_	
119-15	18354-18357	LPC	1	
119-16	18358-18360	16	_	
119-17	18360-18361	:	6	
119-18	18361-18362	0	2	
119-19	18363-18364	,	_	
119-20	18365-18367	18	_	
119-21	18367-18368	:	_	
119-22	18368-18369	1	_	
119-23	18370-18371	,	_	
119-24	18372-18374	17	_	
119-25	18374-18375	:	_	
119-26	18375-18376	0	_	
119-27	18377-18378	,	_	
119-28	18379-18382	and	_	
119-29	18383-18385	12	_	
119-30	18385-18386	:	_	
119-31	18386-18387	0	_	
119-32	18388-18389	.	1	

#Text=The mean CV per lipid class was < 13 % in all analyses , the data are displayed in the S2 Table .
120-1	18390-18393	The	9	
120-2	18394-18398	mean	_	
120-3	18399-18401	CV	_	
120-4	18402-18405	per	_	
120-5	18406-18411	lipid	_	
120-6	18412-18417	class	1	
120-7	18418-18421	was	8	
120-8	18422-18423	<	2	
120-9	18424-18426	13	_	
120-10	18427-18428	%	1	
120-11	18429-18431	in	2	
120-12	18432-18435	all	_	
120-13	18436-18444	analyses	_	
120-14	18445-18446	,	1	
120-15	18447-18450	the	9	
120-16	18451-18455	data	1	
120-17	18456-18459	are	3	
120-18	18460-18469	displayed	1	
120-19	18470-18472	in	2	
120-20	18473-18476	the	_	
120-21	18477-18479	S2	_	
120-22	18480-18485	Table	_	
120-23	18486-18487	.	1	

#Text=All three interventions were 12-weeks in duration .
121-1	18488-18491	All	9	
121-2	18492-18497	three	_	
121-3	18498-18511	interventions	1	
121-4	18512-18516	were	8	
121-5	18517-18519	12	2	
121-6	18519-18520	-	_	
121-7	18520-18525	weeks	_	
121-8	18526-18528	in	_	
121-9	18529-18537	duration	_	
121-10	18538-18539	.	1	

#Text=A central study coordinator carried out randomisation using an online module and permuted block randomisation with varying block sizes with a maximum block size of four patients .
122-1	18540-18541	A	9	
122-2	18542-18549	central	_	
122-3	18550-18555	study	_	
122-4	18556-18567	coordinator	1	
122-5	18568-18575	carried	8	
122-6	18576-18579	out	1	
122-7	18580-18593	randomisation	2	
122-8	18594-18599	using	3	
122-9	18600-18602	an	2	
122-10	18603-18609	online	_	
122-11	18610-18616	module	_	
122-12	18617-18620	and	_	
122-13	18621-18629	permuted	_	
122-14	18630-18635	block	_	
122-15	18636-18649	randomisation	_	
122-16	18650-18654	with	_	
122-17	18655-18662	varying	_	
122-18	18663-18668	block	_	
122-19	18669-18674	sizes	_	
122-20	18675-18679	with	_	
122-21	18680-18681	a	_	
122-22	18682-18689	maximum	_	
122-23	18690-18695	block	_	
122-24	18696-18700	size	_	
122-25	18701-18703	of	_	
122-26	18704-18708	four	_	
122-27	18709-18717	patients	_	
122-28	18718-18719	.	1	

#Text=They received a patient diary for recording daily symptoms and on which day they felt completely cured .
123-1	18720-18724	They	8	
123-2	18725-18733	received	1	
123-3	18734-18735	a	2	
123-4	18736-18743	patient	_	
123-5	18744-18749	diary	_	
123-6	18750-18753	for	_	
123-7	18754-18763	recording	_	
123-8	18764-18769	daily	_	
123-9	18770-18778	symptoms	1	
123-10	18779-18782	and	2	
123-11	18783-18785	on	_	
123-12	18786-18791	which	_	
123-13	18792-18795	day	1	
123-14	18796-18800	they	3	
123-15	18801-18805	felt	_	
123-16	18806-18816	completely	_	
123-17	18817-18822	cured	_	
123-18	18823-18824	.	1	

#Text=VFDs were evaluated using a one-sided Wilcoxon – Mann – Whitney test with an α level of 0.025 .
124-1	18825-18829	VFDs	9	
124-2	18830-18834	were	8	
124-3	18835-18844	evaluated	_	
124-4	18845-18850	using	1	
124-5	18851-18852	a	2	
124-6	18853-18862	one-sided	_	
124-7	18863-18871	Wilcoxon	_	
124-8	18872-18873	–	_	
124-9	18874-18878	Mann	_	
124-10	18879-18880	–	_	
124-11	18881-18888	Whitney	_	
124-12	18889-18893	test	_	
124-13	18894-18898	with	_	
124-14	18899-18901	an	_	
124-15	18902-18903	α	_	
124-16	18904-18909	level	_	
124-17	18910-18912	of	_	
124-18	18913-18918	0.025	_	
124-19	18919-18920	.	1	

#Text=Esoxx ® has been proposed for the treatment of the symptoms of gastroesophageal reflux disease and produces a persistent mucosal barrier , as shown by ex vivo studies performed in the swine model [ 34 ] .
125-1	18921-18926	Esoxx	9	
125-2	18927-18928	®	1	
125-3	18929-18932	has	8	
125-4	18933-18937	been	_	
125-5	18938-18946	proposed	_	
125-6	18947-18950	for	1	
125-7	18951-18954	the	2	
125-8	18955-18964	treatment	_	
125-9	18965-18967	of	_	
125-10	18968-18971	the	_	
125-11	18972-18980	symptoms	_	
125-12	18981-18983	of	_	
125-13	18984-19000	gastroesophageal	_	
125-14	19001-19007	reflux	_	
125-15	19008-19015	disease	1	
125-16	19016-19019	and	3	
125-17	19020-19028	produces	1	
125-18	19029-19030	a	2	
125-19	19031-19041	persistent	_	
125-20	19042-19049	mucosal	_	
125-21	19050-19057	barrier	_	
125-22	19058-19059	,	1	
125-23	19060-19062	as	3	
125-24	19063-19068	shown	_	
125-25	19069-19071	by	1	
125-26	19072-19074	ex	2	
125-27	19075-19079	vivo	_	
125-28	19080-19087	studies	1	
125-29	19088-19097	performed	3	
125-30	19098-19100	in	1	
125-31	19101-19104	the	2	
125-32	19105-19110	swine	_	
125-33	19111-19116	model	1	
125-34	19117-19118	[	5	
125-35	19119-19121	34	_	
125-36	19122-19123	]	_	
125-37	19124-19125	.	1	

#Text=Several sensitivity analyses were conducted to evaluate the effect of missing data , including multiple imputation and adjustment for variables that were found to differ among participants who missed visits .
126-1	19126-19133	Several	9	
126-2	19134-19145	sensitivity	_	
126-3	19146-19154	analyses	1	
126-4	19155-19159	were	8	
126-5	19160-19169	conducted	_	
126-6	19170-19172	to	_	
126-7	19173-19181	evaluate	1	
126-8	19182-19185	the	2	
126-9	19186-19192	effect	_	
126-10	19193-19195	of	_	
126-11	19196-19203	missing	_	
126-12	19204-19208	data	_	
126-13	19209-19210	,	1	
126-14	19211-19220	including	3	
126-15	19221-19229	multiple	2	
126-16	19230-19240	imputation	_	
126-17	19241-19244	and	_	
126-18	19245-19255	adjustment	_	
126-19	19256-19259	for	_	
126-20	19260-19269	variables	1	
126-21	19270-19274	that	3	
126-22	19275-19279	were	_	
126-23	19280-19285	found	_	
126-24	19286-19288	to	_	
126-25	19289-19295	differ	1	
126-26	19296-19301	among	2	
126-27	19302-19314	participants	_	
126-28	19315-19318	who	_	
126-29	19319-19325	missed	_	
126-30	19326-19332	visits	_	
126-31	19333-19334	.	1	

#Text=To investigate whether less food intake due to diminished appetite during acute infection influences phospholipid levels in serum , we enrolled 12 healthy subjects ( six males and six females ) for a fasting experiment .
127-1	19335-19337	To	1	
127-2	19338-19349	investigate	1	
127-3	19350-19357	whether	6	
127-4	19358-19362	less	2	
127-5	19363-19367	food	_	
127-6	19368-19374	intake	_	
127-7	19375-19378	due	_	
127-8	19379-19381	to	_	
127-9	19382-19392	diminished	_	
127-10	19393-19401	appetite	_	
127-11	19402-19408	during	_	
127-12	19409-19414	acute	_	
127-13	19415-19424	infection	1	
127-14	19425-19435	influences	3	
127-15	19436-19448	phospholipid	2	
127-16	19449-19455	levels	_	
127-17	19456-19458	in	_	
127-18	19459-19464	serum	_	
127-19	19465-19466	,	1	
127-20	19467-19469	we	8	
127-21	19470-19478	enrolled	1	
127-22	19479-19481	12	2	
127-23	19482-19489	healthy	_	
127-24	19490-19498	subjects	1	
127-25	19499-19500	(	5	
127-26	19501-19504	six	_	
127-27	19505-19510	males	_	
127-28	19511-19514	and	_	
127-29	19515-19518	six	_	
127-30	19519-19526	females	_	
127-31	19527-19528	)	1	
127-32	19529-19532	for	2	
127-33	19533-19534	a	_	
127-34	19535-19542	fasting	_	
127-35	19543-19553	experiment	_	
127-36	19554-19555	.	1	

#Text=Tai Chi and physical therapy ran concurrently to minimize seasonal influences on disease activity .
128-1	19556-19559	Tai	9	
128-2	19560-19563	Chi	1	
128-3	19564-19567	and	9	
128-4	19568-19576	physical	_	
128-5	19577-19584	therapy	1	
128-6	19585-19588	ran	8	
128-7	19589-19601	concurrently	_	
128-8	19602-19604	to	_	
128-9	19605-19613	minimize	1	
128-10	19614-19622	seasonal	2	
128-11	19623-19633	influences	_	
128-12	19634-19636	on	_	
128-13	19637-19644	disease	_	
128-14	19645-19653	activity	_	
128-15	19654-19655	.	1	

#Text=The procedures were performed by surgeons experienced in laparoscopic surgery , defined as performing more than 100 laparoscopic procedures yearly .
129-1	19656-19659	The	9	
129-2	19660-19670	procedures	1	
129-3	19671-19675	were	8	
129-4	19676-19685	performed	_	
129-5	19686-19688	by	1	
129-6	19689-19697	surgeons	2	
129-7	19698-19709	experienced	_	
129-8	19710-19712	in	_	
129-9	19713-19725	laparoscopic	_	
129-10	19726-19733	surgery	_	
129-11	19734-19735	,	1	
129-12	19736-19743	defined	3	
129-13	19744-19746	as	1	
129-14	19747-19757	performing	3	
129-15	19758-19762	more	2	
129-16	19763-19767	than	_	
129-17	19768-19771	100	_	
129-18	19772-19784	laparoscopic	_	
129-19	19785-19795	procedures	_	
129-20	19796-19802	yearly	_	
129-21	19803-19804	.	1	

#Text=The study was approved by the Tufts Health Sciences Institutional Review Board and overseen by an independent data and safety monitoring board .
130-1	19805-19808	The	9	
130-2	19809-19814	study	1	
130-3	19815-19818	was	8	
130-4	19819-19827	approved	_	
130-5	19828-19830	by	1	
130-6	19831-19834	the	2	
130-7	19835-19840	Tufts	_	
130-8	19841-19847	Health	_	
130-9	19848-19856	Sciences	_	
130-10	19857-19870	Institutional	_	
130-11	19871-19877	Review	_	
130-12	19878-19883	Board	1	
130-13	19884-19887	and	3	
130-14	19888-19896	overseen	_	
130-15	19897-19899	by	1	
130-16	19900-19902	an	2	
130-17	19903-19914	independent	_	
130-18	19915-19919	data	_	
130-19	19920-19923	and	_	
130-20	19924-19930	safety	_	
130-21	19931-19941	monitoring	_	
130-22	19942-19947	board	_	
130-23	19948-19949	.	1	

#Text=Patients that clinically were judged to require hospitalization due to a primary suspicion of CAP were eligible for inclusion if they gave written informed consent , were not pregnant , and were not immunocompromised .
131-1	19950-19958	Patients	9	
131-2	19959-19963	that	6	
131-3	19964-19974	clinically	3	
131-4	19975-19979	were	_	
131-5	19980-19986	judged	_	
131-6	19987-19989	to	_	
131-7	19990-19997	require	1	
131-8	19998-20013	hospitalization	2	
131-9	20014-20017	due	_	
131-10	20018-20020	to	_	
131-11	20021-20022	a	_	
131-12	20023-20030	primary	_	
131-13	20031-20040	suspicion	_	
131-14	20041-20043	of	_	
131-15	20044-20047	CAP	1	
131-16	20048-20052	were	8	
131-17	20053-20061	eligible	_	
131-18	20062-20065	for	1	
131-19	20066-20075	inclusion	1	
131-20	20076-20078	if	6	
131-21	20079-20083	they	3	
131-22	20084-20088	gave	1	
131-23	20089-20096	written	2	
131-24	20097-20105	informed	_	
131-25	20106-20113	consent	_	
131-26	20114-20115	,	1	
131-27	20116-20120	were	3	
131-28	20121-20124	not	7	
131-29	20125-20133	pregnant	_	
131-30	20134-20135	,	7	
131-31	20136-20139	and	3	
131-32	20140-20144	were	1	
131-33	20145-20148	not	7	
131-34	20149-20166	immunocompromised	_	
131-35	20167-20168	.	1	

#Text=The concept of “ Second Opinion Medical Consulting Network ” has been reviewed elsewhere [ 27–31 ] .
132-1	20169-20172	The	9	
132-2	20173-20180	concept	_	
132-3	20181-20183	of	_	
132-4	20184-20185	“	_	
132-5	20186-20192	Second	_	
132-6	20193-20200	Opinion	_	
132-7	20201-20208	Medical	_	
132-8	20209-20219	Consulting	_	
132-9	20220-20227	Network	_	
132-10	20228-20229	”	1	
132-11	20230-20233	has	8	
132-12	20234-20238	been	_	
132-13	20239-20247	reviewed	_	
132-14	20248-20257	elsewhere	1	
132-15	20258-20259	[	5	
132-16	20260-20262	27	_	
132-17	20262-20263	–	_	
132-18	20263-20265	31	_	
132-19	20266-20267	]	_	
132-20	20268-20269	.	1	

#Text=Thrombectomy was performed with any FDA-approved thrombectomy device , at the discretion of the neurointerventionalist .
133-1	20270-20282	Thrombectomy	9	
133-2	20283-20286	was	8	
133-3	20287-20296	performed	_	
133-4	20297-20301	with	1	
133-5	20302-20305	any	2	
133-6	20306-20318	FDA-approved	_	
133-7	20319-20331	thrombectomy	_	
133-8	20332-20338	device	_	
133-9	20339-20340	,	1	
133-10	20341-20343	at	2	
133-11	20344-20347	the	_	
133-12	20348-20358	discretion	_	
133-13	20359-20361	of	_	
133-14	20362-20365	the	_	
133-15	20366-20388	neurointerventionalist	_	
133-16	20389-20390	.	1	

#Text=Participants were not required to discontinue use of their pain medications before formal assessment visits .
134-1	20391-20403	Participants	9	
134-2	20404-20408	were	8	
134-3	20409-20412	not	_	
134-4	20413-20421	required	_	
134-5	20422-20424	to	_	
134-6	20425-20436	discontinue	1	
134-7	20437-20440	use	2	
134-8	20441-20443	of	_	
134-9	20444-20449	their	_	
134-10	20450-20454	pain	_	
134-11	20455-20466	medications	1	
134-12	20467-20473	before	2	
134-13	20474-20480	formal	_	
134-14	20481-20491	assessment	_	
134-15	20492-20498	visits	_	
134-16	20499-20500	.	1	

#Text=The study was conducted from January 2003-May 2005 and 4 of the authors were the clinical investigators who made the diagnosis of AOM on study entry and the determination of clinical outcome at TOC ( JC , SB , JH and MP ) .
135-1	20501-20504	The	9	
135-2	20505-20510	study	1	
135-3	20511-20514	was	8	
135-4	20515-20524	conducted	_	
135-5	20525-20529	from	1	
135-6	20530-20537	January	2	
135-7	20538-20542	2003	_	
135-8	20542-20543	-	_	
135-9	20543-20546	May	_	
135-10	20547-20551	2005	1	
135-11	20552-20555	and	2	
135-12	20556-20557	4	_	
135-13	20558-20560	of	_	
135-14	20561-20564	the	_	
135-15	20565-20572	authors	1	
135-16	20573-20577	were	3	
135-17	20578-20581	the	2	
135-18	20582-20590	clinical	_	
135-19	20591-20604	investigators	_	
135-20	20605-20608	who	_	
135-21	20609-20613	made	_	
135-22	20614-20617	the	_	
135-23	20618-20627	diagnosis	_	
135-24	20628-20630	of	_	
135-25	20631-20634	AOM	_	
135-26	20635-20637	on	_	
135-27	20638-20643	study	_	
135-28	20644-20649	entry	_	
135-29	20650-20653	and	_	
135-30	20654-20657	the	_	
135-31	20658-20671	determination	_	
135-32	20672-20674	of	_	
135-33	20675-20683	clinical	_	
135-34	20684-20691	outcome	_	
135-35	20692-20694	at	_	
135-36	20695-20698	TOC	1	
135-37	20699-20700	(	2	
135-38	20701-20703	JC	_	
135-39	20704-20705	,	_	
135-40	20706-20708	SB	_	
135-41	20709-20710	,	_	
135-42	20711-20713	JH	_	
135-43	20714-20717	and	_	
135-44	20718-20720	MP	_	
135-45	20721-20722	)	_	
135-46	20723-20724	.	1	

#Text=The study coordinator opened the consecutive envelopes individually after obtaining consent and confirming eligibility .
136-1	20725-20728	The	9	
136-2	20729-20734	study	_	
136-3	20735-20746	coordinator	1	
136-4	20747-20753	opened	8	
136-5	20754-20757	the	2	
136-6	20758-20769	consecutive	_	
136-7	20770-20779	envelopes	_	
136-8	20780-20792	individually	1	
136-9	20793-20798	after	3	
136-10	20799-20808	obtaining	1	
136-11	20809-20816	consent	2	
136-12	20817-20820	and	3	
136-13	20821-20831	confirming	1	
136-14	20832-20843	eligibility	2	
136-15	20844-20845	.	1	

#Text=There were 2 assessment visits when symptoms and signs were recorded : one at the time of diagnosis and a second at the TOC visit 12 - 15 days later .
137-1	20846-20851	There	8	
137-2	20852-20856	were	_	
137-3	20857-20858	2	_	
137-4	20859-20869	assessment	_	
137-5	20870-20876	visits	1	
137-6	20877-20881	when	6	
137-7	20882-20890	symptoms	9	
137-8	20891-20894	and	9	
137-9	20895-20900	signs	1	
137-10	20901-20905	were	3	
137-11	20906-20914	recorded	1	
137-12	20915-20916	:	6	
137-13	20917-20920	one	2	
137-14	20921-20923	at	_	
137-15	20924-20927	the	_	
137-16	20928-20932	time	_	
137-17	20933-20935	of	_	
137-18	20936-20945	diagnosis	1	
137-19	20946-20949	and	2	
137-20	20950-20951	a	_	
137-21	20952-20958	second	_	
137-22	20959-20961	at	_	
137-23	20962-20965	the	_	
137-24	20966-20969	TOC	_	
137-25	20970-20975	visit	_	
137-26	20976-20978	12	_	
137-27	20979-20980	-	_	
137-28	20981-20983	15	_	
137-29	20984-20988	days	_	
137-30	20989-20994	later	_	
137-31	20995-20996	.	1	

#Text=The group YE intervention was led by a certified , trained yoga instructor .
138-1	20997-21000	The	9	
138-2	21001-21006	group	_	
138-3	21007-21009	YE	_	
138-4	21010-21022	intervention	1	
138-5	21023-21026	was	8	
138-6	21027-21030	led	_	
138-7	21031-21033	by	1	
138-8	21034-21035	a	2	
138-9	21036-21045	certified	_	
138-10	21046-21047	,	_	
138-11	21048-21055	trained	_	
138-12	21056-21060	yoga	_	
138-13	21061-21071	instructor	_	
138-14	21072-21073	.	1	

#Text=This was based on the results of a Dutch retrospective cohort study and a systematic review analysing the safety and effectiveness of percutaneous drainage in elderly and critically ill patients.
139-1	21074-21078	This	8	
139-2	21079-21082	was	_	
139-3	21083-21088	based	_	
139-4	21089-21091	on	1	
139-5	21092-21095	the	2	
139-6	21096-21103	results	_	
139-7	21104-21106	of	_	
139-8	21107-21108	a	_	
139-9	21109-21114	Dutch	_	
139-10	21115-21128	retrospective	_	
139-11	21129-21135	cohort	_	
139-12	21136-21141	study	1	
139-13	21142-21145	and	2	
139-14	21146-21147	a	_	
139-15	21148-21158	systematic	_	
139-16	21159-21165	review	1	
139-17	21166-21175	analysing	3	
139-18	21176-21179	the	2	
139-19	21180-21186	safety	_	
139-20	21187-21190	and	_	
139-21	21191-21204	effectiveness	_	
139-22	21205-21207	of	_	
139-23	21208-21220	percutaneous	_	
139-24	21221-21229	drainage	_	
139-25	21230-21232	in	_	
139-26	21233-21240	elderly	_	
139-27	21241-21244	and	_	
139-28	21245-21255	critically	_	
139-29	21256-21259	ill	_	
139-30	21260-21268	patients	_	
139-31	21268-21269	.	1	

#Text=Attendance was monitored during each in-person session by using attendance forms and sign-in sheets .
140-1	21270-21280	Attendance	9	
140-2	21281-21284	was	8	
140-3	21285-21294	monitored	_	
140-4	21295-21301	during	1	
140-5	21302-21306	each	2	
140-6	21307-21316	in-person	_	
140-7	21317-21324	session	1	
140-8	21325-21327	by	3	
140-9	21328-21333	using	1	
140-10	21334-21344	attendance	2	
140-11	21345-21350	forms	2	
140-12	21351-21354	and	2	
140-13	21355-21362	sign-in	_	
140-14	21363-21369	sheets	_	
140-15	21370-21371	.	1	

#Text=We encouraged participants to maintain routine activities but refrain from new exercises outside the study .
141-1	21372-21374	We	8	
141-2	21375-21385	encouraged	1	
141-3	21386-21398	participants	2	
141-4	21399-21401	to	3	
141-5	21402-21410	maintain	1	
141-6	21411-21418	routine	2	
141-7	21419-21429	activities	1	
141-8	21430-21433	but	3	
141-9	21434-21441	refrain	_	
141-10	21442-21446	from	1	
141-11	21447-21450	new	2	
141-12	21451-21460	exercises	1	
141-13	21461-21468	outside	2	
141-14	21469-21472	the	_	
141-15	21473-21478	study	_	
141-16	21479-21480	.	1	

#Text=Assuming no difference between the treatment groups in the proportion of patients feeling cured after 4 days , we calculated that 316 patients ( 158 in each arm ) were required in the primary full analysis set ( FAS ) analyses to be 80 % confident that the 1-sided 95 % confidence limit would exclude a difference in favor of pivmecillinam of more than 10 % .
142-1	21481-21489	Assuming	3	
142-2	21490-21492	no	2	
142-3	21493-21503	difference	_	
142-4	21504-21511	between	_	
142-5	21512-21515	the	_	
142-6	21516-21525	treatment	_	
142-7	21526-21532	groups	_	
142-8	21533-21535	in	_	
142-9	21536-21539	the	_	
142-10	21540-21550	proportion	_	
142-11	21551-21553	of	_	
142-12	21554-21562	patients	_	
142-13	21563-21570	feeling	_	
142-14	21571-21576	cured	_	
142-15	21577-21582	after	_	
142-16	21583-21584	4	_	
142-17	21585-21589	days	_	
142-18	21590-21591	,	1	
142-19	21592-21594	we	8	
142-20	21595-21605	calculated	1	
142-21	21606-21610	that	6	
142-22	21611-21614	316	9	
142-23	21615-21623	patients	1	
142-24	21624-21625	(	5	
142-25	21626-21629	158	_	
142-26	21630-21632	in	_	
142-27	21633-21637	each	_	
142-28	21638-21641	arm	_	
142-29	21642-21643	)	1	
142-30	21644-21648	were	3	
142-31	21649-21657	required	1	
142-32	21658-21660	in	2	
142-33	21661-21664	the	_	
142-34	21665-21672	primary	_	
142-35	21673-21677	full	_	
142-36	21678-21686	analysis	_	
142-37	21687-21690	set	1	
142-38	21691-21692	(	5	
142-39	21693-21696	FAS	_	
142-40	21697-21698	)	1	
142-41	21699-21707	analyses	2	
142-42	21708-21710	to	3	
142-43	21711-21713	be	1	
142-44	21714-21716	80	7	
142-45	21717-21718	%	_	
142-46	21719-21728	confident	1	
142-47	21729-21733	that	6	
142-48	21734-21737	the	9	
142-49	21738-21739	1	_	
142-50	21739-21740	-	_	
142-51	21740-21745	sided	_	
142-52	21746-21748	95	_	
142-53	21749-21750	%	_	
142-54	21751-21761	confidence	_	
142-55	21762-21767	limit	7	
142-56	21768-21773	would	3	
142-57	21774-21781	exclude	1	
142-58	21782-21783	a	2	
142-59	21784-21794	difference	_	
142-60	21795-21797	in	_	
142-61	21798-21803	favor	_	
142-62	21804-21806	of	_	
142-63	21807-21820	pivmecillinam	_	
142-64	21821-21823	of	_	
142-65	21824-21828	more	_	
142-66	21829-21833	than	_	
142-67	21834-21836	10	_	
142-68	21837-21838	%	_	
142-69	21839-21840	.	1	

#Text=Participants were permitted to continue using routine medications , such as NSAIDs and acetaminophen , and maintain their usual physician visits throughout the study .
143-1	21841-21853	Participants	9	
143-2	21854-21858	were	8	
143-3	21859-21868	permitted	_	
143-4	21869-21871	to	_	
143-5	21872-21880	continue	_	
143-6	21881-21886	using	1	
143-7	21887-21894	routine	2	
143-8	21895-21906	medications	_	
143-9	21907-21908	,	1	
143-10	21909-21913	such	2	
143-11	21914-21916	as	_	
143-12	21917-21923	NSAIDs	_	
143-13	21924-21927	and	_	
143-14	21928-21941	acetaminophen	_	
143-15	21942-21943	,	1	
143-16	21944-21947	and	3	
143-17	21948-21956	maintain	1	
143-18	21957-21962	their	2	
143-19	21963-21968	usual	_	
143-20	21969-21978	physician	_	
143-21	21979-21985	visits	1	
143-22	21986-21996	throughout	2	
143-23	21997-22000	the	_	
143-24	22001-22006	study	_	
143-25	22007-22008	.	1	

#Text=For LPCs under < 5 μM ( 10 μM for LPC 18:1 ) , no correction was applied because no adduct could be measured for these concentrations .
144-1	22009-22012	For	2	
144-2	22013-22017	LPCs	_	
144-3	22018-22023	under	_	
144-4	22024-22025	<	_	
144-5	22026-22027	5	_	
144-6	22028-22030	μM	1	
144-7	22031-22032	(	5	
144-8	22033-22035	10	_	
144-9	22036-22038	μM	_	
144-10	22039-22042	for	_	
144-11	22043-22046	LPC	_	
144-12	22047-22049	18	_	
144-13	22049-22050	:	_	
144-14	22050-22051	1	_	
144-15	22052-22053	)	_	
144-16	22054-22055	,	1	
144-17	22056-22058	no	9	
144-18	22059-22069	correction	1	
144-19	22070-22073	was	8	
144-20	22074-22081	applied	1	
144-21	22082-22089	because	6	
144-22	22090-22092	no	9	
144-23	22093-22099	adduct	1	
144-24	22100-22105	could	3	
144-25	22106-22108	be	_	
144-26	22109-22117	measured	1	
144-27	22118-22121	for	2	
144-28	22122-22127	these	_	
144-29	22128-22142	concentrations	_	
144-30	22143-22144	.	1	

#Text=Standards were run in duplicates and samples as singles .
145-1	22145-22154	Standards	9	
145-2	22155-22159	were	8	
145-3	22160-22163	run	_	
145-4	22164-22166	in	1	
145-5	22167-22177	duplicates	2	
145-6	22178-22181	and	2	
145-7	22182-22189	samples	1	
145-8	22190-22192	as	2	
145-9	22193-22200	singles	_	
145-10	22201-22202	.	1	

#Text=The PASS values are those in which scores equal or above are deemed “ unacceptable ” to live with by individuals with OA [ 42 ] .
146-1	22203-22206	The	9	
146-2	22207-22211	PASS	_	
146-3	22212-22218	values	1	
146-4	22219-22222	are	8	
146-5	22223-22228	those	7	
146-6	22229-22231	in	6	
146-7	22232-22237	which	1	
146-8	22238-22244	scores	9	
146-9	22245-22250	equal	_	
146-10	22251-22253	or	_	
146-11	22254-22259	above	1	
146-12	22260-22263	are	3	
146-13	22264-22270	deemed	7	
146-14	22271-22272	“	_	
146-15	22273-22285	unacceptable	_	
146-16	22286-22287	”	1	
146-17	22288-22290	to	3	
146-18	22291-22295	live	_	
146-19	22296-22300	with	_	
146-20	22301-22303	by	1	
146-21	22304-22315	individuals	2	
146-22	22316-22320	with	_	
146-23	22321-22323	OA	1	
146-24	22324-22325	[	5	
146-25	22326-22328	42	_	
146-26	22329-22330	]	_	
146-27	22331-22332	.	1	

#Text=Since there is no analyte free matrix , validation at the LLOQ was performed by spiking the LPC standards to water .
147-1	22333-22338	Since	6	
147-2	22339-22344	there	2	
147-3	22345-22347	is	_	
147-4	22348-22350	no	_	
147-5	22351-22358	analyte	_	
147-6	22359-22363	free	_	
147-7	22364-22370	matrix	_	
147-8	22371-22372	,	1	
147-9	22373-22383	validation	9	
147-10	22384-22386	at	_	
147-11	22387-22390	the	_	
147-12	22391-22395	LLOQ	1	
147-13	22396-22399	was	8	
147-14	22400-22409	performed	_	
147-15	22410-22412	by	1	
147-16	22413-22420	spiking	3	
147-17	22421-22424	the	2	
147-18	22425-22428	LPC	_	
147-19	22429-22438	standards	_	
147-20	22439-22441	to	_	
147-21	22442-22447	water	_	
147-22	22448-22449	.	1	

#Text=Participants were provided with verbal encouragement and visual feedback to maximize voluntary effort .
148-1	22450-22462	Participants	9	
148-2	22463-22467	were	8	
148-3	22468-22476	provided	_	
148-4	22477-22481	with	1	
148-5	22482-22488	verbal	2	
148-6	22489-22502	encouragement	1	
148-7	22503-22506	and	2	
148-8	22507-22513	visual	_	
148-9	22514-22522	feedback	1	
148-10	22523-22525	to	3	
148-11	22526-22534	maximize	1	
148-12	22535-22544	voluntary	2	
148-13	22545-22551	effort	_	
148-14	22552-22553	.	1	

#Text=No antibiotic was given for AOM on or before the last day of the visit window .
149-1	22554-22556	No	9	
149-2	22557-22567	antibiotic	1	
149-3	22568-22571	was	8	
149-4	22572-22577	given	_	
149-5	22578-22581	for	1	
149-6	22582-22585	AOM	2	
149-7	22586-22588	on	2	
149-8	22589-22591	or	_	
149-9	22592-22598	before	_	
149-10	22599-22602	the	_	
149-11	22603-22607	last	_	
149-12	22608-22611	day	_	
149-13	22612-22614	of	_	
149-14	22615-22618	the	_	
149-15	22619-22624	visit	_	
149-16	22625-22631	window	_	
149-17	22632-22633	.	1	

#Text=The DEFUSE 3 trial was a randomized , open-label trial , with blinded outcome assessment , that compared endovascular therapy plus standard medical therapy with standard medical therapy alone in patients with acute ischemic stroke .
150-1	22634-22637	The	9	
150-2	22638-22644	DEFUSE	_	
150-3	22645-22646	3	_	
150-4	22647-22652	trial	1	
150-5	22653-22656	was	8	
150-6	22657-22658	a	2	
150-7	22659-22669	randomized	_	
150-8	22670-22671	,	_	
150-9	22672-22682	open-label	_	
150-10	22683-22688	trial	_	
150-11	22689-22690	,	1	
150-12	22691-22695	with	2	
150-13	22696-22703	blinded	_	
150-14	22704-22711	outcome	_	
150-15	22712-22722	assessment	_	
150-16	22723-22724	,	2	
150-17	22725-22729	that	3	
150-18	22730-22738	compared	1	
150-19	22739-22751	endovascular	2	
150-20	22752-22759	therapy	_	
150-21	22760-22764	plus	_	
150-22	22765-22773	standard	_	
150-23	22774-22781	medical	_	
150-24	22782-22789	therapy	1	
150-25	22790-22794	with	2	
150-26	22795-22803	standard	_	
150-27	22804-22811	medical	_	
150-28	22812-22819	therapy	_	
150-29	22820-22825	alone	1	
150-30	22826-22828	in	2	
150-31	22829-22837	patients	_	
150-32	22838-22842	with	_	
150-33	22843-22848	acute	_	
150-34	22849-22857	ischemic	_	
150-35	22858-22864	stroke	_	
150-36	22865-22866	.	1	

#Text=The primary outcome was the change in WOMAC pain subscale score between baseline and 12 weeks .
151-1	22867-22870	The	9	
151-2	22871-22878	primary	_	
151-3	22879-22886	outcome	1	
151-4	22887-22890	was	8	
151-5	22891-22894	the	2	
151-6	22895-22901	change	_	
151-7	22902-22904	in	_	
151-8	22905-22910	WOMAC	_	
151-9	22911-22915	pain	_	
151-10	22916-22924	subscale	_	
151-11	22925-22930	score	1	
151-12	22931-22938	between	2	
151-13	22939-22947	baseline	_	
151-14	22948-22951	and	_	
151-15	22952-22954	12	_	
151-16	22955-22960	weeks	_	
151-17	22961-22962	.	1	

#Text=The study medicine was packed in 2 different kits , one with 9 capsules containing 200 mg pivmecillinam each , the other with 9 capsules containing 600 mg ibuprofen each .
152-1	22963-22966	The	9	
152-2	22967-22972	study	_	
152-3	22973-22981	medicine	1	
152-4	22982-22985	was	8	
152-5	22986-22992	packed	_	
152-6	22993-22995	in	1	
152-7	22996-22997	2	2	
152-8	22998-23007	different	_	
152-9	23008-23012	kits	_	
152-10	23013-23014	,	_	
152-11	23015-23018	one	_	
152-12	23019-23023	with	_	
152-13	23024-23025	9	_	
152-14	23026-23034	capsules	_	
152-15	23035-23045	containing	_	
152-16	23046-23049	200	_	
152-17	23050-23052	mg	_	
152-18	23053-23066	pivmecillinam	_	
152-19	23067-23071	each	_	
152-20	23072-23073	,	1	
152-21	23074-23077	the	2	
152-22	23078-23083	other	_	
152-23	23084-23088	with	_	
152-24	23089-23090	9	_	
152-25	23091-23099	capsules	_	
152-26	23100-23110	containing	_	
152-27	23111-23114	600	_	
152-28	23115-23117	mg	_	
152-29	23118-23127	ibuprofen	_	
152-30	23128-23132	each	_	
152-31	23133-23134	.	1	

#Text=Participants were randomly assigned in a 1:1 ratio to Tai Chi or physical therapy after the baseline evaluation .
153-1	23135-23147	Participants	9	
153-2	23148-23152	were	8	
153-3	23153-23161	randomly	_	
153-4	23162-23170	assigned	_	
153-5	23171-23173	in	_	
153-6	23174-23175	a	_	
153-7	23176-23177	1	_	
153-8	23177-23178	:	_	
153-9	23178-23179	1	_	
153-10	23180-23185	ratio	_	
153-11	23186-23188	to	1	
153-12	23189-23192	Tai	2	
153-13	23193-23196	Chi	1	
153-14	23197-23199	or	2	
153-15	23200-23208	physical	_	
153-16	23209-23216	therapy	1	
153-17	23217-23222	after	2	
153-18	23223-23226	the	_	
153-19	23227-23235	baseline	_	
153-20	23236-23246	evaluation	_	
153-21	23247-23248	.	1	

#Text=Patients were enrolled if they met clinical and imaging eligibility requirements and could undergo initiation of endovascular therapy between 6 and 16 hours after the time that they had last been known to be well , including if they had awakened from sleep with symptoms of a stroke .
154-1	23249-23257	Patients	9	
154-2	23258-23262	were	8	
154-3	23263-23271	enrolled	1	
154-4	23272-23274	if	1	
154-5	23275-23279	they	3	
154-6	23280-23283	met	1	
154-7	23284-23292	clinical	2	
154-8	23293-23296	and	_	
154-9	23297-23304	imaging	_	
154-10	23305-23316	eligibility	_	
154-11	23317-23329	requirements	1	
154-12	23330-23333	and	3	
154-13	23334-23339	could	_	
154-14	23340-23347	undergo	1	
154-15	23348-23358	initiation	2	
154-16	23359-23361	of	_	
154-17	23362-23374	endovascular	_	
154-18	23375-23382	therapy	1	
154-19	23383-23390	between	2	
154-20	23391-23392	6	_	
154-21	23393-23396	and	_	
154-22	23397-23399	16	_	
154-23	23400-23405	hours	_	
154-24	23406-23411	after	_	
154-25	23412-23415	the	_	
154-26	23416-23420	time	1	
154-27	23421-23425	that	6	
154-28	23426-23430	they	3	
154-29	23431-23434	had	_	
154-30	23435-23439	last	_	
154-31	23440-23444	been	_	
154-32	23445-23450	known	_	
154-33	23451-23453	to	_	
154-34	23454-23456	be	_	
154-35	23457-23461	well	_	
154-36	23462-23463	,	1	
154-37	23464-23473	including	3	
154-38	23474-23476	if	6	
154-39	23477-23481	they	3	
154-40	23482-23485	had	_	
154-41	23486-23494	awakened	_	
154-42	23495-23499	from	1	
154-43	23500-23505	sleep	2	
154-44	23506-23510	with	2	
154-45	23511-23519	symptoms	_	
154-46	23520-23522	of	_	
154-47	23523-23524	a	_	
154-48	23525-23531	stroke	_	
154-49	23532-23533	.	1	

#Text=A convalescent sample was obtained ≥60 days after admission ( ≥ 60 days ) .
155-1	23534-23535	A	9	
155-2	23536-23548	convalescent	_	
155-3	23549-23555	sample	1	
155-4	23556-23559	was	8	
155-5	23560-23568	obtained	1	
155-6	23569-23570	≥	2	
155-7	23570-23572	60	_	
155-8	23573-23577	days	_	
155-9	23578-23583	after	_	
155-10	23584-23593	admission	1	
155-11	23594-23595	(	5	
155-12	23596-23597	≥	_	
155-13	23598-23600	60	_	
155-14	23601-23605	days	_	
155-15	23606-23607	)	_	
155-16	23608-23609	.	1	

#Text=The secondary efficacy outcome was functional independence ( defined as a score on the modified Rankin scale of 0 to 2 ) at day 90 .
156-1	23610-23613	The	9	
156-2	23614-23623	secondary	_	
156-3	23624-23632	efficacy	_	
156-4	23633-23640	outcome	1	
156-5	23641-23644	was	8	
156-6	23645-23655	functional	2	
156-7	23656-23668	independence	1	
156-8	23669-23670	(	5	
156-9	23671-23678	defined	_	
156-10	23679-23681	as	_	
156-11	23682-23683	a	_	
156-12	23684-23689	score	_	
156-13	23690-23692	on	_	
156-14	23693-23696	the	_	
156-15	23697-23705	modified	_	
156-16	23706-23712	Rankin	_	
156-17	23713-23718	scale	_	
156-18	23719-23721	of	_	
156-19	23722-23723	0	_	
156-20	23724-23726	to	_	
156-21	23727-23728	2	_	
156-22	23729-23730	)	1	
156-23	23731-23733	at	2	
156-24	23734-23737	day	_	
156-25	23738-23740	90	_	
156-26	23741-23742	.	1	

#Text=Self-reported physical function was assessed using the LEFS , as well as the function in activities of daily living ( ADL ) and sport and recreation ( SR ) subscales of the KOOS .
157-1	23743-23756	Self-reported	9	
157-2	23757-23765	physical	_	
157-3	23766-23774	function	1	
157-4	23775-23778	was	8	
157-5	23779-23787	assessed	_	
157-6	23788-23793	using	1	
157-7	23794-23797	the	2	
157-8	23798-23802	LEFS	_	
157-9	23803-23804	,	1	
157-10	23805-23807	as	2	
157-11	23808-23812	well	_	
157-12	23813-23815	as	_	
157-13	23816-23819	the	_	
157-14	23820-23828	function	_	
157-15	23829-23831	in	_	
157-16	23832-23842	activities	_	
157-17	23843-23845	of	_	
157-18	23846-23851	daily	_	
157-19	23852-23858	living	1	
157-20	23859-23860	(	5	
157-21	23861-23864	ADL	_	
157-22	23865-23866	)	5	
157-23	23867-23870	and	2	
157-24	23871-23876	sport	_	
157-25	23877-23880	and	_	
157-26	23881-23891	recreation	_	
157-27	23892-23893	(	5	
157-28	23894-23896	SR	_	
157-29	23897-23898	)	1	
157-30	23899-23908	subscales	_	
157-31	23909-23911	of	_	
157-32	23912-23915	the	_	
157-33	23916-23920	KOOS	_	
157-34	23921-23922	.	1	

#Text=A steering committee provided guidance during monthly telephone conferences .
158-1	23923-23924	A	9	
158-2	23925-23933	steering	_	
158-3	23934-23943	committee	1	
158-4	23944-23952	provided	8	
158-5	23953-23961	guidance	2	
158-6	23962-23968	during	2	
158-7	23969-23976	monthly	_	
158-8	23977-23986	telephone	_	
158-9	23987-23998	conferences	_	
158-10	23999-24000	.	1	

#Text=For all analytes , the coefficient of variation ( CV ) was within a range of ± 20 % and the accuracy was within 80%-120 % , S1 Table .
159-1	24001-24004	For	2	
159-2	24005-24008	all	_	
159-3	24009-24017	analytes	_	
159-4	24018-24019	,	1	
159-5	24020-24023	the	9	
159-6	24024-24035	coefficient	_	
159-7	24036-24038	of	_	
159-8	24039-24048	variation	1	
159-9	24049-24050	(	5	
159-10	24051-24053	CV	_	
159-11	24054-24055	)	1	
159-12	24056-24059	was	8	
159-13	24060-24066	within	1	
159-14	24067-24068	a	2	
159-15	24069-24074	range	_	
159-16	24075-24077	of	_	
159-17	24078-24079	±	_	
159-18	24080-24082	20	_	
159-19	24083-24084	%	1	
159-20	24085-24088	and	9	
159-21	24089-24092	the	_	
159-22	24093-24101	accuracy	1	
159-23	24102-24105	was	3	
159-24	24106-24112	within	1	
159-25	24113-24116	80%	2	
159-26	24116-24117	-	_	
159-27	24117-24120	120	_	
159-28	24121-24122	%	_	
159-29	24123-24124	,	1	
159-30	24125-24127	S1	2	
159-31	24128-24133	Table	_	
159-32	24134-24135	.	1	

#Text=Pain was assessed using the pain subscale of the Knee Injury and Osteoarthritis Outcome Score ( KOOS ) and the Measure of Intermittent and Constant Osteoarthritis Pain ( ICOAP ) .
160-1	24136-24140	Pain	9	
160-2	24141-24144	was	8	
160-3	24145-24153	assessed	_	
160-4	24154-24159	using	1	
160-5	24160-24163	the	2	
160-6	24164-24168	pain	_	
160-7	24169-24177	subscale	_	
160-8	24178-24180	of	_	
160-9	24181-24184	the	_	
160-10	24185-24189	Knee	_	
160-11	24190-24196	Injury	_	
160-12	24197-24200	and	_	
160-13	24201-24215	Osteoarthritis	_	
160-14	24216-24223	Outcome	_	
160-15	24224-24229	Score	1	
160-16	24230-24231	(	5	
160-17	24232-24236	KOOS	_	
160-18	24237-24238	)	1	
160-19	24239-24242	and	2	
160-20	24243-24246	the	_	
160-21	24247-24254	Measure	_	
160-22	24255-24257	of	_	
160-23	24258-24270	Intermittent	_	
160-24	24271-24274	and	_	
160-25	24275-24283	Constant	_	
160-26	24284-24298	Osteoarthritis	_	
160-27	24299-24303	Pain	1	
160-28	24304-24305	(	5	
160-29	24306-24311	ICOAP	_	
160-30	24312-24313	)	_	
160-31	24314-24315	.	1	

#Text=Enrolled patients or their surrogates provided written informed consent .
161-1	24316-24324	Enrolled	9	
161-2	24325-24333	patients	_	
161-3	24334-24336	or	_	
161-4	24337-24342	their	_	
161-5	24343-24353	surrogates	1	
161-6	24354-24362	provided	8	
161-7	24363-24370	written	2	
161-8	24371-24379	informed	_	
161-9	24380-24387	consent	_	
161-10	24388-24389	.	1	

#Text=In Norway and Denmark , the urine sample was transported in a plastic container with boric acid .
162-1	24390-24392	In	2	
162-2	24393-24399	Norway	_	
162-3	24400-24403	and	_	
162-4	24404-24411	Denmark	_	
162-5	24412-24413	,	1	
162-6	24414-24417	the	9	
162-7	24418-24423	urine	_	
162-8	24424-24430	sample	1	
162-9	24431-24434	was	8	
162-10	24435-24446	transported	_	
162-11	24447-24449	in	1	
162-12	24450-24451	a	2	
162-13	24452-24459	plastic	_	
162-14	24460-24469	container	_	
162-15	24470-24474	with	_	
162-16	24475-24480	boric	_	
162-17	24481-24485	acid	_	
162-18	24486-24487	.	1	

#Text=Gallbladder puncture was directed through the transhepatic or transperitoneal route , depending on the preference of the radiologist and the location of the gallbladder .
163-1	24488-24499	Gallbladder	9	
163-2	24500-24508	puncture	1	
163-3	24509-24512	was	8	
163-4	24513-24521	directed	_	
163-5	24522-24529	through	1	
163-6	24530-24533	the	2	
163-7	24534-24546	transhepatic	_	
163-8	24547-24549	or	_	
163-9	24550-24565	transperitoneal	_	
163-10	24566-24571	route	_	
163-11	24572-24573	,	1	
163-12	24574-24583	depending	3	
163-13	24584-24586	on	1	
163-14	24587-24590	the	2	
163-15	24591-24601	preference	_	
163-16	24602-24604	of	_	
163-17	24605-24608	the	_	
163-18	24609-24620	radiologist	1	
163-19	24621-24624	and	2	
163-20	24625-24628	the	_	
163-21	24629-24637	location	_	
163-22	24638-24640	of	_	
163-23	24641-24644	the	_	
163-24	24645-24656	gallbladder	_	
163-25	24657-24658	.	1	

#Text=Randomization was based on a central randomization schedule stratified by investigational site using an automated interactive voice/web response system accessed by the TI or study coordinator .
164-1	24659-24672	Randomization	9	
164-2	24673-24676	was	8	
164-3	24677-24682	based	_	
164-4	24683-24685	on	1	
164-5	24686-24687	a	2	
164-6	24688-24695	central	_	
164-7	24696-24709	randomization	_	
164-8	24710-24718	schedule	1	
164-9	24719-24729	stratified	3	
164-10	24730-24732	by	1	
164-11	24733-24748	investigational	2	
164-12	24749-24753	site	1	
164-13	24754-24759	using	1	
164-14	24760-24762	an	2	
164-15	24763-24772	automated	_	
164-16	24773-24784	interactive	_	
164-17	24785-24790	voice	_	
164-18	24790-24791	/	_	
164-19	24791-24794	web	_	
164-20	24795-24803	response	_	
164-21	24804-24810	system	1	
164-22	24811-24819	accessed	3	
164-23	24820-24822	by	1	
164-24	24823-24826	the	2	
164-25	24827-24829	TI	_	
164-26	24830-24832	or	_	
164-27	24833-24838	study	_	
164-28	24839-24850	coordinator	_	
164-29	24851-24852	.	1	

#Text=The LEFS has 20 items that assess difficulty during mobility tasks .
165-1	24853-24856	The	9	
165-2	24857-24861	LEFS	1	
165-3	24862-24865	has	8	
165-4	24866-24868	20	2	
165-5	24869-24874	items	1	
165-6	24875-24879	that	6	
165-7	24880-24886	assess	3	
165-8	24887-24897	difficulty	2	
165-9	24898-24904	during	2	
165-10	24905-24913	mobility	_	
165-11	24914-24919	tasks	_	
165-12	24920-24921	.	1	

#Text=In batch 1 , these species were analyzed in the patient ’s sera drawn at admission , 3 h , Day 1 , and ≥ 60 days .
166-1	24922-24924	In	2	
166-2	24925-24930	batch	_	
166-3	24931-24932	1	_	
166-4	24933-24934	,	1	
166-5	24935-24940	these	9	
166-6	24941-24948	species	1	
166-7	24949-24953	were	8	
166-8	24954-24962	analyzed	_	
166-9	24963-24965	in	1	
166-10	24966-24969	the	2	
166-11	24970-24977	patient	_	
166-12	24978-24979	’	_	
166-13	24979-24980	s	_	
166-14	24981-24985	sera	_	
166-15	24986-24991	drawn	_	
166-16	24992-24994	at	_	
166-17	24995-25004	admission	_	
166-18	25005-25006	,	_	
166-19	25007-25008	3	_	
166-20	25009-25010	h	_	
166-21	25011-25012	,	_	
166-22	25013-25016	Day	_	
166-23	25017-25018	1	_	
166-24	25019-25020	,	_	
166-25	25021-25024	and	_	
166-26	25025-25026	≥	_	
166-27	25027-25029	60	_	
166-28	25030-25034	days	_	
166-29	25035-25036	.	1	

#Text=Contact information and routines were described in the consent form .
167-1	25037-25044	Contact	9	
167-2	25045-25056	information	_	
167-3	25057-25060	and	_	
167-4	25061-25069	routines	1	
167-5	25070-25074	were	8	
167-6	25075-25084	described	_	
167-7	25085-25087	in	1	
167-8	25088-25091	the	2	
167-9	25092-25099	consent	_	
167-10	25100-25104	form	_	
167-11	25105-25106	.	1	

#Text=For all outcomes , we fit longitudinal models incorporating all values recorded for each patient at baseline and 12 , 24 , and 52 weeks with a term for the interaction between treatment and each time point to assess differences in the effect of treatment over time .
168-1	25107-25110	For	2	
168-2	25111-25114	all	_	
168-3	25115-25123	outcomes	_	
168-4	25124-25125	,	1	
168-5	25126-25128	we	8	
168-6	25129-25132	fit	1	
168-7	25133-25145	longitudinal	2	
168-8	25146-25152	models	1	
168-9	25153-25166	incorporating	3	
168-10	25167-25170	all	2	
168-11	25171-25177	values	1	
168-12	25178-25186	recorded	3	
168-13	25187-25190	for	2	
168-14	25191-25195	each	_	
168-15	25196-25203	patient	1	
168-16	25204-25206	at	2	
168-17	25207-25215	baseline	_	
168-18	25216-25219	and	_	
168-19	25220-25222	12	_	
168-20	25223-25224	,	_	
168-21	25225-25227	24	_	
168-22	25228-25229	,	_	
168-23	25230-25233	and	_	
168-24	25234-25236	52	_	
168-25	25237-25242	weeks	1	
168-26	25243-25247	with	2	
168-27	25248-25249	a	_	
168-28	25250-25254	term	_	
168-29	25255-25258	for	_	
168-30	25259-25262	the	_	
168-31	25263-25274	interaction	_	
168-32	25275-25282	between	_	
168-33	25283-25292	treatment	_	
168-34	25293-25296	and	_	
168-35	25297-25301	each	_	
168-36	25302-25306	time	_	
168-37	25307-25312	point	1	
168-38	25313-25315	to	3	
168-39	25316-25322	assess	3	
168-40	25323-25334	differences	3	
168-41	25335-25337	in	_	
168-42	25338-25341	the	_	
168-43	25342-25348	effect	_	
168-44	25349-25351	of	_	
168-45	25352-25361	treatment	_	
168-46	25362-25366	over	_	
168-47	25367-25371	time	_	
168-48	25372-25373	.	1	

#Text=There was no independent data monitoring committee for the trial .
169-1	25374-25379	There	8	
169-2	25380-25383	was	_	
169-3	25384-25386	no	1	
169-4	25387-25398	independent	2	
169-5	25399-25403	data	_	
169-6	25404-25414	monitoring	_	
169-7	25415-25424	committee	_	
169-8	25425-25428	for	_	
169-9	25429-25432	the	_	
169-10	25433-25438	trial	_	
169-11	25439-25440	.	1	

#Text=Patients were randomized in a 1:1 ratio to treatment with either ibuprofen or pivmecillinam .
170-1	25441-25449	Patients	9	
170-2	25450-25454	were	8	
170-3	25455-25465	randomized	_	
170-4	25466-25468	in	_	
170-5	25469-25470	a	_	
170-6	25471-25472	1	_	
170-7	25472-25473	:	_	
170-8	25473-25474	1	_	
170-9	25475-25480	ratio	_	
170-10	25481-25483	to	1	
170-11	25484-25493	treatment	2	
170-12	25494-25498	with	_	
170-13	25499-25505	either	_	
170-14	25506-25515	ibuprofen	_	
170-15	25516-25518	or	_	
170-16	25519-25532	pivmecillinam	_	
170-17	25533-25534	.	1	

#Text=All analyses used all randomly assigned patients under the intention-to-treat assumption .
171-1	25535-25538	All	9	
171-2	25539-25547	analyses	1	
171-3	25548-25552	used	8	
171-4	25553-25556	all	2	
171-5	25557-25565	randomly	_	
171-6	25566-25574	assigned	_	
171-7	25575-25583	patients	1	
171-8	25584-25589	under	2	
171-9	25590-25593	the	_	
171-10	25594-25612	intention-to-treat	_	
171-11	25613-25623	assumption	_	
171-12	25624-25625	.	1	

#Text=After completing the 12-week intervention ( 24 sessions ) , participants were instructed to continue Tai Chi practice for 52 weeks with the aid of provided homework materials .
172-1	25626-25631	After	2	
172-2	25632-25642	completing	_	
172-3	25643-25646	the	_	
172-4	25647-25649	12	_	
172-5	25649-25650	-	_	
172-6	25650-25654	week	_	
172-7	25655-25667	intervention	1	
172-8	25668-25669	(	5	
172-9	25670-25672	24	_	
172-10	25673-25681	sessions	_	
172-11	25682-25683	)	_	
172-12	25684-25685	,	1	
172-13	25686-25698	participants	9	
172-14	25699-25703	were	8	
172-15	25704-25714	instructed	_	
172-16	25715-25717	to	_	
172-17	25718-25726	continue	1	
172-18	25727-25730	Tai	2	
172-19	25731-25734	Chi	_	
172-20	25735-25743	practice	1	
172-21	25744-25747	for	2	
172-22	25748-25750	52	_	
172-23	25751-25756	weeks	1	
172-24	25757-25761	with	2	
172-25	25762-25765	the	_	
172-26	25766-25769	aid	_	
172-27	25770-25772	of	_	
172-28	25773-25781	provided	_	
172-29	25782-25790	homework	_	
172-30	25791-25800	materials	_	
172-31	25801-25802	.	1	

#Text=An adjudication committee consisting of four experienced surgeons and one radiologist carried out a blinded assessment of primary and secondary outcomes .
173-1	25803-25805	An	9	
173-2	25806-25818	adjudication	_	
173-3	25819-25828	committee	_	
173-4	25829-25839	consisting	_	
173-5	25840-25842	of	_	
173-6	25843-25847	four	_	
173-7	25848-25859	experienced	_	
173-8	25860-25868	surgeons	_	
173-9	25869-25872	and	_	
173-10	25873-25876	one	_	
173-11	25877-25888	radiologist	1	
173-12	25889-25896	carried	8	
173-13	25897-25900	out	1	
173-14	25901-25902	a	2	
173-15	25903-25910	blinded	_	
173-16	25911-25921	assessment	_	
173-17	25922-25924	of	_	
173-18	25925-25932	primary	_	
173-19	25933-25936	and	_	
173-20	25937-25946	secondary	_	
173-21	25947-25955	outcomes	_	
173-22	25956-25957	.	1	

#Text=A 1-sided exact binomial test was used to evaluate whether the responder rate for VYC-17.5L at 6 months was significantly greater than 50 % and to compare injection characteristics between the 2 products .
174-1	25958-25959	A	9	
174-2	25960-25961	1	_	
174-3	25961-25962	-	_	
174-4	25962-25967	sided	_	
174-5	25968-25973	exact	_	
174-6	25974-25982	binomial	_	
174-7	25983-25987	test	1	
174-8	25988-25991	was	8	
174-9	25992-25996	used	_	
174-10	25997-25999	to	_	
174-11	26000-26008	evaluate	1	
174-12	26009-26016	whether	6	
174-13	26017-26020	the	9	
174-14	26021-26030	responder	_	
174-15	26031-26035	rate	_	
174-16	26036-26039	for	_	
174-17	26040-26043	VYC	_	
174-18	26043-26044	-	_	
174-19	26044-26049	17.5L	_	
174-20	26050-26052	at	_	
174-21	26053-26054	6	_	
174-22	26055-26061	months	1	
174-23	26062-26065	was	8	
174-24	26066-26079	significantly	7	
174-25	26080-26087	greater	1	
174-26	26088-26092	than	6	
174-27	26093-26095	50	2	
174-28	26096-26097	%	1	
174-29	26098-26101	and	3	
174-30	26102-26104	to	_	
174-31	26105-26112	compare	1	
174-32	26113-26122	injection	2	
174-33	26123-26138	characteristics	_	
174-34	26139-26146	between	_	
174-35	26147-26150	the	_	
174-36	26151-26152	2	_	
174-37	26153-26161	products	_	
174-38	26162-26163	.	1	

#Text=The doctors were not aware of the 2 different classifications during the study , and we had to rely on their clinical notes in the patient record and the CRP value to make the classifications .
175-1	26164-26167	The	9	
175-2	26168-26175	doctors	1	
175-3	26176-26180	were	8	
175-4	26181-26184	not	7	
175-5	26185-26190	aware	7	
175-6	26191-26193	of	2	
175-7	26194-26197	the	_	
175-8	26198-26199	2	_	
175-9	26200-26209	different	_	
175-10	26210-26225	classifications	1	
175-11	26226-26232	during	2	
175-12	26233-26236	the	_	
175-13	26237-26242	study	_	
175-14	26243-26244	,	1	
175-15	26245-26248	and	3	
175-16	26249-26251	we	_	
175-17	26252-26255	had	_	
175-18	26256-26258	to	_	
175-19	26259-26263	rely	_	
175-20	26264-26266	on	1	
175-21	26267-26272	their	2	
175-22	26273-26281	clinical	_	
175-23	26282-26287	notes	_	
175-24	26288-26290	in	_	
175-25	26291-26294	the	_	
175-26	26295-26302	patient	_	
175-27	26303-26309	record	1	
175-28	26310-26313	and	2	
175-29	26314-26317	the	_	
175-30	26318-26321	CRP	_	
175-31	26322-26327	value	1	
175-32	26328-26330	to	3	
175-33	26331-26335	make	1	
175-34	26336-26339	the	2	
175-35	26340-26355	classifications	_	
175-36	26356-26357	.	1	

#Text=Subjects and EIs remained blinded to the treatment assignment for each NLF throughout the study duration .
176-1	26358-26366	Subjects	9	
176-2	26367-26370	and	_	
176-3	26371-26374	EIs	1	
176-4	26375-26383	remained	8	
176-5	26384-26391	blinded	_	
176-6	26392-26394	to	1	
176-7	26395-26398	the	2	
176-8	26399-26408	treatment	_	
176-9	26409-26419	assignment	_	
176-10	26420-26423	for	_	
176-11	26424-26428	each	_	
176-12	26429-26432	NLF	1	
176-13	26433-26443	throughout	2	
176-14	26444-26447	the	_	
176-15	26448-26453	study	_	
176-16	26454-26462	duration	_	
176-17	26463-26464	.	1	

#Text=The results of a urine dipstick ( leukocytes , protein , nitrite , and blood ) were recorded at inclusion .
177-1	26465-26468	The	9	
177-2	26469-26476	results	_	
177-3	26477-26479	of	_	
177-4	26480-26481	a	_	
177-5	26482-26487	urine	_	
177-6	26488-26496	dipstick	1	
177-7	26497-26498	(	5	
177-8	26499-26509	leukocytes	_	
177-9	26510-26511	,	_	
177-10	26512-26519	protein	_	
177-11	26520-26521	,	_	
177-12	26522-26529	nitrite	_	
177-13	26530-26531	,	_	
177-14	26532-26535	and	_	
177-15	26536-26541	blood	_	
177-16	26542-26543	)	1	
177-17	26544-26548	were	8	
177-18	26549-26557	recorded	_	
177-19	26558-26560	at	1	
177-20	26561-26570	inclusion	2	
177-21	26571-26572	.	1	

#Text=Patients   ≥   18   years of age with sCAP ( diagnosed clinically and radiologically ) , requiring IMV and receiving standard antibiotics , were enrolled .
178-1	26573-26581	Patients	9	
178-2	26584-26585	≥	_	
178-3	26588-26590	18	_	
178-4	26591-26592	 	_	
178-5	26593-26598	years	_	
178-6	26599-26601	of	_	
178-7	26602-26605	age	_	
178-8	26606-26610	with	_	
178-9	26611-26615	sCAP	_	
178-10	26616-26617	(	5	
178-11	26618-26627	diagnosed	_	
178-12	26628-26638	clinically	_	
178-13	26639-26642	and	_	
178-14	26643-26657	radiologically	_	
178-15	26658-26659	)	1	
178-16	26660-26661	,	_	
178-17	26662-26671	requiring	_	
178-18	26672-26675	IMV	_	
178-19	26676-26679	and	_	
178-20	26680-26689	receiving	_	
178-21	26690-26698	standard	_	
178-22	26699-26710	antibiotics	_	
178-23	26711-26712	,	1	
178-24	26713-26717	were	8	
178-25	26718-26726	enrolled	_	
178-26	26727-26728	.	1	

#Text=They were allowed to take paracetamol if they needed additional pain relief .
179-1	26729-26733	They	8	
179-2	26734-26738	were	_	
179-3	26739-26746	allowed	_	
179-4	26747-26749	to	_	
179-5	26750-26754	take	1	
179-6	26755-26766	paracetamol	2	
179-7	26767-26769	if	6	
179-8	26770-26774	they	3	
179-9	26775-26781	needed	1	
179-10	26782-26792	additional	2	
179-11	26793-26797	pain	_	
179-12	26798-26804	relief	_	
179-13	26805-26806	.	1	

#Text=In addition , subjects completed the Appraisal of Nasolabial Folds scale of the FACE-Q questionnaire for each NLF at screening and at Months 3 and 6 .
180-1	26807-26809	In	6	
180-2	26810-26818	addition	_	
180-3	26819-26820	,	1	
180-4	26821-26829	subjects	9	
180-5	26830-26839	completed	8	
180-6	26840-26843	the	2	
180-7	26844-26853	Appraisal	_	
180-8	26854-26856	of	_	
180-9	26857-26867	Nasolabial	_	
180-10	26868-26873	Folds	_	
180-11	26874-26879	scale	_	
180-12	26880-26882	of	_	
180-13	26883-26886	the	_	
180-14	26887-26893	FACE-Q	_	
180-15	26894-26907	questionnaire	1	
180-16	26908-26911	for	2	
180-17	26912-26916	each	_	
180-18	26917-26920	NLF	1	
180-19	26921-26923	at	2	
180-20	26924-26933	screening	_	
180-21	26934-26937	and	_	
180-22	26938-26940	at	_	
180-23	26941-26947	Months	_	
180-24	26948-26949	3	_	
180-25	26950-26953	and	_	
180-26	26954-26955	6	_	
180-27	26956-26957	.	1	

#Text=Renal function was monitored through serum creatinine .
181-1	26958-26963	Renal	9	
181-2	26964-26972	function	1	
181-3	26973-26976	was	8	
181-4	26977-26986	monitored	1	
181-5	26987-26994	through	2	
181-6	26995-27000	serum	_	
181-7	27001-27011	creatinine	_	
181-8	27012-27013	.	1	

#Text=Study staff made monthly calls to monitor adherence throughout the 1-year follow-up .
182-1	27014-27019	Study	9	
182-2	27020-27025	staff	1	
182-3	27026-27030	made	8	
182-4	27031-27038	monthly	2	
182-5	27039-27044	calls	1	
182-6	27045-27047	to	3	
182-7	27048-27055	monitor	1	
182-8	27056-27065	adherence	2	
182-9	27066-27076	throughout	2	
182-10	27077-27080	the	_	
182-11	27081-27082	1	_	
182-12	27082-27083	-	_	
182-13	27083-27087	year	_	
182-14	27088-27097	follow-up	_	
182-15	27098-27099	.	1	

#Text=It was designed such that it is easy to administer and score and applicable to a wide range of people with lower limb conditions .
183-1	27100-27102	It	3	
183-2	27103-27106	was	_	
183-3	27107-27115	designed	_	
183-4	27116-27120	such	_	
183-5	27121-27125	that	1	
183-6	27126-27128	it	8	
183-7	27129-27131	is	_	
183-8	27132-27136	easy	_	
183-9	27137-27139	to	_	
183-10	27140-27150	administer	_	
183-11	27151-27154	and	_	
183-12	27155-27160	score	1	
183-13	27161-27164	and	7	
183-14	27165-27175	applicable	1	
183-15	27176-27178	to	2	
183-16	27179-27180	a	_	
183-17	27181-27185	wide	_	
183-18	27186-27191	range	_	
183-19	27192-27194	of	_	
183-20	27195-27201	people	_	
183-21	27202-27206	with	_	
183-22	27207-27212	lower	_	
183-23	27213-27217	limb	_	
183-24	27218-27228	conditions	_	
183-25	27229-27230	.	1	

#Text=The Peto approach was followed , meaning that the study would only be stopped for beneficial effects in case of a P value < 0.001 .
184-1	27231-27234	The	9	
184-2	27235-27239	Peto	_	
184-3	27240-27248	approach	1	
184-4	27249-27252	was	8	
184-5	27253-27261	followed	_	
184-6	27262-27263	,	1	
184-7	27264-27271	meaning	6	
184-8	27272-27276	that	1	
184-9	27277-27280	the	9	
184-10	27281-27286	study	1	
184-11	27287-27292	would	3	
184-12	27293-27297	only	_	
184-13	27298-27300	be	_	
184-14	27301-27308	stopped	_	
184-15	27309-27312	for	1	
184-16	27313-27323	beneficial	2	
184-17	27324-27331	effects	1	
184-18	27332-27334	in	2	
184-19	27335-27339	case	_	
184-20	27340-27342	of	_	
184-21	27343-27344	a	_	
184-22	27345-27346	P	_	
184-23	27347-27352	value	_	
184-24	27353-27354	<	_	
184-25	27355-27360	0.001	_	
184-26	27361-27362	.	1	

#Text=The instructor explained mind – body exercise theory and procedures .
185-1	27363-27366	The	9	
185-2	27367-27377	instructor	1	
185-3	27378-27387	explained	8	
185-4	27388-27392	mind	2	
185-5	27393-27394	–	_	
185-6	27395-27399	body	_	
185-7	27400-27408	exercise	_	
185-8	27409-27415	theory	_	
185-9	27416-27419	and	_	
185-10	27420-27430	procedures	_	
185-11	27431-27432	.	1	

#Text=Through consensus , two investigators not involved in patient care resolved discrepancies detected by the study coordinator .
186-1	27433-27440	Through	2	
186-2	27441-27450	consensus	_	
186-3	27451-27452	,	1	
186-4	27453-27456	two	9	
186-5	27457-27470	investigators	_	
186-6	27471-27474	not	_	
186-7	27475-27483	involved	_	
186-8	27484-27486	in	_	
186-9	27487-27494	patient	_	
186-10	27495-27499	care	1	
186-11	27500-27508	resolved	8	
186-12	27509-27522	discrepancies	2	
186-13	27523-27531	detected	3	
186-14	27532-27534	by	1	
186-15	27535-27538	the	2	
186-16	27539-27544	study	_	
186-17	27545-27556	coordinator	_	
186-18	27557-27558	.	1	

#Text=VAS , a scoring system from 0 ( minimum pain ) to 100   mm ( severe pain ) , was used to rate the primary endpoint , i.e. , improvement in gastritis-related upper abdominal pain/discomfort at 5-week follow-up .
187-1	27559-27562	VAS	9	
187-2	27563-27564	,	1	
187-3	27565-27566	a	2	
187-4	27567-27574	scoring	_	
187-5	27575-27581	system	_	
187-6	27582-27586	from	_	
187-7	27587-27588	0	_	
187-8	27589-27590	(	5	
187-9	27591-27598	minimum	_	
187-10	27599-27603	pain	_	
187-11	27604-27605	)	1	
187-12	27606-27608	to	_	
187-13	27609-27612	100	_	
187-14	27613-27614	 	_	
187-15	27615-27617	mm	_	
187-16	27618-27619	(	5	
187-17	27620-27626	severe	_	
187-18	27627-27631	pain	_	
187-19	27632-27633	)	1	
187-20	27634-27635	,	1	
187-21	27636-27639	was	8	
187-22	27640-27644	used	_	
187-23	27645-27647	to	_	
187-24	27648-27652	rate	1	
187-25	27653-27656	the	2	
187-26	27657-27664	primary	_	
187-27	27665-27673	endpoint	_	
187-28	27674-27675	,	_	
187-29	27676-27679	i.e	_	
187-30	27679-27680	.	_	
187-31	27681-27682	,	_	
187-32	27683-27694	improvement	_	
187-33	27695-27697	in	_	
187-34	27698-27715	gastritis-related	_	
187-35	27716-27721	upper	_	
187-36	27722-27731	abdominal	_	
187-37	27732-27736	pain	_	
187-38	27736-27737	/	_	
187-39	27737-27747	discomfort	_	
187-40	27748-27750	at	_	
187-41	27751-27752	5	_	
187-42	27752-27753	-	_	
187-43	27753-27757	week	_	
187-44	27758-27767	follow-up	_	
187-45	27768-27769	.	1	

#Text=Patients with suspected hospital-acquired pneumonia ; severe lung diseases interfering with sCAP therapy ( e.g. , cystic fibrosis ) ; life expectancy of ≤   28   days due to medical conditions not related to sCAP or to sCAP-associated sepsis ; selective , absolute IgA deficiency with antibodies to IgA , neutrophil count <   1000/mm3 ; or platelet count <   50,000/mm3 were excluded .
188-1	27770-27778	Patients	9	
188-2	27779-27783	with	_	
188-3	27784-27793	suspected	_	
188-4	27794-27811	hospital-acquired	_	
188-5	27812-27821	pneumonia	1	
188-6	27822-27823	;	6	
188-7	27824-27830	severe	9	
188-8	27831-27835	lung	_	
188-9	27836-27844	diseases	_	
188-10	27845-27856	interfering	_	
188-11	27857-27861	with	_	
188-12	27862-27866	sCAP	_	
188-13	27867-27874	therapy	_	
188-14	27875-27876	(	5	
188-15	27877-27880	e.g	_	
188-16	27880-27881	.	_	
188-17	27882-27883	,	_	
188-18	27884-27890	cystic	_	
188-19	27891-27899	fibrosis	_	
188-20	27900-27901	)	1	
188-21	27902-27903	;	6	
188-22	27904-27908	life	9	
188-23	27909-27919	expectancy	_	
188-24	27920-27922	of	_	
188-25	27923-27924	≤	_	
188-26	27927-27929	28	_	
188-27	27930-27931	 	_	
188-28	27932-27936	days	_	
188-29	27937-27940	due	_	
188-30	27941-27943	to	_	
188-31	27944-27951	medical	_	
188-32	27952-27962	conditions	_	
188-33	27963-27966	not	_	
188-34	27967-27974	related	_	
188-35	27975-27977	to	_	
188-36	27978-27982	sCAP	_	
188-37	27983-27985	or	_	
188-38	27986-27988	to	_	
188-39	27989-28004	sCAP-associated	_	
188-40	28005-28011	sepsis	1	
188-41	28012-28013	;	6	
188-42	28014-28023	selective	9	
188-43	28024-28025	,	_	
188-44	28026-28034	absolute	_	
188-45	28035-28038	IgA	_	
188-46	28039-28049	deficiency	_	
188-47	28050-28054	with	_	
188-48	28055-28065	antibodies	_	
188-49	28066-28068	to	_	
188-50	28069-28072	IgA	_	
188-51	28073-28074	,	_	
188-52	28075-28085	neutrophil	_	
188-53	28086-28091	count	_	
188-54	28092-28093	<	_	
188-55	28096-28100	1000	_	
188-56	28100-28101	/	_	
188-57	28101-28104	mm3	1	
188-58	28105-28106	;	6	
188-59	28107-28109	or	2	
188-60	28110-28118	platelet	_	
188-61	28119-28124	count	_	
188-62	28125-28126	<	_	
188-63	28129-28135	50,000	_	
188-64	28135-28136	/	_	
188-65	28136-28139	mm3	1	
188-66	28140-28144	were	8	
188-67	28145-28153	excluded	_	
188-68	28154-28155	.	1	

#Text=The polytomous complications variable was analyzed using Fisher ’s exact methods for contingency tables and Newcombe ’s hybrid score method for calculation of risk difference confidence intervals .
189-1	28156-28159	The	9	
189-2	28160-28170	polytomous	_	
189-3	28171-28184	complications	_	
189-4	28185-28193	variable	1	
189-5	28194-28197	was	8	
189-6	28198-28206	analyzed	_	
189-7	28207-28212	using	1	
189-8	28213-28219	Fisher	2	
189-9	28220-28221	’	_	
189-10	28221-28222	s	_	
189-11	28223-28228	exact	_	
189-12	28229-28236	methods	_	
189-13	28237-28240	for	_	
189-14	28241-28252	contingency	_	
189-15	28253-28259	tables	1	
189-16	28260-28263	and	2	
189-17	28264-28272	Newcombe	_	
189-18	28273-28274	’	_	
189-19	28274-28275	s	_	
189-20	28276-28282	hybrid	_	
189-21	28283-28288	score	_	
189-22	28289-28295	method	_	
189-23	28296-28299	for	_	
189-24	28300-28311	calculation	_	
189-25	28312-28314	of	_	
189-26	28315-28319	risk	_	
189-27	28320-28330	difference	_	
189-28	28331-28341	confidence	_	
189-29	28342-28351	intervals	_	
189-30	28352-28353	.	1	

#Text=The list linking the study number to the active substance was kept at Kragerø Tablettproduksjon .
190-1	28354-28357	The	9	
190-2	28358-28362	list	_	
190-3	28363-28370	linking	_	
190-4	28371-28374	the	_	
190-5	28375-28380	study	_	
190-6	28381-28387	number	_	
190-7	28388-28390	to	_	
190-8	28391-28394	the	_	
190-9	28395-28401	active	_	
190-10	28402-28411	substance	1	
190-11	28412-28415	was	8	
190-12	28416-28420	kept	1	
190-13	28421-28423	at	2	
190-14	28424-28431	Kragerø	_	
190-15	28432-28449	Tablettproduksjon	_	
190-16	28450-28451	.	1	

#Text=All model assumptions were checked with standard regression diagnostic evaluations ( 33 ) .
191-1	28452-28455	All	9	
191-2	28456-28461	model	_	
191-3	28462-28473	assumptions	1	
191-4	28474-28478	were	8	
191-5	28479-28486	checked	_	
191-6	28487-28491	with	1	
191-7	28492-28500	standard	2	
191-8	28501-28511	regression	_	
191-9	28512-28522	diagnostic	_	
191-10	28523-28534	evaluations	1	
191-11	28535-28536	(	5	
191-12	28537-28539	33	_	
191-13	28540-28541	)	_	
191-14	28542-28543	.	1	

#Text=There were written routines at each study site for health personnel to follow when a study patient came back for a second medical consultation .
192-1	28544-28549	There	8	
192-2	28550-28554	were	_	
192-3	28555-28562	written	_	
192-4	28563-28571	routines	1	
192-5	28572-28574	at	2	
192-6	28575-28579	each	_	
192-7	28580-28585	study	_	
192-8	28586-28590	site	1	
192-9	28591-28594	for	2	
192-10	28595-28601	health	_	
192-11	28602-28611	personnel	1	
192-12	28612-28614	to	3	
192-13	28615-28621	follow	1	
192-14	28622-28626	when	6	
192-15	28627-28628	a	9	
192-16	28629-28634	study	_	
192-17	28635-28642	patient	1	
192-18	28643-28647	came	3	
192-19	28648-28652	back	1	
192-20	28653-28656	for	2	
192-21	28657-28658	a	_	
192-22	28659-28665	second	_	
192-23	28666-28673	medical	_	
192-24	28674-28686	consultation	_	
192-25	28687-28688	.	1	

#Text=Effectiveness analyses were conducted on the modified intent-to-treat population , which included all randomized subjects who received study treatment .
193-1	28689-28702	Effectiveness	9	
193-2	28703-28711	analyses	1	
193-3	28712-28716	were	8	
193-4	28717-28726	conducted	_	
193-5	28727-28729	on	1	
193-6	28730-28733	the	2	
193-7	28734-28742	modified	_	
193-8	28743-28758	intent-to-treat	_	
193-9	28759-28769	population	_	
193-10	28770-28771	,	1	
193-11	28772-28777	which	6	
193-12	28778-28786	included	3	
193-13	28787-28790	all	2	
193-14	28791-28801	randomized	_	
193-15	28802-28810	subjects	_	
193-16	28811-28814	who	_	
193-17	28815-28823	received	_	
193-18	28824-28829	study	_	
193-19	28830-28839	treatment	_	
193-20	28840-28841	.	1	

#Text=Adjusted treatment effects and P values for the primary efficacy outcome were calculated with the use of ordinal regression on the full modified Rankin scale and stratified Cochran – Mantel – Haenszel tests , with the randomization stratification variables split at their medians as the covariates .
194-1	28842-28850	Adjusted	9	
194-2	28851-28860	treatment	_	
194-3	28861-28868	effects	_	
194-4	28869-28872	and	_	
194-5	28873-28874	P	_	
194-6	28875-28881	values	_	
194-7	28882-28885	for	_	
194-8	28886-28889	the	_	
194-9	28890-28897	primary	_	
194-10	28898-28906	efficacy	_	
194-11	28907-28914	outcome	1	
194-12	28915-28919	were	8	
194-13	28920-28930	calculated	_	
194-14	28931-28935	with	1	
194-15	28936-28939	the	2	
194-16	28940-28943	use	_	
194-17	28944-28946	of	_	
194-18	28947-28954	ordinal	_	
194-19	28955-28965	regression	_	
194-20	28966-28968	on	_	
194-21	28969-28972	the	_	
194-22	28973-28977	full	_	
194-23	28978-28986	modified	_	
194-24	28987-28993	Rankin	_	
194-25	28994-28999	scale	1	
194-26	29000-29003	and	3	
194-27	29004-29014	stratified	3	
194-28	29015-29022	Cochran	2	
194-29	29023-29024	–	_	
194-30	29025-29031	Mantel	_	
194-31	29032-29033	–	_	
194-32	29034-29042	Haenszel	_	
194-33	29043-29048	tests	_	
194-34	29049-29050	,	1	
194-35	29051-29055	with	2	
194-36	29056-29059	the	_	
194-37	29060-29073	randomization	_	
194-38	29074-29088	stratification	_	
194-39	29089-29098	variables	_	
194-40	29099-29104	split	_	
194-41	29105-29107	at	_	
194-42	29108-29113	their	_	
194-43	29114-29121	medians	_	
194-44	29122-29124	as	_	
194-45	29125-29128	the	_	
194-46	29129-29139	covariates	_	
194-47	29140-29141	.	1	

#Text=Patients who received additional treatment , had an allergic reaction , or were admitted to the hospital remained in the study unless they expressed a wish to withdraw their consent .
195-1	29142-29150	Patients	9	
195-2	29151-29154	who	6	
195-3	29155-29163	received	3	
195-4	29164-29174	additional	2	
195-5	29175-29184	treatment	_	
195-6	29185-29186	,	1	
195-7	29187-29190	had	3	
195-8	29191-29193	an	2	
195-9	29194-29202	allergic	_	
195-10	29203-29211	reaction	_	
195-11	29212-29213	,	1	
195-12	29214-29216	or	3	
195-13	29217-29221	were	_	
195-14	29222-29230	admitted	_	
195-15	29231-29233	to	1	
195-16	29234-29237	the	2	
195-17	29238-29246	hospital	1	
195-18	29247-29255	remained	8	
195-19	29256-29258	in	2	
195-20	29259-29262	the	_	
195-21	29263-29268	study	1	
195-22	29269-29275	unless	6	
195-23	29276-29280	they	3	
195-24	29281-29290	expressed	1	
195-25	29291-29292	a	2	
195-26	29293-29297	wish	_	
195-27	29298-29300	to	_	
195-28	29301-29309	withdraw	_	
195-29	29310-29315	their	_	
195-30	29316-29323	consent	_	
195-31	29324-29325	.	1	

#Text=In our study , the distinction between febrile UTI and pyelonephritis was not described in the protocol .
196-1	29326-29328	In	2	
196-2	29329-29332	our	_	
196-3	29333-29338	study	_	
196-4	29339-29340	,	1	
196-5	29341-29344	the	9	
196-6	29345-29356	distinction	_	
196-7	29357-29364	between	_	
196-8	29365-29372	febrile	_	
196-9	29373-29376	UTI	_	
196-10	29377-29380	and	_	
196-11	29381-29395	pyelonephritis	1	
196-12	29396-29399	was	8	
196-13	29400-29403	not	_	
196-14	29404-29413	described	_	
196-15	29414-29416	in	1	
196-16	29417-29420	the	2	
196-17	29421-29429	protocol	_	
196-18	29430-29431	.	1	

#Text=All statistical methods , unless otherwise specified , were prespecified in the study protocol .
197-1	29432-29435	All	9	
197-2	29436-29447	statistical	_	
197-3	29448-29455	methods	_	
197-4	29456-29457	,	_	
197-5	29458-29464	unless	_	
197-6	29465-29474	otherwise	_	
197-7	29475-29484	specified	_	
197-8	29485-29486	,	1	
197-9	29487-29491	were	8	
197-10	29492-29504	prespecified	_	
197-11	29505-29507	in	1	
197-12	29508-29511	the	2	
197-13	29512-29517	study	_	
197-14	29518-29526	protocol	_	
197-15	29527-29528	.	1	

#Text=Percutaneous catheter drainage was performed under local anaesthesia and aseptic circumstances , with image guidance using either ultrasonography or computed tomography .
198-1	29529-29541	Percutaneous	9	
198-2	29542-29550	catheter	_	
198-3	29551-29559	drainage	1	
198-4	29560-29563	was	8	
198-5	29564-29573	performed	_	
198-6	29574-29579	under	1	
198-7	29580-29585	local	2	
198-8	29586-29597	anaesthesia	_	
198-9	29598-29601	and	_	
198-10	29602-29609	aseptic	_	
198-11	29610-29623	circumstances	_	
198-12	29624-29625	,	1	
198-13	29626-29630	with	2	
198-14	29631-29636	image	_	
198-15	29637-29645	guidance	1	
198-16	29646-29651	using	3	
198-17	29652-29658	either	1	
198-18	29659-29674	ultrasonography	2	
198-19	29675-29677	or	_	
198-20	29678-29686	computed	_	
198-21	29687-29697	tomography	_	
198-22	29698-29699	.	1	

#Text=The tool was designed to distinguish the OA pain experience into constant pain and intermittent pain , and yields scores for the most troublesome joint and the resulting impact on mood , sleep , and quality of life .
199-1	29700-29703	The	9	
199-2	29704-29708	tool	1	
199-3	29709-29712	was	8	
199-4	29713-29721	designed	_	
199-5	29722-29724	to	_	
199-6	29725-29736	distinguish	1	
199-7	29737-29740	the	2	
199-8	29741-29743	OA	_	
199-9	29744-29748	pain	_	
199-10	29749-29759	experience	_	
199-11	29760-29764	into	_	
199-12	29765-29773	constant	_	
199-13	29774-29778	pain	_	
199-14	29779-29782	and	_	
199-15	29783-29795	intermittent	_	
199-16	29796-29800	pain	_	
199-17	29801-29802	,	1	
199-18	29803-29806	and	3	
199-19	29807-29813	yields	3	
199-20	29814-29820	scores	1	
199-21	29821-29824	for	2	
199-22	29825-29828	the	_	
199-23	29829-29833	most	_	
199-24	29834-29845	troublesome	_	
199-25	29846-29851	joint	1	
199-26	29852-29855	and	2	
199-27	29856-29859	the	_	
199-28	29860-29869	resulting	_	
199-29	29870-29876	impact	_	
199-30	29877-29879	on	_	
199-31	29880-29884	mood	_	
199-32	29885-29886	,	_	
199-33	29887-29892	sleep	_	
199-34	29893-29894	,	_	
199-35	29895-29898	and	_	
199-36	29899-29906	quality	_	
199-37	29907-29909	of	_	
199-38	29910-29914	life	_	
199-39	29915-29916	.	1	

#Text=The uropathogens were quantified in colony-forming units per milliliter .
200-1	29917-29920	The	9	
200-2	29921-29933	uropathogens	1	
200-3	29934-29938	were	8	
200-4	29939-29949	quantified	_	
200-5	29950-29952	in	1	
200-6	29953-29967	colony-forming	2	
200-7	29968-29973	units	_	
200-8	29974-29977	per	_	
200-9	29978-29988	milliliter	_	
200-10	29989-29990	.	1	

#Text=Previously unthawed sera stored at -80 ° C were thawed on ice and 50 μL pipetted into Eppendorf tubes ( Sarstedt , Biosphere SafeSeal Microtube 1.5 ml ) .
201-1	29991-30001	Previously	9	
201-2	30002-30010	unthawed	_	
201-3	30011-30015	sera	_	
201-4	30016-30022	stored	_	
201-5	30023-30025	at	_	
201-6	30026-30027	-	_	
201-7	30027-30029	80	_	
201-8	30030-30031	°	_	
201-9	30032-30033	C	1	
201-10	30034-30038	were	8	
201-11	30039-30045	thawed	_	
201-12	30046-30048	on	1	
201-13	30049-30052	ice	2	
201-14	30053-30056	and	_	
201-15	30057-30059	50	_	
201-16	30060-30062	μL	_	
201-17	30063-30071	pipetted	1	
201-18	30072-30076	into	2	
201-19	30077-30086	Eppendorf	_	
201-20	30087-30092	tubes	1	
201-21	30093-30094	(	2	
201-22	30095-30103	Sarstedt	_	
201-23	30104-30105	,	_	
201-24	30106-30115	Biosphere	_	
201-25	30116-30124	SafeSeal	_	
201-26	30125-30134	Microtube	_	
201-27	30135-30138	1.5	_	
201-28	30139-30141	ml	_	
201-29	30142-30143	)	_	
201-30	30144-30145	.	1	

#Text=The null hypothesis was tested on the 1-sided 5 % significance level as predefined in the SAP .
202-1	30146-30149	The	9	
202-2	30150-30154	null	_	
202-3	30155-30165	hypothesis	1	
202-4	30166-30169	was	8	
202-5	30170-30176	tested	_	
202-6	30177-30179	on	1	
202-7	30180-30183	the	2	
202-8	30184-30185	1	_	
202-9	30185-30186	-	_	
202-10	30186-30191	sided	_	
202-11	30192-30193	5	_	
202-12	30194-30195	%	_	
202-13	30196-30208	significance	_	
202-14	30209-30214	level	2	
202-15	30215-30217	as	3	
202-16	30218-30228	predefined	1	
202-17	30229-30231	in	2	
202-18	30232-30235	the	_	
202-19	30236-30239	SAP	_	
202-20	30240-30241	.	1	

#Text=Subjects recorded the severity of ISRs in the safety diary as mild , moderate , or severe .
203-1	30242-30250	Subjects	9	
203-2	30251-30259	recorded	8	
203-3	30260-30263	the	2	
203-4	30264-30272	severity	_	
203-5	30273-30275	of	_	
203-6	30276-30280	ISRs	_	
203-7	30281-30283	in	_	
203-8	30284-30287	the	_	
203-9	30288-30294	safety	_	
203-10	30295-30300	diary	1	
203-11	30301-30303	as	7	
203-12	30304-30308	mild	_	
203-13	30309-30310	,	_	
203-14	30311-30319	moderate	_	
203-15	30320-30321	,	_	
203-16	30322-30324	or	_	
203-17	30325-30331	severe	_	
203-18	30332-30333	.	1	

#Text=Data for co-morbidity and medication were recorded per the study protocol .
204-1	30334-30338	Data	9	
204-2	30339-30342	for	_	
204-3	30343-30355	co-morbidity	_	
204-4	30356-30359	and	_	
204-5	30360-30370	medication	1	
204-6	30371-30375	were	8	
204-7	30376-30384	recorded	1	
204-8	30385-30388	per	2	
204-9	30389-30392	the	_	
204-10	30393-30398	study	_	
204-11	30399-30407	protocol	_	
204-12	30408-30409	.	1	

#Text=Patients who met all eligibility criteria were randomly assigned in a 1:1 ratio to endovascular therapy plus medical therapy or medical therapy alone with the use of a Web-based dynamic randomization system ( Table S1 in the Supplementary Appendix ) .
205-1	30410-30418	Patients	9	
205-2	30419-30422	who	6	
205-3	30423-30426	met	3	
205-4	30427-30430	all	2	
205-5	30431-30442	eligibility	_	
205-6	30443-30451	criteria	1	
205-7	30452-30456	were	8	
205-8	30457-30465	randomly	_	
205-9	30466-30474	assigned	_	
205-10	30475-30477	in	_	
205-11	30478-30479	a	_	
205-12	30480-30481	1	_	
205-13	30481-30482	:	_	
205-14	30482-30483	1	_	
205-15	30484-30489	ratio	_	
205-16	30490-30492	to	1	
205-17	30493-30505	endovascular	2	
205-18	30506-30513	therapy	_	
205-19	30514-30518	plus	_	
205-20	30519-30526	medical	_	
205-21	30527-30534	therapy	1	
205-22	30535-30537	or	2	
205-23	30538-30545	medical	_	
205-24	30546-30553	therapy	_	
205-25	30554-30559	alone	1	
205-26	30560-30564	with	2	
205-27	30565-30568	the	_	
205-28	30569-30572	use	_	
205-29	30573-30575	of	_	
205-30	30576-30577	a	_	
205-31	30578-30587	Web-based	_	
205-32	30588-30595	dynamic	_	
205-33	30596-30609	randomization	_	
205-34	30610-30616	system	1	
205-35	30617-30618	(	5	
205-36	30619-30624	Table	_	
205-37	30625-30627	S1	_	
205-38	30628-30630	in	_	
205-39	30631-30634	the	_	
205-40	30635-30648	Supplementary	_	
205-41	30649-30657	Appendix	_	
205-42	30658-30659	)	_	
205-43	30660-30661	.	1	

#Text=The primary efficacy outcome was the ordinal score on the modified Rankin scale ( range , 0 [ no symptoms ] to 6 [ death ] ) at day 90 ; the score was assessed in person , or by telephone if an in-person visit was not feasible , by a certified rater who was not aware of the trial-group assignments .
206-1	30662-30665	The	9	
206-2	30666-30673	primary	_	
206-3	30674-30682	efficacy	_	
206-4	30683-30690	outcome	1	
206-5	30691-30694	was	8	
206-6	30695-30698	the	2	
206-7	30699-30706	ordinal	_	
206-8	30707-30712	score	_	
206-9	30713-30715	on	_	
206-10	30716-30719	the	_	
206-11	30720-30728	modified	_	
206-12	30729-30735	Rankin	_	
206-13	30736-30741	scale	1	
206-14	30742-30743	(	5	
206-15	30744-30749	range	_	
206-16	30750-30751	,	_	
206-17	30752-30753	0	_	
206-18	30754-30755	[	_	
206-19	30756-30758	no	_	
206-20	30759-30767	symptoms	_	
206-21	30768-30769	]	_	
206-22	30770-30772	to	_	
206-23	30773-30774	6	_	
206-24	30775-30776	[	_	
206-25	30777-30782	death	_	
206-26	30783-30784	]	_	
206-27	30785-30786	)	1	
206-28	30787-30789	at	2	
206-29	30790-30793	day	_	
206-30	30794-30796	90	1	
206-31	30797-30798	;	6	
206-32	30799-30802	the	9	
206-33	30803-30808	score	1	
206-34	30809-30812	was	3	
206-35	30813-30821	assessed	_	
206-36	30822-30824	in	1	
206-37	30825-30831	person	2	
206-38	30832-30833	,	1	
206-39	30834-30836	or	2	
206-40	30837-30839	by	_	
206-41	30840-30849	telephone	1	
206-42	30850-30852	if	6	
206-43	30853-30855	an	9	
206-44	30856-30865	in-person	_	
206-45	30866-30871	visit	1	
206-46	30872-30875	was	3	
206-47	30876-30879	not	7	
206-48	30880-30888	feasible	_	
206-49	30889-30890	,	1	
206-50	30891-30893	by	2	
206-51	30894-30895	a	_	
206-52	30896-30905	certified	_	
206-53	30906-30911	rater	_	
206-54	30912-30915	who	_	
206-55	30916-30919	was	_	
206-56	30920-30923	not	_	
206-57	30924-30929	aware	_	
206-58	30930-30932	of	_	
206-59	30933-30936	the	_	
206-60	30937-30948	trial-group	_	
206-61	30949-30960	assignments	_	
206-62	30961-30962	.	1	

#Text=Thus , these analyses should be regarded as exploratory .
207-1	30963-30967	Thus	6	
207-2	30968-30969	,	1	
207-3	30970-30975	these	9	
207-4	30976-30984	analyses	1	
207-5	30985-30991	should	8	
207-6	30992-30994	be	_	
207-7	30995-31003	regarded	_	
207-8	31004-31006	as	1	
207-9	31007-31018	exploratory	7	
207-10	31019-31020	.	1	

#Text=Sidak adjustments were performed to account for multiple comparisons between groups ; alpha values of 0.05 were used .
208-1	31021-31026	Sidak	9	
208-2	31027-31038	adjustments	1	
208-3	31039-31043	were	8	
208-4	31044-31053	performed	_	
208-5	31054-31056	to	_	
208-6	31057-31064	account	_	
208-7	31065-31068	for	1	
208-8	31069-31077	multiple	2	
208-9	31078-31089	comparisons	_	
208-10	31090-31097	between	_	
208-11	31098-31104	groups	1	
208-12	31105-31106	;	6	
208-13	31107-31112	alpha	9	
208-14	31113-31119	values	_	
208-15	31120-31122	of	_	
208-16	31123-31127	0.05	1	
208-17	31128-31132	were	3	
208-18	31133-31137	used	_	
208-19	31138-31139	.	1	

#Text=The patients were consecutively allocated to active treatment with either pivmecillinam 200 mg or ibuprofen 600 mg 3 times a day for 3 days .
209-1	31140-31143	The	9	
209-2	31144-31152	patients	1	
209-3	31153-31157	were	8	
209-4	31158-31171	consecutively	_	
209-5	31172-31181	allocated	_	
209-6	31182-31184	to	1	
209-7	31185-31191	active	2	
209-8	31192-31201	treatment	_	
209-9	31202-31206	with	_	
209-10	31207-31213	either	_	
209-11	31214-31227	pivmecillinam	_	
209-12	31228-31231	200	_	
209-13	31232-31234	mg	_	
209-14	31235-31237	or	_	
209-15	31238-31247	ibuprofen	_	
209-16	31248-31251	600	_	
209-17	31252-31254	mg	_	
209-18	31255-31256	3	_	
209-19	31257-31262	times	_	
209-20	31263-31264	a	_	
209-21	31265-31268	day	_	
209-22	31269-31272	for	_	
209-23	31273-31274	3	_	
209-24	31275-31279	days	_	
209-25	31280-31281	.	1	

#Text=All P values are two sided and not corrected for multiple testing .
210-1	31282-31285	All	9	
210-2	31286-31287	P	_	
210-3	31288-31294	values	1	
210-4	31295-31298	are	8	
210-5	31299-31302	two	2	
210-6	31303-31308	sided	1	
210-7	31309-31312	and	3	
210-8	31313-31316	not	_	
210-9	31317-31326	corrected	_	
210-10	31327-31330	for	1	
210-11	31331-31339	multiple	2	
210-12	31340-31347	testing	_	
210-13	31348-31349	.	1	

#Text=An ANCOVA comparing mean change scores across the intervention ( follow-up minus baseline ) , with baseline data used as covariates in the models were used to detect between-group differences for each outcome .
211-1	31350-31352	An	9	
211-2	31353-31359	ANCOVA	1	
211-3	31360-31369	comparing	3	
211-4	31370-31374	mean	2	
211-5	31375-31381	change	_	
211-6	31382-31388	scores	_	
211-7	31389-31395	across	_	
211-8	31396-31399	the	_	
211-9	31400-31412	intervention	1	
211-10	31413-31414	(	5	
211-11	31415-31424	follow-up	_	
211-12	31425-31430	minus	_	
211-13	31431-31439	baseline	_	
211-14	31440-31441	)	_	
211-15	31442-31443	,	1	
211-16	31444-31448	with	2	
211-17	31449-31457	baseline	_	
211-18	31458-31462	data	_	
211-19	31463-31467	used	3	
211-20	31468-31470	as	1	
211-21	31471-31481	covariates	2	
211-22	31482-31484	in	_	
211-23	31485-31488	the	_	
211-24	31489-31495	models	1	
211-25	31496-31500	were	8	
211-26	31501-31505	used	_	
211-27	31506-31508	to	_	
211-28	31509-31515	detect	1	
211-29	31516-31529	between-group	2	
211-30	31530-31541	differences	_	
211-31	31542-31545	for	_	
211-32	31546-31550	each	_	
211-33	31551-31558	outcome	_	
211-34	31559-31560	.	1	

#Text=Each kit was labeled with a study number .
212-1	31561-31565	Each	9	
212-2	31566-31569	kit	1	
212-3	31570-31573	was	8	
212-4	31574-31581	labeled	_	
212-5	31582-31586	with	1	
212-6	31587-31588	a	2	
212-7	31589-31594	study	_	
212-8	31595-31601	number	_	
212-9	31602-31603	.	1	

#Text=We recruited study participants over the age of 18 with suspected CAP during 2011–2014 at the infectious diseases clinic at Norrlands University Hospital ( Umeå , Sweden ) .
213-1	31604-31606	We	8	
213-2	31607-31616	recruited	1	
213-3	31617-31622	study	2	
213-4	31623-31635	participants	_	
213-5	31636-31640	over	_	
213-6	31641-31644	the	_	
213-7	31645-31648	age	_	
213-8	31649-31651	of	_	
213-9	31652-31654	18	_	
213-10	31655-31659	with	_	
213-11	31660-31669	suspected	_	
213-12	31670-31673	CAP	1	
213-13	31674-31680	during	2	
213-14	31681-31685	2011	_	
213-15	31685-31686	–	_	
213-16	31686-31690	2014	1	
213-17	31691-31693	at	2	
213-18	31694-31697	the	_	
213-19	31698-31708	infectious	_	
213-20	31709-31717	diseases	_	
213-21	31718-31724	clinic	2	
213-22	31725-31727	at	1	
213-23	31728-31737	Norrlands	_	
213-24	31738-31748	University	_	
213-25	31749-31757	Hospital	1	
213-26	31758-31759	(	5	
213-27	31760-31764	Umeå	_	
213-28	31765-31766	,	_	
213-29	31767-31773	Sweden	_	
213-30	31774-31775	)	_	
213-31	31776-31777	.	1	

#Text=Before the beginning of the study , the patients underwent a complete physical examination .
214-1	31778-31784	Before	2	
214-2	31785-31788	the	_	
214-3	31789-31798	beginning	_	
214-4	31799-31801	of	_	
214-5	31802-31805	the	_	
214-6	31806-31811	study	_	
214-7	31812-31813	,	1	
214-8	31814-31817	the	9	
214-9	31818-31826	patients	1	
214-10	31827-31836	underwent	8	
214-11	31837-31838	a	2	
214-12	31839-31847	complete	_	
214-13	31848-31856	physical	_	
214-14	31857-31868	examination	_	
214-15	31869-31870	.	1	

#Text=The total study duration was up to 20 months ( 1 month for treatment and up to 19 months of follow-up ) .
215-1	31871-31874	The	9	
215-2	31875-31880	total	_	
215-3	31881-31886	study	_	
215-4	31887-31895	duration	1	
215-5	31896-31899	was	8	
215-6	31900-31902	up	2	
215-7	31903-31905	to	_	
215-8	31906-31908	20	_	
215-9	31909-31915	months	1	
215-10	31916-31917	(	5	
215-11	31918-31919	1	_	
215-12	31920-31925	month	_	
215-13	31926-31929	for	_	
215-14	31930-31939	treatment	_	
215-15	31940-31943	and	_	
215-16	31944-31946	up	_	
215-17	31947-31949	to	_	
215-18	31950-31952	19	_	
215-19	31953-31959	months	_	
215-20	31960-31962	of	_	
215-21	31963-31972	follow-up	_	
215-22	31973-31974	)	_	
215-23	31975-31976	.	1	

#Text=If we had no information on these endpoints , they were interpreted as not present ( best case imputation ) .
216-1	31977-31979	If	6	
216-2	31980-31982	we	3	
216-3	31983-31986	had	1	
216-4	31987-31989	no	2	
216-5	31990-32001	information	_	
216-6	32002-32004	on	_	
216-7	32005-32010	these	_	
216-8	32011-32020	endpoints	_	
216-9	32021-32022	,	1	
216-10	32023-32027	they	8	
216-11	32028-32032	were	_	
216-12	32033-32044	interpreted	_	
216-13	32045-32047	as	1	
216-14	32048-32051	not	7	
216-15	32052-32059	present	1	
216-16	32060-32061	(	5	
216-17	32062-32066	best	_	
216-18	32067-32071	case	_	
216-19	32072-32082	imputation	_	
216-20	32083-32084	)	_	
216-21	32085-32086	.	1	

#Text=Potential 3-way interactions of treatment and time with 14 covariates ( age , sex , body mass index [ BMI ] , education , marital status , employment , living alone , NSAID or analgesic use , hypertension , diabetes , heart disease , weight , and class attendance ) were examined to explore whether they modified the effect of treatment across time .
217-1	32087-32096	Potential	9	
217-2	32097-32098	3	_	
217-3	32098-32099	-	_	
217-4	32099-32102	way	_	
217-5	32103-32115	interactions	_	
217-6	32116-32118	of	_	
217-7	32119-32128	treatment	_	
217-8	32129-32132	and	_	
217-9	32133-32137	time	_	
217-10	32138-32142	with	_	
217-11	32143-32145	14	_	
217-12	32146-32156	covariates	1	
217-13	32157-32158	(	5	
217-14	32159-32162	age	_	
217-15	32163-32164	,	_	
217-16	32165-32168	sex	_	
217-17	32169-32170	,	_	
217-18	32171-32175	body	_	
217-19	32176-32180	mass	_	
217-20	32181-32186	index	_	
217-21	32187-32188	[	_	
217-22	32189-32192	BMI	_	
217-23	32193-32194	]	_	
217-24	32195-32196	,	_	
217-25	32197-32206	education	_	
217-26	32207-32208	,	_	
217-27	32209-32216	marital	_	
217-28	32217-32223	status	_	
217-29	32224-32225	,	_	
217-30	32226-32236	employment	_	
217-31	32237-32238	,	_	
217-32	32239-32245	living	_	
217-33	32246-32251	alone	_	
217-34	32252-32253	,	_	
217-35	32254-32259	NSAID	_	
217-36	32260-32262	or	_	
217-37	32263-32272	analgesic	_	
217-38	32273-32276	use	_	
217-39	32277-32278	,	_	
217-40	32279-32291	hypertension	_	
217-41	32292-32293	,	_	
217-42	32294-32302	diabetes	_	
217-43	32303-32304	,	_	
217-44	32305-32310	heart	_	
217-45	32311-32318	disease	_	
217-46	32319-32320	,	_	
217-47	32321-32327	weight	_	
217-48	32328-32329	,	_	
217-49	32330-32333	and	_	
217-50	32334-32339	class	_	
217-51	32340-32350	attendance	_	
217-52	32351-32352	)	1	
217-53	32353-32357	were	8	
217-54	32358-32366	examined	_	
217-55	32367-32369	to	_	
217-56	32370-32377	explore	1	
217-57	32378-32385	whether	6	
217-58	32386-32390	they	3	
217-59	32391-32399	modified	1	
217-60	32400-32403	the	2	
217-61	32404-32410	effect	_	
217-62	32411-32413	of	_	
217-63	32414-32423	treatment	_	
217-64	32424-32430	across	_	
217-65	32431-32435	time	_	
217-66	32436-32437	.	1	

#Text=We estimated the difference between these interventions to be 70 points ( SD , 100 ) .
218-1	32438-32440	We	8	
218-2	32441-32450	estimated	1	
218-3	32451-32454	the	2	
218-4	32455-32465	difference	_	
218-5	32466-32473	between	_	
218-6	32474-32479	these	_	
218-7	32480-32493	interventions	1	
218-8	32494-32496	to	3	
218-9	32497-32499	be	1	
218-10	32500-32502	70	2	
218-11	32503-32509	points	1	
218-12	32510-32511	(	5	
218-13	32512-32514	SD	_	
218-14	32515-32516	,	_	
218-15	32517-32520	100	_	
218-16	32521-32522	)	_	
218-17	32523-32524	.	1	

#Text=Disagreement was resolved in a plenary consensus meeting , with concealment of the treatment assignment .
219-1	32525-32537	Disagreement	9	
219-2	32538-32541	was	8	
219-3	32542-32550	resolved	_	
219-4	32551-32553	in	1	
219-5	32554-32555	a	2	
219-6	32556-32563	plenary	_	
219-7	32564-32573	consensus	_	
219-8	32574-32581	meeting	_	
219-9	32582-32583	,	1	
219-10	32584-32588	with	2	
219-11	32589-32600	concealment	_	
219-12	32601-32603	of	_	
219-13	32604-32607	the	_	
219-14	32608-32617	treatment	_	
219-15	32618-32628	assignment	_	
219-16	32629-32630	.	1	

#Text=High risk was defined as an APACHE II score of 7 or more .
220-1	32631-32635	High	9	
220-2	32636-32640	risk	1	
220-3	32641-32644	was	8	
220-4	32645-32652	defined	_	
220-5	32653-32655	as	1	
220-6	32656-32658	an	2	
220-7	32659-32665	APACHE	_	
220-8	32666-32668	II	_	
220-9	32669-32674	score	_	
220-10	32675-32677	of	_	
220-11	32678-32679	7	_	
220-12	32680-32682	or	_	
220-13	32683-32687	more	_	
220-14	32688-32689	.	1	

#Text=The principal investigator monitored all sessions by regularly reviewing video recordings and providing feedback throughout the study .
221-1	32690-32693	The	9	
221-2	32694-32703	principal	_	
221-3	32704-32716	investigator	1	
221-4	32717-32726	monitored	8	
221-5	32727-32730	all	2	
221-6	32731-32739	sessions	1	
221-7	32740-32742	by	3	
221-8	32743-32752	regularly	_	
221-9	32753-32762	reviewing	1	
221-10	32763-32768	video	2	
221-11	32769-32779	recordings	1	
221-12	32780-32783	and	3	
221-13	32784-32793	providing	1	
221-14	32794-32802	feedback	2	
221-15	32803-32813	throughout	2	
221-16	32814-32817	the	_	
221-17	32818-32823	study	_	
221-18	32824-32825	.	1	

#Text=Other exclusion criteria were pregnancy , decompensated liver cirrhosis , admission to the intensive care unit at the time of cholecystitis diagnosis , and mental illness prohibiting informed consent .
222-1	32826-32831	Other	9	
222-2	32832-32841	exclusion	_	
222-3	32842-32850	criteria	1	
222-4	32851-32855	were	8	
222-5	32856-32865	pregnancy	2	
222-6	32866-32867	,	_	
222-7	32868-32881	decompensated	_	
222-8	32882-32887	liver	_	
222-9	32888-32897	cirrhosis	_	
222-10	32898-32899	,	_	
222-11	32900-32909	admission	_	
222-12	32910-32912	to	_	
222-13	32913-32916	the	_	
222-14	32917-32926	intensive	_	
222-15	32927-32931	care	_	
222-16	32932-32936	unit	_	
222-17	32937-32939	at	_	
222-18	32940-32943	the	_	
222-19	32944-32948	time	_	
222-20	32949-32951	of	_	
222-21	32952-32965	cholecystitis	_	
222-22	32966-32975	diagnosis	_	
222-23	32976-32977	,	_	
222-24	32978-32981	and	_	
222-25	32982-32988	mental	_	
222-26	32989-32996	illness	_	
222-27	32997-33008	prohibiting	_	
222-28	33009-33017	informed	_	
222-29	33018-33025	consent	_	
222-30	33026-33027	.	1	

#Text=To show this effect with 80 % power , a two sided α level of 5 % , and a loss to follow-up of 1 % , we needed at least 284 patients in total .
223-1	33028-33030	To	3	
223-2	33031-33035	show	1	
223-3	33036-33040	this	2	
223-4	33041-33047	effect	_	
223-5	33048-33052	with	_	
223-6	33053-33055	80	_	
223-7	33056-33057	%	_	
223-8	33058-33063	power	_	
223-9	33064-33065	,	_	
223-10	33066-33067	a	_	
223-11	33068-33071	two	_	
223-12	33072-33077	sided	_	
223-13	33078-33079	α	_	
223-14	33080-33085	level	_	
223-15	33086-33088	of	_	
223-16	33089-33090	5	_	
223-17	33091-33092	%	_	
223-18	33093-33094	,	_	
223-19	33095-33098	and	_	
223-20	33099-33100	a	_	
223-21	33101-33105	loss	_	
223-22	33106-33108	to	_	
223-23	33109-33118	follow-up	_	
223-24	33119-33121	of	_	
223-25	33122-33123	1	_	
223-26	33124-33125	%	_	
223-27	33126-33127	,	1	
223-28	33128-33130	we	8	
223-29	33131-33137	needed	_	
223-30	33138-33140	at	_	
223-31	33141-33146	least	1	
223-32	33147-33150	284	2	
223-33	33151-33159	patients	1	
223-34	33160-33162	in	2	
223-35	33163-33168	total	_	
223-36	33169-33170	.	1	

#Text=After stratification , randomization was performed using custom Matlab ® software , with a block size of n = 6 and 1:1:1 allocation ratio .
224-1	33171-33176	After	2	
224-2	33177-33191	stratification	_	
224-3	33192-33193	,	1	
224-4	33194-33207	randomization	9	
224-5	33208-33211	was	8	
224-6	33212-33221	performed	_	
224-7	33222-33227	using	1	
224-8	33228-33234	custom	2	
224-9	33235-33241	Matlab	_	
224-10	33242-33243	®	_	
224-11	33244-33252	software	_	
224-12	33253-33254	,	1	
224-13	33255-33259	with	2	
224-14	33260-33261	a	_	
224-15	33262-33267	block	_	
224-16	33268-33272	size	_	
224-17	33273-33275	of	_	
224-18	33276-33277	n	_	
224-19	33278-33279	=	_	
224-20	33280-33281	6	_	
224-21	33282-33285	and	_	
224-22	33286-33287	1	_	
224-23	33287-33288	:	_	
224-24	33288-33289	1	_	
224-25	33289-33290	:	_	
224-26	33290-33291	1	_	
224-27	33292-33302	allocation	_	
224-28	33303-33308	ratio	_	
224-29	33309-33310	.	1	

#Text=Subject had received the prescribed dosing regimen during the first 72 hours of study .
225-1	33311-33318	Subject	9	
225-2	33319-33322	had	8	
225-3	33323-33331	received	1	
225-4	33332-33335	the	2	
225-5	33336-33346	prescribed	_	
225-6	33347-33353	dosing	_	
225-7	33354-33361	regimen	1	
225-8	33362-33368	during	2	
225-9	33369-33372	the	_	
225-10	33373-33378	first	_	
225-11	33379-33381	72	_	
225-12	33382-33387	hours	_	
225-13	33388-33390	of	_	
225-14	33391-33396	study	_	
225-15	33397-33398	.	1	

#Text=The diagnosis of AOM was based on examination with pneumatic otoscopy that identified a bulging or full tympanic membrane ( TM ) ; and purulent middle ear effusion , and reduced TM mobility as documented by both pneumatic otoscopy and an abnormal tympanogram as evidenced by a “ B ” or “ C ” curve .
226-1	33399-33402	The	9	
226-2	33403-33412	diagnosis	_	
226-3	33413-33415	of	_	
226-4	33416-33419	AOM	1	
226-5	33420-33423	was	8	
226-6	33424-33429	based	_	
226-7	33430-33432	on	1	
226-8	33433-33444	examination	2	
226-9	33445-33449	with	_	
226-10	33450-33459	pneumatic	_	
226-11	33460-33468	otoscopy	1	
226-12	33469-33473	that	6	
226-13	33474-33484	identified	3	
226-14	33485-33486	a	2	
226-15	33487-33494	bulging	_	
226-16	33495-33497	or	_	
226-17	33498-33502	full	_	
226-18	33503-33511	tympanic	_	
226-19	33512-33520	membrane	1	
226-20	33521-33522	(	5	
226-21	33523-33525	TM	_	
226-22	33526-33527	)	1	
226-23	33528-33529	;	6	
226-24	33530-33533	and	2	
226-25	33534-33542	purulent	_	
226-26	33543-33549	middle	_	
226-27	33550-33553	ear	_	
226-28	33554-33562	effusion	_	
226-29	33563-33564	,	1	
226-30	33565-33568	and	2	
226-31	33569-33576	reduced	_	
226-32	33577-33579	TM	_	
226-33	33580-33588	mobility	1	
226-34	33589-33591	as	3	
226-35	33592-33602	documented	_	
226-36	33603-33605	by	1	
226-37	33606-33610	both	2	
226-38	33611-33620	pneumatic	_	
226-39	33621-33629	otoscopy	_	
226-40	33630-33633	and	_	
226-41	33634-33636	an	_	
226-42	33637-33645	abnormal	_	
226-43	33646-33657	tympanogram	1	
226-44	33658-33660	as	3	
226-45	33661-33670	evidenced	_	
226-46	33671-33673	by	1	
226-47	33674-33675	a	2	
226-48	33676-33677	“	_	
226-49	33678-33679	B	_	
226-50	33680-33681	”	_	
226-51	33682-33684	or	_	
226-52	33685-33686	“	_	
226-53	33687-33688	C	_	
226-54	33689-33690	”	_	
226-55	33691-33696	curve	_	
226-56	33697-33698	.	1	

#Text=LPC , PC , and SM species were analyzed in two separate sample batches .
227-1	33699-33702	LPC	9	
227-2	33703-33704	,	_	
227-3	33705-33707	PC	_	
227-4	33708-33709	,	_	
227-5	33710-33713	and	_	
227-6	33714-33716	SM	_	
227-7	33717-33724	species	1	
227-8	33725-33729	were	8	
227-9	33730-33738	analyzed	_	
227-10	33739-33741	in	1	
227-11	33742-33745	two	2	
227-12	33746-33754	separate	_	
227-13	33755-33761	sample	_	
227-14	33762-33769	batches	_	
227-15	33770-33771	.	1	

#Text=Before removal of the drain , antegrade cholangiography was performed to assess for duodenal backflow and a patent cystic duct .
228-1	33772-33778	Before	2	
228-2	33779-33786	removal	_	
228-3	33787-33789	of	_	
228-4	33790-33793	the	_	
228-5	33794-33799	drain	_	
228-6	33800-33801	,	1	
228-7	33802-33811	antegrade	9	
228-8	33812-33827	cholangiography	1	
228-9	33828-33831	was	8	
228-10	33832-33841	performed	_	
228-11	33842-33844	to	_	
228-12	33845-33851	assess	_	
228-13	33852-33855	for	1	
228-14	33856-33864	duodenal	2	
228-15	33865-33873	backflow	_	
228-16	33874-33877	and	_	
228-17	33878-33879	a	_	
228-18	33880-33886	patent	_	
228-19	33887-33893	cystic	_	
228-20	33894-33898	duct	_	
228-21	33899-33900	.	1	

#Text=Each product was administered via injection using a 30-gauge half-inch needle in accordance with each product 's respective directions for use .
229-1	33901-33905	Each	9	
229-2	33906-33913	product	1	
229-3	33914-33917	was	8	
229-4	33918-33930	administered	_	
229-5	33931-33934	via	1	
229-6	33935-33944	injection	2	
229-7	33945-33950	using	3	
229-8	33951-33952	a	2	
229-9	33953-33955	30	_	
229-10	33955-33956	-	_	
229-11	33956-33961	gauge	_	
229-12	33962-33971	half-inch	_	
229-13	33972-33978	needle	1	
229-14	33979-33981	in	2	
229-15	33982-33992	accordance	_	
229-16	33993-33997	with	_	
229-17	33998-34002	each	_	
229-18	34003-34010	product	_	
229-19	34011-34012	'	_	
229-20	34012-34013	s	_	
229-21	34014-34024	respective	_	
229-22	34025-34035	directions	_	
229-23	34036-34039	for	_	
229-24	34040-34043	use	_	
229-25	34044-34045	.	1	

#Text=For binary outcomes , we used a generalized linear mixed model with random intercepts .
230-1	34046-34049	For	2	
230-2	34050-34056	binary	_	
230-3	34057-34065	outcomes	_	
230-4	34066-34067	,	1	
230-5	34068-34070	we	8	
230-6	34071-34075	used	1	
230-7	34076-34077	a	2	
230-8	34078-34089	generalized	_	
230-9	34090-34096	linear	_	
230-10	34097-34102	mixed	_	
230-11	34103-34108	model	_	
230-12	34109-34113	with	_	
230-13	34114-34120	random	_	
230-14	34121-34131	intercepts	_	
230-15	34132-34133	.	1	

#Text=C-reactive protein ( CRP ) and IgM cutoff values were chosen to identify maximal differences between the trimodulin and placebo groups ( Supplementary Figs.  
231-1	34134-34144	C-reactive	9	
231-2	34145-34152	protein	_	
231-3	34153-34154	(	5	
231-4	34155-34158	CRP	_	
231-5	34159-34160	)	1	
231-6	34161-34164	and	_	
231-7	34165-34168	IgM	_	
231-8	34169-34175	cutoff	_	
231-9	34176-34182	values	1	
231-10	34183-34187	were	8	
231-11	34188-34194	chosen	_	
231-12	34195-34197	to	_	
231-13	34198-34206	identify	1	
231-14	34207-34214	maximal	2	
231-15	34215-34226	differences	_	
231-16	34227-34234	between	_	
231-17	34235-34238	the	_	
231-18	34239-34249	trimodulin	_	
231-19	34250-34253	and	_	
231-20	34254-34261	placebo	_	
231-21	34262-34268	groups	1	
231-22	34269-34270	(	5	
231-23	34271-34284	Supplementary	_	
231-24	34285-34289	Figs	_	
231-25	34289-34290	.	1	
231-26	34291-34292	 	_	

#Text=S1 and S2 ) .
232-1	34293-34295	S1	_	
232-2	34296-34299	and	_	
232-3	34300-34302	S2	_	
232-4	34303-34304	)	_	
232-5	34305-34306	.	_	

#Text=In brief , we analyzed changes in phospholipid profiles of PCs , SMs and LPCs in blood using liquid chromatography coupled to time-of-flight mass spectrometry ( LC-TOF-MS ) and performed lipid separation by hydrophilic liquid interaction chromatography ( HILIC ) .
233-1	34307-34309	In	1	
233-2	34310-34315	brief	_	
233-3	34316-34317	,	1	
233-4	34318-34320	we	8	
233-5	34321-34329	analyzed	1	
233-6	34330-34337	changes	2	
233-7	34338-34340	in	_	
233-8	34341-34353	phospholipid	_	
233-9	34354-34362	profiles	_	
233-10	34363-34365	of	_	
233-11	34366-34369	PCs	_	
233-12	34370-34371	,	_	
233-13	34372-34375	SMs	_	
233-14	34376-34379	and	_	
233-15	34380-34384	LPCs	_	
233-16	34385-34387	in	_	
233-17	34388-34393	blood	1	
233-18	34394-34399	using	3	
233-19	34400-34406	liquid	2	
233-20	34407-34421	chromatography	_	
233-21	34422-34429	coupled	_	
233-22	34430-34432	to	_	
233-23	34433-34447	time-of-flight	_	
233-24	34448-34452	mass	_	
233-25	34453-34465	spectrometry	1	
233-26	34466-34467	(	5	
233-27	34468-34477	LC-TOF-MS	_	
233-28	34478-34479	)	1	
233-29	34480-34483	and	3	
233-30	34484-34493	performed	1	
233-31	34494-34499	lipid	2	
233-32	34500-34510	separation	1	
233-33	34511-34513	by	2	
233-34	34514-34525	hydrophilic	_	
233-35	34526-34532	liquid	_	
233-36	34533-34544	interaction	_	
233-37	34545-34559	chromatography	1	
233-38	34560-34561	(	5	
233-39	34562-34567	HILIC	_	
233-40	34568-34569	)	_	
233-41	34570-34571	.	1	

#Text=The patients were directed to continue taking all prescription drugs as usual throughout the trial and to record all prescription and non-prescription drugs in the patient diary .
234-1	34572-34575	The	9	
234-2	34576-34584	patients	1	
234-3	34585-34589	were	8	
234-4	34590-34598	directed	_	
234-5	34599-34601	to	_	
234-6	34602-34610	continue	_	
234-7	34611-34617	taking	1	
234-8	34618-34621	all	2	
234-9	34622-34634	prescription	_	
234-10	34635-34640	drugs	1	
234-11	34641-34643	as	7	
234-12	34644-34649	usual	1	
234-13	34650-34660	throughout	2	
234-14	34661-34664	the	_	
234-15	34665-34670	trial	1	
234-16	34671-34674	and	3	
234-17	34675-34677	to	_	
234-18	34678-34684	record	1	
234-19	34685-34688	all	2	
234-20	34689-34701	prescription	_	
234-21	34702-34705	and	_	
234-22	34706-34722	non-prescription	_	
234-23	34723-34728	drugs	_	
234-24	34729-34731	in	_	
234-25	34732-34735	the	_	
234-26	34736-34743	patient	_	
234-27	34744-34749	diary	_	
234-28	34750-34751	.	1	

#Text=Samples were centrifuged at 10,000 × g for 10 min at 4 ° C for removal of any residual platelets and precipitates , diluted fourfold with Bio-Plex sample diluent , and analyzed according to the protocol Bio-Plex Pro Human Cytokine 17-plex Assay ( Bio-Rad , USA ) .
235-1	34752-34759	Samples	9	
235-2	34760-34764	were	8	
235-3	34765-34776	centrifuged	1	
235-4	34777-34779	at	2	
235-5	34780-34786	10,000	_	
235-6	34787-34788	×	_	
235-7	34789-34790	g	_	
235-8	34791-34794	for	_	
235-9	34795-34797	10	_	
235-10	34798-34801	min	_	
235-11	34802-34804	at	_	
235-12	34805-34806	4	_	
235-13	34807-34808	°	_	
235-14	34809-34810	C	1	
235-15	34811-34814	for	2	
235-16	34815-34822	removal	_	
235-17	34823-34825	of	_	
235-18	34826-34829	any	_	
235-19	34830-34838	residual	_	
235-20	34839-34848	platelets	_	
235-21	34849-34852	and	_	
235-22	34853-34865	precipitates	_	
235-23	34866-34867	,	_	
235-24	34868-34875	diluted	_	
235-25	34876-34884	fourfold	_	
235-26	34885-34889	with	_	
235-27	34890-34898	Bio-Plex	_	
235-28	34899-34905	sample	_	
235-29	34906-34913	diluent	_	
235-30	34914-34915	,	1	
235-31	34916-34919	and	3	
235-32	34920-34928	analyzed	_	
235-33	34929-34938	according	_	
235-34	34939-34941	to	1	
235-35	34942-34945	the	2	
235-36	34946-34954	protocol	_	
235-37	34955-34963	Bio-Plex	_	
235-38	34964-34967	Pro	_	
235-39	34968-34973	Human	_	
235-40	34974-34982	Cytokine	_	
235-41	34983-34985	17	_	
235-42	34985-34986	-	_	
235-43	34986-34990	plex	_	
235-44	34991-34996	Assay	1	
235-45	34997-34998	(	5	
235-46	34999-35006	Bio-Rad	_	
235-47	35007-35008	,	_	
235-48	35009-35012	USA	_	
235-49	35013-35014	)	_	
235-50	35015-35016	.	1	

#Text=Acute cholecystitis was defined according to the Tokyo guidelines.
236-1	35017-35022	Acute	9	
236-2	35023-35036	cholecystitis	1	
236-3	35037-35040	was	8	
236-4	35041-35048	defined	_	
236-5	35049-35058	according	_	
236-6	35059-35061	to	1	
236-7	35062-35065	the	2	
236-8	35066-35071	Tokyo	_	
236-9	35072-35082	guidelines	_	
236-10	35082-35083	.	1	

#Text=Their data were included in the analyses according to the principle of intention to treat .
237-1	35084-35089	Their	9	
237-2	35090-35094	data	1	
237-3	35095-35099	were	8	
237-4	35100-35108	included	_	
237-5	35109-35111	in	1	
237-6	35112-35115	the	2	
237-7	35116-35124	analyses	1	
237-8	35125-35134	according	2	
237-9	35135-35137	to	_	
237-10	35138-35141	the	_	
237-11	35142-35151	principle	_	
237-12	35152-35154	of	_	
237-13	35155-35164	intention	_	
237-14	35165-35167	to	_	
237-15	35168-35173	treat	_	
237-16	35174-35175	.	1	

#Text=For patients lost to follow-up at 90 days , the missing 90-day score on the modified Rankin scale was imputed from the 30-day score by the last-observation-carried-forward method .
238-1	35176-35179	For	2	
238-2	35180-35188	patients	_	
238-3	35189-35193	lost	3	
238-4	35194-35196	to	1	
238-5	35197-35206	follow-up	2	
238-6	35207-35209	at	_	
238-7	35210-35212	90	_	
238-8	35213-35217	days	_	
238-9	35218-35219	,	1	
238-10	35220-35223	the	9	
238-11	35224-35231	missing	_	
238-12	35232-35234	90	_	
238-13	35234-35235	-	_	
238-14	35235-35238	day	_	
238-15	35239-35244	score	_	
238-16	35245-35247	on	_	
238-17	35248-35251	the	_	
238-18	35252-35260	modified	_	
238-19	35261-35267	Rankin	_	
238-20	35268-35273	scale	1	
238-21	35274-35277	was	8	
238-22	35278-35285	imputed	_	
238-23	35286-35290	from	1	
238-24	35291-35294	the	2	
238-25	35295-35297	30	_	
238-26	35297-35298	-	_	
238-27	35298-35301	day	_	
238-28	35302-35307	score	1	
238-29	35308-35310	by	2	
238-30	35311-35314	the	_	
238-31	35315-35347	last-observation-carried-forward	_	
238-32	35348-35354	method	_	
238-33	35355-35356	.	1	

#Text=Twenty μL of serum sample was added and lipids were extracted by means of an updated Bligh and Dyer method ( 2 ) .
239-1	35357-35363	Twenty	9	
239-2	35364-35366	μL	_	
239-3	35367-35369	of	_	
239-4	35370-35375	serum	_	
239-5	35376-35382	sample	1	
239-6	35383-35386	was	8	
239-7	35387-35392	added	1	
239-8	35393-35396	and	9	
239-9	35397-35403	lipids	1	
239-10	35404-35408	were	3	
239-11	35409-35418	extracted	_	
239-12	35419-35421	by	_	
239-13	35422-35427	means	_	
239-14	35428-35430	of	1	
239-15	35431-35433	an	2	
239-16	35434-35441	updated	_	
239-17	35442-35447	Bligh	_	
239-18	35448-35451	and	_	
239-19	35452-35456	Dyer	_	
239-20	35457-35463	method	1	
239-21	35464-35465	(	2	
239-22	35466-35467	2	_	
239-23	35468-35469	)	_	
239-24	35470-35471	.	1	

#Text=Lastly , time taken to ascend a 9-step staircase as quickly as possible , with or without the use of a handrail , was recorded for the SA test .
240-1	35472-35478	Lastly	6	
240-2	35479-35480	,	1	
240-3	35481-35485	time	9	
240-4	35486-35491	taken	3	
240-5	35492-35494	to	_	
240-6	35495-35501	ascend	1	
240-7	35502-35503	a	2	
240-8	35504-35505	9	_	
240-9	35505-35506	-	_	
240-10	35506-35510	step	_	
240-11	35511-35520	staircase	1	
240-12	35521-35523	as	7	
240-13	35524-35531	quickly	_	
240-14	35532-35534	as	_	
240-15	35535-35543	possible	_	
240-16	35544-35545	,	1	
240-17	35546-35550	with	2	
240-18	35551-35553	or	_	
240-19	35554-35561	without	_	
240-20	35562-35565	the	_	
240-21	35566-35569	use	_	
240-22	35570-35572	of	_	
240-23	35573-35574	a	_	
240-24	35575-35583	handrail	_	
240-25	35584-35585	,	1	
240-26	35586-35589	was	8	
240-27	35590-35598	recorded	_	
240-28	35599-35602	for	1	
240-29	35603-35606	the	2	
240-30	35607-35609	SA	_	
240-31	35610-35614	test	_	
240-32	35615-35616	.	1	

#Text=Participants were also asked to rate their knee pain on a visual analog scale [ 26 ] prior to each session and ensure that pain levels were not exacerbated by more than two points .
241-1	35617-35629	Participants	9	
241-2	35630-35634	were	1	
241-3	35635-35639	also	_	
241-4	35640-35645	asked	_	
241-5	35646-35648	to	_	
241-6	35649-35653	rate	1	
241-7	35654-35659	their	2	
241-8	35660-35664	knee	_	
241-9	35665-35669	pain	1	
241-10	35670-35672	on	2	
241-11	35673-35674	a	_	
241-12	35675-35681	visual	_	
241-13	35682-35688	analog	_	
241-14	35689-35694	scale	1	
241-15	35695-35696	[	5	
241-16	35697-35699	26	_	
241-17	35700-35701	]	1	
241-18	35702-35707	prior	2	
241-19	35708-35710	to	_	
241-20	35711-35715	each	_	
241-21	35716-35723	session	1	
241-22	35724-35727	and	3	
241-23	35728-35734	ensure	1	
241-24	35735-35739	that	6	
241-25	35740-35744	pain	9	
241-26	35745-35751	levels	1	
241-27	35752-35756	were	3	
241-28	35757-35760	not	_	
241-29	35761-35772	exacerbated	_	
241-30	35773-35775	by	1	
241-31	35776-35780	more	2	
241-32	35781-35785	than	_	
241-33	35786-35789	two	_	
241-34	35790-35796	points	_	
241-35	35797-35798	.	1	

#Text=In the SMWT test , participants were instructed to walk as far as possible in six-minutes ; the distance travelled was recorded .
242-1	35799-35801	In	2	
242-2	35802-35805	the	_	
242-3	35806-35810	SMWT	_	
242-4	35811-35815	test	_	
242-5	35816-35817	,	1	
242-6	35818-35830	participants	9	
242-7	35831-35835	were	8	
242-8	35836-35846	instructed	_	
242-9	35847-35849	to	_	
242-10	35850-35854	walk	1	
242-11	35855-35857	as	7	
242-12	35858-35861	far	_	
242-13	35862-35864	as	_	
242-14	35865-35873	possible	1	
242-15	35874-35876	in	2	
242-16	35877-35888	six-minutes	1	
242-17	35889-35890	;	6	
242-18	35891-35894	the	_	
242-19	35895-35903	distance	9	
242-20	35904-35913	travelled	1	
242-21	35914-35917	was	3	
242-22	35918-35926	recorded	_	
242-23	35927-35928	.	1	

#Text=The Spearman´s rank test was used to evaluate association between the concentrations of LPC , blood cells , and C-reactive protein ( CRP ) , respectively .
243-1	35929-35932	The	9	
243-2	35933-35941	Spearman	_	
243-3	35941-35942	´	_	
243-4	35942-35943	s	_	
243-5	35944-35948	rank	_	
243-6	35949-35953	test	1	
243-7	35954-35957	was	8	
243-8	35958-35962	used	_	
243-9	35963-35965	to	_	
243-10	35966-35974	evaluate	1	
243-11	35975-35986	association	2	
243-12	35987-35994	between	_	
243-13	35995-35998	the	_	
243-14	35999-36013	concentrations	_	
243-15	36014-36016	of	_	
243-16	36017-36020	LPC	_	
243-17	36021-36022	,	_	
243-18	36023-36028	blood	_	
243-19	36029-36034	cells	_	
243-20	36035-36036	,	_	
243-21	36037-36040	and	_	
243-22	36041-36051	C-reactive	_	
243-23	36052-36059	protein	1	
243-24	36060-36061	(	5	
243-25	36062-36065	CRP	_	
243-26	36066-36067	)	_	
243-27	36068-36069	,	1	
243-28	36070-36082	respectively	6	
243-29	36083-36084	.	1	

#Text=In the event that pain increased more than two points during a session , participants were asked to notify the instructor for an appropriate modification [ 10 ] .
244-1	36085-36087	In	2	
244-2	36088-36091	the	_	
244-3	36092-36097	event	1	
244-4	36098-36102	that	6	
244-5	36103-36107	pain	9	
244-6	36108-36117	increased	3	
244-7	36118-36122	more	2	
244-8	36123-36127	than	_	
244-9	36128-36131	two	_	
244-10	36132-36138	points	1	
244-11	36139-36145	during	2	
244-12	36146-36147	a	_	
244-13	36148-36155	session	_	
244-14	36156-36157	,	1	
244-15	36158-36170	participants	9	
244-16	36171-36175	were	8	
244-17	36176-36181	asked	_	
244-18	36182-36184	to	_	
244-19	36185-36191	notify	1	
244-20	36192-36195	the	2	
244-21	36196-36206	instructor	1	
244-22	36207-36210	for	2	
244-23	36211-36213	an	_	
244-24	36214-36225	appropriate	_	
244-25	36226-36238	modification	1	
244-26	36239-36240	[	5	
244-27	36241-36243	10	_	
244-28	36244-36245	]	_	
244-29	36246-36247	.	1	

#Text=Subjects with an uncontrolled disease , active inflammation , infection , or lesions in the NLF area , or who had a tendency for developing hypertrophic scarring were also excluded .
245-1	36248-36256	Subjects	9	
245-2	36257-36261	with	_	
245-3	36262-36264	an	_	
245-4	36265-36277	uncontrolled	_	
245-5	36278-36285	disease	_	
245-6	36286-36287	,	_	
245-7	36288-36294	active	_	
245-8	36295-36307	inflammation	_	
245-9	36308-36309	,	_	
245-10	36310-36319	infection	_	
245-11	36320-36321	,	_	
245-12	36322-36324	or	_	
245-13	36325-36332	lesions	_	
245-14	36333-36335	in	_	
245-15	36336-36339	the	_	
245-16	36340-36343	NLF	_	
245-17	36344-36348	area	_	
245-18	36349-36350	,	1	
245-19	36351-36353	or	6	
245-20	36354-36357	who	1	
245-21	36358-36361	had	3	
245-22	36362-36363	a	2	
245-23	36364-36372	tendency	_	
245-24	36373-36376	for	_	
245-25	36377-36387	developing	_	
245-26	36388-36400	hypertrophic	_	
245-27	36401-36409	scarring	1	
245-28	36410-36414	were	8	
245-29	36415-36419	also	_	
245-30	36420-36428	excluded	_	
245-31	36429-36430	.	1	

#Text=The samples were handled as described above .
246-1	36431-36434	The	9	
246-2	36435-36442	samples	1	
246-3	36443-36447	were	8	
246-4	36448-36455	handled	_	
246-5	36456-36458	as	_	
246-6	36459-36468	described	_	
246-7	36469-36474	above	_	
246-8	36475-36476	.	1	

#Text=Reinterventions were either surgical , radiological , or endoscopic and had to be directly or indirectly related to acute cholecystitis .
247-1	36477-36492	Reinterventions	9	
247-2	36493-36497	were	8	
247-3	36498-36504	either	6	
247-4	36505-36513	surgical	7	
247-5	36514-36515	,	_	
247-6	36516-36528	radiological	_	
247-7	36529-36530	,	_	
247-8	36531-36533	or	_	
247-9	36534-36544	endoscopic	1	
247-10	36545-36548	and	3	
247-11	36549-36552	had	_	
247-12	36553-36555	to	_	
247-13	36556-36558	be	_	
247-14	36559-36567	directly	_	
247-15	36568-36570	or	_	
247-16	36571-36581	indirectly	_	
247-17	36582-36589	related	_	
247-18	36590-36592	to	1	
247-19	36593-36598	acute	2	
247-20	36599-36612	cholecystitis	_	
247-21	36613-36614	.	1	

#Text=The trial was approved by the StrokeNet central institutional review board and the Food and Drug Administration ( FDA ) for an investigational device exemption ( IDE G150028 ) .
248-1	36615-36618	The	9	
248-2	36619-36624	trial	1	
248-3	36625-36628	was	8	
248-4	36629-36637	approved	_	
248-5	36638-36640	by	1	
248-6	36641-36644	the	2	
248-7	36645-36654	StrokeNet	_	
248-8	36655-36662	central	_	
248-9	36663-36676	institutional	_	
248-10	36677-36683	review	_	
248-11	36684-36689	board	_	
248-12	36690-36693	and	_	
248-13	36694-36697	the	_	
248-14	36698-36702	Food	_	
248-15	36703-36706	and	_	
248-16	36707-36711	Drug	_	
248-17	36712-36726	Administration	1	
248-18	36727-36728	(	5	
248-19	36729-36732	FDA	_	
248-20	36733-36734	)	1	
248-21	36735-36738	for	2	
248-22	36739-36741	an	_	
248-23	36742-36757	investigational	_	
248-24	36758-36764	device	_	
248-25	36765-36774	exemption	1	
248-26	36775-36776	(	5	
248-27	36777-36780	IDE	_	
248-28	36781-36788	G150028	_	
248-29	36789-36790	)	_	
248-30	36791-36792	.	1	

#Text=Recurrent biliary disease was considered an endpoint only if readmission was required ( so we did not include patients with recurrent biliary disease presenting to the general practitioner or emergency department without subsequent admission to hospital ) .
249-1	36793-36802	Recurrent	9	
249-2	36803-36810	biliary	_	
249-3	36811-36818	disease	1	
249-4	36819-36822	was	8	
249-5	36823-36833	considered	1	
249-6	36834-36836	an	2	
249-7	36837-36845	endpoint	1	
249-8	36846-36850	only	6	
249-9	36851-36853	if	1	
249-10	36854-36865	readmission	9	
249-11	36866-36869	was	3	
249-12	36870-36878	required	1	
249-13	36879-36880	(	5	
249-14	36881-36883	so	_	
249-15	36884-36886	we	_	
249-16	36887-36890	did	_	
249-17	36891-36894	not	_	
249-18	36895-36902	include	_	
249-19	36903-36911	patients	_	
249-20	36912-36916	with	_	
249-21	36917-36926	recurrent	_	
249-22	36927-36934	biliary	_	
249-23	36935-36942	disease	_	
249-24	36943-36953	presenting	_	
249-25	36954-36956	to	_	
249-26	36957-36960	the	_	
249-27	36961-36968	general	_	
249-28	36969-36981	practitioner	_	
249-29	36982-36984	or	_	
249-30	36985-36994	emergency	_	
249-31	36995-37005	department	_	
249-32	37006-37013	without	_	
249-33	37014-37024	subsequent	_	
249-34	37025-37034	admission	_	
249-35	37035-37037	to	_	
249-36	37038-37046	hospital	_	
249-37	37047-37048	)	_	
249-38	37049-37050	.	1	

#Text=The DEFUSE 3 trial was funded by the National Institutes of Health ( NIH ) through StrokeNet , a network of more than 300 U.S. hospitals .
250-1	37051-37054	The	9	
250-2	37055-37061	DEFUSE	_	
250-3	37062-37063	3	_	
250-4	37064-37069	trial	1	
250-5	37070-37073	was	8	
250-6	37074-37080	funded	_	
250-7	37081-37083	by	1	
250-8	37084-37087	the	2	
250-9	37088-37096	National	_	
250-10	37097-37107	Institutes	_	
250-11	37108-37110	of	_	
250-12	37111-37117	Health	1	
250-13	37118-37119	(	5	
250-14	37120-37123	NIH	_	
250-15	37124-37125	)	1	
250-16	37126-37133	through	2	
250-17	37134-37143	StrokeNet	_	
250-18	37144-37145	,	_	
250-19	37146-37147	a	_	
250-20	37148-37155	network	_	
250-21	37156-37158	of	_	
250-22	37159-37163	more	_	
250-23	37164-37168	than	_	
250-24	37169-37172	300	_	
250-25	37173-37176	U.S	_	
250-26	37176-37177	.	_	
250-27	37178-37187	hospitals	_	
250-28	37188-37189	.	1	

#Text=They were all given routine advice to stay hydrated alongside information on proper self-care .
251-1	37190-37194	They	8	
251-2	37195-37199	were	_	
251-3	37200-37203	all	_	
251-4	37204-37209	given	1	
251-5	37210-37217	routine	2	
251-6	37218-37224	advice	_	
251-7	37225-37227	to	_	
251-8	37228-37232	stay	_	
251-9	37233-37241	hydrated	1	
251-10	37242-37251	alongside	2	
251-11	37252-37263	information	_	
251-12	37264-37266	on	_	
251-13	37267-37273	proper	_	
251-14	37274-37283	self-care	_	
251-15	37284-37285	.	1	

#Text=We realized that the results of their main trial were in favor of antibiotic treatment , but with 67 % in the ibuprofen group recovering with only 1 more day of symptoms , we were still optimistic regarding the outcome of our trial .
252-1	37286-37288	We	8	
252-2	37289-37297	realized	1	
252-3	37298-37302	that	6	
252-4	37303-37306	the	9	
252-5	37307-37314	results	_	
252-6	37315-37317	of	_	
252-7	37318-37323	their	_	
252-8	37324-37328	main	_	
252-9	37329-37334	trial	1	
252-10	37335-37339	were	3	
252-11	37340-37342	in	1	
252-12	37343-37348	favor	7	
252-13	37349-37351	of	2	
252-14	37352-37362	antibiotic	_	
252-15	37363-37372	treatment	_	
252-16	37373-37374	,	1	
252-17	37375-37378	but	2	
252-18	37379-37383	with	_	
252-19	37384-37386	67	_	
252-20	37387-37388	%	_	
252-21	37389-37391	in	_	
252-22	37392-37395	the	_	
252-23	37396-37405	ibuprofen	_	
252-24	37406-37411	group	_	
252-25	37412-37422	recovering	_	
252-26	37423-37427	with	_	
252-27	37428-37432	only	_	
252-28	37433-37434	1	_	
252-29	37435-37439	more	_	
252-30	37440-37443	day	_	
252-31	37444-37446	of	_	
252-32	37447-37455	symptoms	_	
252-33	37456-37457	,	1	
252-34	37458-37460	we	3	
252-35	37461-37465	were	1	
252-36	37466-37471	still	7	
252-37	37472-37482	optimistic	1	
252-38	37483-37492	regarding	3	
252-39	37493-37496	the	2	
252-40	37497-37504	outcome	_	
252-41	37505-37507	of	_	
252-42	37508-37511	our	_	
252-43	37512-37517	trial	_	
252-44	37518-37519	.	1	

#Text=Participants were encouraged to integrate at least 30 minutes of Tai Chi or physical therapy into their daily routine throughout follow-up .
253-1	37520-37532	Participants	9	
253-2	37533-37537	were	8	
253-3	37538-37548	encouraged	_	
253-4	37549-37551	to	_	
253-5	37552-37561	integrate	_	
253-6	37562-37564	at	_	
253-7	37565-37570	least	1	
253-8	37571-37573	30	2	
253-9	37574-37581	minutes	_	
253-10	37582-37584	of	_	
253-11	37585-37588	Tai	_	
253-12	37589-37592	Chi	_	
253-13	37593-37595	or	_	
253-14	37596-37604	physical	_	
253-15	37605-37612	therapy	1	
253-16	37613-37617	into	2	
253-17	37618-37623	their	_	
253-18	37624-37629	daily	_	
253-19	37630-37637	routine	1	
253-20	37638-37648	throughout	2	
253-21	37649-37658	follow-up	_	
253-22	37659-37660	.	1	

#Text=Subsequent sessions started with a warm-up and a review of Tai Chi principles and movement , breathing techniques , and relaxation methods .
254-1	37661-37671	Subsequent	9	
254-2	37672-37680	sessions	1	
254-3	37681-37688	started	8	
254-4	37689-37693	with	1	
254-5	37694-37695	a	2	
254-6	37696-37703	warm-up	_	
254-7	37704-37707	and	_	
254-8	37708-37709	a	_	
254-9	37710-37716	review	_	
254-10	37717-37719	of	_	
254-11	37720-37723	Tai	_	
254-12	37724-37727	Chi	_	
254-13	37728-37738	principles	_	
254-14	37739-37742	and	_	
254-15	37743-37751	movement	_	
254-16	37752-37753	,	_	
254-17	37754-37763	breathing	_	
254-18	37764-37774	techniques	_	
254-19	37775-37776	,	_	
254-20	37777-37780	and	_	
254-21	37781-37791	relaxation	_	
254-22	37792-37799	methods	_	
254-23	37800-37801	.	1	

#Text=When the patients had completed the diary , they were asked to return it to the study site .
255-1	37802-37806	When	6	
255-2	37807-37810	the	9	
255-3	37811-37819	patients	1	
255-4	37820-37823	had	8	
255-5	37824-37833	completed	1	
255-6	37834-37837	the	2	
255-7	37838-37843	diary	_	
255-8	37844-37845	,	1	
255-9	37846-37850	they	8	
255-10	37851-37855	were	_	
255-11	37856-37861	asked	_	
255-12	37862-37864	to	_	
255-13	37865-37871	return	_	
255-14	37872-37874	it	_	
255-15	37875-37877	to	1	
255-16	37878-37881	the	2	
255-17	37882-37887	study	_	
255-18	37888-37892	site	_	
255-19	37893-37894	.	1	

#Text=Patients were recruited from the accident and emergency outpatient clinics ( AEOCs ) in Oslo and Bergen , Norway , 7 general practices in Denmark , and 7 general practices in Sweden .
256-1	37895-37903	Patients	9	
256-2	37904-37908	were	8	
256-3	37909-37918	recruited	_	
256-4	37919-37923	from	1	
256-5	37924-37927	the	2	
256-6	37928-37936	accident	_	
256-7	37937-37940	and	_	
256-8	37941-37950	emergency	_	
256-9	37951-37961	outpatient	_	
256-10	37962-37969	clinics	1	
256-11	37970-37971	(	5	
256-12	37972-37977	AEOCs	_	
256-13	37978-37979	)	1	
256-14	37980-37982	in	2	
256-15	37983-37987	Oslo	_	
256-16	37988-37991	and	_	
256-17	37992-37998	Bergen	_	
256-18	37999-38000	,	_	
256-19	38001-38007	Norway	_	
256-20	38008-38009	,	1	
256-21	38010-38011	7	2	
256-22	38012-38019	general	_	
256-23	38020-38029	practices	1	
256-24	38030-38032	in	2	
256-25	38033-38040	Denmark	_	
256-26	38041-38042	,	1	
256-27	38043-38046	and	2	
256-28	38047-38048	7	_	
256-29	38049-38056	general	_	
256-30	38057-38066	practices	1	
256-31	38067-38069	in	2	
256-32	38070-38076	Sweden	_	
256-33	38077-38078	.	1	

#Text=Patients were required to have an occlusion of the cervical or intracranial internal carotid artery or the proximal middle cerebral artery on CT angiography ( CTA ) or magnetic resonance angiography ( MRA ) .
257-1	38079-38087	Patients	9	
257-2	38088-38092	were	8	
257-3	38093-38101	required	_	
257-4	38102-38104	to	_	
257-5	38105-38109	have	1	
257-6	38110-38112	an	2	
257-7	38113-38122	occlusion	_	
257-8	38123-38125	of	_	
257-9	38126-38129	the	_	
257-10	38130-38138	cervical	_	
257-11	38139-38141	or	_	
257-12	38142-38154	intracranial	_	
257-13	38155-38163	internal	_	
257-14	38164-38171	carotid	_	
257-15	38172-38178	artery	_	
257-16	38179-38181	or	_	
257-17	38182-38185	the	_	
257-18	38186-38194	proximal	_	
257-19	38195-38201	middle	_	
257-20	38202-38210	cerebral	_	
257-21	38211-38217	artery	1	
257-22	38218-38220	on	_	
257-23	38221-38223	CT	_	
257-24	38224-38235	angiography	_	
257-25	38236-38237	(	_	
257-26	38238-38241	CTA	_	
257-27	38242-38243	)	_	
257-28	38244-38246	or	_	
257-29	38247-38255	magnetic	_	
257-30	38256-38265	resonance	_	
257-31	38266-38277	angiography	_	
257-32	38278-38279	(	_	
257-33	38280-38283	MRA	_	
257-34	38284-38285	)	_	
257-35	38286-38287	.	_	

#Text=After 6 weeks , participants were instructed to continue exercises in 30-minute sessions 4 times per week for 6 weeks .
258-1	38288-38293	After	2	
258-2	38294-38295	6	_	
258-3	38296-38301	weeks	_	
258-4	38302-38303	,	1	
258-5	38304-38316	participants	9	
258-6	38317-38321	were	8	
258-7	38322-38332	instructed	_	
258-8	38333-38335	to	_	
258-9	38336-38344	continue	1	
258-10	38345-38354	exercises	2	
258-11	38355-38357	in	2	
258-12	38358-38360	30	_	
258-13	38360-38361	-	_	
258-14	38361-38367	minute	_	
258-15	38368-38376	sessions	_	
258-16	38377-38378	4	_	
258-17	38379-38384	times	_	
258-18	38385-38388	per	_	
258-19	38389-38393	week	_	
258-20	38394-38397	for	_	
258-21	38398-38399	6	_	
258-22	38400-38405	weeks	_	
258-23	38406-38407	.	1	

#Text=Treating investigators evaluated the ease of injection and the moldability of each product on 3-point scales ( left side easier , both sides the same , right side easier ) .
259-1	38408-38416	Treating	9	
259-2	38417-38430	investigators	1	
259-3	38431-38440	evaluated	8	
259-4	38441-38444	the	2	
259-5	38445-38449	ease	_	
259-6	38450-38452	of	_	
259-7	38453-38462	injection	_	
259-8	38463-38466	and	_	
259-9	38467-38470	the	_	
259-10	38471-38482	moldability	_	
259-11	38483-38485	of	_	
259-12	38486-38490	each	_	
259-13	38491-38498	product	1	
259-14	38499-38501	on	2	
259-15	38502-38503	3	_	
259-16	38503-38504	-	_	
259-17	38504-38509	point	_	
259-18	38510-38516	scales	1	
259-19	38517-38518	(	5	
259-20	38519-38523	left	_	
259-21	38524-38528	side	_	
259-22	38529-38535	easier	_	
259-23	38536-38537	,	_	
259-24	38538-38542	both	_	
259-25	38543-38548	sides	_	
259-26	38549-38552	the	_	
259-27	38553-38557	same	_	
259-28	38558-38559	,	_	
259-29	38560-38565	right	_	
259-30	38566-38570	side	_	
259-31	38571-38577	easier	_	
259-32	38578-38579	)	_	
259-33	38580-38581	.	1	

#Text=No indeterminate criteria apply .
260-1	38582-38584	No	9	
260-2	38585-38598	indeterminate	_	
260-3	38599-38607	criteria	1	
260-4	38608-38613	apply	8	
260-5	38614-38615	.	1	

#Text=The noninferiority margin was set at 20 points ( 32 ) for the primary outcome of WOMAC pain score .
261-1	38616-38619	The	9	
261-2	38620-38634	noninferiority	_	
261-3	38635-38641	margin	1	
261-4	38642-38645	was	8	
261-5	38646-38649	set	_	
261-6	38650-38652	at	2	
261-7	38653-38655	20	2	
261-8	38656-38662	points	1	
261-9	38663-38664	(	5	
261-10	38665-38667	32	_	
261-11	38668-38669	)	1	
261-12	38670-38673	for	2	
261-13	38674-38677	the	_	
261-14	38678-38685	primary	_	
261-15	38686-38693	outcome	_	
261-16	38694-38696	of	_	
261-17	38697-38702	WOMAC	_	
261-18	38703-38707	pain	_	
261-19	38708-38713	score	_	
261-20	38714-38715	.	1	

#Text=Participants were also provided a study telephone number for reporting of adverse events throughout the study .
262-1	38716-38728	Participants	1	
262-2	38729-38733	were	8	
262-3	38734-38738	also	_	
262-4	38739-38747	provided	1	
262-5	38748-38749	a	2	
262-6	38750-38755	study	_	
262-7	38756-38765	telephone	_	
262-8	38766-38772	number	_	
262-9	38773-38776	for	_	
262-10	38777-38786	reporting	_	
262-11	38787-38789	of	_	
262-12	38790-38797	adverse	_	
262-13	38798-38804	events	_	
262-14	38805-38815	throughout	_	
262-15	38816-38819	the	_	
262-16	38820-38825	study	_	
262-17	38826-38827	.	1	

#Text=For intra- and inter-day precision , the LPC standards were added to a 1.5 mL-Eppendorf tube at two different levels together with the IS LPC 19:0 , evaporated , and subsequently the matrix was added and prepared and analyzed as described above .
263-1	38828-38831	For	2	
263-2	38832-38837	intra	_	
263-3	38837-38838	-	_	
263-4	38839-38842	and	_	
263-5	38843-38852	inter-day	_	
263-6	38853-38862	precision	_	
263-7	38863-38864	,	1	
263-8	38865-38868	the	9	
263-9	38869-38872	LPC	_	
263-10	38873-38882	standards	1	
263-11	38883-38887	were	8	
263-12	38888-38893	added	_	
263-13	38894-38896	to	1	
263-14	38897-38898	a	2	
263-15	38899-38902	1.5	_	
263-16	38903-38915	mL-Eppendorf	_	
263-17	38916-38920	tube	1	
263-18	38921-38923	at	2	
263-19	38924-38927	two	_	
263-20	38928-38937	different	_	
263-21	38938-38944	levels	1	
263-22	38945-38953	together	2	
263-23	38954-38958	with	_	
263-24	38959-38962	the	_	
263-25	38963-38965	IS	_	
263-26	38966-38969	LPC	_	
263-27	38970-38972	19	_	
263-28	38972-38973	:	_	
263-29	38973-38974	0	_	
263-30	38975-38976	,	1	
263-31	38977-38987	evaporated	3	
263-32	38988-38989	,	_	
263-33	38990-38993	and	6	
263-34	38994-39006	subsequently	1	
263-35	39007-39010	the	9	
263-36	39011-39017	matrix	1	
263-37	39018-39021	was	3	
263-38	39022-39027	added	_	
263-39	39028-39031	and	_	
263-40	39032-39040	prepared	_	
263-41	39041-39044	and	_	
263-42	39045-39053	analyzed	_	
263-43	39054-39056	as	_	
263-44	39057-39066	described	_	
263-45	39067-39072	above	_	
263-46	39073-39074	.	1	

#Text=The calculated overlap was subtracted from the Area/IS ratios .
264-1	39075-39078	The	9	
264-2	39079-39089	calculated	_	
264-3	39090-39097	overlap	1	
264-4	39098-39101	was	8	
264-5	39102-39112	subtracted	_	
264-6	39113-39117	from	1	
264-7	39118-39121	the	2	
264-8	39122-39126	Area	_	
264-9	39126-39127	/	_	
264-10	39127-39129	IS	_	
264-11	39130-39136	ratios	_	
264-12	39137-39138	.	1	

#Text=All phospholipid species were corrected for isotopic overlap .
265-1	39139-39142	All	9	
265-2	39143-39155	phospholipid	_	
265-3	39156-39163	species	1	
265-4	39164-39168	were	8	
265-5	39169-39178	corrected	_	
265-6	39179-39182	for	1	
265-7	39183-39191	isotopic	2	
265-8	39192-39199	overlap	_	
265-9	39200-39201	.	1	

#Text=Efficacy analyses were performed in the intent-to-treat set , which included all randomized patients who received at least one dose of study drug and at least one efficacy assessment , assigned as randomized .
266-1	39202-39210	Efficacy	9	
266-2	39211-39219	analyses	1	
266-3	39220-39224	were	8	
266-4	39225-39234	performed	_	
266-5	39235-39237	in	1	
266-6	39238-39241	the	2	
266-7	39242-39257	intent-to-treat	_	
266-8	39258-39261	set	_	
266-9	39262-39263	,	1	
266-10	39264-39269	which	6	
266-11	39270-39278	included	3	
266-12	39279-39282	all	2	
266-13	39283-39293	randomized	_	
266-14	39294-39302	patients	_	
266-15	39303-39306	who	_	
266-16	39307-39315	received	_	
266-17	39316-39318	at	_	
266-18	39319-39324	least	_	
266-19	39325-39328	one	_	
266-20	39329-39333	dose	_	
266-21	39334-39336	of	_	
266-22	39337-39342	study	_	
266-23	39343-39347	drug	_	
266-24	39348-39351	and	_	
266-25	39352-39354	at	_	
266-26	39355-39360	least	_	
266-27	39361-39364	one	_	
266-28	39365-39373	efficacy	_	
266-29	39374-39384	assessment	_	
266-30	39385-39386	,	_	
266-31	39387-39395	assigned	_	
266-32	39396-39398	as	_	
266-33	39399-39409	randomized	_	
266-34	39410-39411	.	1	

#Text=If necessary , the envelope would be opened , and the patient and the doctor treating the patient would be informed which active substance the patient had received .
267-1	39412-39414	If	6	
267-2	39415-39424	necessary	7	
267-3	39425-39426	,	1	
267-4	39427-39430	the	9	
267-5	39431-39439	envelope	1	
267-6	39440-39445	would	3	
267-7	39446-39448	be	_	
267-8	39449-39455	opened	_	
267-9	39456-39457	,	1	
267-10	39458-39461	and	9	
267-11	39462-39465	the	_	
267-12	39466-39473	patient	_	
267-13	39474-39477	and	_	
267-14	39478-39481	the	_	
267-15	39482-39488	doctor	_	
267-16	39489-39497	treating	_	
267-17	39498-39501	the	_	
267-18	39502-39509	patient	1	
267-19	39510-39515	would	8	
267-20	39516-39518	be	_	
267-21	39519-39527	informed	1	
267-22	39528-39533	which	6	
267-23	39534-39540	active	9	
267-24	39541-39550	substance	_	
267-25	39551-39554	the	_	
267-26	39555-39562	patient	1	
267-27	39563-39566	had	3	
267-28	39567-39575	received	_	
267-29	39576-39577	.	1	

#Text=This stair climbing assessment produced reliable data ( ICC 0.72–0.88 , SEM < 0.4s ) in 29 healthy adults in our laboratory .
268-1	39578-39582	This	9	
268-2	39583-39588	stair	_	
268-3	39589-39597	climbing	_	
268-4	39598-39608	assessment	1	
268-5	39609-39617	produced	8	
268-6	39618-39626	reliable	2	
268-7	39627-39631	data	1	
268-8	39632-39633	(	5	
268-9	39634-39637	ICC	_	
268-10	39638-39642	0.72	_	
268-11	39642-39643	–	_	
268-12	39643-39647	0.88	_	
268-13	39648-39649	,	_	
268-14	39650-39653	SEM	_	
268-15	39654-39655	<	_	
268-16	39656-39660	0.4s	_	
268-17	39661-39662	)	1	
268-18	39663-39665	in	2	
268-19	39666-39668	29	_	
268-20	39669-39676	healthy	_	
268-21	39677-39683	adults	1	
268-22	39684-39686	in	2	
268-23	39687-39690	our	_	
268-24	39691-39701	laboratory	_	
268-25	39702-39703	.	1	

#Text=Routine elective cholecystectomy after percutaneous catheter drainage was not included in the primary endpoint ( ie , only cholecystectomies for recurrent gallstone related complications were considered as matching the endpoint “ need for reintervention ” ) .
269-1	39704-39711	Routine	9	
269-2	39712-39720	elective	_	
269-3	39721-39736	cholecystectomy	_	
269-4	39737-39742	after	_	
269-5	39743-39755	percutaneous	_	
269-6	39756-39764	catheter	_	
269-7	39765-39773	drainage	1	
269-8	39774-39777	was	8	
269-9	39778-39781	not	_	
269-10	39782-39790	included	_	
269-11	39791-39793	in	8	
269-12	39794-39797	the	2	
269-13	39798-39805	primary	_	
269-14	39806-39814	endpoint	1	
269-15	39815-39816	(	5	
269-16	39817-39819	ie	_	
269-17	39820-39821	,	_	
269-18	39822-39826	only	_	
269-19	39827-39844	cholecystectomies	_	
269-20	39845-39848	for	_	
269-21	39849-39858	recurrent	_	
269-22	39859-39868	gallstone	_	
269-23	39869-39876	related	_	
269-24	39877-39890	complications	_	
269-25	39891-39895	were	_	
269-26	39896-39906	considered	_	
269-27	39907-39909	as	_	
269-28	39910-39918	matching	_	
269-29	39919-39922	the	_	
269-30	39923-39931	endpoint	_	
269-31	39932-39933	“	_	
269-32	39934-39938	need	_	
269-33	39939-39942	for	_	
269-34	39943-39957	reintervention	_	
269-35	39958-39959	”	_	
269-36	39960-39961	)	_	
269-37	39962-39963	.	1	

#Text=The determination of compliance was monitored by use of a MEMS Cap dispenser and per protocol analysis required a minimum of 80 % compliance with the prescribed dosing regimen .
270-1	39964-39967	The	9	
270-2	39968-39981	determination	_	
270-3	39982-39984	of	_	
270-4	39985-39995	compliance	1	
270-5	39996-39999	was	8	
270-6	40000-40009	monitored	_	
270-7	40010-40012	by	1	
270-8	40013-40016	use	2	
270-9	40017-40019	of	_	
270-10	40020-40021	a	_	
270-11	40022-40026	MEMS	_	
270-12	40027-40030	Cap	_	
270-13	40031-40040	dispenser	1	
270-14	40041-40044	and	2	
270-15	40045-40048	per	_	
270-16	40049-40057	protocol	_	
270-17	40058-40066	analysis	1	
270-18	40067-40075	required	3	
270-19	40076-40077	a	2	
270-20	40078-40085	minimum	_	
270-21	40086-40088	of	_	
270-22	40089-40091	80	_	
270-23	40092-40093	%	_	
270-24	40094-40104	compliance	_	
270-25	40105-40109	with	_	
270-26	40110-40113	the	_	
270-27	40114-40124	prescribed	_	
270-28	40125-40131	dosing	_	
270-29	40132-40139	regimen	_	
270-30	40140-40141	.	1	

#Text=Patients were divided into two groups made up of 9 females and 16 males each and were randomised to receive either the medical device or placebo .
271-1	40142-40150	Patients	9	
271-2	40151-40155	were	8	
271-3	40156-40163	divided	_	
271-4	40164-40168	into	1	
271-5	40169-40172	two	2	
271-6	40173-40179	groups	_	
271-7	40180-40184	made	_	
271-8	40185-40187	up	_	
271-9	40188-40190	of	_	
271-10	40191-40192	9	_	
271-11	40193-40200	females	_	
271-12	40201-40204	and	_	
271-13	40205-40207	16	_	
271-14	40208-40213	males	_	
271-15	40214-40218	each	1	
271-16	40219-40222	and	3	
271-17	40223-40227	were	_	
271-18	40228-40238	randomised	_	
271-19	40239-40241	to	_	
271-20	40242-40249	receive	_	
271-21	40250-40256	either	1	
271-22	40257-40260	the	2	
271-23	40261-40268	medical	_	
271-24	40269-40275	device	1	
271-25	40276-40278	or	2	
271-26	40279-40286	placebo	_	
271-27	40287-40288	.	1	

#Text=The trial was designed by the first three authors and the last author .
272-1	40289-40292	The	9	
272-2	40293-40298	trial	1	
272-3	40299-40302	was	8	
272-4	40303-40311	designed	_	
272-5	40312-40314	by	1	
272-6	40315-40318	the	2	
272-7	40319-40324	first	_	
272-8	40325-40330	three	_	
272-9	40331-40338	authors	_	
272-10	40339-40342	and	_	
272-11	40343-40346	the	_	
272-12	40347-40351	last	_	
272-13	40352-40358	author	_	
272-14	40359-40360	.	1	

#Text=We excluded persons who had participated in Tai Chi or physical therapy in the past year ; those with current serious medical conditions , such as dementia , symptomatic heart or vascular disease , or recent stroke , that would limit full participation ; those with intra-articular steroid or intra-articular hyaluronic acid injections in the past 3 or 6 months or reconstructive surgery before baseline screening on the most severely affected knee ; and those with a score less than 24 on the Mini-Mental State Examination ( 19 ) .
273-1	40361-40363	We	8	
273-2	40364-40372	excluded	1	
273-3	40373-40380	persons	2	
273-4	40381-40384	who	_	
273-5	40385-40388	had	_	
273-6	40389-40401	participated	_	
273-7	40402-40404	in	_	
273-8	40405-40408	Tai	_	
273-9	40409-40412	Chi	_	
273-10	40413-40415	or	_	
273-11	40416-40424	physical	_	
273-12	40425-40432	therapy	_	
273-13	40433-40435	in	_	
273-14	40436-40439	the	_	
273-15	40440-40444	past	_	
273-16	40445-40449	year	1	
273-17	40450-40451	;	6	
273-18	40452-40457	those	2	
273-19	40458-40462	with	_	
273-20	40463-40470	current	_	
273-21	40471-40478	serious	_	
273-22	40479-40486	medical	_	
273-23	40487-40497	conditions	_	
273-24	40498-40499	,	_	
273-25	40500-40504	such	_	
273-26	40505-40507	as	_	
273-27	40508-40516	dementia	_	
273-28	40517-40518	,	1	
273-29	40519-40530	symptomatic	2	
273-30	40531-40536	heart	_	
273-31	40537-40539	or	_	
273-32	40540-40548	vascular	_	
273-33	40549-40556	disease	_	
273-34	40557-40558	,	1	
273-35	40559-40561	or	2	
273-36	40562-40568	recent	_	
273-37	40569-40575	stroke	_	
273-38	40576-40577	,	1	
273-39	40578-40582	that	3	
273-40	40583-40588	would	_	
273-41	40589-40594	limit	1	
273-42	40595-40599	full	2	
273-43	40600-40613	participation	1	
273-44	40614-40615	;	6	
273-45	40616-40621	those	2	
273-46	40622-40626	with	_	
273-47	40627-40642	intra-articular	_	
273-48	40643-40650	steroid	_	
273-49	40651-40653	or	_	
273-50	40654-40669	intra-articular	_	
273-51	40670-40680	hyaluronic	_	
273-52	40681-40685	acid	_	
273-53	40686-40696	injections	_	
273-54	40697-40699	in	_	
273-55	40700-40703	the	_	
273-56	40704-40708	past	_	
273-57	40709-40710	3	_	
273-58	40711-40713	or	_	
273-59	40714-40715	6	_	
273-60	40716-40722	months	1	
273-61	40723-40725	or	2	
273-62	40726-40740	reconstructive	_	
273-63	40741-40748	surgery	_	
273-64	40749-40755	before	_	
273-65	40756-40764	baseline	_	
273-66	40765-40774	screening	_	
273-67	40775-40777	on	_	
273-68	40778-40781	the	_	
273-69	40782-40786	most	_	
273-70	40787-40795	severely	_	
273-71	40796-40804	affected	_	
273-72	40805-40809	knee	1	
273-73	40810-40811	;	6	
273-74	40812-40815	and	2	
273-75	40816-40821	those	_	
273-76	40822-40826	with	_	
273-77	40827-40828	a	_	
273-78	40829-40834	score	_	
273-79	40835-40839	less	_	
273-80	40840-40844	than	_	
273-81	40845-40847	24	_	
273-82	40848-40850	on	_	
273-83	40851-40854	the	_	
273-84	40855-40866	Mini-Mental	_	
273-85	40867-40872	State	_	
273-86	40873-40884	Examination	1	
273-87	40885-40886	(	5	
273-88	40887-40889	19	_	
273-89	40890-40891	)	_	
273-90	40892-40893	.	1	

#Text=Lipid standard stock solutions were prepared by dissolving standards from Avanti Polar Lipids ( Alabaster , USA ) in chloroform ( 10 mg/mL ) .
274-1	40894-40899	Lipid	9	
274-2	40900-40908	standard	_	
274-3	40909-40914	stock	_	
274-4	40915-40924	solutions	1	
274-5	40925-40929	were	8	
274-6	40930-40938	prepared	_	
274-7	40939-40941	by	_	
274-8	40942-40952	dissolving	1	
274-9	40953-40962	standards	2	
274-10	40963-40967	from	_	
274-11	40968-40974	Avanti	_	
274-12	40975-40980	Polar	_	
274-13	40981-40987	Lipids	1	
274-14	40988-40989	(	5	
274-15	40990-40999	Alabaster	_	
274-16	41000-41001	,	_	
274-17	41002-41005	USA	_	
274-18	41006-41007	)	1	
274-19	41008-41010	in	2	
274-20	41011-41021	chloroform	1	
274-21	41022-41023	(	5	
274-22	41024-41026	10	_	
274-23	41027-41029	mg	_	
274-24	41029-41030	/	_	
274-25	41030-41032	mL	_	
274-26	41033-41034	)	_	
274-27	41035-41036	.	1	

#Text=In batch 2 , the patient ’s sera drawn at Day 2 and the sera from the fasting experiment were analyzed .
275-1	41037-41039	In	2	
275-2	41040-41045	batch	_	
275-3	41046-41047	2	_	
275-4	41048-41049	,	1	
275-5	41050-41053	the	2	
275-6	41054-41061	patient	_	
275-7	41062-41063	’	_	
275-8	41063-41064	s	_	
275-9	41065-41069	sera	_	
275-10	41070-41075	drawn	_	
275-11	41076-41078	at	_	
275-12	41079-41082	Day	_	
275-13	41083-41084	2	1	
275-14	41085-41088	and	2	
275-15	41089-41092	the	_	
275-16	41093-41097	sera	_	
275-17	41098-41102	from	_	
275-18	41103-41106	the	_	
275-19	41107-41114	fasting	_	
275-20	41115-41125	experiment	1	
275-21	41126-41130	were	8	
275-22	41131-41139	analyzed	_	
275-23	41140-41141	.	1	

#Text=The drain was left in place for three weeks .
276-1	41142-41145	The	9	
276-2	41146-41151	drain	1	
276-3	41152-41155	was	8	
276-4	41156-41160	left	_	
276-5	41161-41163	in	_	
276-6	41164-41169	place	1	
276-7	41170-41173	for	3	
276-8	41174-41179	three	_	
276-9	41180-41185	weeks	_	
276-10	41186-41187	.	1	

#Text=Sample sizes were chosen on the basis of effects observed in 2 prior knee osteoarthritis trials .
277-1	41188-41194	Sample	9	
277-2	41195-41200	sizes	1	
277-3	41201-41205	were	8	
277-4	41206-41212	chosen	_	
277-5	41213-41215	on	_	
277-6	41216-41219	the	_	
277-7	41220-41225	basis	_	
277-8	41226-41228	of	1	
277-9	41229-41236	effects	2	
277-10	41237-41245	observed	_	
277-11	41246-41248	in	_	
277-12	41249-41250	2	_	
277-13	41251-41256	prior	_	
277-14	41257-41261	knee	_	
277-15	41262-41276	osteoarthritis	_	
277-16	41277-41283	trials	_	
277-17	41284-41285	.	1	

#Text=On Day 3 , subjects completed the items on the Recovery Early Symptoms scale of the FACE-Q questionnaire , and EIs compared the smoothness of each NLF region using a 3-point scale ( left side felt smoother ; both sides felt equally smooth ; right side felt smoother ) and natural look of each NLF region using a 3-point scale ( left side looked more natural ; both sides looked equally natural ; right side looked more natural ) .
278-1	41286-41288	On	2	
278-2	41289-41292	Day	_	
278-3	41293-41294	3	_	
278-4	41295-41296	,	1	
278-5	41297-41305	subjects	9	
278-6	41306-41315	completed	8	
278-7	41316-41319	the	2	
278-8	41320-41325	items	_	
278-9	41326-41328	on	_	
278-10	41329-41332	the	_	
278-11	41333-41341	Recovery	_	
278-12	41342-41347	Early	_	
278-13	41348-41356	Symptoms	_	
278-14	41357-41362	scale	_	
278-15	41363-41365	of	_	
278-16	41366-41369	the	_	
278-17	41370-41376	FACE-Q	_	
278-18	41377-41390	questionnaire	_	
278-19	41391-41392	,	1	
278-20	41393-41396	and	9	
278-21	41397-41400	EIs	1	
278-22	41401-41409	compared	3	
278-23	41410-41413	the	2	
278-24	41414-41424	smoothness	_	
278-25	41425-41427	of	_	
278-26	41428-41432	each	_	
278-27	41433-41436	NLF	_	
278-28	41437-41443	region	1	
278-29	41444-41449	using	3	
278-30	41450-41451	a	2	
278-31	41452-41453	3	_	
278-32	41453-41454	-	_	
278-33	41454-41459	point	_	
278-34	41460-41465	scale	1	
278-35	41466-41467	(	5	
278-36	41468-41472	left	_	
278-37	41473-41477	side	_	
278-38	41478-41482	felt	_	
278-39	41483-41491	smoother	_	
278-40	41492-41493	;	_	
278-41	41494-41498	both	_	
278-42	41499-41504	sides	_	
278-43	41505-41509	felt	_	
278-44	41510-41517	equally	_	
278-45	41518-41524	smooth	_	
278-46	41525-41526	;	_	
278-47	41527-41532	right	_	
278-48	41533-41537	side	_	
278-49	41538-41542	felt	_	
278-50	41543-41551	smoother	_	
278-51	41552-41553	)	1	
278-52	41554-41557	and	2	
278-53	41558-41565	natural	_	
278-54	41566-41570	look	_	
278-55	41571-41573	of	_	
278-56	41574-41578	each	_	
278-57	41579-41582	NLF	_	
278-58	41583-41589	region	1	
278-59	41590-41595	using	3	
278-60	41596-41597	a	2	
278-61	41598-41599	3	_	
278-62	41599-41600	-	_	
278-63	41600-41605	point	_	
278-64	41606-41611	scale	1	
278-65	41612-41613	(	5	
278-66	41614-41618	left	_	
278-67	41619-41623	side	_	
278-68	41624-41630	looked	_	
278-69	41631-41635	more	_	
278-70	41636-41643	natural	_	
278-71	41644-41645	;	_	
278-72	41646-41650	both	_	
278-73	41651-41656	sides	_	
278-74	41657-41663	looked	_	
278-75	41664-41671	equally	_	
278-76	41672-41679	natural	_	
278-77	41680-41681	;	_	
278-78	41682-41687	right	_	
278-79	41688-41692	side	_	
278-80	41693-41699	looked	_	
278-81	41700-41704	more	_	
278-82	41705-41712	natural	_	
278-83	41713-41714	)	_	
278-84	41715-41716	.	1	

#Text=The sera were aliquoted into Eppendorf tubes ( Sarstedt , Biosphere SafeSeal Micro tube 1.5 ml ) and cryo tubes ( Sarstedt , Micro tube 2 ml , PP ) and frozen at -80 ° C < 1 h.
279-1	41717-41720	The	9	
279-2	41721-41725	sera	1	
279-3	41726-41730	were	8	
279-4	41731-41740	aliquoted	_	
279-5	41741-41745	into	1	
279-6	41746-41755	Eppendorf	2	
279-7	41756-41761	tubes	1	
279-8	41762-41763	(	5	
279-9	41764-41772	Sarstedt	_	
279-10	41773-41774	,	_	
279-11	41775-41784	Biosphere	_	
279-12	41785-41793	SafeSeal	_	
279-13	41794-41799	Micro	_	
279-14	41800-41804	tube	_	
279-15	41805-41808	1.5	_	
279-16	41809-41811	ml	_	
279-17	41812-41813	)	1	
279-18	41814-41817	and	2	
279-19	41818-41822	cryo	_	
279-20	41823-41828	tubes	1	
279-21	41829-41830	(	5	
279-22	41831-41839	Sarstedt	_	
279-23	41840-41841	,	_	
279-24	41842-41847	Micro	_	
279-25	41848-41852	tube	_	
279-26	41853-41854	2	_	
279-27	41855-41857	ml	_	
279-28	41858-41859	,	_	
279-29	41860-41862	PP	_	
279-30	41863-41864	)	1	
279-31	41865-41868	and	3	
279-32	41869-41875	frozen	1	
279-33	41876-41878	at	2	
279-34	41879-41880	-	_	
279-35	41880-41882	80	_	
279-36	41883-41884	°	_	
279-37	41885-41886	C	_	
279-38	41887-41888	<	_	
279-39	41889-41890	1	_	
279-40	41891-41892	h	_	
279-41	41892-41893	.	1	

#Text=Blood for clinical chemistry analyses was obtained at admission , Day 1 , Day 2 , and ≥60 d.
280-1	41894-41899	Blood	9	
280-2	41900-41903	for	_	
280-3	41904-41912	clinical	_	
280-4	41913-41922	chemistry	_	
280-5	41923-41931	analyses	1	
280-6	41932-41935	was	8	
280-7	41936-41944	obtained	_	
280-8	41945-41947	at	1	
280-9	41948-41957	admission	2	
280-10	41958-41959	,	_	
280-11	41960-41963	Day	_	
280-12	41964-41965	1	_	
280-13	41966-41967	,	_	
280-14	41968-41971	Day	_	
280-15	41972-41973	2	_	
280-16	41974-41975	,	_	
280-17	41976-41979	and	_	
280-18	41980-41981	≥	_	
280-19	41981-41983	60	_	
280-20	41984-41985	d	_	
280-21	41985-41986	.	1	

#Text=The variables of the clinical prediction score CURB-65 were assessed at admission [ 12 ] .
281-1	41987-41990	The	9	
281-2	41991-42000	variables	_	
281-3	42001-42003	of	_	
281-4	42004-42007	the	_	
281-5	42008-42016	clinical	_	
281-6	42017-42027	prediction	_	
281-7	42028-42033	score	_	
281-8	42034-42038	CURB	_	
281-9	42038-42039	-	_	
281-10	42039-42041	65	1	
281-11	42042-42046	were	8	
281-12	42047-42055	assessed	_	
281-13	42056-42058	at	1	
281-14	42059-42068	admission	2	
281-15	42069-42070	[	5	
281-16	42071-42073	12	_	
281-17	42074-42075	]	_	
281-18	42076-42077	.	1	

#Text=If the patient had flank pain and self-reported fever but CRP < 40 mg/l , she was characterized as having a febrile UTI .
282-1	42078-42080	If	6	
282-2	42081-42084	the	9	
282-3	42085-42092	patient	1	
282-4	42093-42096	had	3	
282-5	42097-42102	flank	2	
282-6	42103-42107	pain	_	
282-7	42108-42111	and	_	
282-8	42112-42125	self-reported	_	
282-9	42126-42131	fever	1	
282-10	42132-42135	but	2	
282-11	42136-42139	CRP	_	
282-12	42140-42141	<	_	
282-13	42142-42144	40	_	
282-14	42145-42147	mg	_	
282-15	42147-42148	/	_	
282-16	42148-42149	l	_	
282-17	42150-42151	,	1	
282-18	42152-42155	she	8	
282-19	42156-42159	was	_	
282-20	42160-42173	characterized	_	
282-21	42174-42176	as	_	
282-22	42177-42183	having	1	
282-23	42184-42185	a	2	
282-24	42186-42193	febrile	_	
282-25	42194-42197	UTI	_	
282-26	42198-42199	.	1	

#Text=Research study nurses , physical function assessors , and sponsor personnel were blinded to the treatment assignments during enrollment .
283-1	42200-42208	Research	2	
283-2	42209-42214	study	_	
283-3	42215-42221	nurses	_	
283-4	42222-42223	,	_	
283-5	42224-42232	physical	_	
283-6	42233-42241	function	_	
283-7	42242-42251	assessors	_	
283-8	42252-42253	,	_	
283-9	42254-42257	and	_	
283-10	42258-42265	sponsor	_	
283-11	42266-42275	personnel	1	
283-12	42276-42280	were	8	
283-13	42281-42288	blinded	_	
283-14	42289-42291	to	1	
283-15	42292-42295	the	2	
283-16	42296-42305	treatment	_	
283-17	42306-42317	assignments	1	
283-18	42318-42324	during	2	
283-19	42325-42335	enrollment	_	
283-20	42336-42337	.	1	

#Text=The medical device ( Esoxx ® , Alfa Wassermann , Bologna , Italy ) is based on a mixture of hyaluronic acid and chondroitin sulfate in a bioadhesive carrier Lutrol ® F 127 ( poloxamer 407 ; BASF , Milan , Italy ) that acts as a buffering agent to form a barrier and prolong the action on the esophageal mucosa [ 33 ] .
284-1	42338-42341	The	9	
284-2	42342-42349	medical	_	
284-3	42350-42356	device	1	
284-4	42357-42358	(	5	
284-5	42359-42364	Esoxx	_	
284-6	42365-42366	®	_	
284-7	42367-42368	,	_	
284-8	42369-42373	Alfa	_	
284-9	42374-42384	Wassermann	_	
284-10	42385-42386	,	_	
284-11	42387-42394	Bologna	_	
284-12	42395-42396	,	_	
284-13	42397-42402	Italy	_	
284-14	42403-42404	)	1	
284-15	42405-42407	is	8	
284-16	42408-42413	based	_	
284-17	42414-42416	on	1	
284-18	42417-42418	a	2	
284-19	42419-42426	mixture	_	
284-20	42427-42429	of	_	
284-21	42430-42440	hyaluronic	_	
284-22	42441-42445	acid	_	
284-23	42446-42449	and	_	
284-24	42450-42461	chondroitin	_	
284-25	42462-42469	sulfate	_	
284-26	42470-42472	in	_	
284-27	42473-42474	a	_	
284-28	42475-42486	bioadhesive	_	
284-29	42487-42494	carrier	_	
284-30	42495-42501	Lutrol	_	
284-31	42502-42503	®	_	
284-32	42504-42505	F	_	
284-33	42506-42509	127	1	
284-34	42510-42511	(	5	
284-35	42512-42521	poloxamer	_	
284-36	42522-42525	407	_	
284-37	42526-42527	;	_	
284-38	42528-42532	BASF	_	
284-39	42533-42534	,	_	
284-40	42535-42540	Milan	_	
284-41	42541-42542	,	_	
284-42	42543-42548	Italy	_	
284-43	42549-42550	)	1	
284-44	42551-42555	that	6	
284-45	42556-42560	acts	3	
284-46	42561-42563	as	1	
284-47	42564-42565	a	2	
284-48	42566-42575	buffering	_	
284-49	42576-42581	agent	1	
284-50	42582-42584	to	3	
284-51	42585-42589	form	1	
284-52	42590-42591	a	2	
284-53	42592-42599	barrier	1	
284-54	42600-42603	and	3	
284-55	42604-42611	prolong	1	
284-56	42612-42615	the	2	
284-57	42616-42622	action	_	
284-58	42623-42625	on	_	
284-59	42626-42629	the	_	
284-60	42630-42640	esophageal	_	
284-61	42641-42647	mucosa	1	
284-62	42648-42649	[	5	
284-63	42650-42652	33	_	
284-64	42653-42654	]	_	
284-65	42655-42656	.	1	

#Text=We compared the occurrence of the primary endpoints between the treatment groups .
285-1	42657-42659	We	8	
285-2	42660-42668	compared	1	
285-3	42669-42672	the	2	
285-4	42673-42683	occurrence	_	
285-5	42684-42686	of	_	
285-6	42687-42690	the	_	
285-7	42691-42698	primary	_	
285-8	42699-42708	endpoints	_	
285-9	42709-42716	between	_	
285-10	42717-42720	the	_	
285-11	42721-42730	treatment	_	
285-12	42731-42737	groups	_	
285-13	42738-42739	.	1	

#Text=The patients were asked to record possible adverse effects or complications in the diary .
286-1	42740-42743	The	9	
286-2	42744-42752	patients	1	
286-3	42753-42757	were	8	
286-4	42758-42763	asked	_	
286-5	42764-42766	to	_	
286-6	42767-42773	record	1	
286-7	42774-42782	possible	2	
286-8	42783-42790	adverse	_	
286-9	42791-42798	effects	_	
286-10	42799-42801	or	_	
286-11	42802-42815	complications	1	
286-12	42816-42818	in	2	
286-13	42819-42822	the	_	
286-14	42823-42828	diary	_	
286-15	42829-42830	.	1	

#Text=Detailed inclusion and exclusion criteria for the trial are provided in the Supplementary Appendix .
287-1	42831-42839	Detailed	9	
287-2	42840-42849	inclusion	_	
287-3	42850-42853	and	_	
287-4	42854-42863	exclusion	_	
287-5	42864-42872	criteria	_	
287-6	42873-42876	for	_	
287-7	42877-42880	the	_	
287-8	42881-42886	trial	1	
287-9	42887-42890	are	8	
287-10	42891-42899	provided	_	
287-11	42900-42902	in	1	
287-12	42903-42906	the	2	
287-13	42907-42920	Supplementary	_	
287-14	42921-42929	Appendix	_	
287-15	42930-42931	.	1	

#Text=Measurements of [M+Na]+ adducts before and after the application of the Na+ removal algorithm is shown in the S2 Fig.
288-1	42932-42944	Measurements	9	
288-2	42945-42947	of	_	
288-3	42948-42949	[	_	
288-4	42949-42950	M	_	
288-5	42950-42951	+	_	
288-6	42951-42953	Na	_	
288-7	42953-42954	]	_	
288-8	42954-42955	+	_	
288-9	42956-42963	adducts	_	
288-10	42964-42970	before	_	
288-11	42971-42974	and	_	
288-12	42975-42980	after	_	
288-13	42981-42984	the	_	
288-14	42985-42996	application	_	
288-15	42997-42999	of	_	
288-16	43000-43003	the	_	
288-17	43004-43006	Na	_	
288-18	43006-43007	+	_	
288-19	43008-43015	removal	_	
288-20	43016-43025	algorithm	1	
288-21	43026-43028	is	8	
288-22	43029-43034	shown	1	
288-23	43035-43037	in	2	
288-24	43038-43041	the	_	
288-25	43042-43044	S2	_	
288-26	43045-43048	Fig	_	
288-27	43048-43049	.	1	

#Text=Briefly , the analytes were spiked to water , the H+ as well as the Na+ adducts were measured , and a polynomic fit function of second order was used to describe the Na+ adduct formation based on plotting the area/IS ratio of Na+ adducts against the spiked concentration levels .
289-1	43050-43057	Briefly	6	
289-2	43058-43059	,	1	
289-3	43060-43063	the	9	
289-4	43064-43072	analytes	1	
289-5	43073-43077	were	8	
289-6	43078-43084	spiked	_	
289-7	43085-43087	to	1	
289-8	43088-43093	water	2	
289-9	43094-43095	,	1	
289-10	43096-43099	the	9	
289-11	43100-43101	H	_	
289-12	43101-43102	+	_	
289-13	43103-43105	as	_	
289-14	43106-43110	well	_	
289-15	43111-43113	as	_	
289-16	43114-43117	the	_	
289-17	43118-43120	Na	_	
289-18	43120-43121	+	_	
289-19	43122-43129	adducts	1	
289-20	43130-43134	were	3	
289-21	43135-43143	measured	_	
289-22	43144-43145	,	1	
289-23	43146-43149	and	9	
289-24	43150-43151	a	_	
289-25	43152-43161	polynomic	_	
289-26	43162-43165	fit	_	
289-27	43166-43174	function	_	
289-28	43175-43177	of	_	
289-29	43178-43184	second	_	
289-30	43185-43190	order	1	
289-31	43191-43194	was	3	
289-32	43195-43199	used	_	
289-33	43200-43202	to	_	
289-34	43203-43211	describe	1	
289-35	43212-43215	the	2	
289-36	43216-43218	Na	_	
289-37	43218-43219	+	_	
289-38	43220-43226	adduct	_	
289-39	43227-43236	formation	1	
289-40	43237-43242	based	3	
289-41	43243-43245	on	_	
289-42	43246-43254	plotting	1	
289-43	43255-43258	the	2	
289-44	43259-43263	area	_	
289-45	43263-43264	/	_	
289-46	43264-43266	IS	_	
289-47	43267-43272	ratio	_	
289-48	43273-43275	of	_	
289-49	43276-43278	Na	_	
289-50	43278-43279	+	_	
289-51	43280-43287	adducts	_	
289-52	43288-43295	against	_	
289-53	43296-43299	the	_	
289-54	43300-43306	spiked	_	
289-55	43307-43320	concentration	_	
289-56	43321-43327	levels	_	
289-57	43328-43329	.	1	

#Text=We used the OMERACT-OARSI responder criteria ( 30 ) to indicate clinically meaningful improvement .
290-1	43330-43332	We	8	
290-2	43333-43337	used	1	
290-3	43338-43341	the	2	
290-4	43342-43355	OMERACT-OARSI	_	
290-5	43356-43365	responder	_	
290-6	43366-43374	criteria	1	
290-7	43375-43376	(	5	
290-8	43377-43379	30	_	
290-9	43380-43381	)	1	
290-10	43382-43384	to	3	
290-11	43385-43393	indicate	1	
290-12	43394-43404	clinically	2	
290-13	43405-43415	meaningful	_	
290-14	43416-43427	improvement	_	
290-15	43428-43429	.	1	

#Text=Dosing of trimodulin based on IgM content ( 42   mg   IgM/kg body weight ) or placebo was once daily for five consecutive days .
291-1	43430-43436	Dosing	9	
291-2	43437-43439	of	_	
291-3	43440-43450	trimodulin	1	
291-4	43451-43456	based	3	
291-5	43457-43459	on	1	
291-6	43460-43463	IgM	2	
291-7	43464-43471	content	1	
291-8	43472-43473	(	5	
291-9	43474-43476	42	_	
291-10	43477-43478	 	_	
291-11	43479-43481	mg	_	
291-12	43482-43483	 	_	
291-13	43484-43487	IgM	_	
291-14	43487-43488	/	_	
291-15	43488-43490	kg	_	
291-16	43491-43495	body	_	
291-17	43496-43502	weight	_	
291-18	43503-43504	)	1	
291-19	43505-43507	or	9	
291-20	43508-43515	placebo	1	
291-21	43516-43519	was	8	
291-22	43520-43524	once	2	
291-23	43525-43530	daily	_	
291-24	43531-43534	for	_	
291-25	43535-43539	five	_	
291-26	43540-43551	consecutive	_	
291-27	43552-43556	days	_	
291-28	43557-43558	.	1	

#Text=We also excluded patients with symptoms that lasted longer than seven days at time of first presentation , since these patients should undergo delayed cholecystectomy according to the Dutch treatment guidelines.
292-1	43559-43561	We	8	
292-2	43562-43566	also	_	
292-3	43567-43575	excluded	1	
292-4	43576-43584	patients	2	
292-5	43585-43589	with	_	
292-6	43590-43598	symptoms	_	
292-7	43599-43603	that	_	
292-8	43604-43610	lasted	_	
292-9	43611-43617	longer	_	
292-10	43618-43622	than	_	
292-11	43623-43628	seven	_	
292-12	43629-43633	days	_	
292-13	43634-43636	at	_	
292-14	43637-43641	time	_	
292-15	43642-43644	of	_	
292-16	43645-43650	first	_	
292-17	43651-43663	presentation	_	
292-18	43664-43665	,	1	
292-19	43666-43671	since	6	
292-20	43672-43677	these	9	
292-21	43678-43686	patients	1	
292-22	43687-43693	should	3	
292-23	43694-43701	undergo	1	
292-24	43702-43709	delayed	2	
292-25	43710-43725	cholecystectomy	_	
292-26	43726-43735	according	_	
292-27	43736-43738	to	_	
292-28	43739-43742	the	_	
292-29	43743-43748	Dutch	_	
292-30	43749-43758	treatment	_	
292-31	43759-43769	guidelines	_	
292-32	43769-43770	.	1	

#Text=Exclusion criteria for the present study were presence of ulcers at any gastric segment , pyloric stenosis , Helicobacter pylori infection ( ruled out by breath test ) , esophageal stricture or intestinal obstruction , previous gastrointestinal surgery , and a known hypersensitivity to the compounds object of the present study .
293-1	43771-43780	Exclusion	9	
293-2	43781-43789	criteria	_	
293-3	43790-43793	for	_	
293-4	43794-43797	the	_	
293-5	43798-43805	present	_	
293-6	43806-43811	study	1	
293-7	43812-43816	were	8	
293-8	43817-43825	presence	2	
293-9	43826-43828	of	_	
293-10	43829-43835	ulcers	_	
293-11	43836-43838	at	_	
293-12	43839-43842	any	_	
293-13	43843-43850	gastric	_	
293-14	43851-43858	segment	_	
293-15	43859-43860	,	1	
293-16	43861-43868	pyloric	2	
293-17	43869-43877	stenosis	_	
293-18	43878-43879	,	_	
293-19	43880-43892	Helicobacter	_	
293-20	43893-43899	pylori	_	
293-21	43900-43909	infection	1	
293-22	43910-43911	(	5	
293-23	43912-43917	ruled	_	
293-24	43918-43921	out	_	
293-25	43922-43924	by	_	
293-26	43925-43931	breath	_	
293-27	43932-43936	test	_	
293-28	43937-43938	)	_	
293-29	43939-43940	,	1	
293-30	43941-43951	esophageal	2	
293-31	43952-43961	stricture	_	
293-32	43962-43964	or	_	
293-33	43965-43975	intestinal	_	
293-34	43976-43987	obstruction	_	
293-35	43988-43989	,	_	
293-36	43990-43998	previous	_	
293-37	43999-44015	gastrointestinal	_	
293-38	44016-44023	surgery	_	
293-39	44024-44025	,	1	
293-40	44026-44029	and	2	
293-41	44030-44031	a	_	
293-42	44032-44037	known	_	
293-43	44038-44054	hypersensitivity	_	
293-44	44055-44057	to	_	
293-45	44058-44061	the	_	
293-46	44062-44071	compounds	_	
293-47	44072-44078	object	_	
293-48	44079-44081	of	_	
293-49	44082-44085	the	_	
293-50	44086-44093	present	_	
293-51	44094-44099	study	_	
293-52	44100-44101	.	1	

#Text=This prospective , multicenter , randomized , within-subject controlled study was conducted at 6 sites in the United States ; each site had an unblinded treating investigator ( TI ) along with a blinded evaluating investigator ( EI ) who performed all safety and effectiveness assessments .
294-1	44102-44106	This	9	
294-2	44107-44118	prospective	_	
294-3	44119-44120	,	_	
294-4	44121-44132	multicenter	_	
294-5	44133-44134	,	_	
294-6	44135-44145	randomized	_	
294-7	44146-44147	,	_	
294-8	44148-44162	within-subject	_	
294-9	44163-44173	controlled	_	
294-10	44174-44179	study	1	
294-11	44180-44183	was	8	
294-12	44184-44193	conducted	_	
294-13	44194-44196	at	1	
294-14	44197-44198	6	2	
294-15	44199-44204	sites	_	
294-16	44205-44207	in	_	
294-17	44208-44211	the	_	
294-18	44212-44218	United	_	
294-19	44219-44225	States	1	
294-20	44226-44227	;	6	
294-21	44228-44232	each	9	
294-22	44233-44237	site	1	
294-23	44238-44241	had	3	
294-24	44242-44244	an	2	
294-25	44245-44254	unblinded	_	
294-26	44255-44263	treating	_	
294-27	44264-44276	investigator	1	
294-28	44277-44278	(	5	
294-29	44279-44281	TI	_	
294-30	44282-44283	)	1	
294-31	44284-44289	along	2	
294-32	44290-44294	with	_	
294-33	44295-44296	a	_	
294-34	44297-44304	blinded	_	
294-35	44305-44315	evaluating	_	
294-36	44316-44328	investigator	_	
294-37	44329-44330	(	5	
294-38	44331-44333	EI	_	
294-39	44334-44335	)	1	
294-40	44336-44339	who	_	
294-41	44340-44349	performed	_	
294-42	44350-44353	all	_	
294-43	44354-44360	safety	_	
294-44	44361-44364	and	_	
294-45	44365-44378	effectiveness	_	
294-46	44379-44390	assessments	_	
294-47	44391-44392	.	1	

#Text=All of these mobility performance measures produce valid and reliable data in individuals with knee OA [ 35–38 ] .
295-1	44393-44396	All	9	
295-2	44397-44399	of	_	
295-3	44400-44405	these	_	
295-4	44406-44414	mobility	_	
295-5	44415-44426	performance	_	
295-6	44427-44435	measures	1	
295-7	44436-44443	produce	8	
295-8	44444-44449	valid	2	
295-9	44450-44453	and	_	
295-10	44454-44462	reliable	_	
295-11	44463-44467	data	_	
295-12	44468-44470	in	_	
295-13	44471-44482	individuals	_	
295-14	44483-44487	with	_	
295-15	44488-44492	knee	_	
295-16	44493-44495	OA	1	
295-17	44496-44497	[	5	
295-18	44498-44500	35	_	
295-19	44500-44501	–	_	
295-20	44501-44503	38	_	
295-21	44504-44505	]	_	
295-22	44506-44507	.	1	

#Text=The lower limit of quantification ( LLOQ ) was 0.5 μM , and lower levels were quantified by extrapolating down to 0.4 μM.
296-1	44508-44511	The	9	
296-2	44512-44517	lower	_	
296-3	44518-44523	limit	_	
296-4	44524-44526	of	_	
296-5	44527-44541	quantification	1	
296-6	44542-44543	(	5	
296-7	44544-44548	LLOQ	_	
296-8	44549-44550	)	1	
296-9	44551-44554	was	8	
296-10	44555-44558	0.5	_	
296-11	44559-44561	μM	2	
296-12	44562-44563	,	1	
296-13	44564-44567	and	9	
296-14	44568-44573	lower	_	
296-15	44574-44580	levels	1	
296-16	44581-44585	were	2	
296-17	44586-44596	quantified	_	
296-18	44597-44599	by	_	
296-19	44600-44613	extrapolating	_	
296-20	44614-44618	down	_	
296-21	44619-44621	to	1	
296-22	44622-44625	0.4	2	
296-23	44626-44628	μM	_	
296-24	44628-44629	.	1	

#Text=Each analyte peak area of LPCs , PCs , and SMs was divided by the peak area of a known concentration of the Internal Standard ( IS ) LPC 19:0 to obtain relative levels of each lipid species .
297-1	44630-44634	Each	9	
297-2	44635-44642	analyte	_	
297-3	44643-44647	peak	_	
297-4	44648-44652	area	_	
297-5	44653-44655	of	_	
297-6	44656-44660	LPCs	_	
297-7	44661-44662	,	_	
297-8	44663-44666	PCs	_	
297-9	44667-44668	,	_	
297-10	44669-44672	and	_	
297-11	44673-44676	SMs	1	
297-12	44677-44680	was	8	
297-13	44681-44688	divided	_	
297-14	44689-44691	by	1	
297-15	44692-44695	the	2	
297-16	44696-44700	peak	_	
297-17	44701-44705	area	_	
297-18	44706-44708	of	_	
297-19	44709-44710	a	_	
297-20	44711-44716	known	_	
297-21	44717-44730	concentration	_	
297-22	44731-44733	of	_	
297-23	44734-44737	the	_	
297-24	44738-44746	Internal	_	
297-25	44747-44755	Standard	_	
297-26	44756-44757	(	5	
297-27	44758-44760	IS	_	
297-28	44761-44762	)	1	
297-29	44763-44766	LPC	_	
297-30	44767-44769	19	_	
297-31	44769-44770	:	_	
297-32	44770-44771	0	1	
297-33	44772-44774	to	3	
297-34	44775-44781	obtain	1	
297-35	44782-44790	relative	2	
297-36	44791-44797	levels	_	
297-37	44798-44800	of	_	
297-38	44801-44805	each	_	
297-39	44806-44811	lipid	_	
297-40	44812-44819	species	_	
297-41	44820-44821	.	1	

#Text=Depending on the diagnostic findings in the initial musculoskeletal examination , the therapist targeted physical therapy regimens to address specific treatment goals developed collaboratively with the participant .
298-1	44822-44831	Depending	6	
298-2	44832-44834	on	1	
298-3	44835-44838	the	2	
298-4	44839-44849	diagnostic	_	
298-5	44850-44858	findings	_	
298-6	44859-44861	in	_	
298-7	44862-44865	the	_	
298-8	44866-44873	initial	_	
298-9	44874-44889	musculoskeletal	_	
298-10	44890-44901	examination	_	
298-11	44902-44903	,	1	
298-12	44904-44907	the	9	
298-13	44908-44917	therapist	1	
298-14	44918-44926	targeted	8	
298-15	44927-44935	physical	2	
298-16	44936-44943	therapy	_	
298-17	44944-44952	regimens	1	
298-18	44953-44955	to	3	
298-19	44956-44963	address	1	
298-20	44964-44972	specific	2	
298-21	44973-44982	treatment	_	
298-22	44983-44988	goals	_	
298-23	44989-44998	developed	_	
298-24	44999-45014	collaboratively	_	
298-25	45015-45019	with	_	
298-26	45020-45023	the	_	
298-27	45024-45035	participant	_	
298-28	45036-45037	.	1	

#Text=The main outcome was tested according to non-inferiority , the secondary outcomes according to superiority .
299-1	45038-45041	The	9	
299-2	45042-45046	main	_	
299-3	45047-45054	outcome	1	
299-4	45055-45058	was	8	
299-5	45059-45065	tested	_	
299-6	45066-45075	according	_	
299-7	45076-45078	to	1	
299-8	45079-45094	non-inferiority	2	
299-9	45095-45096	,	1	
299-10	45097-45100	the	2	
299-11	45101-45110	secondary	_	
299-12	45111-45119	outcomes	_	
299-13	45120-45129	according	_	
299-14	45130-45132	to	_	
299-15	45133-45144	superiority	_	
299-16	45145-45146	.	1	

#Text=In contrast to the KOOS , the ICOAP provides information on pain intensity and frequency , and the consequent effects on aspects of life independent of the effects of pain on physical function .
300-1	45147-45149	In	6	
300-2	45150-45158	contrast	_	
300-3	45159-45161	to	1	
300-4	45162-45165	the	2	
300-5	45166-45170	KOOS	_	
300-6	45171-45172	,	1	
300-7	45173-45176	the	9	
300-8	45177-45182	ICOAP	1	
300-9	45183-45191	provides	8	
300-10	45192-45203	information	2	
300-11	45204-45206	on	_	
300-12	45207-45211	pain	_	
300-13	45212-45221	intensity	_	
300-14	45222-45225	and	_	
300-15	45226-45235	frequency	_	
300-16	45236-45237	,	_	
300-17	45238-45241	and	_	
300-18	45242-45245	the	_	
300-19	45246-45256	consequent	_	
300-20	45257-45264	effects	_	
300-21	45265-45267	on	_	
300-22	45268-45275	aspects	_	
300-23	45276-45278	of	_	
300-24	45279-45283	life	_	
300-25	45284-45295	independent	_	
300-26	45296-45298	of	_	
300-27	45299-45302	the	_	
300-28	45303-45310	effects	_	
300-29	45311-45313	of	_	
300-30	45314-45318	pain	_	
300-31	45319-45321	on	_	
300-32	45322-45330	physical	_	
300-33	45331-45339	function	_	
300-34	45340-45341	.	1	

#Text=The accrual rate was , however , slower than expected .
301-1	45342-45345	The	9	
301-2	45346-45353	accrual	_	
301-3	45354-45358	rate	1	
301-4	45359-45362	was	8	
301-5	45363-45364	,	1	
301-6	45365-45372	however	6	
301-7	45373-45374	,	1	
301-8	45375-45381	slower	7	
301-9	45382-45386	than	_	
301-10	45387-45395	expected	_	
301-11	45396-45397	.	1	

#Text=Two of these were of primary interest : the interaction of time with treatment , which indicates whether treatment has an effect , and the effect of instructor within the Tai Chi group .
302-1	45398-45401	Two	9	
302-2	45402-45404	of	_	
302-3	45405-45410	these	1	
302-4	45411-45415	were	8	
302-5	45416-45418	of	1	
302-6	45419-45426	primary	2	
302-7	45427-45435	interest	1	
302-8	45436-45437	:	1	
302-9	45438-45441	the	2	
302-10	45442-45453	interaction	_	
302-11	45454-45456	of	_	
302-12	45457-45461	time	_	
302-13	45462-45466	with	_	
302-14	45467-45476	treatment	_	
302-15	45477-45478	,	1	
302-16	45479-45484	which	6	
302-17	45485-45494	indicates	3	
302-18	45495-45502	whether	6	
302-19	45503-45512	treatment	9	
302-20	45513-45516	has	3	
302-21	45517-45519	an	2	
302-22	45520-45526	effect	_	
302-23	45527-45528	,	1	
302-24	45529-45532	and	2	
302-25	45533-45536	the	_	
302-26	45537-45543	effect	_	
302-27	45544-45546	of	_	
302-28	45547-45557	instructor	_	
302-29	45558-45564	within	_	
302-30	45565-45568	the	_	
302-31	45569-45572	Tai	_	
302-32	45573-45576	Chi	_	
302-33	45577-45582	group	_	
302-34	45583-45584	.	1	

#Text=The selected weight-bearing , static poses were performed barefoot and included squats and lunges with varying foot , trunk , and arm positioning .
303-1	45585-45588	The	9	
303-2	45589-45597	selected	_	
303-3	45598-45612	weight-bearing	_	
303-4	45613-45614	,	_	
303-5	45615-45621	static	_	
303-6	45622-45627	poses	1	
303-7	45628-45632	were	8	
303-8	45633-45642	performed	_	
303-9	45643-45651	barefoot	_	
303-10	45652-45655	and	_	
303-11	45656-45664	included	1	
303-12	45665-45671	squats	2	
303-13	45672-45675	and	_	
303-14	45676-45682	lunges	_	
303-15	45683-45687	with	_	
303-16	45688-45695	varying	_	
303-17	45696-45700	foot	_	
303-18	45701-45702	,	_	
303-19	45703-45708	trunk	_	
303-20	45709-45710	,	_	
303-21	45711-45714	and	_	
303-22	45715-45718	arm	_	
303-23	45719-45730	positioning	_	
303-24	45731-45732	.	1	

#Text=Time spent walking the initial 40 meters of the SMWT was used as 40mW score .
304-1	45733-45737	Time	9	
304-2	45738-45743	spent	_	
304-3	45744-45751	walking	_	
304-4	45752-45755	the	_	
304-5	45756-45763	initial	_	
304-6	45764-45766	40	_	
304-7	45767-45773	meters	_	
304-8	45774-45776	of	_	
304-9	45777-45780	the	_	
304-10	45781-45785	SMWT	1	
304-11	45786-45789	was	8	
304-12	45790-45794	used	_	
304-13	45795-45797	as	1	
304-14	45798-45802	40mW	2	
304-15	45803-45808	score	_	
304-16	45809-45810	.	1	

#Text=The extensions to the box indicate the range of the data after removing outliers , while outliers are indicated individually .
305-1	45811-45814	The	9	
305-2	45815-45825	extensions	_	
305-3	45826-45828	to	_	
305-4	45829-45832	the	_	
305-5	45833-45836	box	1	
305-6	45837-45845	indicate	8	
305-7	45846-45849	the	2	
305-8	45850-45855	range	_	
305-9	45856-45858	of	_	
305-10	45859-45862	the	_	
305-11	45863-45867	data	_	
305-12	45868-45873	after	_	
305-13	45874-45882	removing	_	
305-14	45883-45891	outliers	_	
305-15	45892-45893	,	1	
305-16	45894-45899	while	6	
305-17	45900-45908	outliers	9	
305-18	45909-45912	are	3	
305-19	45913-45922	indicated	_	
305-20	45923-45935	individually	_	
305-21	45936-45937	.	1	

#Text=They were also asked to record whether they had completed the treatment , and , if they had not , they were asked how many capsules they had left .
306-1	45938-45942	They	8	
306-2	45943-45947	were	_	
306-3	45948-45952	also	_	
306-4	45953-45958	asked	_	
306-5	45959-45961	to	_	
306-6	45962-45968	record	1	
306-7	45969-45976	whether	6	
306-8	45977-45981	they	3	
306-9	45982-45985	had	_	
306-10	45986-45995	completed	1	
306-11	45996-45999	the	2	
306-12	46000-46009	treatment	_	
306-13	46010-46011	,	1	
306-14	46012-46015	and	6	
306-15	46016-46017	,	_	
306-16	46018-46020	if	1	
306-17	46021-46025	they	3	
306-18	46026-46029	had	_	
306-19	46030-46033	not	_	
306-20	46034-46035	,	1	
306-21	46036-46040	they	3	
306-22	46041-46045	were	_	
306-23	46046-46051	asked	1	
306-24	46052-46055	how	2	
306-25	46056-46060	many	_	
306-26	46061-46069	capsules	1	
306-27	46070-46074	they	3	
306-28	46075-46078	had	_	
306-29	46079-46083	left	_	
306-30	46084-46085	.	1	

#Text=Subjects were classified with a global overall assessment as clinical cure , failure , or indeterminate at TOC as follows :
#Text=The used formulations were manufactured by Alfa Wasserman Spa ( Bologna , Italy ) .
307-1	46086-46094	Subjects	9	
307-2	46095-46099	were	8	
307-3	46100-46110	classified	_	
307-4	46111-46115	with	1	
307-5	46116-46117	a	2	
307-6	46118-46124	global	_	
307-7	46125-46132	overall	_	
307-8	46133-46143	assessment	1	
307-9	46144-46146	as	2	
307-10	46147-46155	clinical	_	
307-11	46156-46160	cure	_	
307-12	46161-46162	,	_	
307-13	46163-46170	failure	_	
307-14	46171-46172	,	_	
307-15	46173-46175	or	_	
307-16	46176-46189	indeterminate	1	
307-17	46190-46192	at	2	
307-18	46193-46196	TOC	1	
307-19	46197-46199	as	6	
307-20	46200-46207	follows	_	
307-21	46208-46209	:	1	
307-22	46210-46213	The	9	
307-23	46214-46218	used	_	
307-24	46219-46231	formulations	1	
307-25	46232-46236	were	3	
307-26	46237-46249	manufactured	_	
307-27	46250-46252	by	1	
307-28	46253-46257	Alfa	2	
307-29	46258-46267	Wasserman	_	
307-30	46268-46271	Spa	1	
307-31	46272-46273	(	5	
307-32	46274-46281	Bologna	_	
307-33	46282-46283	,	_	
307-34	46284-46289	Italy	_	
307-35	46290-46291	)	_	
307-36	46292-46293	.	1	

#Text=The study was conducted in accordance with the International Council for Harmonisation , Good Clinical Practice standards , and the Declaration of Helsinki , and with local institutional review board/independent ethics committee approval .
308-1	46294-46297	The	9	
308-2	46298-46303	study	1	
308-3	46304-46307	was	8	
308-4	46308-46317	conducted	_	
308-5	46318-46320	in	_	
308-6	46321-46331	accordance	_	
308-7	46332-46336	with	1	
308-8	46337-46340	the	2	
308-9	46341-46354	International	_	
308-10	46355-46362	Council	_	
308-11	46363-46366	for	_	
308-12	46367-46380	Harmonisation	_	
308-13	46381-46382	,	_	
308-14	46383-46387	Good	_	
308-15	46388-46396	Clinical	_	
308-16	46397-46405	Practice	_	
308-17	46406-46415	standards	_	
308-18	46416-46417	,	1	
308-19	46418-46421	and	2	
308-20	46422-46425	the	_	
308-21	46426-46437	Declaration	_	
308-22	46438-46440	of	_	
308-23	46441-46449	Helsinki	_	
308-24	46450-46451	,	1	
308-25	46452-46455	and	2	
308-26	46456-46460	with	_	
308-27	46461-46466	local	_	
308-28	46467-46480	institutional	_	
308-29	46481-46487	review	_	
308-30	46488-46493	board	_	
308-31	46493-46494	/	_	
308-32	46494-46505	independent	_	
308-33	46506-46512	ethics	_	
308-34	46513-46522	committee	_	
308-35	46523-46531	approval	_	
308-36	46532-46533	.	1	

#Text=The sample included ambulatory , community-dwelling women , 50 years of age or over , who met the diagnostic criteria for clinical knee OA according to the American College of Rheumatology [ 20 ] .
309-1	46534-46537	The	9	
309-2	46538-46544	sample	1	
309-3	46545-46553	included	8	
309-4	46554-46564	ambulatory	1	
309-5	46565-46566	,	_	
309-6	46567-46585	community-dwelling	_	
309-7	46586-46591	women	_	
309-8	46592-46593	,	_	
309-9	46594-46596	50	_	
309-10	46597-46602	years	_	
309-11	46603-46605	of	_	
309-12	46606-46609	age	_	
309-13	46610-46612	or	_	
309-14	46613-46617	over	_	
309-15	46618-46619	,	_	
309-16	46620-46623	who	_	
309-17	46624-46627	met	_	
309-18	46628-46631	the	_	
309-19	46632-46642	diagnostic	_	
309-20	46643-46651	criteria	_	
309-21	46652-46655	for	_	
309-22	46656-46664	clinical	_	
309-23	46665-46669	knee	_	
309-24	46670-46672	OA	_	
309-25	46673-46682	according	_	
309-26	46683-46685	to	_	
309-27	46686-46689	the	_	
309-28	46690-46698	American	_	
309-29	46699-46706	College	_	
309-30	46707-46709	of	_	
309-31	46710-46722	Rheumatology	1	
309-32	46723-46724	[	5	
309-33	46725-46727	20	_	
309-34	46728-46729	]	_	
309-35	46730-46731	.	1	

#Text=Routine follow-up visits for assessment of safety and effectiveness occurred at 1 , 3 , and 6 months after the last treatment ( initial or touch-up ) .
310-1	46732-46739	Routine	9	
310-2	46740-46749	follow-up	_	
310-3	46750-46756	visits	_	
310-4	46757-46760	for	_	
310-5	46761-46771	assessment	_	
310-6	46772-46774	of	_	
310-7	46775-46781	safety	_	
310-8	46782-46785	and	_	
310-9	46786-46799	effectiveness	1	
310-10	46800-46808	occurred	8	
310-11	46809-46811	at	1	
310-12	46812-46813	1	2	
310-13	46814-46815	,	_	
310-14	46816-46817	3	_	
310-15	46818-46819	,	_	
310-16	46820-46823	and	_	
310-17	46824-46825	6	_	
310-18	46826-46832	months	_	
310-19	46833-46838	after	_	
310-20	46839-46842	the	_	
310-21	46843-46847	last	_	
310-22	46848-46857	treatment	1	
310-23	46858-46859	(	5	
310-24	46860-46867	initial	_	
310-25	46868-46870	or	_	
310-26	46871-46879	touch-up	_	
310-27	46880-46881	)	_	
310-28	46882-46883	.	1	

#Text=Disease severity was determined using the Lower Extremity Functional Scale ( LEFS ) , [ 22,23 ] a 20-item measure addressing lower extremity physical function limitations associated with musculoskeletal conditions affecting the lower extremity .
311-1	46884-46891	Disease	9	
311-2	46892-46900	severity	1	
311-3	46901-46904	was	8	
311-4	46905-46915	determined	_	
311-5	46916-46921	using	1	
311-6	46922-46925	the	2	
311-7	46926-46931	Lower	_	
311-8	46932-46941	Extremity	_	
311-9	46942-46952	Functional	_	
311-10	46953-46958	Scale	1	
311-11	46959-46960	(	5	
311-12	46961-46965	LEFS	_	
311-13	46966-46967	)	_	
311-14	46968-46969	,	1	
311-15	46970-46971	[	5	
311-16	46972-46977	22,23	_	
311-17	46978-46979	]	1	
311-18	46980-46981	a	2	
311-19	46982-46984	20	_	
311-20	46984-46985	-	_	
311-21	46985-46989	item	_	
311-22	46990-46997	measure	_	
311-23	46998-47008	addressing	_	
311-24	47009-47014	lower	_	
311-25	47015-47024	extremity	_	
311-26	47025-47033	physical	_	
311-27	47034-47042	function	_	
311-28	47043-47054	limitations	_	
311-29	47055-47065	associated	_	
311-30	47066-47070	with	_	
311-31	47071-47086	musculoskeletal	_	
311-32	47087-47097	conditions	_	
311-33	47098-47107	affecting	_	
311-34	47108-47111	the	_	
311-35	47112-47117	lower	_	
311-36	47118-47127	extremity	_	
311-37	47128-47129	.	1	

#Text=The patients received equipment to take a second urine sample at home and send it to the laboratory for a new culture after 2 weeks .
312-1	47130-47133	The	9	
312-2	47134-47142	patients	1	
312-3	47143-47151	received	8	
312-4	47152-47161	equipment	2	
312-5	47162-47164	to	3	
312-6	47165-47169	take	1	
312-7	47170-47171	a	2	
312-8	47172-47178	second	_	
312-9	47179-47184	urine	_	
312-10	47185-47191	sample	1	
312-11	47192-47194	at	2	
312-12	47195-47199	home	1	
312-13	47200-47203	and	3	
312-14	47204-47208	send	_	
312-15	47209-47211	it	_	
312-16	47212-47214	to	1	
312-17	47215-47218	the	2	
312-18	47219-47229	laboratory	1	
312-19	47230-47233	for	2	
312-20	47234-47235	a	_	
312-21	47236-47239	new	_	
312-22	47240-47247	culture	1	
312-23	47248-47253	after	2	
312-24	47254-47255	2	_	
312-25	47256-47261	weeks	_	
312-26	47262-47263	.	1	

#Text=Blinding was maintained by a similar appearance of placebo to trimodulin , and vials were covered with transparent colored foil .
313-1	47264-47272	Blinding	9	
313-2	47273-47276	was	8	
313-3	47277-47287	maintained	_	
313-4	47288-47290	by	1	
313-5	47291-47292	a	2	
313-6	47293-47300	similar	_	
313-7	47301-47311	appearance	_	
313-8	47312-47314	of	_	
313-9	47315-47322	placebo	_	
313-10	47323-47325	to	_	
313-11	47326-47336	trimodulin	_	
313-12	47337-47338	,	1	
313-13	47339-47342	and	9	
313-14	47343-47348	vials	1	
313-15	47349-47353	were	3	
313-16	47354-47361	covered	_	
313-17	47362-47366	with	1	
313-18	47367-47378	transparent	2	
313-19	47379-47386	colored	_	
313-20	47387-47391	foil	_	
313-21	47392-47393	.	1	

#Text=Assuming a dropout rate of approximately 20 % , we aimed to randomize 400 patients .
314-1	47394-47402	Assuming	3	
314-2	47403-47404	a	2	
314-3	47405-47412	dropout	_	
314-4	47413-47417	rate	_	
314-5	47418-47420	of	_	
314-6	47421-47434	approximately	_	
314-7	47435-47437	20	_	
314-8	47438-47439	%	_	
314-9	47440-47441	,	1	
314-10	47442-47444	we	8	
314-11	47445-47450	aimed	_	
314-12	47451-47453	to	_	
314-13	47454-47463	randomize	1	
314-14	47464-47467	400	2	
314-15	47468-47476	patients	_	
314-16	47477-47478	.	1	

#Text=Participants who satisfied eligibility criteria were offered enrollment .
315-1	47479-47491	Participants	9	
315-2	47492-47495	who	_	
315-3	47496-47505	satisfied	_	
315-4	47506-47517	eligibility	_	
315-5	47518-47526	criteria	1	
315-6	47527-47531	were	8	
315-7	47532-47539	offered	1	
315-8	47540-47550	enrollment	2	
315-9	47551-47552	.	1	

#Text=Adverse events were tracked by having participants complete a report at follow-up that asked whether they experienced an event that may have affected their quality of life or function since the last visit .
316-1	47553-47560	Adverse	9	
316-2	47561-47567	events	1	
316-3	47568-47572	were	8	
316-4	47573-47580	tracked	_	
316-5	47581-47583	by	_	
316-6	47584-47590	having	1	
316-7	47591-47603	participants	2	
316-8	47604-47612	complete	3	
316-9	47613-47614	a	2	
316-10	47615-47621	report	1	
316-11	47622-47624	at	2	
316-12	47625-47634	follow-up	1	
316-13	47635-47639	that	6	
316-14	47640-47645	asked	3	
316-15	47646-47653	whether	6	
316-16	47654-47658	they	3	
316-17	47659-47670	experienced	1	
316-18	47671-47673	an	2	
316-19	47674-47679	event	1	
316-20	47680-47684	that	3	
316-21	47685-47688	may	_	
316-22	47689-47693	have	_	
316-23	47694-47702	affected	1	
316-24	47703-47708	their	2	
316-25	47709-47716	quality	_	
316-26	47717-47719	of	_	
316-27	47720-47724	life	_	
316-28	47725-47727	or	_	
316-29	47728-47736	function	1	
316-30	47737-47742	since	2	
316-31	47743-47746	the	_	
316-32	47747-47751	last	_	
316-33	47752-47757	visit	_	
316-34	47758-47759	.	1	

#Text=All data collection was led by an investigator who was blind to group allocation and uninvolved in the interventions .
317-1	47760-47763	All	9	
317-2	47764-47768	data	_	
317-3	47769-47779	collection	1	
317-4	47780-47783	was	8	
317-5	47784-47787	led	_	
317-6	47788-47790	by	1	
317-7	47791-47793	an	2	
317-8	47794-47806	investigator	_	
317-9	47807-47810	who	_	
317-10	47811-47814	was	_	
317-11	47815-47820	blind	_	
317-12	47821-47823	to	_	
317-13	47824-47829	group	_	
317-14	47830-47840	allocation	_	
317-15	47841-47844	and	_	
317-16	47845-47855	uninvolved	_	
317-17	47856-47858	in	_	
317-18	47859-47862	the	_	
317-19	47863-47876	interventions	_	
317-20	47877-47878	.	1	

#Text=For placement of the pigtail catheter into the gallbladder , either the trocar technique ( one step technique ) or the Seldinger technique ( multiple step technique ) was used .
318-1	47879-47882	For	2	
318-2	47883-47892	placement	_	
318-3	47893-47895	of	_	
318-4	47896-47899	the	_	
318-5	47900-47907	pigtail	_	
318-6	47908-47916	catheter	_	
318-7	47917-47921	into	_	
318-8	47922-47925	the	_	
318-9	47926-47937	gallbladder	_	
318-10	47938-47939	,	1	
318-11	47940-47946	either	9	
318-12	47947-47950	the	_	
318-13	47951-47957	trocar	_	
318-14	47958-47967	technique	_	
318-15	47968-47969	(	5	
318-16	47970-47973	one	_	
318-17	47974-47978	step	_	
318-18	47979-47988	technique	_	
318-19	47989-47990	)	1	
318-20	47991-47993	or	_	
318-21	47994-47997	the	_	
318-22	47998-48007	Seldinger	_	
318-23	48008-48017	technique	1	
318-24	48018-48019	(	5	
318-25	48020-48028	multiple	_	
318-26	48029-48033	step	_	
318-27	48034-48043	technique	_	
318-28	48044-48045	)	1	
318-29	48046-48049	was	8	
318-30	48050-48054	used	_	
318-31	48055-48056	.	1	

#Text=Baseline and follow-up MRI and CT images were assessed independent of each other at the core imaging laboratory at Stanford University by assessors who were unaware of the trial-group assignments .
319-1	48057-48065	Baseline	9	
319-2	48066-48069	and	_	
319-3	48070-48079	follow-up	_	
319-4	48080-48083	MRI	_	
319-5	48084-48087	and	_	
319-6	48088-48090	CT	_	
319-7	48091-48097	images	1	
319-8	48098-48102	were	8	
319-9	48103-48111	assessed	1	
319-10	48112-48123	independent	7	
319-11	48124-48126	of	_	
319-12	48127-48131	each	_	
319-13	48132-48137	other	1	
319-14	48138-48140	at	2	
319-15	48141-48144	the	_	
319-16	48145-48149	core	_	
319-17	48150-48157	imaging	_	
319-18	48158-48168	laboratory	1	
319-19	48169-48171	at	2	
319-20	48172-48180	Stanford	_	
319-21	48181-48191	University	1	
319-22	48192-48194	by	2	
319-23	48195-48204	assessors	_	
319-24	48205-48208	who	_	
319-25	48209-48213	were	_	
319-26	48214-48221	unaware	_	
319-27	48222-48224	of	_	
319-28	48225-48228	the	_	
319-29	48229-48240	trial-group	_	
319-30	48241-48252	assignments	_	
319-31	48253-48254	.	1	

#Text=We had not predefined flank pain ; hence , we decided that this would include both where the doctor perceived the patient as having flank pain upon examination and where patients self-reported flank pain .
320-1	48255-48257	We	8	
320-2	48258-48261	had	_	
320-3	48262-48265	not	_	
320-4	48266-48276	predefined	1	
320-5	48277-48282	flank	2	
320-6	48283-48287	pain	1	
320-7	48288-48289	;	6	
320-8	48290-48295	hence	_	
320-9	48296-48297	,	1	
320-10	48298-48300	we	3	
320-11	48301-48308	decided	_	
320-12	48309-48313	that	_	
320-13	48314-48318	this	_	
320-14	48319-48324	would	_	
320-15	48325-48332	include	1	
320-16	48333-48337	both	2	
320-17	48338-48343	where	6	
320-18	48344-48347	the	9	
320-19	48348-48354	doctor	1	
320-20	48355-48364	perceived	3	
320-21	48365-48368	the	2	
320-22	48369-48376	patient	1	
320-23	48377-48379	as	3	
320-24	48380-48386	having	1	
320-25	48387-48392	flank	2	
320-26	48393-48397	pain	_	
320-27	48398-48402	upon	_	
320-28	48403-48414	examination	1	
320-29	48415-48418	and	6	
320-30	48419-48424	where	1	
320-31	48425-48433	patients	9	
320-32	48434-48447	self-reported	3	
320-33	48448-48453	flank	2	
320-34	48454-48458	pain	_	
320-35	48459-48460	.	1	

#Text=The program emphasized knee strengthening but also involved an aerobic warm-up , balance exercises , and stretching .
321-1	48461-48464	The	9	
321-2	48465-48472	program	1	
321-3	48473-48483	emphasized	8	
321-4	48484-48488	knee	2	
321-5	48489-48502	strengthening	1	
321-6	48503-48506	but	3	
321-7	48507-48511	also	_	
321-8	48512-48520	involved	1	
321-9	48521-48523	an	2	
321-10	48524-48531	aerobic	_	
321-11	48532-48539	warm-up	_	
321-12	48540-48541	,	_	
321-13	48542-48549	balance	_	
321-14	48550-48559	exercises	_	
321-15	48560-48561	,	_	
321-16	48562-48565	and	_	
321-17	48566-48576	stretching	_	
321-18	48577-48578	.	1	

#Text=At each visit , EIs evaluated NLF severity and the natural look of NLF regions , and facial digital photography was performed .
322-1	48579-48581	At	2	
322-2	48582-48586	each	_	
322-3	48587-48592	visit	_	
322-4	48593-48594	,	1	
322-5	48595-48598	EIs	9	
322-6	48599-48608	evaluated	8	
322-7	48609-48612	NLF	2	
322-8	48613-48621	severity	1	
322-9	48622-48625	and	2	
322-10	48626-48629	the	_	
322-11	48630-48637	natural	_	
322-12	48638-48642	look	_	
322-13	48643-48645	of	_	
322-14	48646-48649	NLF	_	
322-15	48650-48657	regions	_	
322-16	48658-48659	,	1	
322-17	48660-48663	and	9	
322-18	48664-48670	facial	_	
322-19	48671-48678	digital	_	
322-20	48679-48690	photography	1	
322-21	48691-48694	was	3	
322-22	48695-48704	performed	_	
322-23	48705-48706	.	1	

#Text=A Norwegian pharmaceutical preparation company , Kragerø Tablettproduksjon , over-encapsulated the medicine used in the study .
323-1	48707-48708	A	2	
323-2	48709-48718	Norwegian	_	
323-3	48719-48733	pharmaceutical	_	
323-4	48734-48745	preparation	_	
323-5	48746-48753	company	_	
323-6	48754-48755	,	1	
323-7	48756-48763	Kragerø	2	
323-8	48764-48781	Tablettproduksjon	_	
323-9	48782-48783	,	1	
323-10	48784-48801	over-encapsulated	8	
323-11	48802-48805	the	2	
323-12	48806-48814	medicine	1	
323-13	48815-48819	used	3	
323-14	48820-48822	in	2	
323-15	48823-48826	the	_	
323-16	48827-48832	study	_	
323-17	48833-48834	.	1	

#Text=Finally , 20 μL MilliQ water was added and extracted .
324-1	48835-48842	Finally	6	
324-2	48843-48844	,	_	
324-3	48845-48847	20	9	
324-4	48848-48850	μL	_	
324-5	48851-48857	MilliQ	_	
324-6	48858-48863	water	1	
324-7	48864-48867	was	8	
324-8	48868-48873	added	_	
324-9	48874-48877	and	_	
324-10	48878-48887	extracted	_	
324-11	48888-48889	.	1	

#Text=Further treatment was left to the discretion of the treating clinician .
325-1	48890-48897	Further	9	
325-2	48898-48907	treatment	1	
325-3	48908-48911	was	8	
325-4	48912-48916	left	_	
325-5	48917-48919	to	1	
325-6	48920-48923	the	2	
325-7	48924-48934	discretion	_	
325-8	48935-48937	of	_	
325-9	48938-48941	the	_	
325-10	48942-48950	treating	_	
325-11	48951-48960	clinician	_	
325-12	48961-48962	.	1	

#Text=The TOF-MS sampling took place with 5 Hz in extended dynamic range with 1599 transients/spectrum .
326-1	48963-48966	The	9	
326-2	48967-48973	TOF-MS	_	
326-3	48974-48982	sampling	1	
326-4	48983-48987	took	8	
326-5	48988-48993	place	_	
326-6	48994-48998	with	1	
326-7	48999-49000	5	2	
326-8	49001-49003	Hz	_	
326-9	49004-49006	in	_	
326-10	49007-49015	extended	_	
326-11	49016-49023	dynamic	_	
326-12	49024-49029	range	_	
326-13	49030-49034	with	_	
326-14	49035-49039	1599	_	
326-15	49040-49050	transients	_	
326-16	49050-49051	/	_	
326-17	49051-49059	spectrum	_	
326-18	49060-49061	.	1	

#Text=For continuous outcomes , we assumed normally distributed errors with an unstructured covariance matrix and used restricted maximum likelihood estimation .
327-1	49062-49065	For	2	
327-2	49066-49076	continuous	_	
327-3	49077-49085	outcomes	_	
327-4	49086-49087	,	1	
327-5	49088-49090	we	8	
327-6	49091-49098	assumed	1	
327-7	49099-49107	normally	2	
327-8	49108-49119	distributed	_	
327-9	49120-49126	errors	_	
327-10	49127-49131	with	_	
327-11	49132-49134	an	_	
327-12	49135-49147	unstructured	_	
327-13	49148-49158	covariance	_	
327-14	49159-49165	matrix	1	
327-15	49166-49169	and	3	
327-16	49170-49174	used	1	
327-17	49175-49185	restricted	2	
327-18	49186-49193	maximum	_	
327-19	49194-49204	likelihood	_	
327-20	49205-49215	estimation	_	
327-21	49216-49217	.	1	

#Text=Regarding safety , we were specifically interested in how many patients developed an upper UTI ( pyelonephritis/febrile UTI ) and how many patients experienced adverse events and serious adverse events ( SAEs ) ( defined as any event leading to hospitalization ) .
328-1	49218-49227	Regarding	2	
328-2	49228-49234	safety	_	
328-3	49235-49236	,	1	
328-4	49237-49239	we	8	
328-5	49240-49244	were	8	
328-6	49245-49257	specifically	7	
328-7	49258-49268	interested	1	
328-8	49269-49271	in	9	
328-9	49272-49275	how	_	
328-10	49276-49280	many	_	
328-11	49281-49289	patients	1	
328-12	49290-49299	developed	3	
328-13	49300-49302	an	2	
328-14	49303-49308	upper	_	
328-15	49309-49312	UTI	1	
328-16	49313-49314	(	5	
328-17	49315-49329	pyelonephritis	_	
328-18	49329-49330	/	_	
328-19	49330-49337	febrile	_	
328-20	49338-49341	UTI	_	
328-21	49342-49343	)	1	
328-22	49344-49347	and	9	
328-23	49348-49351	how	_	
328-24	49352-49356	many	_	
328-25	49357-49365	patients	1	
328-26	49366-49377	experienced	3	
328-27	49378-49385	adverse	2	
328-28	49386-49392	events	_	
328-29	49393-49396	and	_	
328-30	49397-49404	serious	_	
328-31	49405-49412	adverse	_	
328-32	49413-49419	events	1	
328-33	49420-49421	(	5	
328-34	49422-49426	SAEs	_	
328-35	49427-49428	)	1	
328-36	49429-49430	(	5	
328-37	49431-49438	defined	_	
328-38	49439-49441	as	_	
328-39	49442-49445	any	_	
328-40	49446-49451	event	_	
328-41	49452-49459	leading	_	
328-42	49460-49462	to	_	
328-43	49463-49478	hospitalization	_	
328-44	49479-49480	)	_	
328-45	49481-49482	.	1	

#Text=Lipid species were detected by peak integration using the software Mass Hunter Quantitative Analysis Version B.05.02 ( Agilent , Waldbronn , Germany ) .
329-1	49483-49488	Lipid	9	
329-2	49489-49496	species	1	
329-3	49497-49501	were	8	
329-4	49502-49510	detected	_	
329-5	49511-49513	by	1	
329-6	49514-49518	peak	2	
329-7	49519-49530	integration	1	
329-8	49531-49536	using	2	
329-9	49537-49540	the	2	
329-10	49541-49549	software	_	
329-11	49550-49554	Mass	_	
329-12	49555-49561	Hunter	_	
329-13	49562-49574	Quantitative	_	
329-14	49575-49583	Analysis	_	
329-15	49584-49591	Version	_	
329-16	49592-49593	B	_	
329-17	49593-49599	.05.02	1	
329-18	49600-49601	(	5	
329-19	49602-49609	Agilent	_	
329-20	49610-49611	,	_	
329-21	49612-49621	Waldbronn	_	
329-22	49622-49623	,	_	
329-23	49624-49631	Germany	_	
329-24	49632-49633	)	_	
329-25	49634-49635	.	1	

#Text=The anticipated rate of feeling cured after 4 days was 85 % in both groups .
330-1	49636-49639	The	9	
330-2	49640-49651	anticipated	_	
330-3	49652-49656	rate	_	
330-4	49657-49659	of	_	
330-5	49660-49667	feeling	_	
330-6	49668-49673	cured	_	
330-7	49674-49679	after	_	
330-8	49680-49681	4	_	
330-9	49682-49686	days	1	
330-10	49687-49690	was	8	
330-11	49691-49693	85	2	
330-12	49694-49695	%	1	
330-13	49696-49698	in	2	
330-14	49699-49703	both	_	
330-15	49704-49710	groups	_	
330-16	49711-49712	.	1	

#Text=Details of the trial design and conduct have been published ( 17 ) and registered at ClinicalTrials.gov ( { " type":"clinical-trial","attrs":{"text":"NCT01258985","term_id":"NCT01258985"}}NCT01258985 ) .
331-1	49713-49720	Details	9	
331-2	49721-49723	of	_	
331-3	49724-49727	the	_	
331-4	49728-49733	trial	_	
331-5	49734-49740	design	_	
331-6	49741-49744	and	_	
331-7	49745-49752	conduct	1	
331-8	49753-49757	have	8	
331-9	49758-49762	been	_	
331-10	49763-49772	published	_	
331-11	49773-49774	(	5	
331-12	49775-49777	17	_	
331-13	49778-49779	)	1	
331-14	49780-49783	and	_	
331-15	49784-49794	registered	_	
331-16	49795-49797	at	1	
331-17	49798-49816	ClinicalTrials.gov	2	
331-18	49817-49818	(	5	
331-19	49819-49820	{	_	
331-20	49821-49822	"	_	
331-21	49823-49827	type	_	
331-22	49827-49828	"	_	
331-23	49828-49829	:	_	
331-24	49829-49830	"	_	
331-25	49830-49844	clinical-trial	_	
331-26	49844-49845	"	_	
331-27	49845-49846	,	_	
331-28	49846-49847	"	_	
331-29	49847-49852	attrs	_	
331-30	49852-49853	"	_	
331-31	49853-49854	:	_	
331-32	49854-49855	{	_	
331-33	49855-49856	"	_	
331-34	49856-49860	text	_	
331-35	49860-49861	"	_	
331-36	49861-49862	:	_	
331-37	49862-49863	"	_	
331-38	49863-49874	NCT01258985	_	
331-39	49874-49875	"	_	
331-40	49875-49876	,	_	
331-41	49876-49877	"	_	
331-42	49877-49884	term_id	_	
331-43	49884-49885	"	_	
331-44	49885-49886	:	_	
331-45	49886-49887	"	_	
331-46	49887-49898	NCT01258985	_	
331-47	49898-49899	"	_	
331-48	49899-49900	}	_	
331-49	49900-49901	}	_	
331-50	49901-49912	NCT01258985	_	
331-51	49913-49914	)	_	
331-52	49915-49916	.	1	

#Text=Participants were recruited through rheumatology , orthopaedic , and physical therapy clinics , as well as by word-of-mouth and newspaper advertisements in the Hamilton , Ontario , Canada region between April and June 2015 .
332-1	49917-49929	Participants	9	
332-2	49930-49934	were	8	
332-3	49935-49944	recruited	_	
332-4	49945-49952	through	1	
332-5	49953-49965	rheumatology	_	
332-6	49966-49967	,	_	
332-7	49968-49979	orthopaedic	_	
332-8	49980-49981	,	_	
332-9	49982-49985	and	_	
332-10	49986-49994	physical	_	
332-11	49995-50002	therapy	_	
332-12	50003-50010	clinics	_	
332-13	50011-50012	,	1	
332-14	50013-50015	as	2	
332-15	50016-50020	well	_	
332-16	50021-50023	as	_	
332-17	50024-50026	by	_	
332-18	50027-50040	word-of-mouth	_	
332-19	50041-50044	and	_	
332-20	50045-50054	newspaper	_	
332-21	50055-50069	advertisements	1	
332-22	50070-50072	in	2	
332-23	50073-50076	the	_	
332-24	50077-50085	Hamilton	_	
332-25	50086-50087	,	_	
332-26	50088-50095	Ontario	_	
332-27	50096-50097	,	_	
332-28	50098-50104	Canada	_	
332-29	50105-50111	region	1	
332-30	50112-50119	between	2	
332-31	50120-50125	April	_	
332-32	50126-50129	and	_	
332-33	50130-50134	June	_	
332-34	50135-50139	2015	_	
332-35	50140-50141	.	1	

#Text=For LPC species , absolute concentrations were in addition measured using the calibration standards LPC 12:0 , LPC 16:0 , LPC 17:0 , and LPC 18:1 .
333-1	50142-50145	For	2	
333-2	50146-50149	LPC	_	
333-3	50150-50157	species	_	
333-4	50158-50159	,	1	
333-5	50160-50168	absolute	9	
333-6	50169-50183	concentrations	1	
333-7	50184-50188	were	8	
333-8	50189-50191	in	_	
333-9	50192-50200	addition	_	
333-10	50201-50209	measured	_	
333-11	50210-50215	using	1	
333-12	50216-50219	the	2	
333-13	50220-50231	calibration	_	
333-14	50232-50241	standards	_	
333-15	50242-50245	LPC	_	
333-16	50246-50248	12	_	
333-17	50248-50249	:	_	
333-18	50249-50250	0	_	
333-19	50251-50252	,	_	
333-20	50253-50256	LPC	_	
333-21	50257-50259	16	_	
333-22	50259-50260	:	_	
333-23	50260-50261	0	_	
333-24	50262-50263	,	_	
333-25	50264-50267	LPC	_	
333-26	50268-50270	17	_	
333-27	50270-50271	:	_	
333-28	50271-50272	0	_	
333-29	50273-50274	,	_	
333-30	50275-50278	and	_	
333-31	50279-50282	LPC	_	
333-32	50283-50285	18	_	
333-33	50285-50286	:	_	
333-34	50286-50287	1	_	
333-35	50288-50289	.	1	

#Text=Within each batch QC samples were included ; the QC samples were prepared and measured in a randomized order to investigate the analytical repeatability of the method ( N = 11 in batch 1 ; N = 9 in batch 2 ) .
334-1	50290-50296	Within	2	
334-2	50297-50301	each	_	
334-3	50302-50307	batch	1	
334-4	50308-50310	QC	9	
334-5	50311-50318	samples	1	
334-6	50319-50323	were	3	
334-7	50324-50332	included	1	
334-8	50333-50334	;	6	
334-9	50335-50338	the	9	
334-10	50339-50341	QC	_	
334-11	50342-50349	samples	1	
334-12	50350-50354	were	8	
334-13	50355-50363	prepared	_	
334-14	50364-50367	and	_	
334-15	50368-50376	measured	_	
334-16	50377-50379	in	1	
334-17	50380-50381	a	2	
334-18	50382-50392	randomized	_	
334-19	50393-50398	order	1	
334-20	50399-50401	to	2	
334-21	50402-50413	investigate	1	
334-22	50414-50417	the	2	
334-23	50418-50428	analytical	_	
334-24	50429-50442	repeatability	_	
334-25	50443-50445	of	_	
334-26	50446-50449	the	_	
334-27	50450-50456	method	1	
334-28	50457-50458	(	5	
334-29	50459-50460	N	_	
334-30	50461-50462	=	_	
334-31	50463-50465	11	_	
334-32	50466-50468	in	_	
334-33	50469-50474	batch	_	
334-34	50475-50476	1	_	
334-35	50477-50478	;	_	
334-36	50479-50480	N	_	
334-37	50481-50482	=	_	
334-38	50483-50484	9	_	
334-39	50485-50487	in	_	
334-40	50488-50493	batch	_	
334-41	50494-50495	2	_	
334-42	50496-50497	)	_	
334-43	50498-50499	.	1	

#Text=Laparoscopic cholecystectomy was performed by the four trocar technique , with transection of the cystic duct and artery after reaching the critical view of safety , as described in national and international guidelines.
335-1	50500-50512	Laparoscopic	9	
335-2	50513-50528	cholecystectomy	1	
335-3	50529-50532	was	8	
335-4	50533-50542	performed	_	
335-5	50543-50545	by	1	
335-6	50546-50549	the	2	
335-7	50550-50554	four	_	
335-8	50555-50561	trocar	_	
335-9	50562-50571	technique	_	
335-10	50572-50573	,	1	
335-11	50574-50578	with	2	
335-12	50579-50590	transection	_	
335-13	50591-50593	of	_	
335-14	50594-50597	the	_	
335-15	50598-50604	cystic	_	
335-16	50605-50609	duct	_	
335-17	50610-50613	and	_	
335-18	50614-50620	artery	_	
335-19	50621-50626	after	_	
335-20	50627-50635	reaching	_	
335-21	50636-50639	the	_	
335-22	50640-50648	critical	_	
335-23	50649-50653	view	_	
335-24	50654-50656	of	_	
335-25	50657-50663	safety	_	
335-26	50664-50665	,	1	
335-27	50666-50668	as	3	
335-28	50669-50678	described	_	
335-29	50679-50681	in	1	
335-30	50682-50690	national	2	
335-31	50691-50694	and	_	
335-32	50695-50708	international	_	
335-33	50709-50719	guidelines	_	
335-34	50719-50720	.	1	

#Text=The patients from the pilot studies were included in the main study .
336-1	50721-50724	The	9	
336-2	50725-50733	patients	_	
336-3	50734-50738	from	_	
336-4	50739-50742	the	_	
336-5	50743-50748	pilot	_	
336-6	50749-50756	studies	1	
336-7	50757-50761	were	8	
336-8	50762-50770	included	_	
336-9	50771-50773	in	1	
336-10	50774-50777	the	2	
336-11	50778-50782	main	_	
336-12	50783-50788	study	_	
336-13	50789-50790	.	1	

#Text=The labeling was done following a computer-generated randomization list created by an independent statistician using randomized block sizes of 2 , 4 , 6 , or 8 , stratified by country [ 16 ] .
337-1	50791-50794	The	9	
337-2	50795-50803	labeling	1	
337-3	50804-50807	was	8	
337-4	50808-50812	done	_	
337-5	50813-50822	following	1	
337-6	50823-50824	a	2	
337-7	50825-50843	computer-generated	_	
337-8	50844-50857	randomization	_	
337-9	50858-50862	list	_	
337-10	50863-50870	created	_	
337-11	50871-50873	by	_	
337-12	50874-50876	an	_	
337-13	50877-50888	independent	_	
337-14	50889-50901	statistician	1	
337-15	50902-50907	using	3	
337-16	50908-50918	randomized	2	
337-17	50919-50924	block	_	
337-18	50925-50930	sizes	_	
337-19	50931-50933	of	_	
337-20	50934-50935	2	_	
337-21	50936-50937	,	_	
337-22	50938-50939	4	_	
337-23	50940-50941	,	_	
337-24	50942-50943	6	_	
337-25	50944-50945	,	_	
337-26	50946-50948	or	_	
337-27	50949-50950	8	_	
337-28	50951-50952	,	_	
337-29	50953-50963	stratified	_	
337-30	50964-50966	by	_	
337-31	50967-50974	country	1	
337-32	50975-50976	[	5	
337-33	50977-50979	16	_	
337-34	50980-50981	]	_	
337-35	50982-50983	.	1	

#Text=The ICOAP is an 11-item questionnaire where higher scores are indicative of more severe pain .
338-1	50984-50987	The	9	
338-2	50988-50993	ICOAP	1	
338-3	50994-50996	is	8	
338-4	50997-50999	an	2	
338-5	51000-51002	11	_	
338-6	51002-51003	-	_	
338-7	51003-51007	item	_	
338-8	51008-51021	questionnaire	1	
338-9	51022-51027	where	6	
338-10	51028-51034	higher	9	
338-11	51035-51041	scores	1	
338-12	51042-51045	are	3	
338-13	51046-51056	indicative	7	
338-14	51057-51059	of	1	
338-15	51060-51064	more	2	
338-16	51065-51071	severe	_	
338-17	51072-51076	pain	_	
338-18	51077-51078	.	1	

#Text=The study was approved by the Regional ethical review board at Umeå University , Umeå , Sweden ( Dnr 09 - 215 M ; 2009 - 1421 - 31 ) .
339-1	51079-51082	The	9	
339-2	51083-51088	study	1	
339-3	51089-51092	was	8	
339-4	51093-51101	approved	_	
339-5	51102-51104	by	1	
339-6	51105-51108	the	2	
339-7	51109-51117	Regional	_	
339-8	51118-51125	ethical	_	
339-9	51126-51132	review	_	
339-10	51133-51138	board	1	
339-11	51139-51141	at	2	
339-12	51142-51146	Umeå	_	
339-13	51147-51157	University	_	
339-14	51158-51159	,	_	
339-15	51160-51164	Umeå	_	
339-16	51165-51166	,	_	
339-17	51167-51173	Sweden	1	
339-18	51174-51175	(	5	
339-19	51176-51179	Dnr	_	
339-20	51180-51182	09	_	
339-21	51183-51184	-	_	
339-22	51185-51188	215	_	
339-23	51189-51190	M	_	
339-24	51191-51192	;	_	
339-25	51193-51197	2009	_	
339-26	51198-51199	-	_	
339-27	51200-51204	1421	_	
339-28	51205-51206	-	_	
339-29	51207-51209	31	_	
339-30	51210-51211	)	_	
339-31	51212-51213	.	1	

#Text=The blood was allowed to clot for 30 min before centrifugation at 1,620 × g for 10 min at 4 ° C .
340-1	51214-51217	The	9	
340-2	51218-51223	blood	1	
340-3	51224-51227	was	8	
340-4	51228-51235	allowed	_	
340-5	51236-51238	to	_	
340-6	51239-51243	clot	_	
340-7	51244-51247	for	1	
340-8	51248-51250	30	2	
340-9	51251-51254	min	_	
340-10	51255-51261	before	_	
340-11	51262-51276	centrifugation	1	
340-12	51277-51279	at	2	
340-13	51280-51285	1,620	_	
340-14	51286-51287	×	_	
340-15	51288-51289	g	1	
340-16	51290-51293	for	2	
340-17	51294-51296	10	_	
340-18	51297-51300	min	1	
340-19	51301-51303	at	2	
340-20	51304-51305	4	_	
340-21	51306-51307	°	_	
340-22	51308-51309	C	_	
340-23	51310-51311	.	1	

#Text=The plan was modified in June 2017 to accommodate the results of the DAWN trial , which involved patients and treatments similar to those in our trial and which showed clinical benefit of endovascular thrombectomy over medical therapy when treatment was initiated 6 to 24 hours after the onset of stroke symptoms .
341-1	51312-51315	The	9	
341-2	51316-51320	plan	1	
341-3	51321-51324	was	8	
341-4	51325-51333	modified	_	
341-5	51334-51336	in	1	
341-6	51337-51341	June	2	
341-7	51342-51346	2017	1	
341-8	51347-51349	to	3	
341-9	51350-51361	accommodate	1	
341-10	51362-51365	the	2	
341-11	51366-51373	results	_	
341-12	51374-51376	of	_	
341-13	51377-51380	the	_	
341-14	51381-51385	DAWN	_	
341-15	51386-51391	trial	_	
341-16	51392-51393	,	1	
341-17	51394-51399	which	6	
341-18	51400-51408	involved	3	
341-19	51409-51417	patients	2	
341-20	51418-51421	and	_	
341-21	51422-51432	treatments	_	
341-22	51433-51440	similar	_	
341-23	51441-51443	to	_	
341-24	51444-51449	those	_	
341-25	51450-51452	in	_	
341-26	51453-51456	our	_	
341-27	51457-51462	trial	1	
341-28	51463-51466	and	6	
341-29	51467-51472	which	1	
341-30	51473-51479	showed	3	
341-31	51480-51488	clinical	2	
341-32	51489-51496	benefit	_	
341-33	51497-51499	of	_	
341-34	51500-51512	endovascular	_	
341-35	51513-51525	thrombectomy	_	
341-36	51526-51530	over	_	
341-37	51531-51538	medical	_	
341-38	51539-51546	therapy	1	
341-39	51547-51551	when	6	
341-40	51552-51561	treatment	9	
341-41	51562-51565	was	3	
341-42	51566-51575	initiated	1	
341-43	51576-51577	6	2	
341-44	51578-51580	to	_	
341-45	51581-51583	24	_	
341-46	51584-51589	hours	_	
341-47	51590-51595	after	_	
341-48	51596-51599	the	_	
341-49	51600-51605	onset	_	
341-50	51606-51608	of	_	
341-51	51609-51615	stroke	_	
341-52	51616-51624	symptoms	_	
341-53	51625-51626	.	1	

#Text=The secondary endpoints were evaluation of the effect of the medical device on gastritis-related mucosal erosions , blood oozing , and hyperemia (redness)/edema , compared to placebo , as assessed by photographic endoscopy evaluation performed by two blinded pathologists at 5-week follow-up .
342-1	51627-51630	The	9	
342-2	51631-51640	secondary	_	
342-3	51641-51650	endpoints	1	
342-4	51651-51655	were	8	
342-5	51656-51666	evaluation	2	
342-6	51667-51669	of	_	
342-7	51670-51673	the	_	
342-8	51674-51680	effect	_	
342-9	51681-51683	of	_	
342-10	51684-51687	the	_	
342-11	51688-51695	medical	_	
342-12	51696-51702	device	_	
342-13	51703-51705	on	_	
342-14	51706-51723	gastritis-related	_	
342-15	51724-51731	mucosal	_	
342-16	51732-51740	erosions	_	
342-17	51741-51742	,	_	
342-18	51743-51748	blood	_	
342-19	51749-51755	oozing	_	
342-20	51756-51757	,	_	
342-21	51758-51761	and	_	
342-22	51762-51771	hyperemia	_	
342-23	51772-51773	(	5	
342-24	51773-51780	redness	_	
342-25	51780-51781	)	1	
342-26	51781-51782	/	_	
342-27	51782-51787	edema	_	
342-28	51788-51789	,	1	
342-29	51790-51798	compared	3	
342-30	51799-51801	to	1	
342-31	51802-51809	placebo	2	
342-32	51810-51811	,	1	
342-33	51812-51814	as	3	
342-34	51815-51823	assessed	_	
342-35	51824-51826	by	1	
342-36	51827-51839	photographic	2	
342-37	51840-51849	endoscopy	_	
342-38	51850-51860	evaluation	1	
342-39	51861-51870	performed	3	
342-40	51871-51873	by	1	
342-41	51874-51877	two	2	
342-42	51878-51885	blinded	_	
342-43	51886-51898	pathologists	1	
342-44	51899-51901	at	2	
342-45	51902-51903	5	_	
342-46	51903-51904	-	_	
342-47	51904-51908	week	_	
342-48	51909-51918	follow-up	_	
342-49	51919-51920	.	1	

#Text=In the first follow-up , the patients were asked if they felt cured , and if so , how many days it had taken ; they were asked this question again in the second follow-up if they answered “ no ” in the first follow-up .
343-1	51921-51923	In	2	
343-2	51924-51927	the	_	
343-3	51928-51933	first	_	
343-4	51934-51943	follow-up	_	
343-5	51944-51945	,	1	
343-6	51946-51949	the	9	
343-7	51950-51958	patients	1	
343-8	51959-51963	were	8	
343-9	51964-51969	asked	1	
343-10	51970-51972	if	6	
343-11	51973-51977	they	3	
343-12	51978-51982	felt	_	
343-13	51983-51988	cured	_	
343-14	51989-51990	,	1	
343-15	51991-51994	and	6	
343-16	51995-51997	if	_	
343-17	51998-52000	so	_	
343-18	52001-52002	,	1	
343-19	52003-52006	how	2	
343-20	52007-52011	many	_	
343-21	52012-52016	days	1	
343-22	52017-52019	it	3	
343-23	52020-52023	had	_	
343-24	52024-52029	taken	1	
343-25	52030-52031	;	6	
343-26	52032-52036	they	3	
343-27	52037-52041	were	_	
343-28	52042-52047	asked	1	
343-29	52048-52052	this	2	
343-30	52053-52061	question	1	
343-31	52062-52067	again	2	
343-32	52068-52070	in	_	
343-33	52071-52074	the	_	
343-34	52075-52081	second	_	
343-35	52082-52091	follow-up	1	
343-36	52092-52094	if	6	
343-37	52095-52099	they	3	
343-38	52100-52108	answered	1	
343-39	52109-52110	“	2	
343-40	52111-52113	no	_	
343-41	52114-52115	”	1	
343-42	52116-52118	in	2	
343-43	52119-52122	the	_	
343-44	52123-52128	first	_	
343-45	52129-52138	follow-up	_	
343-46	52139-52140	.	1	

#Text=The 60-minute Tai Chi sessions occurred twice per week for 12 weeks .
344-1	52141-52144	The	9	
344-2	52145-52147	60	_	
344-3	52147-52148	-	_	
344-4	52148-52154	minute	_	
344-5	52155-52158	Tai	_	
344-6	52159-52162	Chi	_	
344-7	52163-52171	sessions	1	
344-8	52172-52180	occurred	8	
344-9	52181-52186	twice	2	
344-10	52187-52190	per	_	
344-11	52191-52195	week	_	
344-12	52196-52199	for	_	
344-13	52200-52202	12	_	
344-14	52203-52208	weeks	_	
344-15	52209-52210	.	1	

#Text=Adults with acute calculous cholecystitis and a high surgical risk were enrolled in 11 teaching hospitals in the Netherlands .
345-1	52211-52217	Adults	9	
345-2	52218-52222	with	_	
345-3	52223-52228	acute	_	
345-4	52229-52238	calculous	_	
345-5	52239-52252	cholecystitis	_	
345-6	52253-52256	and	_	
345-7	52257-52258	a	_	
345-8	52259-52263	high	_	
345-9	52264-52272	surgical	_	
345-10	52273-52277	risk	1	
345-11	52278-52282	were	8	
345-12	52283-52291	enrolled	_	
345-13	52292-52294	in	1	
345-14	52295-52297	11	2	
345-15	52298-52306	teaching	_	
345-16	52307-52316	hospitals	1	
345-17	52317-52319	in	2	
345-18	52320-52323	the	_	
345-19	52324-52335	Netherlands	_	
345-20	52336-52337	.	1	

#Text=Assumptions of ANCOVA were tested and met [ 41 ] .
346-1	52338-52349	Assumptions	9	
346-2	52350-52352	of	_	
346-3	52353-52359	ANCOVA	1	
346-4	52360-52364	were	8	
346-5	52365-52371	tested	_	
346-6	52372-52375	and	_	
346-7	52376-52379	met	1	
346-8	52380-52381	[	5	
346-9	52382-52384	41	_	
346-10	52385-52386	]	_	
346-11	52387-52388	.	1	

#Text=The physical therapy protocol followed U.S. guidelines for knee osteoarthritis treatment ( 15 ) and consisted of two 30-minute outpatient sessions per week for 6 weeks .
347-1	52389-52392	The	9	
347-2	52393-52401	physical	_	
347-3	52402-52409	therapy	_	
347-4	52410-52418	protocol	1	
347-5	52419-52427	followed	8	
347-6	52428-52431	U.S	2	
347-7	52431-52432	.	_	
347-8	52433-52443	guidelines	_	
347-9	52444-52447	for	_	
347-10	52448-52452	knee	_	
347-11	52453-52467	osteoarthritis	_	
347-12	52468-52477	treatment	1	
347-13	52478-52479	(	5	
347-14	52480-52482	15	_	
347-15	52483-52484	)	1	
347-16	52485-52488	and	2	
347-17	52489-52498	consisted	_	
347-18	52499-52501	of	1	
347-19	52502-52505	two	2	
347-20	52506-52508	30	_	
347-21	52508-52509	-	_	
347-22	52509-52515	minute	_	
347-23	52516-52526	outpatient	_	
347-24	52527-52535	sessions	_	
347-25	52536-52539	per	_	
347-26	52540-52544	week	_	
347-27	52545-52548	for	_	
347-28	52549-52550	6	_	
347-29	52551-52556	weeks	_	
347-30	52557-52558	.	1	

#Text=Blood was collected at 2 pm two hours after eating lunch , and the next morning after 14 hours of fasting .
348-1	52559-52564	Blood	9	
348-2	52565-52568	was	8	
348-3	52569-52578	collected	_	
348-4	52579-52581	at	1	
348-5	52582-52583	2	2	
348-6	52584-52586	pm	_	
348-7	52587-52590	two	_	
348-8	52591-52596	hours	_	
348-9	52597-52602	after	_	
348-10	52603-52609	eating	_	
348-11	52610-52615	lunch	_	
348-12	52616-52617	,	1	
348-13	52618-52621	and	2	
348-14	52622-52625	the	_	
348-15	52626-52630	next	_	
348-16	52631-52638	morning	_	
348-17	52639-52644	after	_	
348-18	52645-52647	14	_	
348-19	52648-52653	hours	_	
348-20	52654-52656	of	_	
348-21	52657-52664	fasting	_	
348-22	52665-52666	.	1	

#Text=The trial was conducted at Tufts Medical Center in Boston , Massachusetts , between October 2010 and September 2014 .
349-1	52667-52670	The	9	
349-2	52671-52676	trial	1	
349-3	52677-52680	was	8	
349-4	52681-52690	conducted	_	
349-5	52691-52693	at	1	
349-6	52694-52699	Tufts	2	
349-7	52700-52707	Medical	_	
349-8	52708-52714	Center	1	
349-9	52715-52717	in	2	
349-10	52718-52724	Boston	_	
349-11	52725-52726	,	_	
349-12	52727-52740	Massachusetts	_	
349-13	52741-52742	,	1	
349-14	52743-52750	between	2	
349-15	52751-52758	October	_	
349-16	52759-52763	2010	_	
349-17	52764-52767	and	_	
349-18	52768-52777	September	_	
349-19	52778-52782	2014	_	
349-20	52783-52784	.	1	

#Text=For statistical methods and sample size calculation , refer to the Supplementary Methods .
350-1	52785-52788	For	2	
350-2	52789-52800	statistical	_	
350-3	52801-52808	methods	_	
350-4	52809-52812	and	_	
350-5	52813-52819	sample	_	
350-6	52820-52824	size	_	
350-7	52825-52836	calculation	_	
350-8	52837-52838	,	1	
350-9	52839-52844	refer	8	
350-10	52845-52847	to	1	
350-11	52848-52851	the	2	
350-12	52852-52865	Supplementary	_	
350-13	52866-52873	Methods	_	
350-14	52874-52875	.	1	

#Text=Primary analyses were performed in accordance with a pre-established analysis plan and according to the intention to treat principle .
351-1	52876-52883	Primary	9	
351-2	52884-52892	analyses	1	
351-3	52893-52897	were	8	
351-4	52898-52907	performed	_	
351-5	52908-52910	in	_	
351-6	52911-52921	accordance	_	
351-7	52922-52926	with	1	
351-8	52927-52928	a	2	
351-9	52929-52944	pre-established	_	
351-10	52945-52953	analysis	_	
351-11	52954-52958	plan	1	
351-12	52959-52962	and	2	
351-13	52963-52972	according	_	
351-14	52973-52975	to	_	
351-15	52976-52979	the	_	
351-16	52980-52989	intention	_	
351-17	52990-52992	to	_	
351-18	52993-52998	treat	_	
351-19	52999-53008	principle	_	
351-20	53009-53010	.	1	

#Text=They were not allowed to take any additional NSAIDs during the trial .
352-1	53011-53015	They	8	
352-2	53016-53020	were	_	
352-3	53021-53024	not	_	
352-4	53025-53032	allowed	_	
352-5	53033-53035	to	_	
352-6	53036-53040	take	1	
352-7	53041-53044	any	2	
352-8	53045-53055	additional	_	
352-9	53056-53062	NSAIDs	1	
352-10	53063-53069	during	2	
352-11	53070-53073	the	_	
352-12	53074-53079	trial	_	
352-13	53080-53081	.	1	

#Text=The primary efficacy analyses were performed in the FAS , consisting of all randomized patients with at least 1 efficacy assessment after randomization .
353-1	53082-53085	The	9	
353-2	53086-53093	primary	_	
353-3	53094-53102	efficacy	_	
353-4	53103-53111	analyses	1	
353-5	53112-53116	were	8	
353-6	53117-53126	performed	_	
353-7	53127-53129	in	2	
353-8	53130-53133	the	2	
353-9	53134-53137	FAS	_	
353-10	53138-53139	,	1	
353-11	53140-53150	consisting	3	
353-12	53151-53153	of	1	
353-13	53154-53157	all	2	
353-14	53158-53168	randomized	_	
353-15	53169-53177	patients	1	
353-16	53178-53182	with	2	
353-17	53183-53185	at	_	
353-18	53186-53191	least	_	
353-19	53192-53193	1	_	
353-20	53194-53202	efficacy	_	
353-21	53203-53213	assessment	_	
353-22	53214-53219	after	_	
353-23	53220-53233	randomization	_	
353-24	53234-53235	.	1	

#Text=Missing dichotomous endpoints were imputed with the worse outcome , except for febrile UTI , pyelonephritis , and SAEs .
354-1	53236-53243	Missing	9	
354-2	53244-53255	dichotomous	_	
354-3	53256-53265	endpoints	1	
354-4	53266-53270	were	8	
354-5	53271-53278	imputed	_	
354-6	53279-53283	with	1	
354-7	53284-53287	the	2	
354-8	53288-53293	worse	_	
354-9	53294-53301	outcome	_	
354-10	53302-53303	,	1	
354-11	53304-53310	except	2	
354-12	53311-53314	for	_	
354-13	53315-53322	febrile	_	
354-14	53323-53326	UTI	_	
354-15	53327-53328	,	_	
354-16	53329-53343	pyelonephritis	_	
354-17	53344-53345	,	_	
354-18	53346-53349	and	_	
354-19	53350-53354	SAEs	_	
354-20	53355-53356	.	1	

#Text=The independent data safety monitoring board evaluated the results of the interim analysis .
355-1	53357-53360	The	9	
355-2	53361-53372	independent	_	
355-3	53373-53377	data	_	
355-4	53378-53384	safety	_	
355-5	53385-53395	monitoring	_	
355-6	53396-53401	board	1	
355-7	53402-53411	evaluated	8	
355-8	53412-53415	the	2	
355-9	53416-53423	results	_	
355-10	53424-53426	of	_	
355-11	53427-53430	the	_	
355-12	53431-53438	interim	_	
355-13	53439-53447	analysis	_	
355-14	53448-53449	.	1	

#Text=The protocol required that femoral puncture occur within 90 minutes after the end of qualifying imaging .
356-1	53450-53453	The	9	
356-2	53454-53462	protocol	1	
356-3	53463-53471	required	8	
356-4	53472-53476	that	6	
356-5	53477-53484	femoral	9	
356-6	53485-53493	puncture	1	
356-7	53494-53499	occur	3	
356-8	53500-53506	within	1	
356-9	53507-53509	90	2	
356-10	53510-53517	minutes	_	
356-11	53518-53523	after	_	
356-12	53524-53527	the	_	
356-13	53528-53531	end	_	
356-14	53532-53534	of	_	
356-15	53535-53545	qualifying	_	
356-16	53546-53553	imaging	_	
356-17	53554-53555	.	1	

#Text=Children with chronic otitis media , chronic middle ear effusion , ventilation tubes , perferoated tympanic membranes or otorrhea and patients with “ A ” curves and “ B ” curves with obvious dry perforation ( high volume ) were excluded .
357-1	53556-53564	Children	9	
357-2	53565-53569	with	_	
357-3	53570-53577	chronic	_	
357-4	53578-53584	otitis	_	
357-5	53585-53590	media	_	
357-6	53591-53592	,	_	
357-7	53593-53600	chronic	_	
357-8	53601-53607	middle	_	
357-9	53608-53611	ear	_	
357-10	53612-53620	effusion	_	
357-11	53621-53622	,	_	
357-12	53623-53634	ventilation	_	
357-13	53635-53640	tubes	_	
357-14	53641-53642	,	_	
357-15	53643-53654	perferoated	_	
357-16	53655-53663	tympanic	_	
357-17	53664-53673	membranes	_	
357-18	53674-53676	or	_	
357-19	53677-53685	otorrhea	_	
357-20	53686-53689	and	1	
357-21	53690-53698	patients	9	
357-22	53699-53703	with	_	
357-23	53704-53705	“	_	
357-24	53706-53707	A	_	
357-25	53708-53709	”	_	
357-26	53710-53716	curves	_	
357-27	53717-53720	and	_	
357-28	53721-53722	“	_	
357-29	53723-53724	B	_	
357-30	53725-53726	”	_	
357-31	53727-53733	curves	_	
357-32	53734-53738	with	_	
357-33	53739-53746	obvious	_	
357-34	53747-53750	dry	_	
357-35	53751-53762	perforation	1	
357-36	53763-53764	(	5	
357-37	53765-53769	high	_	
357-38	53770-53776	volume	_	
357-39	53777-53778	)	1	
357-40	53779-53783	were	8	
357-41	53784-53792	excluded	_	
357-42	53793-53794	.	1	

#Text=Both sites had 2 investigators who are validated expert otoscopists .
358-1	53795-53799	Both	9	
358-2	53800-53805	sites	1	
358-3	53806-53809	had	8	
358-4	53810-53811	2	9	
358-5	53812-53825	investigators	_	
358-6	53826-53829	who	_	
358-7	53830-53833	are	_	
358-8	53834-53843	validated	_	
358-9	53844-53850	expert	_	
358-10	53851-53862	otoscopists	_	
358-11	53863-53864	.	1	

#Text=All analyses were performed with SAS , version 9.4 ( SAS Institute ) , and R.
359-1	53865-53868	All	9	
359-2	53869-53877	analyses	1	
359-3	53878-53882	were	8	
359-4	53883-53892	performed	_	
359-5	53893-53897	with	1	
359-6	53898-53901	SAS	2	
359-7	53902-53903	,	_	
359-8	53904-53911	version	_	
359-9	53912-53915	9.4	1	
359-10	53916-53917	(	5	
359-11	53918-53921	SAS	_	
359-12	53922-53931	Institute	_	
359-13	53932-53933	)	_	
359-14	53934-53935	,	1	
359-15	53936-53939	and	2	
359-16	53940-53941	R	_	
359-17	53941-53942	.	1	

#Text=Samples were prepared by adding 20 μL of 50 μM LPC 19:0 in methanol to a 2-mL Eppendorf vial and evaporate until complete dryness using a vacuum concentrator ( miVac , Quattro concentrator , Barnstead Genevac , Ipswich , UK ) .
360-1	53943-53950	Samples	9	
360-2	53951-53955	were	8	
360-3	53956-53964	prepared	_	
360-4	53965-53967	by	_	
360-5	53968-53974	adding	1	
360-6	53975-53977	20	2	
360-7	53978-53980	μL	_	
360-8	53981-53983	of	_	
360-9	53984-53986	50	_	
360-10	53987-53989	μM	_	
360-11	53990-53993	LPC	_	
360-12	53994-53996	19	_	
360-13	53996-53997	:	_	
360-14	53997-53998	0	_	
360-15	53999-54001	in	_	
360-16	54002-54010	methanol	_	
360-17	54011-54013	to	_	
360-18	54014-54015	a	_	
360-19	54016-54017	2	_	
360-20	54017-54018	-	_	
360-21	54018-54020	mL	_	
360-22	54021-54030	Eppendorf	_	
360-23	54031-54035	vial	1	
360-24	54036-54039	and	3	
360-25	54040-54049	evaporate	_	
360-26	54050-54055	until	1	
360-27	54056-54064	complete	2	
360-28	54065-54072	dryness	1	
360-29	54073-54078	using	3	
360-30	54079-54080	a	2	
360-31	54081-54087	vacuum	_	
360-32	54088-54100	concentrator	1	
360-33	54101-54102	(	5	
360-34	54103-54108	miVac	_	
360-35	54109-54110	,	_	
360-36	54111-54118	Quattro	_	
360-37	54119-54131	concentrator	_	
360-38	54132-54133	,	_	
360-39	54134-54143	Barnstead	_	
360-40	54144-54151	Genevac	_	
360-41	54152-54153	,	_	
360-42	54154-54161	Ipswich	_	
360-43	54162-54163	,	_	
360-44	54164-54166	UK	_	
360-45	54167-54168	)	_	
360-46	54169-54170	.	1	

#Text=Prior to treatment , EIs evaluated the severity of NLFs using the NLFSS ( 0 = none ; 1 = mild ; 2 = moderate ; 3 = severe ; 4 = extreme ) .
361-1	54171-54176	Prior	2	
361-2	54177-54179	to	_	
361-3	54180-54189	treatment	_	
361-4	54190-54191	,	1	
361-5	54192-54195	EIs	9	
361-6	54196-54205	evaluated	8	
361-7	54206-54209	the	2	
361-8	54210-54218	severity	_	
361-9	54219-54221	of	_	
361-10	54222-54226	NLFs	1	
361-11	54227-54232	using	3	
361-12	54233-54236	the	2	
361-13	54237-54242	NLFSS	1	
361-14	54243-54244	(	5	
361-15	54245-54246	0	_	
361-16	54247-54248	=	_	
361-17	54249-54253	none	_	
361-18	54254-54255	;	_	
361-19	54256-54257	1	_	
361-20	54258-54259	=	_	
361-21	54260-54264	mild	_	
361-22	54265-54266	;	_	
361-23	54267-54268	2	_	
361-24	54269-54270	=	_	
361-25	54271-54279	moderate	_	
361-26	54280-54281	;	_	
361-27	54282-54283	3	_	
361-28	54284-54285	=	_	
361-29	54286-54292	severe	_	
361-30	54293-54294	;	_	
361-31	54295-54296	4	_	
361-32	54297-54298	=	_	
361-33	54299-54306	extreme	_	
361-34	54307-54308	)	_	
361-35	54309-54310	.	1	

#Text=Committee members individually evaluated the data in a standardised format for every patient , including all available data collected during follow-up .
362-1	54311-54320	Committee	9	
362-2	54321-54328	members	1	
362-3	54329-54341	individually	8	
362-4	54342-54351	evaluated	1	
362-5	54352-54355	the	2	
362-6	54356-54360	data	1	
362-7	54361-54363	in	2	
362-8	54364-54365	a	_	
362-9	54366-54378	standardised	_	
362-10	54379-54385	format	1	
362-11	54386-54389	for	2	
362-12	54390-54395	every	_	
362-13	54396-54403	patient	_	
362-14	54404-54405	,	1	
362-15	54406-54415	including	3	
362-16	54416-54419	all	2	
362-17	54420-54429	available	_	
362-18	54430-54434	data	_	
362-19	54435-54444	collected	_	
362-20	54445-54451	during	_	
362-21	54452-54461	follow-up	_	
362-22	54462-54463	.	1	

#Text=Afterwards , the patients underwent 2-week further treatment according to the above-described protocol .
363-1	54464-54474	Afterwards	6	
363-2	54475-54476	,	1	
363-3	54477-54480	the	9	
363-4	54481-54489	patients	1	
363-5	54490-54499	underwent	8	
363-6	54500-54501	2	2	
363-7	54501-54502	-	_	
363-8	54502-54506	week	_	
363-9	54507-54514	further	_	
363-10	54515-54524	treatment	1	
363-11	54525-54534	according	2	
363-12	54535-54537	to	_	
363-13	54538-54541	the	_	
363-14	54542-54557	above-described	_	
363-15	54558-54566	protocol	_	
363-16	54567-54568	.	1	

#Text=Autotaxin levels were determined by diluting serum samples 20 times with water and using the immunoassay Human ENPP-2/ATX ELISA ( R&D Systems , Minneapolis , USA ) and a microplate reader ( Sunrise , Tecan , Männedorf , Switzerland ) per the manufacturer ’s protocol .
364-1	54569-54578	Autotaxin	9	
364-2	54579-54585	levels	1	
364-3	54586-54590	were	8	
364-4	54591-54601	determined	_	
364-5	54602-54604	by	_	
364-6	54605-54613	diluting	1	
364-7	54614-54619	serum	2	
364-8	54620-54627	samples	_	
364-9	54628-54630	20	_	
364-10	54631-54636	times	1	
364-11	54637-54641	with	2	
364-12	54642-54647	water	1	
364-13	54648-54651	and	3	
364-14	54652-54657	using	1	
364-15	54658-54661	the	2	
364-16	54662-54673	immunoassay	_	
364-17	54674-54679	Human	_	
364-18	54680-54684	ENPP	_	
364-19	54684-54685	-	_	
364-20	54685-54686	2	_	
364-21	54686-54687	/	_	
364-22	54687-54690	ATX	_	
364-23	54691-54696	ELISA	1	
364-24	54697-54698	(	5	
364-25	54699-54700	R	_	
364-26	54700-54701	&	_	
364-27	54701-54702	D	_	
364-28	54703-54710	Systems	_	
364-29	54711-54712	,	_	
364-30	54713-54724	Minneapolis	_	
364-31	54725-54726	,	_	
364-32	54727-54730	USA	_	
364-33	54731-54732	)	1	
364-34	54733-54736	and	2	
364-35	54737-54738	a	_	
364-36	54739-54749	microplate	_	
364-37	54750-54756	reader	1	
364-38	54757-54758	(	5	
364-39	54759-54766	Sunrise	_	
364-40	54767-54768	,	_	
364-41	54769-54774	Tecan	_	
364-42	54775-54776	,	_	
364-43	54777-54786	Männedorf	_	
364-44	54787-54788	,	_	
364-45	54789-54800	Switzerland	_	
364-46	54801-54802	)	1	
364-47	54803-54806	per	2	
364-48	54807-54810	the	_	
364-49	54811-54823	manufacturer	_	
364-50	54824-54825	’	_	
364-51	54825-54826	s	_	
364-52	54827-54835	protocol	_	
364-53	54836-54837	.	1	

#Text=This report was standard across participants .
365-1	54838-54842	This	9	
365-2	54843-54849	report	1	
365-3	54850-54853	was	8	
365-4	54854-54862	standard	7	
365-5	54863-54869	across	2	
365-6	54870-54882	participants	_	
365-7	54883-54884	.	1	

#Text=For continuous variables , we calculated differences with the student ’s t test for normally distributed data and the Mann-Whitney U test for non-normally distributed data .
366-1	54885-54888	For	2	
366-2	54889-54899	continuous	_	
366-3	54900-54909	variables	_	
366-4	54910-54911	,	1	
366-5	54912-54914	we	8	
366-6	54915-54925	calculated	1	
366-7	54926-54937	differences	2	
366-8	54938-54942	with	_	
366-9	54943-54946	the	_	
366-10	54947-54954	student	_	
366-11	54955-54956	’	_	
366-12	54956-54957	s	_	
366-13	54958-54959	t	_	
366-14	54960-54964	test	_	
366-15	54965-54968	for	_	
366-16	54969-54977	normally	_	
366-17	54978-54989	distributed	_	
366-18	54990-54994	data	1	
366-19	54995-54998	and	2	
366-20	54999-55002	the	_	
366-21	55003-55015	Mann-Whitney	_	
366-22	55016-55017	U	_	
366-23	55018-55022	test	_	
366-24	55023-55026	for	_	
366-25	55027-55039	non-normally	_	
366-26	55040-55051	distributed	_	
366-27	55052-55056	data	_	
366-28	55057-55058	.	1	

#Text=Further statistical details are described in the SAP ( S1 Appendix ) .
367-1	55059-55066	Further	9	
367-2	55067-55078	statistical	_	
367-3	55079-55086	details	1	
367-4	55087-55090	are	8	
367-5	55091-55100	described	_	
367-6	55101-55103	in	1	
367-7	55104-55107	the	2	
367-8	55108-55111	SAP	1	
367-9	55112-55113	(	5	
367-10	55114-55116	S1	_	
367-11	55117-55125	Appendix	_	
367-12	55126-55127	)	_	
367-13	55128-55129	.	1	

#Text=Emergency cholecystectomy was performed in case of clinical deterioration , persisting fever , or an increase in serum white blood cell count or C reactive protein within 48 hours , despite accurate position and function of the drain .
368-1	55130-55139	Emergency	9	
368-2	55140-55155	cholecystectomy	1	
368-3	55156-55159	was	8	
368-4	55160-55169	performed	_	
368-5	55170-55172	in	_	
368-6	55173-55177	case	_	
368-7	55178-55180	of	1	
368-8	55181-55189	clinical	2	
368-9	55190-55203	deterioration	_	
368-10	55204-55205	,	_	
368-11	55206-55216	persisting	_	
368-12	55217-55222	fever	_	
368-13	55223-55224	,	_	
368-14	55225-55227	or	_	
368-15	55228-55230	an	_	
368-16	55231-55239	increase	_	
368-17	55240-55242	in	_	
368-18	55243-55248	serum	_	
368-19	55249-55254	white	_	
368-20	55255-55260	blood	_	
368-21	55261-55265	cell	_	
368-22	55266-55271	count	_	
368-23	55272-55274	or	_	
368-24	55275-55276	C	_	
368-25	55277-55285	reactive	_	
368-26	55286-55293	protein	_	
368-27	55294-55300	within	_	
368-28	55301-55303	48	_	
368-29	55304-55309	hours	_	
368-30	55310-55311	,	1	
368-31	55312-55319	despite	2	
368-32	55320-55328	accurate	_	
368-33	55329-55337	position	_	
368-34	55338-55341	and	_	
368-35	55342-55350	function	_	
368-36	55351-55353	of	_	
368-37	55354-55357	the	_	
368-38	55358-55363	drain	_	
368-39	55364-55365	.	1	

#Text=Exploratory post hoc analyses were performed to identify patient subsets that may benefit most from trimodulin treatment .
369-1	55366-55377	Exploratory	9	
369-2	55378-55382	post	_	
369-3	55383-55386	hoc	_	
369-4	55387-55395	analyses	_	
369-5	55396-55400	were	1	
369-6	55401-55410	performed	8	
369-7	55411-55413	to	_	
369-8	55414-55422	identify	1	
369-9	55423-55430	patient	2	
369-10	55431-55438	subsets	1	
369-11	55439-55443	that	6	
369-12	55444-55447	may	3	
369-13	55448-55455	benefit	_	
369-14	55456-55460	most	_	
369-15	55461-55465	from	1	
369-16	55466-55476	trimodulin	2	
369-17	55477-55486	treatment	_	
369-18	55487-55488	.	1	

#Text=The maximal sample size was calculated to be 476 , with two planned interim analyses after 200 and 350 patients had data on 90-day outcomes that could be evaluated .
370-1	55489-55492	The	9	
370-2	55493-55500	maximal	_	
370-3	55501-55507	sample	_	
370-4	55508-55512	size	1	
370-5	55513-55516	was	8	
370-6	55517-55527	calculated	_	
370-7	55528-55530	to	_	
370-8	55531-55533	be	1	
370-9	55534-55537	476	2	
370-10	55538-55539	,	1	
370-11	55540-55544	with	2	
370-12	55545-55548	two	_	
370-13	55549-55556	planned	_	
370-14	55557-55564	interim	_	
370-15	55565-55573	analyses	1	
370-16	55574-55579	after	6	
370-17	55580-55583	200	9	
370-18	55584-55587	and	_	
370-19	55588-55591	350	_	
370-20	55592-55600	patients	1	
370-21	55601-55604	had	3	
370-22	55605-55609	data	2	
370-23	55610-55612	on	2	
370-24	55613-55615	90	_	
370-25	55615-55616	-	_	
370-26	55616-55619	day	_	
370-27	55620-55628	outcomes	1	
370-28	55629-55633	that	3	
370-29	55634-55639	could	_	
370-30	55640-55642	be	_	
370-31	55643-55652	evaluated	_	
370-32	55653-55654	.	1	

#Text=The classes/sessions were supervised .
371-1	55655-55658	The	9	
371-2	55659-55666	classes	_	
371-3	55666-55667	/	_	
371-4	55667-55675	sessions	1	
371-5	55676-55680	were	8	
371-6	55681-55691	supervised	_	
371-7	55692-55693	.	1	

#Text=The inclusion criteria for gastritis were epigastric burning , bloatedness , nausea , meteorism , and belching , accompanied by mucosal erosions , blood oozing , hyperemia (redness)/edema , and upper abdominal pain/discomfort ≥   40   mm , as measured by Visual Analogue Scale ( VAS ) .
372-1	55694-55697	The	9	
372-2	55698-55707	inclusion	_	
372-3	55708-55716	criteria	_	
372-4	55717-55720	for	_	
372-5	55721-55730	gastritis	1	
372-6	55731-55735	were	8	
372-7	55736-55746	epigastric	2	
372-8	55747-55754	burning	_	
372-9	55755-55756	,	_	
372-10	55757-55768	bloatedness	_	
372-11	55769-55770	,	_	
372-12	55771-55777	nausea	_	
372-13	55778-55779	,	_	
372-14	55780-55789	meteorism	_	
372-15	55790-55791	,	_	
372-16	55792-55795	and	_	
372-17	55796-55804	belching	_	
372-18	55805-55806	,	_	
372-19	55807-55818	accompanied	_	
372-20	55819-55821	by	_	
372-21	55822-55829	mucosal	_	
372-22	55830-55838	erosions	_	
372-23	55839-55840	,	_	
372-24	55841-55846	blood	_	
372-25	55847-55853	oozing	_	
372-26	55854-55855	,	_	
372-27	55856-55865	hyperemia	_	
372-28	55866-55867	(	5	
372-29	55867-55874	redness	_	
372-30	55874-55875	)	1	
372-31	55875-55876	/	_	
372-32	55876-55881	edema	_	
372-33	55882-55883	,	_	
372-34	55884-55887	and	_	
372-35	55888-55893	upper	_	
372-36	55894-55903	abdominal	_	
372-37	55904-55908	pain	_	
372-38	55908-55909	/	_	
372-39	55909-55919	discomfort	_	
372-40	55920-55921	≥	_	
372-41	55924-55926	40	_	
372-42	55927-55928	 	_	
372-43	55929-55931	mm	_	
372-44	55932-55933	,	1	
372-45	55934-55936	as	3	
372-46	55937-55945	measured	_	
372-47	55946-55948	by	1	
372-48	55949-55955	Visual	2	
372-49	55956-55964	Analogue	_	
372-50	55965-55970	Scale	_	
372-51	55971-55972	(	_	
372-52	55973-55976	VAS	_	
372-53	55977-55978	)	_	
372-54	55979-55980	.	1	

#Text=The first draft of the manuscript was written by the first author .
373-1	55981-55984	The	9	
373-2	55985-55990	first	_	
373-3	55991-55996	draft	_	
373-4	55997-55999	of	_	
373-5	56000-56003	the	_	
373-6	56004-56014	manuscript	1	
373-7	56015-56018	was	8	
373-8	56019-56026	written	_	
373-9	56027-56029	by	1	
373-10	56030-56033	the	2	
373-11	56034-56039	first	_	
373-12	56040-56046	author	_	
373-13	56047-56048	.	1	

#Text=Clinical OA diagnostic criteria were chosen given that radiographic disease severity does not appear to influence the effectiveness of exercise [ 21 ] .
374-1	56049-56057	Clinical	9	
374-2	56058-56060	OA	_	
374-3	56061-56071	diagnostic	_	
374-4	56072-56080	criteria	1	
374-5	56081-56085	were	8	
374-6	56086-56092	chosen	_	
374-7	56093-56098	given	1	
374-8	56099-56103	that	6	
374-9	56104-56116	radiographic	9	
374-10	56117-56124	disease	_	
374-11	56125-56133	severity	1	
374-12	56134-56138	does	8	
374-13	56139-56142	not	_	
374-14	56143-56149	appear	_	
374-15	56150-56152	to	_	
374-16	56153-56162	influence	1	
374-17	56163-56166	the	2	
374-18	56167-56180	effectiveness	_	
374-19	56181-56183	of	_	
374-20	56184-56192	exercise	1	
374-21	56193-56194	[	5	
374-22	56195-56197	21	_	
374-23	56198-56199	]	_	
374-24	56200-56201	.	1	

#Text=In both follow-ups , they were asked if they had experienced a relapse of symptoms , if they had seen a doctor again , and if they had received antibiotic treatment .
375-1	56202-56204	In	2	
375-2	56205-56209	both	_	
375-3	56210-56220	follow-ups	_	
375-4	56221-56222	,	1	
375-5	56223-56227	they	8	
375-6	56228-56232	were	_	
375-7	56233-56238	asked	1	
375-8	56239-56241	if	6	
375-9	56242-56246	they	3	
375-10	56247-56250	had	_	
375-11	56251-56262	experienced	1	
375-12	56263-56264	a	2	
375-13	56265-56272	relapse	_	
375-14	56273-56275	of	_	
375-15	56276-56284	symptoms	_	
375-16	56285-56286	,	1	
375-17	56287-56289	if	6	
375-18	56290-56294	they	3	
375-19	56295-56298	had	_	
375-20	56299-56303	seen	1	
375-21	56304-56305	a	2	
375-22	56306-56312	doctor	_	
375-23	56313-56318	again	_	
375-24	56319-56320	,	1	
375-25	56321-56324	and	6	
375-26	56325-56327	if	7	
375-27	56328-56332	they	3	
375-28	56333-56336	had	_	
375-29	56337-56345	received	1	
375-30	56346-56356	antibiotic	2	
375-31	56357-56366	treatment	_	
375-32	56367-56368	.	1	

#Text=Eligible subjects were randomized to treatment with VYC-17.5L in either the right or left NLF and control in the contralateral NLF ; the order of the injections ( left or right side ) was also randomized .
376-1	56369-56377	Eligible	9	
376-2	56378-56386	subjects	1	
376-3	56387-56391	were	8	
376-4	56392-56402	randomized	_	
376-5	56403-56405	to	1	
376-6	56406-56415	treatment	2	
376-7	56416-56420	with	_	
376-8	56421-56424	VYC	_	
376-9	56424-56425	-	_	
376-10	56425-56430	17.5L	_	
376-11	56431-56433	in	_	
376-12	56434-56440	either	_	
376-13	56441-56444	the	_	
376-14	56445-56450	right	_	
376-15	56451-56453	or	_	
376-16	56454-56458	left	_	
376-17	56459-56462	NLF	1	
376-18	56463-56466	and	2	
376-19	56467-56474	control	_	
376-20	56475-56477	in	_	
376-21	56478-56481	the	_	
376-22	56482-56495	contralateral	_	
376-23	56496-56499	NLF	1	
376-24	56500-56501	;	6	
376-25	56502-56505	the	9	
376-26	56506-56511	order	_	
376-27	56512-56514	of	_	
376-28	56515-56518	the	_	
376-29	56519-56529	injections	1	
376-30	56530-56531	(	5	
376-31	56532-56536	left	_	
376-32	56537-56539	or	_	
376-33	56540-56545	right	_	
376-34	56546-56550	side	_	
376-35	56551-56552	)	1	
376-36	56553-56556	was	3	
376-37	56557-56561	also	_	
376-38	56562-56572	randomized	_	
376-39	56573-56574	.	1	

#Text=A subject was classified as indeterminate at the TOC visit and censored in the analysis at TOC if : less than 80 % of the prescribed treatment was taken ; or inadequate data to assess clinical outcome due to lack of follow up .
377-1	56575-56576	A	9	
377-2	56577-56584	subject	1	
377-3	56585-56588	was	8	
377-4	56589-56599	classified	_	
377-5	56600-56602	as	1	
377-6	56603-56616	indeterminate	7	
377-7	56617-56619	at	2	
377-8	56620-56623	the	_	
377-9	56624-56627	TOC	_	
377-10	56628-56633	visit	1	
377-11	56634-56637	and	2	
377-12	56638-56646	censored	_	
377-13	56647-56649	in	1	
377-14	56650-56653	the	2	
377-15	56654-56662	analysis	1	
377-16	56663-56665	at	2	
377-17	56666-56669	TOC	1	
377-18	56670-56672	if	6	
377-19	56673-56674	:	1	
377-20	56675-56679	less	9	
377-21	56680-56684	than	_	
377-22	56685-56687	80	_	
377-23	56688-56689	%	_	
377-24	56690-56692	of	_	
377-25	56693-56696	the	_	
377-26	56697-56707	prescribed	_	
377-27	56708-56717	treatment	1	
377-28	56718-56721	was	3	
377-29	56722-56727	taken	1	
377-30	56728-56729	;	6	
377-31	56730-56732	or	2	
377-32	56733-56743	inadequate	_	
377-33	56744-56748	data	1	
377-34	56749-56751	to	3	
377-35	56752-56758	assess	1	
377-36	56759-56767	clinical	2	
377-37	56768-56775	outcome	1	
377-38	56776-56779	due	2	
377-39	56780-56782	to	_	
377-40	56783-56787	lack	_	
377-41	56788-56790	of	_	
377-42	56791-56797	follow	_	
377-43	56798-56800	up	_	
377-44	56801-56802	.	1	

#Text=Briefly , 225 μL chloroform/methanol ( 2:1 , v : v ) was added to 20 μL serum and vortexed , after 30 min at room temperature , the mix was centrifuged at 4 ° C at 14,000 rpm for 12 min , and 10 μL of the upper lipid phase was diluted with 120 μL methanol and stored at -20 ° C until analysis .
378-1	56803-56810	Briefly	6	
378-2	56811-56812	,	1	
378-3	56813-56816	225	9	
378-4	56817-56819	μL	_	
378-5	56820-56830	chloroform	_	
378-6	56830-56831	/	_	
378-7	56831-56839	methanol	1	
378-8	56840-56841	(	5	
378-9	56842-56843	2	_	
378-10	56843-56844	:	_	
378-11	56844-56845	1	_	
378-12	56846-56847	,	_	
378-13	56848-56849	v	_	
378-14	56850-56851	:	_	
378-15	56852-56853	v	_	
378-16	56854-56855	)	1	
378-17	56856-56859	was	8	
378-18	56860-56865	added	_	
378-19	56866-56868	to	1	
378-20	56869-56871	20	2	
378-21	56872-56874	μL	_	
378-22	56875-56880	serum	1	
378-23	56881-56884	and	3	
378-24	56885-56893	vortexed	_	
378-25	56894-56895	,	1	
378-26	56896-56901	after	2	
378-27	56902-56904	30	_	
378-28	56905-56908	min	_	
378-29	56909-56911	at	_	
378-30	56912-56916	room	_	
378-31	56917-56928	temperature	_	
378-32	56929-56930	,	1	
378-33	56931-56934	the	9	
378-34	56935-56938	mix	1	
378-35	56939-56942	was	3	
378-36	56943-56954	centrifuged	_	
378-37	56955-56957	at	1	
378-38	56958-56959	4	2	
378-39	56960-56961	°	_	
378-40	56962-56963	C	_	
378-41	56964-56966	at	_	
378-42	56967-56973	14,000	_	
378-43	56974-56977	rpm	_	
378-44	56978-56981	for	_	
378-45	56982-56984	12	_	
378-46	56985-56988	min	_	
378-47	56989-56990	,	1	
378-48	56991-56994	and	9	
378-49	56995-56997	10	_	
378-50	56998-57000	μL	_	
378-51	57001-57003	of	_	
378-52	57004-57007	the	_	
378-53	57008-57013	upper	_	
378-54	57014-57019	lipid	_	
378-55	57020-57025	phase	1	
378-56	57026-57029	was	3	
378-57	57030-57037	diluted	_	
378-58	57038-57042	with	1	
378-59	57043-57046	120	2	
378-60	57047-57049	μL	_	
378-61	57050-57058	methanol	1	
378-62	57059-57062	and	3	
378-63	57063-57069	stored	1	
378-64	57070-57072	at	2	
378-65	57073-57074	-	_	
378-66	57074-57076	20	_	
378-67	57077-57078	°	_	
378-68	57079-57080	C	1	
378-69	57081-57086	until	2	
378-70	57087-57095	analysis	_	
378-71	57096-57097	.	1	

#Text=No patients were involved in setting the research question or developing plans for design of the study , nor were they asked to advise on interpretation or writing up of results .
379-1	57098-57100	No	9	
379-2	57101-57109	patients	1	
379-3	57110-57114	were	8	
379-4	57115-57123	involved	_	
379-5	57124-57126	in	_	
379-6	57127-57134	setting	1	
379-7	57135-57138	the	2	
379-8	57139-57147	research	_	
379-9	57148-57156	question	1	
379-10	57157-57159	or	3	
379-11	57160-57170	developing	1	
379-12	57171-57176	plans	2	
379-13	57177-57180	for	_	
379-14	57181-57187	design	_	
379-15	57188-57190	of	_	
379-16	57191-57194	the	_	
379-17	57195-57200	study	_	
379-18	57201-57202	,	1	
379-19	57203-57206	nor	6	
379-20	57207-57211	were	3	
379-21	57212-57216	they	_	
379-22	57217-57222	asked	_	
379-23	57223-57225	to	_	
379-24	57226-57232	advise	_	
379-25	57233-57235	on	1	
379-26	57236-57250	interpretation	2	
379-27	57251-57253	or	3	
379-28	57254-57261	writing	_	
379-29	57262-57264	up	_	
379-30	57265-57267	of	1	
379-31	57268-57275	results	2	
379-32	57276-57277	.	1	

#Text=There were no missing data for the primary endpoint in the FAS .
380-1	57278-57283	There	8	
380-2	57284-57288	were	_	
380-3	57289-57291	no	_	
380-4	57292-57299	missing	_	
380-5	57300-57304	data	1	
380-6	57305-57308	for	2	
380-7	57309-57312	the	_	
380-8	57313-57320	primary	_	
380-9	57321-57329	endpoint	_	
380-10	57330-57332	in	_	
380-11	57333-57336	the	_	
380-12	57337-57340	FAS	_	
380-13	57341-57342	.	1	

#Text=The formulation also contains polyvinylpyrrolidone , xylitol C , sodium benzoate , potassium sorbate , aromas , and demineralized water .
381-1	57343-57346	The	9	
381-2	57347-57358	formulation	1	
381-3	57359-57363	also	8	
381-4	57364-57372	contains	1	
381-5	57373-57393	polyvinylpyrrolidone	2	
381-6	57394-57395	,	_	
381-7	57396-57403	xylitol	_	
381-8	57404-57405	C	_	
381-9	57406-57407	,	_	
381-10	57408-57414	sodium	_	
381-11	57415-57423	benzoate	_	
381-12	57424-57425	,	_	
381-13	57426-57435	potassium	_	
381-14	57436-57443	sorbate	_	
381-15	57444-57445	,	_	
381-16	57446-57452	aromas	_	
381-17	57453-57454	,	_	
381-18	57455-57458	and	_	
381-19	57459-57472	demineralized	_	
381-20	57473-57478	water	_	
381-21	57479-57480	.	1	

#Text=The number of times participants were able to rise from and return to a chair in 30 seconds was the 30sCS score .
382-1	57481-57484	The	9	
382-2	57485-57491	number	_	
382-3	57492-57494	of	_	
382-4	57495-57500	times	_	
382-5	57501-57513	participants	1	
382-6	57514-57518	were	3	
382-7	57519-57523	able	_	
382-8	57524-57526	to	_	
382-9	57527-57531	rise	_	
382-10	57532-57536	from	_	
382-11	57537-57540	and	_	
382-12	57541-57547	return	_	
382-13	57548-57550	to	1	
382-14	57551-57552	a	2	
382-15	57553-57558	chair	1	
382-16	57559-57561	in	2	
382-17	57562-57564	30	_	
382-18	57565-57572	seconds	1	
382-19	57573-57576	was	8	
382-20	57577-57580	the	2	
382-21	57581-57586	30sCS	_	
382-22	57587-57592	score	_	
382-23	57593-57594	.	1	

#Text=Exercise difficulty was progressively increased over the 12-week intervention period .
383-1	57595-57603	Exercise	9	
383-2	57604-57614	difficulty	1	
383-3	57615-57618	was	8	
383-4	57619-57632	progressively	_	
383-5	57633-57642	increased	_	
383-6	57643-57647	over	1	
383-7	57648-57651	the	2	
383-8	57652-57654	12	_	
383-9	57654-57655	-	_	
383-10	57655-57659	week	_	
383-11	57660-57672	intervention	_	
383-12	57673-57679	period	_	
383-13	57680-57681	.	1	

#Text=Knee osteoarthritis outcomes , which were measured at baseline and 12 , 24 , and 52 weeks , were drawn from the core set recommended by the Osteoarthritis Research Society International ( OARSI ) and focused on pain , physical function , and patients ’ overall assessment of their disease severity ( 22 ) .
384-1	57682-57686	Knee	9	
384-2	57687-57701	osteoarthritis	_	
384-3	57702-57710	outcomes	_	
384-4	57711-57712	,	1	
384-5	57713-57718	which	6	
384-6	57719-57723	were	3	
384-7	57724-57732	measured	_	
384-8	57733-57735	at	1	
384-9	57736-57744	baseline	2	
384-10	57745-57748	and	_	
384-11	57749-57751	12	_	
384-12	57752-57753	,	_	
384-13	57754-57756	24	_	
384-14	57757-57758	,	_	
384-15	57759-57762	and	_	
384-16	57763-57765	52	_	
384-17	57766-57771	weeks	_	
384-18	57772-57773	,	1	
384-19	57774-57778	were	8	
384-20	57779-57784	drawn	_	
384-21	57785-57789	from	1	
384-22	57790-57793	the	2	
384-23	57794-57798	core	_	
384-24	57799-57802	set	1	
384-25	57803-57814	recommended	3	
384-26	57815-57817	by	1	
384-27	57818-57821	the	2	
384-28	57822-57836	Osteoarthritis	_	
384-29	57837-57845	Research	_	
384-30	57846-57853	Society	_	
384-31	57854-57867	International	1	
384-32	57868-57869	(	5	
384-33	57870-57875	OARSI	_	
384-34	57876-57877	)	1	
384-35	57878-57881	and	3	
384-36	57882-57889	focused	_	
384-37	57890-57892	on	1	
384-38	57893-57897	pain	2	
384-39	57898-57899	,	_	
384-40	57900-57908	physical	_	
384-41	57909-57917	function	_	
384-42	57918-57919	,	_	
384-43	57920-57923	and	_	
384-44	57924-57932	patients	_	
384-45	57933-57934	’	_	
384-46	57935-57942	overall	_	
384-47	57943-57953	assessment	_	
384-48	57954-57956	of	_	
384-49	57957-57962	their	_	
384-50	57963-57970	disease	_	
384-51	57971-57979	severity	1	
384-52	57980-57981	(	5	
384-53	57982-57984	22	_	
384-54	57985-57986	)	_	
384-55	57987-57988	.	1	

#Text=The TUG test involved measuring the duration of time required for participants to rise from a chair , walk three meters , and return to their seat .
385-1	57989-57992	The	9	
385-2	57993-57996	TUG	_	
385-3	57997-58001	test	1	
385-4	58002-58010	involved	8	
385-5	58011-58020	measuring	1	
385-6	58021-58024	the	2	
385-7	58025-58033	duration	_	
385-8	58034-58036	of	_	
385-9	58037-58041	time	1	
385-10	58042-58050	required	3	
385-11	58051-58054	for	1	
385-12	58055-58067	participants	2	
385-13	58068-58070	to	3	
385-14	58071-58075	rise	_	
385-15	58076-58080	from	1	
385-16	58081-58082	a	1	
385-17	58083-58088	chair	_	
385-18	58089-58090	,	1	
385-19	58091-58095	walk	3	
385-20	58096-58101	three	2	
385-21	58102-58108	meters	_	
385-22	58109-58110	,	1	
385-23	58111-58114	and	3	
385-24	58115-58121	return	_	
385-25	58122-58124	to	1	
385-26	58125-58130	their	_	
385-27	58131-58135	seat	_	
385-28	58136-58137	.	1	

#Text=The CIGMA study ( { " type":"clinical-trial","attrs":{"text":"NCT01420744","term_id":"NCT01420744"}}NCT01420744 [ 18 , 19 ] ) , a randomized , placebo-controlled , double-blind , multicenter , parallel-group , phase II trial , was conducted in hospitals in Germany , Spain , and the UK .
386-1	58138-58141	The	9	
386-2	58142-58147	CIGMA	_	
386-3	58148-58153	study	1	
386-4	58154-58155	(	5	
386-5	58156-58157	{	_	
386-6	58158-58159	"	_	
386-7	58160-58164	type	_	
386-8	58164-58165	"	_	
386-9	58165-58166	:	_	
386-10	58166-58167	"	_	
386-11	58167-58181	clinical-trial	_	
386-12	58181-58182	"	_	
386-13	58182-58183	,	_	
386-14	58183-58184	"	_	
386-15	58184-58189	attrs	_	
386-16	58189-58190	"	_	
386-17	58190-58191	:	_	
386-18	58191-58192	{	_	
386-19	58192-58193	"	_	
386-20	58193-58197	text	_	
386-21	58197-58198	"	_	
386-22	58198-58199	:	_	
386-23	58199-58200	"	_	
386-24	58200-58211	NCT01420744	_	
386-25	58211-58212	"	_	
386-26	58212-58213	,	_	
386-27	58213-58214	"	_	
386-28	58214-58221	term_id	_	
386-29	58221-58222	"	_	
386-30	58222-58223	:	_	
386-31	58223-58224	"	_	
386-32	58224-58235	NCT01420744	_	
386-33	58235-58236	"	_	
386-34	58236-58237	}	_	
386-35	58237-58238	}	_	
386-36	58238-58249	NCT01420744	_	
386-37	58250-58251	[	_	
386-38	58252-58254	18	_	
386-39	58255-58256	,	_	
386-40	58257-58259	19	_	
386-41	58260-58261	]	_	
386-42	58262-58263	)	_	
386-43	58264-58265	,	1	
386-44	58266-58267	a	2	
386-45	58268-58278	randomized	_	
386-46	58279-58280	,	_	
386-47	58281-58299	placebo-controlled	_	
386-48	58300-58301	,	_	
386-49	58302-58314	double-blind	_	
386-50	58315-58316	,	_	
386-51	58317-58328	multicenter	_	
386-52	58329-58330	,	_	
386-53	58331-58345	parallel-group	_	
386-54	58346-58347	,	_	
386-55	58348-58353	phase	_	
386-56	58354-58356	II	_	
386-57	58357-58362	trial	_	
386-58	58363-58364	,	1	
386-59	58365-58368	was	8	
386-60	58369-58378	conducted	_	
386-61	58379-58381	in	1	
386-62	58382-58391	hospitals	2	
386-63	58392-58394	in	2	
386-64	58395-58402	Germany	_	
386-65	58403-58404	,	_	
386-66	58405-58410	Spain	_	
386-67	58411-58412	,	_	
386-68	58413-58416	and	_	
386-69	58417-58420	the	_	
386-70	58421-58423	UK	_	
386-71	58424-58425	.	1	

#Text=Torso , pelvis , thigh , and lower leg restraints were used to minimize the contribution of other muscle groups .
387-1	58426-58431	Torso	9	
387-2	58432-58433	,	_	
387-3	58434-58440	pelvis	_	
387-4	58441-58442	,	_	
387-5	58443-58448	thigh	_	
387-6	58449-58450	,	_	
387-7	58451-58454	and	_	
387-8	58455-58460	lower	_	
387-9	58461-58464	leg	_	
387-10	58465-58475	restraints	1	
387-11	58476-58480	were	8	
387-12	58481-58485	used	_	
387-13	58486-58488	to	_	
387-14	58489-58497	minimize	1	
387-15	58498-58501	the	2	
387-16	58502-58514	contribution	_	
387-17	58515-58517	of	_	
387-18	58518-58523	other	_	
387-19	58524-58530	muscle	_	
387-20	58531-58537	groups	_	
387-21	58538-58539	.	1	

#Text=This retrospective , anecdotal , double-blind randomised placebo-controlled study was conducted in accordance with the Declaration of Helsinki and institutional review board rules .
388-1	58540-58544	This	9	
388-2	58545-58558	retrospective	_	
388-3	58559-58560	,	_	
388-4	58561-58570	anecdotal	_	
388-5	58571-58572	,	_	
388-6	58573-58585	double-blind	_	
388-7	58586-58596	randomised	_	
388-8	58597-58615	placebo-controlled	_	
388-9	58616-58621	study	1	
388-10	58622-58625	was	8	
388-11	58626-58635	conducted	_	
388-12	58636-58638	in	_	
388-13	58639-58649	accordance	_	
388-14	58650-58654	with	1	
388-15	58655-58658	the	2	
388-16	58659-58670	Declaration	_	
388-17	58671-58673	of	_	
388-18	58674-58682	Helsinki	_	
388-19	58683-58686	and	_	
388-20	58687-58700	institutional	_	
388-21	58701-58707	review	_	
388-22	58708-58713	board	_	
388-23	58714-58719	rules	_	
388-24	58720-58721	.	1	

#Text=No surgical procedure was performed for AOM on or before the last day of the visit window .
389-1	58722-58724	No	9	
389-2	58725-58733	surgical	_	
389-3	58734-58743	procedure	1	
389-4	58744-58747	was	8	
389-5	58748-58757	performed	_	
389-6	58758-58761	for	1	
389-7	58762-58765	AOM	2	
389-8	58766-58768	on	2	
389-9	58769-58771	or	_	
389-10	58772-58778	before	_	
389-11	58779-58782	the	_	
389-12	58783-58787	last	_	
389-13	58788-58791	day	_	
389-14	58792-58794	of	_	
389-15	58795-58798	the	_	
389-16	58799-58804	visit	_	
389-17	58805-58811	window	_	
389-18	58812-58813	.	1	

#Text=The null hypothesis of this study was that treatment with ibuprofen would be inferior to pivmecillinam regarding the proportion of patients feeling cured after 4 days by a 10 % margin .
390-1	58814-58817	The	9	
390-2	58818-58822	null	_	
390-3	58823-58833	hypothesis	_	
390-4	58834-58836	of	_	
390-5	58837-58841	this	_	
390-6	58842-58847	study	1	
390-7	58848-58851	was	8	
390-8	58852-58856	that	6	
390-9	58857-58866	treatment	9	
390-10	58867-58871	with	_	
390-11	58872-58881	ibuprofen	1	
390-12	58882-58887	would	3	
390-13	58888-58890	be	_	
390-14	58891-58899	inferior	_	
390-15	58900-58902	to	1	
390-16	58903-58916	pivmecillinam	2	
390-17	58917-58926	regarding	6	
390-18	58927-58930	the	2	
390-19	58931-58941	proportion	_	
390-20	58942-58944	of	_	
390-21	58945-58953	patients	_	
390-22	58954-58961	feeling	_	
390-23	58962-58967	cured	_	
390-24	58968-58973	after	_	
390-25	58974-58975	4	_	
390-26	58976-58980	days	_	
390-27	58981-58983	by	_	
390-28	58984-58985	a	_	
390-29	58986-58988	10	_	
390-30	58989-58990	%	_	
390-31	58991-58997	margin	_	
390-32	58998-58999	.	1	

#Text=The study was powered to detect a difference of two VFDs between the treatment arms .
391-1	59000-59003	The	9	
391-2	59004-59009	study	1	
391-3	59010-59013	was	8	
391-4	59014-59021	powered	_	
391-5	59022-59024	to	_	
391-6	59025-59031	detect	1	
391-7	59032-59033	a	2	
391-8	59034-59044	difference	_	
391-9	59045-59047	of	_	
391-10	59048-59051	two	_	
391-11	59052-59056	VFDs	_	
391-12	59057-59064	between	_	
391-13	59065-59068	the	_	
391-14	59069-59078	treatment	_	
391-15	59079-59083	arms	_	
391-16	59084-59085	.	1	

#Text=Because OA affects multiple elements of health [ 31 ] ; and the mechanisms by which yoga improves health appears multifactorial [ 19 ] , these broader constructs relevant to health and well-being were explored .
392-1	59086-59093	Because	6	
392-2	59094-59096	OA	9	
392-3	59097-59104	affects	3	
392-4	59105-59113	multiple	2	
392-5	59114-59122	elements	_	
392-6	59123-59125	of	_	
392-7	59126-59132	health	1	
392-8	59133-59134	[	5	
392-9	59135-59137	31	_	
392-10	59138-59139	]	1	
392-11	59140-59141	;	6	
392-12	59142-59145	and	9	
392-13	59146-59149	the	_	
392-14	59150-59160	mechanisms	1	
392-15	59161-59163	by	6	
392-16	59164-59169	which	1	
392-17	59170-59174	yoga	9	
392-18	59175-59183	improves	3	
392-19	59184-59190	health	2	
392-20	59191-59198	appears	3	
392-21	59199-59213	multifactorial	7	
392-22	59214-59215	[	5	
392-23	59216-59218	19	_	
392-24	59219-59220	]	_	
392-25	59221-59222	,	1	
392-26	59223-59228	these	9	
392-27	59229-59236	broader	_	
392-28	59237-59247	constructs	_	
392-29	59248-59256	relevant	_	
392-30	59257-59259	to	_	
392-31	59260-59266	health	_	
392-32	59267-59270	and	_	
392-33	59271-59281	well-being	1	
392-34	59282-59286	were	8	
392-35	59287-59295	explored	_	
392-36	59296-59297	.	1	

#Text=The primary effectiveness analysis determined whether VYC-17.5L was noninferior to control in terms of improvement in mean NLFSS scores at Month 6 , wherein 0.5 points was the prespecified margin of noninferiority , and whether the responder rate for VYC-17.5L was statistically significantly greater than 50 % at Month 6 .
393-1	59298-59301	The	9	
393-2	59302-59309	primary	_	
393-3	59310-59323	effectiveness	_	
393-4	59324-59332	analysis	1	
393-5	59333-59343	determined	8	
393-6	59344-59351	whether	6	
393-7	59352-59355	VYC	9	
393-8	59355-59356	-	_	
393-9	59356-59361	17.5L	1	
393-10	59362-59365	was	3	
393-11	59366-59377	noninferior	7	
393-12	59378-59380	to	2	
393-13	59381-59388	control	1	
393-14	59389-59391	in	2	
393-15	59392-59397	terms	_	
393-16	59398-59400	of	_	
393-17	59401-59412	improvement	_	
393-18	59413-59415	in	_	
393-19	59416-59420	mean	_	
393-20	59421-59426	NLFSS	_	
393-21	59427-59433	scores	_	
393-22	59434-59436	at	_	
393-23	59437-59442	Month	_	
393-24	59443-59444	6	_	
393-25	59445-59446	,	1	
393-26	59447-59454	wherein	6	
393-27	59455-59458	0.5	9	
393-28	59459-59465	points	_	
393-29	59466-59469	was	3	
393-30	59470-59473	the	2	
393-31	59474-59486	prespecified	_	
393-32	59487-59493	margin	_	
393-33	59494-59496	of	_	
393-34	59497-59511	noninferiority	_	
393-35	59512-59513	,	1	
393-36	59514-59517	and	6	
393-37	59518-59525	whether	1	
393-38	59526-59529	the	9	
393-39	59530-59539	responder	_	
393-40	59540-59544	rate	_	
393-41	59545-59548	for	_	
393-42	59549-59552	VYC	_	
393-43	59552-59553	-	_	
393-44	59553-59558	17.5L	1	
393-45	59559-59562	was	3	
393-46	59563-59576	statistically	7	
393-47	59577-59590	significantly	_	
393-48	59591-59598	greater	_	
393-49	59599-59603	than	_	
393-50	59604-59606	50	_	
393-51	59607-59608	%	1	
393-52	59609-59611	at	2	
393-53	59612-59617	Month	_	
393-54	59618-59619	6	_	
393-55	59620-59621	.	1	

#Text=Patients seeking acute care at the emergency room with a suspected infection or patients directly admitted to the infectious diseases clinic were all examined by an infectious diseases physician .
394-1	59622-59630	Patients	9	
394-2	59631-59638	seeking	_	
394-3	59639-59644	acute	_	
394-4	59645-59649	care	_	
394-5	59650-59652	at	_	
394-6	59653-59656	the	_	
394-7	59657-59666	emergency	_	
394-8	59667-59671	room	_	
394-9	59672-59676	with	_	
394-10	59677-59678	a	_	
394-11	59679-59688	suspected	_	
394-12	59689-59698	infection	1	
394-13	59699-59701	or	9	
394-14	59702-59710	patients	_	
394-15	59711-59719	directly	_	
394-16	59720-59728	admitted	_	
394-17	59729-59731	to	_	
394-18	59732-59735	the	_	
394-19	59736-59746	infectious	_	
394-20	59747-59755	diseases	_	
394-21	59756-59762	clinic	1	
394-22	59763-59767	were	8	
394-23	59768-59771	all	_	
394-24	59772-59780	examined	_	
394-25	59781-59783	by	1	
394-26	59784-59786	an	2	
394-27	59787-59797	infectious	_	
394-28	59798-59806	diseases	_	
394-29	59807-59816	physician	_	
394-30	59817-59818	.	1	

#Text=LMM can handle concentrations for each individual , missing values , and dependent data and the equation reads.
395-1	59819-59822	LMM	9	
395-2	59823-59826	can	8	
395-3	59827-59833	handle	1	
395-4	59834-59848	concentrations	2	
395-5	59849-59852	for	_	
395-6	59853-59857	each	_	
395-7	59858-59868	individual	_	
395-8	59869-59870	,	_	
395-9	59871-59878	missing	_	
395-10	59879-59885	values	_	
395-11	59886-59887	,	_	
395-12	59888-59891	and	_	
395-13	59892-59901	dependent	_	
395-14	59902-59906	data	1	
395-15	59907-59910	and	2	
395-16	59911-59914	the	_	
395-17	59915-59923	equation	_	
395-18	59924-59929	reads	_	
395-19	59929-59930	.	1	

#Text=Owing to the invasive nature of the intervention and the logistics involved in carrying out the procedures , neither the trial participants nor the investigators could be masked to group allocation .
396-1	59931-59936	Owing	6	
396-2	59937-59939	to	1	
396-3	59940-59943	the	2	
396-4	59944-59952	invasive	_	
396-5	59953-59959	nature	_	
396-6	59960-59962	of	_	
396-7	59963-59966	the	_	
396-8	59967-59979	intervention	1	
396-9	59980-59983	and	2	
396-10	59984-59987	the	_	
396-11	59988-59997	logistics	1	
396-12	59998-60006	involved	3	
396-13	60007-60009	in	_	
396-14	60010-60018	carrying	_	
396-15	60019-60022	out	1	
396-16	60023-60026	the	2	
396-17	60027-60037	procedures	_	
396-18	60038-60039	,	1	
396-19	60040-60047	neither	6	
396-20	60048-60051	the	9	
396-21	60052-60057	trial	_	
396-22	60058-60070	participants	1	
396-23	60071-60074	nor	6	
396-24	60075-60078	the	9	
396-25	60079-60092	investigators	1	
396-26	60093-60098	could	8	
396-27	60099-60101	be	_	
396-28	60102-60108	masked	_	
396-29	60109-60111	to	1	
396-30	60112-60117	group	2	
396-31	60118-60128	allocation	_	
396-32	60129-60130	.	1	

#Text=Given this moderate effect size , high correlation between outcomes , a 5 % chance of type one error ( two-sided ) and 15 % attrition , a sample of 60 participants was recommended to yield 80 % power to detect between group differences .
397-1	60131-60136	Given	3	
397-2	60137-60141	this	2	
397-3	60142-60150	moderate	_	
397-4	60151-60157	effect	_	
397-5	60158-60162	size	_	
397-6	60163-60164	,	_	
397-7	60165-60169	high	_	
397-8	60170-60181	correlation	_	
397-9	60182-60189	between	_	
397-10	60190-60198	outcomes	_	
397-11	60199-60200	,	_	
397-12	60201-60202	a	_	
397-13	60203-60204	5	_	
397-14	60205-60206	%	_	
397-15	60207-60213	chance	_	
397-16	60214-60216	of	_	
397-17	60217-60221	type	_	
397-18	60222-60225	one	_	
397-19	60226-60231	error	_	
397-20	60232-60233	(	5	
397-21	60234-60243	two-sided	_	
397-22	60244-60245	)	1	
397-23	60246-60249	and	_	
397-24	60250-60252	15	_	
397-25	60253-60254	%	_	
397-26	60255-60264	attrition	_	
397-27	60265-60266	,	1	
397-28	60267-60268	a	9	
397-29	60269-60275	sample	_	
397-30	60276-60278	of	_	
397-31	60279-60281	60	_	
397-32	60282-60294	participants	1	
397-33	60295-60298	was	8	
397-34	60299-60310	recommended	_	
397-35	60311-60313	to	_	
397-36	60314-60319	yield	1	
397-37	60320-60322	80	2	
397-38	60323-60324	%	_	
397-39	60325-60330	power	1	
397-40	60331-60333	to	3	
397-41	60334-60340	detect	1	
397-42	60341-60348	between	2	
397-43	60349-60354	group	_	
397-44	60355-60366	differences	_	
397-45	60367-60368	.	1	

#Text=The trial was performed at 38 centers in the United States .
398-1	60369-60372	The	9	
398-2	60373-60378	trial	1	
398-3	60379-60382	was	8	
398-4	60383-60392	performed	_	
398-5	60393-60395	at	1	
398-6	60396-60398	38	2	
398-7	60399-60406	centers	1	
398-8	60407-60409	in	2	
398-9	60410-60413	the	_	
398-10	60414-60420	United	_	
398-11	60421-60427	States	_	
398-12	60428-60429	.	1	

#Text=Patients were randomly assigned to either laparoscopic cholecystectomy or percutaneous catheter drainage , both to be performed within 24 hours after randomisation .
399-1	60430-60438	Patients	9	
399-2	60439-60443	were	8	
399-3	60444-60452	randomly	_	
399-4	60453-60461	assigned	_	
399-5	60462-60464	to	1	
399-6	60465-60471	either	6	
399-7	60472-60484	laparoscopic	2	
399-8	60485-60500	cholecystectomy	1	
399-9	60501-60503	or	2	
399-10	60504-60516	percutaneous	_	
399-11	60517-60525	catheter	_	
399-12	60526-60534	drainage	_	
399-13	60535-60536	,	2	
399-14	60537-60541	both	2	
399-15	60542-60544	to	3	
399-16	60545-60547	be	_	
399-17	60548-60557	performed	_	
399-18	60558-60564	within	1	
399-19	60565-60567	24	2	
399-20	60568-60573	hours	_	
399-21	60574-60579	after	_	
399-22	60580-60593	randomisation	_	
399-23	60594-60595	.	1	

#Text=A sample size calculation for an analysis of covariance ( ANCOVA ) designed to detect significant differences in three primary outcomes between three groups with one covariate ( baseline values ) was performed .
400-1	60596-60597	A	9	
400-2	60598-60604	sample	_	
400-3	60605-60609	size	_	
400-4	60610-60621	calculation	_	
400-5	60622-60625	for	_	
400-6	60626-60628	an	_	
400-7	60629-60637	analysis	_	
400-8	60638-60640	of	_	
400-9	60641-60651	covariance	1	
400-10	60652-60653	(	5	
400-11	60654-60660	ANCOVA	_	
400-12	60661-60662	)	1	
400-13	60663-60671	designed	3	
400-14	60672-60674	to	_	
400-15	60675-60681	detect	1	
400-16	60682-60693	significant	2	
400-17	60694-60705	differences	_	
400-18	60706-60708	in	_	
400-19	60709-60714	three	_	
400-20	60715-60722	primary	_	
400-21	60723-60731	outcomes	_	
400-22	60732-60739	between	_	
400-23	60740-60745	three	_	
400-24	60746-60752	groups	1	
400-25	60753-60757	with	2	
400-26	60758-60761	one	_	
400-27	60762-60771	covariate	1	
400-28	60772-60773	(	5	
400-29	60774-60782	baseline	_	
400-30	60783-60789	values	_	
400-31	60790-60791	)	1	
400-32	60792-60795	was	8	
400-33	60796-60805	performed	_	
400-34	60806-60807	.	1	

#Text=Table 1 provides detailed definitions .
401-1	60808-60813	Table	9	
401-2	60814-60815	1	1	
401-3	60816-60824	provides	8	
401-4	60825-60833	detailed	2	
401-5	60834-60845	definitions	_	
401-6	60846-60847	.	1	

#Text=Patients were eligible if they had an initial infarct volume ( ischemic core ) of less than 70 ml , a ratio of volume of ischemic tissue to initial infarct volume of 1.8 or more , and an absolute volume of potentially reversible ischemia ( penumbra ) of 15 ml or more .
402-1	60848-60856	Patients	9	
402-2	60857-60861	were	8	
402-3	60862-60870	eligible	7	
402-4	60871-60873	if	6	
402-5	60874-60878	they	3	
402-6	60879-60882	had	1	
402-7	60883-60885	an	2	
402-8	60886-60893	initial	_	
402-9	60894-60901	infarct	_	
402-10	60902-60908	volume	_	
402-11	60909-60910	(	5	
402-12	60911-60919	ischemic	_	
402-13	60920-60924	core	_	
402-14	60925-60926	)	1	
402-15	60927-60929	of	_	
402-16	60930-60934	less	_	
402-17	60935-60939	than	_	
402-18	60940-60942	70	_	
402-19	60943-60945	ml	_	
402-20	60946-60947	,	1	
402-21	60948-60949	a	2	
402-22	60950-60955	ratio	_	
402-23	60956-60958	of	_	
402-24	60959-60965	volume	_	
402-25	60966-60968	of	_	
402-26	60969-60977	ischemic	_	
402-27	60978-60984	tissue	_	
402-28	60985-60987	to	_	
402-29	60988-60995	initial	_	
402-30	60996-61003	infarct	_	
402-31	61004-61010	volume	_	
402-32	61011-61013	of	_	
402-33	61014-61017	1.8	_	
402-34	61018-61020	or	_	
402-35	61021-61025	more	_	
402-36	61026-61027	,	1	
402-37	61028-61031	and	2	
402-38	61032-61034	an	_	
402-39	61035-61043	absolute	_	
402-40	61044-61050	volume	_	
402-41	61051-61053	of	_	
402-42	61054-61065	potentially	_	
402-43	61066-61076	reversible	_	
402-44	61077-61085	ischemia	_	
402-45	61086-61087	(	5	
402-46	61088-61096	penumbra	_	
402-47	61097-61098	)	1	
402-48	61099-61101	of	_	
402-49	61102-61104	15	_	
402-50	61105-61107	ml	_	
402-51	61108-61110	or	_	
402-52	61111-61115	more	_	
402-53	61116-61117	.	1	

#Text=For example , PCs containing fatty acid ( FA ) 16:1 and FA 18:1 or FA 16:0 and FA 18:2 or FA 14:0 and FA 20:2 , are all annotated as PC 34:2 .
403-1	61118-61121	For	6	
403-2	61122-61129	example	_	
403-3	61130-61131	,	1	
403-4	61132-61135	PCs	9	
403-5	61136-61146	containing	3	
403-6	61147-61152	fatty	2	
403-7	61153-61157	acid	_	
403-8	61158-61159	(	_	
403-9	61160-61162	FA	_	
403-10	61163-61164	)	_	
403-11	61165-61167	16	_	
403-12	61167-61168	:	_	
403-13	61168-61169	1	_	
403-14	61170-61173	and	_	
403-15	61174-61176	FA	_	
403-16	61177-61179	18	_	
403-17	61179-61180	:	_	
403-18	61180-61181	1	_	
403-19	61182-61184	or	_	
403-20	61185-61187	FA	_	
403-21	61188-61190	16	_	
403-22	61190-61191	:	_	
403-23	61191-61192	0	_	
403-24	61193-61196	and	_	
403-25	61197-61199	FA	_	
403-26	61200-61202	18	_	
403-27	61202-61203	:	_	
403-28	61203-61204	2	_	
403-29	61205-61207	or	_	
403-30	61208-61210	FA	_	
403-31	61211-61213	14	_	
403-32	61213-61214	:	_	
403-33	61214-61215	0	_	
403-34	61216-61219	and	_	
403-35	61220-61222	FA	_	
403-36	61223-61225	20	_	
403-37	61225-61226	:	_	
403-38	61226-61227	2	_	
403-39	61228-61229	,	1	
403-40	61230-61233	are	8	
403-41	61234-61237	all	_	
403-42	61238-61247	annotated	_	
403-43	61248-61250	as	1	
403-44	61251-61253	PC	2	
403-45	61254-61256	34	_	
403-46	61256-61257	:	_	
403-47	61257-61258	2	_	
403-48	61259-61260	.	1	

#Text=For inter-day validation , LPC standards were spiked to an Eppendorf vial and evaporated before adding 20 μL of a serum pool .
404-1	61261-61264	For	2	
404-2	61265-61274	inter-day	_	
404-3	61275-61285	validation	_	
404-4	61286-61287	,	1	
404-5	61288-61291	LPC	9	
404-6	61292-61301	standards	1	
404-7	61302-61306	were	8	
404-8	61307-61313	spiked	_	
404-9	61314-61316	to	1	
404-10	61317-61319	an	2	
404-11	61320-61329	Eppendorf	_	
404-12	61330-61334	vial	1	
404-13	61335-61338	and	3	
404-14	61339-61349	evaporated	_	
404-15	61350-61356	before	_	
404-16	61357-61363	adding	1	
404-17	61364-61366	20	2	
404-18	61367-61369	μL	_	
404-19	61370-61372	of	_	
404-20	61373-61374	a	_	
404-21	61375-61380	serum	_	
404-22	61381-61385	pool	_	
404-23	61386-61387	.	1	

#Text=The patients were instructed to stop previous medical prescriptions for treatment of gastritis including proton pump inhibitors , other buffering and gastroprotective agents , and digestive enzymes 7   days before the beginning of the study .
405-1	61388-61391	The	9	
405-2	61392-61400	patients	1	
405-3	61401-61405	were	8	
405-4	61406-61416	instructed	_	
405-5	61417-61419	to	_	
405-6	61420-61424	stop	1	
405-7	61425-61433	previous	2	
405-8	61434-61441	medical	_	
405-9	61442-61455	prescriptions	_	
405-10	61456-61459	for	_	
405-11	61460-61469	treatment	_	
405-12	61470-61472	of	_	
405-13	61473-61482	gastritis	2	
405-14	61483-61492	including	3	
405-15	61493-61499	proton	2	
405-16	61500-61504	pump	_	
405-17	61505-61515	inhibitors	_	
405-18	61516-61517	,	_	
405-19	61518-61523	other	_	
405-20	61524-61533	buffering	_	
405-21	61534-61537	and	_	
405-22	61538-61554	gastroprotective	_	
405-23	61555-61561	agents	_	
405-24	61562-61563	,	_	
405-25	61564-61567	and	_	
405-26	61568-61577	digestive	_	
405-27	61578-61585	enzymes	1	
405-28	61586-61587	7	2	
405-29	61588-61589	 	_	
405-30	61590-61594	days	_	
405-31	61595-61601	before	_	
405-32	61602-61605	the	_	
405-33	61606-61615	beginning	_	
405-34	61616-61618	of	_	
405-35	61619-61622	the	_	
405-36	61623-61628	study	_	
405-37	61629-61630	.	1	

#Text=These analyses were decided upon after unblinding of the data , which revealed the low cell count in the pivmecillinam group .
406-1	61631-61636	These	9	
406-2	61637-61645	analyses	1	
406-3	61646-61650	were	8	
406-4	61651-61658	decided	_	
406-5	61659-61663	upon	_	
406-6	61664-61669	after	1	
406-7	61670-61680	unblinding	2	
406-8	61681-61683	of	_	
406-9	61684-61687	the	_	
406-10	61688-61692	data	_	
406-11	61693-61694	,	1	
406-12	61695-61700	which	6	
406-13	61701-61709	revealed	1	
406-14	61710-61713	the	2	
406-15	61714-61717	low	_	
406-16	61718-61722	cell	_	
406-17	61723-61728	count	_	
406-18	61729-61731	in	_	
406-19	61732-61735	the	_	
406-20	61736-61749	pivmecillinam	_	
406-21	61750-61755	group	_	
406-22	61756-61757	.	1	

#Text=This process was completed by an investigator who was not involved in data collection .
407-1	61758-61762	This	9	
407-2	61763-61770	process	1	
407-3	61771-61774	was	8	
407-4	61775-61784	completed	_	
407-5	61785-61787	by	1	
407-6	61788-61790	an	2	
407-7	61791-61803	investigator	_	
407-8	61804-61807	who	_	
407-9	61808-61811	was	_	
407-10	61812-61815	not	_	
407-11	61816-61824	involved	_	
407-12	61825-61827	in	_	
407-13	61828-61832	data	_	
407-14	61833-61843	collection	_	
407-15	61844-61845	.	1	

#Text=Secondary efficacy analyses were performed in the per protocol set , consisting of patients in the FAS with a treatment compliance rate of at least 80 % .
408-1	61846-61855	Secondary	9	
408-2	61856-61864	efficacy	_	
408-3	61865-61873	analyses	1	
408-4	61874-61878	were	8	
408-5	61879-61888	performed	_	
408-6	61889-61891	in	1	
408-7	61892-61895	the	2	
408-8	61896-61899	per	_	
408-9	61900-61908	protocol	_	
408-10	61909-61912	set	_	
408-11	61913-61914	,	1	
408-12	61915-61925	consisting	3	
408-13	61926-61928	of	1	
408-14	61929-61937	patients	2	
408-15	61938-61940	in	_	
408-16	61941-61944	the	_	
408-17	61945-61948	FAS	_	
408-18	61949-61953	with	_	
408-19	61954-61955	a	_	
408-20	61956-61965	treatment	_	
408-21	61966-61976	compliance	_	
408-22	61977-61981	rate	_	
408-23	61982-61984	of	_	
408-24	61985-61987	at	_	
408-25	61988-61993	least	_	
408-26	61994-61996	80	_	
408-27	61997-61998	%	_	
408-28	61999-62000	.	1	

#Text=Each symptom was graded on a scale from 0 to 6 where 0 was “ normal/not affected ” and 6 was “ as bad as it could be ” , so the maximum potential sum score each day was 18 .
409-1	62001-62005	Each	9	
409-2	62006-62013	symptom	1	
409-3	62014-62017	was	8	
409-4	62018-62024	graded	_	
409-5	62025-62027	on	1	
409-6	62028-62029	a	2	
409-7	62030-62035	scale	_	
409-8	62036-62040	from	_	
409-9	62041-62042	0	_	
409-10	62043-62045	to	_	
409-11	62046-62047	6	1	
409-12	62048-62053	where	6	
409-13	62054-62055	0	2	
409-14	62056-62059	was	3	
409-15	62060-62061	“	7	
409-16	62062-62068	normal	_	
409-17	62068-62069	/	_	
409-18	62069-62072	not	_	
409-19	62073-62081	affected	_	
409-20	62082-62083	”	1	
409-21	62084-62087	and	2	
409-22	62088-62089	6	1	
409-23	62090-62093	was	8	
409-24	62094-62095	“	7	
409-25	62096-62098	as	_	
409-26	62099-62102	bad	_	
409-27	62103-62105	as	1	
409-28	62106-62108	it	3	
409-29	62109-62114	could	_	
409-30	62115-62117	be	_	
409-31	62118-62119	”	_	
409-32	62120-62121	,	1	
409-33	62122-62124	so	6	
409-34	62125-62128	the	9	
409-35	62129-62136	maximum	_	
409-36	62137-62146	potential	_	
409-37	62147-62150	sum	_	
409-38	62151-62156	score	_	
409-39	62157-62161	each	_	
409-40	62162-62165	day	1	
409-41	62166-62169	was	8	
409-42	62170-62172	18	2	
409-43	62173-62174	.	1	

#Text=Randomization was done in 9 consecutive cycles , comprising about 20 participants each .
410-1	62175-62188	Randomization	9	
410-2	62189-62192	was	8	
410-3	62193-62197	done	_	
410-4	62198-62200	in	1	
410-5	62201-62202	9	2	
410-6	62203-62214	consecutive	_	
410-7	62215-62221	cycles	_	
410-8	62222-62223	,	1	
410-9	62224-62234	comprising	3	
410-10	62235-62240	about	1	
410-11	62241-62243	20	2	
410-12	62244-62256	participants	_	
410-13	62257-62261	each	_	
410-14	62262-62263	.	1	

#Text=Patient Global Assessment scores were multiplied by 10 to convert to a scale of 0 to 100 .
411-1	62264-62271	Patient	9	
411-2	62272-62278	Global	_	
411-3	62279-62289	Assessment	_	
411-4	62290-62296	scores	1	
411-5	62297-62301	were	8	
411-6	62302-62312	multiplied	_	
411-7	62313-62315	by	1	
411-8	62316-62318	10	_	
411-9	62319-62321	to	3	
411-10	62322-62329	convert	_	
411-11	62330-62332	to	1	
411-12	62333-62334	a	2	
411-13	62335-62340	scale	_	
411-14	62341-62343	of	_	
411-15	62344-62345	0	_	
411-16	62346-62348	to	_	
411-17	62349-62352	100	_	
411-18	62353-62354	.	1	

#Text=The secondary endpoints included the individual components of the primary outcome , minor complications , difficulty of cholecystectomy ( as scored by a visual analogue scale from 1 to 10 ) , utilisation of healthcare resources , and total costs .
412-1	62355-62358	The	9	
412-2	62359-62368	secondary	_	
412-3	62369-62378	endpoints	1	
412-4	62379-62387	included	8	
412-5	62388-62391	the	2	
412-6	62392-62402	individual	_	
412-7	62403-62413	components	_	
412-8	62414-62416	of	_	
412-9	62417-62420	the	_	
412-10	62421-62428	primary	_	
412-11	62429-62436	outcome	_	
412-12	62437-62438	,	_	
412-13	62439-62444	minor	_	
412-14	62445-62458	complications	_	
412-15	62459-62460	,	_	
412-16	62461-62471	difficulty	_	
412-17	62472-62474	of	_	
412-18	62475-62490	cholecystectomy	_	
412-19	62491-62492	(	5	
412-20	62493-62495	as	_	
412-21	62496-62502	scored	_	
412-22	62503-62505	by	_	
412-23	62506-62507	a	_	
412-24	62508-62514	visual	_	
412-25	62515-62523	analogue	_	
412-26	62524-62529	scale	_	
412-27	62530-62534	from	_	
412-28	62535-62536	1	_	
412-29	62537-62539	to	_	
412-30	62540-62542	10	_	
412-31	62543-62544	)	_	
412-32	62545-62546	,	1	
412-33	62547-62558	utilisation	_	
412-34	62559-62561	of	_	
412-35	62562-62572	healthcare	_	
412-36	62573-62582	resources	_	
412-37	62583-62584	,	_	
412-38	62585-62588	and	_	
412-39	62589-62594	total	_	
412-40	62595-62600	costs	_	
412-41	62601-62602	.	1	

#Text=In the first session , participants received printed materials on Tai Chi principles , practice techniques , and safety precautions .
413-1	62603-62605	In	2	
413-2	62606-62609	the	_	
413-3	62610-62615	first	_	
413-4	62616-62623	session	_	
413-5	62624-62625	,	1	
413-6	62626-62638	participants	9	
413-7	62639-62647	received	1	
413-8	62648-62655	printed	2	
413-9	62656-62665	materials	_	
413-10	62666-62668	on	_	
413-11	62669-62672	Tai	_	
413-12	62673-62676	Chi	_	
413-13	62677-62687	principles	_	
413-14	62688-62689	,	_	
413-15	62690-62698	practice	_	
413-16	62699-62709	techniques	_	
413-17	62710-62711	,	_	
413-18	62712-62715	and	_	
413-19	62716-62722	safety	_	
413-20	62723-62734	precautions	_	
413-21	62735-62736	.	1	

#Text=The TE intervention reflected the current gold standard of strengthening exercise for knee OA [ 2 ] .
414-1	62737-62740	The	9	
414-2	62741-62743	TE	_	
414-3	62744-62756	intervention	1	
414-4	62757-62766	reflected	8	
414-5	62767-62770	the	2	
414-6	62771-62778	current	_	
414-7	62779-62783	gold	_	
414-8	62784-62792	standard	_	
414-9	62793-62795	of	_	
414-10	62796-62809	strengthening	_	
414-11	62810-62818	exercise	_	
414-12	62819-62822	for	_	
414-13	62823-62827	knee	1	
414-14	62828-62830	OA	_	
414-15	62831-62832	[	5	
414-16	62833-62834	2	_	
414-17	62835-62836	]	_	
414-18	62837-62838	.	1	

#Text=Subjects rated satisfaction with treatment for each NLF using an 11-point scale ( 0 = completely dissatisfied ; 10 = completely satisfied ) and rated NLF preference .
415-1	62839-62847	Subjects	9	
415-2	62848-62853	rated	8	
415-3	62854-62866	satisfaction	2	
415-4	62867-62871	with	_	
415-5	62872-62881	treatment	1	
415-6	62882-62885	for	2	
415-7	62886-62890	each	_	
415-8	62891-62894	NLF	1	
415-9	62895-62900	using	3	
415-10	62901-62903	an	2	
415-11	62904-62906	11	_	
415-12	62906-62907	-	_	
415-13	62907-62912	point	_	
415-14	62913-62918	scale	1	
415-15	62919-62920	(	5	
415-16	62921-62922	0	_	
415-17	62923-62924	=	_	
415-18	62925-62935	completely	_	
415-19	62936-62948	dissatisfied	_	
415-20	62949-62950	;	_	
415-21	62951-62953	10	_	
415-22	62954-62955	=	_	
415-23	62956-62966	completely	_	
415-24	62967-62976	satisfied	_	
415-25	62977-62978	)	1	
415-26	62979-62982	and	3	
415-27	62983-62988	rated	1	
415-28	62989-62992	NLF	2	
415-29	62993-63003	preference	_	
415-30	63004-63005	.	1	

#Text=The same otoscopist did both assessments for each child .
416-1	63006-63009	The	9	
416-2	63010-63014	same	_	
416-3	63015-63025	otoscopist	1	
416-4	63026-63029	did	8	
416-5	63030-63034	both	2	
416-6	63035-63046	assessments	1	
416-7	63047-63050	for	2	
416-8	63051-63055	each	_	
416-9	63056-63061	child	_	
416-10	63062-63063	.	1	

#Text=Pyelonephritis is sometimes also classified as a febrile UTI [ 22 ] , but in this study we use the term febrile UTI to classify a UTI with less severe systemic impact than pyelonephritis .
417-1	63064-63078	Pyelonephritis	9	
417-2	63079-63081	is	8	
417-3	63082-63091	sometimes	_	
417-4	63092-63096	also	_	
417-5	63097-63107	classified	_	
417-6	63108-63110	as	1	
417-7	63111-63112	a	2	
417-8	63113-63120	febrile	_	
417-9	63121-63124	UTI	1	
417-10	63125-63126	[	5	
417-11	63127-63129	22	_	
417-12	63130-63131	]	_	
417-13	63132-63133	,	1	
417-14	63134-63137	but	2	
417-15	63138-63140	in	_	
417-16	63141-63145	this	_	
417-17	63146-63151	study	1	
417-18	63152-63154	we	3	
417-19	63155-63158	use	1	
417-20	63159-63162	the	2	
417-21	63163-63167	term	_	
417-22	63168-63175	febrile	_	
417-23	63176-63179	UTI	1	
417-24	63180-63182	to	3	
417-25	63183-63191	classify	1	
417-26	63192-63193	a	2	
417-27	63194-63197	UTI	_	
417-28	63198-63202	with	_	
417-29	63203-63207	less	_	
417-30	63208-63214	severe	_	
417-31	63215-63223	systemic	_	
417-32	63224-63230	impact	_	
417-33	63231-63235	than	_	
417-34	63236-63250	pyelonephritis	_	
417-35	63251-63252	.	1	

#Text=An independent data and safety monitoring board ( DSMB ) closely monitored the first six sequentially enrolled patients .
418-1	63253-63255	An	9	
418-2	63256-63267	independent	_	
418-3	63268-63272	data	_	
418-4	63273-63276	and	_	
418-5	63277-63283	safety	_	
418-6	63284-63294	monitoring	_	
418-7	63295-63300	board	1	
418-8	63301-63302	(	5	
418-9	63303-63307	DSMB	_	
418-10	63308-63309	)	1	
418-11	63310-63317	closely	8	
418-12	63318-63327	monitored	1	
418-13	63328-63331	the	2	
418-14	63332-63337	first	_	
418-15	63338-63341	six	_	
418-16	63342-63354	sequentially	_	
418-17	63355-63363	enrolled	_	
418-18	63364-63372	patients	_	
418-19	63373-63374	.	1	

#Text=PC and SM species were integrated and divided by the area of the IS LPC 19:0 .
419-1	63375-63377	PC	9	
419-2	63378-63381	and	_	
419-3	63382-63384	SM	_	
419-4	63385-63392	species	1	
419-5	63393-63397	were	8	
419-6	63398-63408	integrated	_	
419-7	63409-63412	and	_	
419-8	63413-63420	divided	_	
419-9	63421-63423	by	1	
419-10	63424-63427	the	2	
419-11	63428-63432	area	_	
419-12	63433-63435	of	_	
419-13	63436-63439	the	_	
419-14	63440-63442	IS	_	
419-15	63443-63446	LPC	_	
419-16	63447-63449	19	_	
419-17	63449-63450	:	_	
419-18	63450-63451	0	_	
419-19	63452-63453	.	1	

#Text=Drugs known to increase coagulation time were withdrawn for 10 days prior to and 3 days after study treatment .
420-1	63454-63459	Drugs	9	
420-2	63460-63465	known	3	
420-3	63466-63468	to	_	
420-4	63469-63477	increase	1	
420-5	63478-63489	coagulation	2	
420-6	63490-63494	time	1	
420-7	63495-63499	were	8	
420-8	63500-63509	withdrawn	_	
420-9	63510-63513	for	1	
420-10	63514-63516	10	2	
420-11	63517-63521	days	_	
420-12	63522-63527	prior	_	
420-13	63528-63530	to	_	
420-14	63531-63534	and	_	
420-15	63535-63536	3	_	
420-16	63537-63541	days	_	
420-17	63542-63547	after	_	
420-18	63548-63553	study	_	
420-19	63554-63563	treatment	_	
420-20	63564-63565	.	1	

#Text=Patients were encouraged to also perform exercises at home .
421-1	63566-63574	Patients	9	
421-2	63575-63579	were	8	
421-3	63580-63590	encouraged	_	
421-4	63591-63593	to	_	
421-5	63594-63598	also	_	
421-6	63599-63606	perform	1	
421-7	63607-63616	exercises	2	
421-8	63617-63619	at	2	
421-9	63620-63624	home	_	
421-10	63625-63626	.	1	

#Text=Low LEFS scores represent poor mobility [ 22 ] .
422-1	63627-63630	Low	9	
422-2	63631-63635	LEFS	_	
422-3	63636-63642	scores	1	
422-4	63643-63652	represent	8	
422-5	63653-63657	poor	2	
422-6	63658-63666	mobility	1	
422-7	63667-63668	[	5	
422-8	63669-63671	22	_	
422-9	63672-63673	]	_	
422-10	63674-63675	.	1	

#Text=The trial was approved by the Regional Ethical Committee in Norway ( REK ) and the Norwegian Medicines Agency ( SLV ) ( 2012/1569 C ) , the Committee on Biomedical Research Ethics for the Capital Region of Denmark ( H-4 - 2013 - 145 ) , the Regional Ethical Committee in Lund , Sweden ( Dnr 2014/28 ) , and the Medical Products Agency , Uppsala , Sweden ( Dnr 5.1 - 2014 - 12072 ) .
423-1	63676-63679	The	9	
423-2	63680-63685	trial	1	
423-3	63686-63689	was	8	
423-4	63690-63698	approved	_	
423-5	63699-63701	by	1	
423-6	63702-63705	the	_	
423-7	63706-63714	Regional	_	
423-8	63715-63722	Ethical	_	
423-9	63723-63732	Committee	_	
423-10	63733-63735	in	_	
423-11	63736-63742	Norway	_	
423-12	63743-63744	(	5	
423-13	63745-63748	REK	_	
423-14	63749-63750	)	1	
423-15	63751-63754	and	_	
423-16	63755-63758	the	_	
423-17	63759-63768	Norwegian	_	
423-18	63769-63778	Medicines	_	
423-19	63779-63785	Agency	_	
423-20	63786-63787	(	5	
423-21	63788-63791	SLV	_	
423-22	63792-63793	)	1	
423-23	63794-63795	(	5	
423-24	63796-63800	2012	_	
423-25	63800-63801	/	_	
423-26	63801-63805	1569	_	
423-27	63806-63807	C	_	
423-28	63808-63809	)	1	
423-29	63810-63811	,	_	
423-30	63812-63815	the	_	
423-31	63816-63825	Committee	_	
423-32	63826-63828	on	_	
423-33	63829-63839	Biomedical	_	
423-34	63840-63848	Research	_	
423-35	63849-63855	Ethics	_	
423-36	63856-63859	for	_	
423-37	63860-63863	the	_	
423-38	63864-63871	Capital	_	
423-39	63872-63878	Region	_	
423-40	63879-63881	of	_	
423-41	63882-63889	Denmark	_	
423-42	63890-63891	(	5	
423-43	63892-63893	H	_	
423-44	63893-63894	-	_	
423-45	63894-63895	4	_	
423-46	63896-63897	-	_	
423-47	63898-63902	2013	_	
423-48	63903-63904	-	_	
423-49	63905-63908	145	_	
423-50	63909-63910	)	1	
423-51	63911-63912	,	_	
423-52	63913-63916	the	_	
423-53	63917-63925	Regional	_	
423-54	63926-63933	Ethical	_	
423-55	63934-63943	Committee	_	
423-56	63944-63946	in	_	
423-57	63947-63951	Lund	_	
423-58	63952-63953	,	_	
423-59	63954-63960	Sweden	_	
423-60	63961-63962	(	5	
423-61	63963-63966	Dnr	_	
423-62	63967-63971	2014	_	
423-63	63971-63972	/	_	
423-64	63972-63974	28	_	
423-65	63975-63976	)	1	
423-66	63977-63978	,	_	
423-67	63979-63982	and	_	
423-68	63983-63986	the	_	
423-69	63987-63994	Medical	_	
423-70	63995-64003	Products	_	
423-71	64004-64010	Agency	_	
423-72	64011-64012	,	_	
423-73	64013-64020	Uppsala	_	
423-74	64021-64022	,	_	
423-75	64023-64029	Sweden	1	
423-76	64030-64031	(	5	
423-77	64032-64035	Dnr	_	
423-78	64036-64039	5.1	_	
423-79	64040-64041	-	_	
423-80	64042-64046	2014	_	
423-81	64047-64048	-	_	
423-82	64049-64054	12072	_	
423-83	64055-64056	)	_	
423-84	64057-64058	.	1	

#Text=A study rheumatologist ( W.H. ) confirmed eligibility of applicants .
424-1	64059-64060	A	9	
424-2	64061-64066	study	_	
424-3	64067-64081	rheumatologist	1	
424-4	64082-64083	(	5	
424-5	64084-64087	W.H	_	
424-6	64087-64088	.	_	
424-7	64089-64090	)	1	
424-8	64091-64100	confirmed	8	
424-9	64101-64112	eligibility	2	
424-10	64113-64115	of	_	
424-11	64116-64126	applicants	_	
424-12	64127-64128	.	1	

#Text=Missing data for these endpoints were handled by the linear mixed model and the Cox regression model , assuming missing at random and non-informative censoring at the last point of contact .
425-1	64129-64136	Missing	9	
425-2	64137-64141	data	_	
425-3	64142-64145	for	_	
425-4	64146-64151	these	_	
425-5	64152-64161	endpoints	1	
425-6	64162-64166	were	8	
425-7	64167-64174	handled	_	
425-8	64175-64177	by	1	
425-9	64178-64181	the	2	
425-10	64182-64188	linear	_	
425-11	64189-64194	mixed	_	
425-12	64195-64200	model	_	
425-13	64201-64204	and	_	
425-14	64205-64208	the	_	
425-15	64209-64212	Cox	_	
425-16	64213-64223	regression	_	
425-17	64224-64229	model	_	
425-18	64230-64231	,	1	
425-19	64232-64240	assuming	3	
425-20	64241-64248	missing	2	
425-21	64249-64251	at	_	
425-22	64252-64258	random	1	
425-23	64259-64262	and	2	
425-24	64263-64278	non-informative	_	
425-25	64279-64288	censoring	1	
425-26	64289-64291	at	2	
425-27	64292-64295	the	_	
425-28	64296-64300	last	_	
425-29	64301-64306	point	_	
425-30	64307-64309	of	_	
425-31	64310-64317	contact	_	
425-32	64318-64319	.	1	

#Text=Lipid species were annotated as described by Liebisch et al. [ 14 ] using the following pattern : Lipid class abbreviation : number of carbon atoms in the radyl side chain : number of double bonds in the radyl side chain .
426-1	64320-64325	Lipid	9	
426-2	64326-64333	species	1	
426-3	64334-64338	were	8	
426-4	64339-64348	annotated	_	
426-5	64349-64351	as	_	
426-6	64352-64361	described	_	
426-7	64362-64364	by	1	
426-8	64365-64373	Liebisch	2	
426-9	64374-64376	et	_	
426-10	64377-64379	al	_	
426-11	64379-64380	.	1	
426-12	64381-64382	[	5	
426-13	64383-64385	14	_	
426-14	64386-64387	]	1	
426-15	64388-64393	using	3	
426-16	64394-64397	the	2	
426-17	64398-64407	following	_	
426-18	64408-64415	pattern	1	
426-19	64416-64417	:	6	
426-20	64418-64423	Lipid	2	
426-21	64424-64429	class	_	
426-22	64430-64442	abbreviation	1	
426-23	64443-64444	:	6	
426-24	64445-64451	number	2	
426-25	64452-64454	of	_	
426-26	64455-64461	carbon	_	
426-27	64462-64467	atoms	_	
426-28	64468-64470	in	_	
426-29	64471-64474	the	_	
426-30	64475-64480	radyl	_	
426-31	64481-64485	side	_	
426-32	64486-64491	chain	1	
426-33	64492-64493	:	6	
426-34	64494-64500	number	2	
426-35	64501-64503	of	_	
426-36	64504-64510	double	_	
426-37	64511-64516	bonds	_	
426-38	64517-64519	in	_	
426-39	64520-64523	the	_	
426-40	64524-64529	radyl	_	
426-41	64530-64534	side	_	
426-42	64535-64540	chain	_	
426-43	64541-64542	.	1	

#Text=The study took place at Legacy Pediatrics in Rochester , NY and Kentucky Pediatric Research in Bardstown , KY .
427-1	64543-64546	The	9	
427-2	64547-64552	study	1	
427-3	64553-64557	took	8	
427-4	64558-64563	place	_	
427-5	64564-64566	at	1	
427-6	64567-64573	Legacy	2	
427-7	64574-64584	Pediatrics	_	
427-8	64585-64587	in	_	
427-9	64588-64597	Rochester	_	
427-10	64598-64599	,	_	
427-11	64600-64602	NY	_	
427-12	64603-64606	and	_	
427-13	64607-64615	Kentucky	_	
427-14	64616-64625	Pediatric	_	
427-15	64626-64634	Research	_	
427-16	64635-64637	in	_	
427-17	64638-64647	Bardstown	_	
427-18	64648-64649	,	_	
427-19	64650-64652	KY	_	
427-20	64653-64654	.	1	

#Text=These analyses are described in detail in Appendix Table 1 ( available at www.annals.org ) .
428-1	64655-64660	These	9	
428-2	64661-64669	analyses	1	
428-3	64670-64673	are	8	
428-4	64674-64683	described	_	
428-5	64684-64686	in	_	
428-6	64687-64693	detail	_	
428-7	64694-64696	in	1	
428-8	64697-64705	Appendix	2	
428-9	64706-64711	Table	_	
428-10	64712-64713	1	1	
428-11	64714-64715	(	5	
428-12	64716-64725	available	_	
428-13	64726-64728	at	_	
428-14	64729-64743	www.annals.org	_	
428-15	64744-64745	)	_	
428-16	64746-64747	.	1	

#Text=The size of the penumbra was estimated from the volume of tissue for which there was delayed arrival of an injected tracer agent ( time to maximum of the residue function [ Tmax ] ) exceeding 6 seconds.
429-1	64748-64751	The	9	
429-2	64752-64756	size	_	
429-3	64757-64759	of	_	
429-4	64760-64763	the	_	
429-5	64764-64772	penumbra	1	
429-6	64773-64776	was	8	
429-7	64777-64786	estimated	_	
429-8	64787-64791	from	1	
429-9	64792-64795	the	2	
429-10	64796-64802	volume	_	
429-11	64803-64805	of	_	
429-12	64806-64812	tissue	1	
429-13	64813-64816	for	6	
429-14	64817-64822	which	1	
429-15	64823-64828	there	9	
429-16	64829-64832	was	1	
429-17	64833-64840	delayed	2	
429-18	64841-64848	arrival	_	
429-19	64849-64851	of	_	
429-20	64852-64854	an	_	
429-21	64855-64863	injected	_	
429-22	64864-64870	tracer	_	
429-23	64871-64876	agent	1	
429-24	64877-64878	(	5	
429-25	64879-64883	time	_	
429-26	64884-64886	to	_	
429-27	64887-64894	maximum	_	
429-28	64895-64897	of	_	
429-29	64898-64901	the	_	
429-30	64902-64909	residue	_	
429-31	64910-64918	function	_	
429-32	64919-64920	[	_	
429-33	64921-64925	Tmax	_	
429-34	64926-64927	]	_	
429-35	64928-64929	)	1	
429-36	64930-64939	exceeding	3	
429-37	64940-64941	6	2	
429-38	64942-64949	seconds	_	
429-39	64949-64950	.	1	

#Text=Participants and exercise instructors were blinded to the study hypothesis .
430-1	64951-64963	Participants	9	
430-2	64964-64967	and	_	
430-3	64968-64976	exercise	_	
430-4	64977-64988	instructors	1	
430-5	64989-64993	were	8	
430-6	64994-65001	blinded	_	
430-7	65002-65004	to	1	
430-8	65005-65008	the	2	
430-9	65009-65014	study	_	
430-10	65015-65025	hypothesis	_	
430-11	65026-65027	.	1	

#Text=Amox/clav HD was given for 10 days and cefdinir for 5 days .
431-1	65028-65032	Amox	9	
431-2	65032-65033	/	_	
431-3	65033-65037	clav	_	
431-4	65038-65040	HD	1	
431-5	65041-65044	was	8	
431-6	65045-65050	given	_	
431-7	65051-65054	for	9	
431-8	65055-65057	10	2	
431-9	65058-65062	days	1	
431-10	65063-65066	and	9	
431-11	65067-65075	cefdinir	1	
431-12	65076-65079	for	2	
431-13	65080-65081	5	_	
431-14	65082-65086	days	_	
431-15	65087-65088	.	1	

#Text=The subjects rated their procedural pain for each NLF ( pain during injection ) on an 11-point scale ( 0 = no pain ; 10 = worst pain imaginable ) and completed a 30-day safety diary after each treatment reporting any injection site responses ( ISRs ) .
432-1	65089-65092	The	9	
432-2	65093-65101	subjects	1	
432-3	65102-65107	rated	8	
432-4	65108-65113	their	2	
432-5	65114-65124	procedural	_	
432-6	65125-65129	pain	1	
432-7	65130-65133	for	2	
432-8	65134-65138	each	_	
432-9	65139-65142	NLF	1	
432-10	65143-65144	(	5	
432-11	65145-65149	pain	_	
432-12	65150-65156	during	_	
432-13	65157-65166	injection	_	
432-14	65167-65168	)	1	
432-15	65169-65171	on	2	
432-16	65172-65174	an	_	
432-17	65175-65177	11	_	
432-18	65177-65178	-	_	
432-19	65178-65183	point	_	
432-20	65184-65189	scale	1	
432-21	65190-65191	(	5	
432-22	65192-65193	0	_	
432-23	65194-65195	=	_	
432-24	65196-65198	no	_	
432-25	65199-65203	pain	_	
432-26	65204-65205	;	_	
432-27	65206-65208	10	_	
432-28	65209-65210	=	_	
432-29	65211-65216	worst	_	
432-30	65217-65221	pain	_	
432-31	65222-65232	imaginable	_	
432-32	65233-65234	)	1	
432-33	65235-65238	and	3	
432-34	65239-65248	completed	1	
432-35	65249-65250	a	2	
432-36	65251-65253	30	_	
432-37	65253-65254	-	_	
432-38	65254-65257	day	_	
432-39	65258-65264	safety	_	
432-40	65265-65270	diary	1	
432-41	65271-65276	after	2	
432-42	65277-65281	each	_	
432-43	65282-65291	treatment	1	
432-44	65292-65301	reporting	3	
432-45	65302-65305	any	2	
432-46	65306-65315	injection	_	
432-47	65316-65320	site	_	
432-48	65321-65330	responses	1	
432-49	65331-65332	(	5	
432-50	65333-65337	ISRs	_	
432-51	65338-65339	)	_	
432-52	65340-65341	.	1	

#Text=Legacy Pediatrics cares for a predominantly suburban , higher socio-economic status ( SES ) population .
433-1	65342-65348	Legacy	9	
433-2	65349-65359	Pediatrics	1	
433-3	65360-65365	cares	8	
433-4	65366-65369	for	1	
433-5	65370-65371	a	2	
433-6	65372-65385	predominantly	_	
433-7	65386-65394	suburban	_	
433-8	65395-65396	,	_	
433-9	65397-65403	higher	_	
433-10	65404-65418	socio-economic	_	
433-11	65419-65425	status	_	
433-12	65426-65427	(	5	
433-13	65428-65431	SES	_	
433-14	65432-65433	)	1	
433-15	65434-65444	population	_	
433-16	65445-65446	.	1	

#Text=The centerline represents the median .
434-1	65447-65450	The	9	
434-2	65451-65461	centerline	1	
434-3	65462-65472	represents	8	
434-4	65473-65476	the	2	
434-5	65477-65483	median	_	
434-6	65484-65485	.	1	

#Text=Patients were followed until day   28 or hospital discharge , whichever occurred first ( with an additional safety follow-up visit at day 43 in the UK ) .
435-1	65486-65494	Patients	9	
435-2	65495-65499	were	8	
435-3	65500-65508	followed	_	
435-4	65509-65514	until	1	
435-5	65515-65518	day	2	
435-6	65519-65520	 	_	
435-7	65521-65523	28	1	
435-8	65524-65526	or	2	
435-9	65527-65535	hospital	_	
435-10	65536-65545	discharge	_	
435-11	65546-65547	,	1	
435-12	65548-65557	whichever	6	
435-13	65558-65566	occurred	3	
435-14	65567-65572	first	7	
435-15	65573-65574	(	5	
435-16	65575-65579	with	_	
435-17	65580-65582	an	_	
435-18	65583-65593	additional	_	
435-19	65594-65600	safety	_	
435-20	65601-65610	follow-up	_	
435-21	65611-65616	visit	_	
435-22	65617-65619	at	_	
435-23	65620-65623	day	_	
435-24	65624-65626	43	_	
435-25	65627-65629	in	_	
435-26	65630-65633	the	_	
435-27	65634-65636	UK	_	
435-28	65637-65638	)	_	
435-29	65639-65640	.	1	

#Text=LC-TOF-MS analysis was performed on an Agilent 6540 UHD Accurate Mass UHPLC-QTOFMSMS ( Agilent , Waldbronn , Germany ) .
436-1	65641-65650	LC-TOF-MS	9	
436-2	65651-65659	analysis	1	
436-3	65660-65663	was	8	
436-4	65664-65673	performed	_	
436-5	65674-65676	on	1	
436-6	65677-65679	an	2	
436-7	65680-65687	Agilent	_	
436-8	65688-65692	6540	_	
436-9	65693-65696	UHD	_	
436-10	65697-65705	Accurate	_	
436-11	65706-65710	Mass	_	
436-12	65711-65725	UHPLC-QTOFMSMS	1	
436-13	65726-65727	(	5	
436-14	65728-65735	Agilent	_	
436-15	65736-65737	,	_	
436-16	65738-65747	Waldbronn	_	
436-17	65748-65749	,	_	
436-18	65750-65757	Germany	_	
436-19	65758-65759	)	_	
436-20	65760-65761	.	1	

#Text=They could send the urine sample by mail in a freepost envelope or deliver it to the study site .
437-1	65762-65766	They	8	
437-2	65767-65772	could	_	
437-3	65773-65777	send	1	
437-4	65778-65781	the	2	
437-5	65782-65787	urine	_	
437-6	65788-65794	sample	1	
437-7	65795-65797	by	2	
437-8	65798-65802	mail	_	
437-9	65803-65805	in	_	
437-10	65806-65807	a	_	
437-11	65808-65816	freepost	_	
437-12	65817-65825	envelope	1	
437-13	65826-65828	or	3	
437-14	65829-65836	deliver	_	
437-15	65837-65839	it	_	
437-16	65840-65842	to	1	
437-17	65843-65846	the	2	
437-18	65847-65852	study	_	
437-19	65853-65857	site	_	
437-20	65858-65859	.	1	

#Text=Participants completed five maximal voluntary isometric muscle actions following a submaximal , isotonic warm-up and familiarization .
438-1	65860-65872	Participants	9	
438-2	65873-65882	completed	1	
438-3	65883-65887	five	2	
438-4	65888-65895	maximal	_	
438-5	65896-65905	voluntary	_	
438-6	65906-65915	isometric	_	
438-7	65916-65922	muscle	_	
438-8	65923-65930	actions	1	
438-9	65931-65940	following	3	
438-10	65941-65942	a	2	
438-11	65943-65953	submaximal	_	
438-12	65954-65955	,	_	
438-13	65956-65964	isotonic	_	
438-14	65965-65972	warm-up	_	
438-15	65973-65976	and	_	
438-16	65977-65992	familiarization	_	
438-17	65993-65994	.	1	

#Text=The diary was based on a previously validated version [ 17,18 ] .
439-1	65995-65998	The	9	
439-2	65999-66004	diary	1	
439-3	66005-66008	was	8	
439-4	66009-66014	based	_	
439-5	66015-66017	on	1	
439-6	66018-66019	a	2	
439-7	66020-66030	previously	_	
439-8	66031-66040	validated	_	
439-9	66041-66048	version	1	
439-10	66049-66050	[	5	
439-11	66051-66056	17,18	_	
439-12	66057-66058	]	_	
439-13	66059-66060	.	1	

#Text=Significant bacteriuria was defined according to current European guidelines for patients with symptoms of UTI as ≥103 /ml for primary pathogens , ≥104/ml for secondary pathogens , and ≥105/ml for doubtful pathogens [ 19 ] .
440-1	66061-66072	Significant	9	
440-2	66073-66084	bacteriuria	1	
440-3	66085-66088	was	8	
440-4	66089-66096	defined	_	
440-5	66097-66106	according	_	
440-6	66107-66109	to	1	
440-7	66110-66117	current	2	
440-8	66118-66126	European	_	
440-9	66127-66137	guidelines	_	
440-10	66138-66141	for	_	
440-11	66142-66150	patients	_	
440-12	66151-66155	with	_	
440-13	66156-66164	symptoms	_	
440-14	66165-66167	of	_	
440-15	66168-66171	UTI	1	
440-16	66172-66174	as	2	
440-17	66175-66176	≥	_	
440-18	66176-66179	103	_	
440-19	66180-66181	/	_	
440-20	66181-66183	ml	_	
440-21	66184-66187	for	_	
440-22	66188-66195	primary	_	
440-23	66196-66205	pathogens	_	
440-24	66206-66207	,	_	
440-25	66208-66209	≥	_	
440-26	66209-66212	104	_	
440-27	66212-66213	/	_	
440-28	66213-66215	ml	_	
440-29	66216-66219	for	_	
440-30	66220-66229	secondary	_	
440-31	66230-66239	pathogens	_	
440-32	66240-66241	,	_	
440-33	66242-66245	and	_	
440-34	66246-66247	≥	_	
440-35	66247-66250	105	_	
440-36	66250-66251	/	_	
440-37	66251-66253	ml	_	
440-38	66254-66257	for	_	
440-39	66258-66266	doubtful	_	
440-40	66267-66276	pathogens	1	
440-41	66277-66278	[	5	
440-42	66279-66281	19	_	
440-43	66282-66283	]	_	
440-44	66284-66285	.	1	

#Text=Mobility performance measures included those recommended by the Osteoarthritis Research Society International : the six-minute walk ( SMWT ) , 40-meter walk ( 40mW ) , 30-second chair stand ( 30sCS ) , timed up and go ( TUG ) , and stair ascent ( SA ) tests [ 35 ] .
441-1	66286-66294	Mobility	9	
441-2	66295-66306	performance	_	
441-3	66307-66315	measures	1	
441-4	66316-66324	included	8	
441-5	66325-66330	those	_	
441-6	66331-66342	recommended	_	
441-7	66343-66345	by	1	
441-8	66346-66349	the	2	
441-9	66350-66364	Osteoarthritis	_	
441-10	66365-66373	Research	_	
441-11	66374-66381	Society	_	
441-12	66382-66395	International	1	
441-13	66396-66397	:	6	
441-14	66398-66401	the	2	
441-15	66402-66412	six-minute	_	
441-16	66413-66417	walk	_	
441-17	66418-66419	(	5	
441-18	66420-66424	SMWT	_	
441-19	66425-66426	)	1	
441-20	66427-66428	,	_	
441-21	66429-66431	40	_	
441-22	66431-66432	-	_	
441-23	66432-66437	meter	_	
441-24	66438-66442	walk	_	
441-25	66443-66444	(	5	
441-26	66445-66449	40mW	_	
441-27	66450-66451	)	1	
441-28	66452-66453	,	_	
441-29	66454-66456	30	_	
441-30	66456-66457	-	_	
441-31	66457-66463	second	_	
441-32	66464-66469	chair	_	
441-33	66470-66475	stand	_	
441-34	66476-66477	(	5	
441-35	66478-66483	30sCS	_	
441-36	66484-66485	)	1	
441-37	66486-66487	,	_	
441-38	66488-66493	timed	_	
441-39	66494-66496	up	_	
441-40	66497-66500	and	_	
441-41	66501-66503	go	_	
441-42	66504-66505	(	5	
441-43	66506-66509	TUG	_	
441-44	66510-66511	)	1	
441-45	66512-66513	,	_	
441-46	66514-66517	and	_	
441-47	66518-66523	stair	_	
441-48	66524-66530	ascent	_	
441-49	66531-66532	(	5	
441-50	66533-66535	SA	_	
441-51	66536-66537	)	1	
441-52	66538-66543	tests	1	
441-53	66544-66545	[	5	
441-54	66546-66548	35	_	
441-55	66549-66550	]	_	
441-56	66551-66552	.	1	

#Text=To have 80 % power for superiority with regard to this primary outcome ( 2-sided significance level of 0.05 ) and noninferiority with a margin of indifference of 20 points using a 1-sided significance level of 0.05 ( 32 ) , and under the assumption of a 15 % dropout rate , the study required 90 patients in each treatment group .
442-1	66553-66555	To	3	
442-2	66556-66560	have	1	
442-3	66561-66563	80	2	
442-4	66564-66565	%	_	
442-5	66566-66571	power	_	
442-6	66572-66575	for	_	
442-7	66576-66587	superiority	_	
442-8	66588-66592	with	_	
442-9	66593-66599	regard	_	
442-10	66600-66602	to	_	
442-11	66603-66607	this	_	
442-12	66608-66615	primary	_	
442-13	66616-66623	outcome	1	
442-14	66624-66625	(	5	
442-15	66626-66627	2	_	
442-16	66627-66628	-	_	
442-17	66628-66633	sided	_	
442-18	66634-66646	significance	_	
442-19	66647-66652	level	_	
442-20	66653-66655	of	_	
442-21	66656-66660	0.05	_	
442-22	66661-66662	)	1	
442-23	66663-66666	and	3	
442-24	66667-66681	noninferiority	_	
442-25	66682-66686	with	_	
442-26	66687-66688	a	_	
442-27	66689-66695	margin	_	
442-28	66696-66698	of	_	
442-29	66699-66711	indifference	_	
442-30	66712-66714	of	_	
442-31	66715-66717	20	_	
442-32	66718-66724	points	1	
442-33	66725-66730	using	3	
442-34	66731-66732	a	2	
442-35	66733-66734	1	_	
442-36	66734-66735	-	_	
442-37	66735-66740	sided	_	
442-38	66741-66753	significance	_	
442-39	66754-66759	level	_	
442-40	66760-66762	of	_	
442-41	66763-66767	0.05	1	
442-42	66768-66769	(	5	
442-43	66770-66772	32	_	
442-44	66773-66774	)	_	
442-45	66775-66776	,	1	
442-46	66777-66780	and	2	
442-47	66781-66786	under	_	
442-48	66787-66790	the	_	
442-49	66791-66801	assumption	_	
442-50	66802-66804	of	_	
442-51	66805-66806	a	_	
442-52	66807-66809	15	_	
442-53	66810-66811	%	_	
442-54	66812-66819	dropout	_	
442-55	66820-66824	rate	_	
442-56	66825-66826	,	1	
442-57	66827-66830	the	9	
442-58	66831-66836	study	1	
442-59	66837-66845	required	8	
442-60	66846-66848	90	2	
442-61	66849-66857	patients	_	
442-62	66858-66860	in	_	
442-63	66861-66865	each	_	
442-64	66866-66875	treatment	_	
442-65	66876-66881	group	_	
442-66	66882-66883	.	1	

#Text=Participants were randomized to one of the three study interventions after stratification for disease severity .
443-1	66884-66896	Participants	9	
443-2	66897-66901	were	8	
443-3	66902-66912	randomized	_	
443-4	66913-66915	to	1	
443-5	66916-66919	one	2	
443-6	66920-66922	of	_	
443-7	66923-66926	the	_	
443-8	66927-66932	three	_	
443-9	66933-66938	study	_	
443-10	66939-66952	interventions	1	
443-11	66953-66958	after	2	
443-12	66959-66973	stratification	_	
443-13	66974-66977	for	_	
443-14	66978-66985	disease	_	
443-15	66986-66994	severity	_	
443-16	66995-66996	.	1	

#Text=All the symptoms described above were present in all the types of gastritis previously mentioned .
444-1	66997-67000	All	9	
444-2	67001-67004	the	_	
444-3	67005-67013	symptoms	1	
444-4	67014-67023	described	3	
444-5	67024-67029	above	1	
444-6	67030-67034	were	8	
444-7	67035-67042	present	_	
444-8	67043-67045	in	1	
444-9	67046-67049	all	2	
444-10	67050-67053	the	_	
444-11	67054-67059	types	_	
444-12	67060-67062	of	_	
444-13	67063-67072	gastritis	_	
444-14	67073-67083	previously	_	
444-15	67084-67093	mentioned	_	
444-16	67094-67095	.	1	

#Text=The Benjamini – Hochberg method was used to correct for statistical multiplicity .
445-1	67096-67099	The	9	
445-2	67100-67109	Benjamini	_	
445-3	67110-67111	–	_	
445-4	67112-67120	Hochberg	_	
445-5	67121-67127	method	1	
445-6	67128-67131	was	8	
445-7	67132-67136	used	_	
445-8	67137-67139	to	_	
445-9	67140-67147	correct	_	
445-10	67148-67151	for	1	
445-11	67152-67163	statistical	2	
445-12	67164-67176	multiplicity	_	
445-13	67177-67178	.	1	

#Text=Consequently , the primary efficacy estimate is reported with a 90 % confidence interval .
446-1	67179-67191	Consequently	6	
446-2	67192-67193	,	1	
446-3	67194-67197	the	9	
446-4	67198-67205	primary	_	
446-5	67206-67214	efficacy	_	
446-6	67215-67223	estimate	1	
446-7	67224-67226	is	8	
446-8	67227-67235	reported	_	
446-9	67236-67240	with	1	
446-10	67241-67242	a	2	
446-11	67243-67245	90	_	
446-12	67246-67247	%	_	
446-13	67248-67258	confidence	_	
446-14	67259-67267	interval	_	
446-15	67268-67269	.	1	

#Text=A urine sample was sent to the local microbiology laboratory for culturing .
447-1	67270-67271	A	9	
447-2	67272-67277	urine	_	
447-3	67278-67284	sample	1	
447-4	67285-67288	was	8	
447-5	67289-67293	sent	_	
447-6	67294-67296	to	1	
447-7	67297-67300	the	2	
447-8	67301-67306	local	_	
447-9	67307-67319	microbiology	_	
447-10	67320-67330	laboratory	1	
447-11	67331-67334	for	2	
447-12	67335-67344	culturing	_	
447-13	67345-67346	.	1	

#Text=The safety and efficacy of the trial was monitored by a data safety monitoring board consisting of three independent , non-participating clinicians and an independent epidemiologist .
448-1	67347-67350	The	9	
448-2	67351-67357	safety	_	
448-3	67358-67361	and	_	
448-4	67362-67370	efficacy	_	
448-5	67371-67373	of	_	
448-6	67374-67377	the	_	
448-7	67378-67383	trial	1	
448-8	67384-67387	was	8	
448-9	67388-67397	monitored	_	
448-10	67398-67400	by	1	
448-11	67401-67402	a	2	
448-12	67403-67407	data	_	
448-13	67408-67414	safety	_	
448-14	67415-67425	monitoring	_	
448-15	67426-67431	board	1	
448-16	67432-67442	consisting	3	
448-17	67443-67445	of	1	
448-18	67446-67451	three	2	
448-19	67452-67463	independent	_	
448-20	67464-67465	,	_	
448-21	67466-67483	non-participating	_	
448-22	67484-67494	clinicians	_	
448-23	67495-67498	and	_	
448-24	67499-67501	an	_	
448-25	67502-67513	independent	_	
448-26	67514-67528	epidemiologist	_	
448-27	67529-67530	.	1	

#Text=Secondary outcomes included muscle strength , symptoms of depression , and health-related quality of life .
449-1	67531-67540	Secondary	9	
449-2	67541-67549	outcomes	1	
449-3	67550-67558	included	3	
449-4	67559-67565	muscle	2	
449-5	67566-67574	strength	_	
449-6	67575-67576	,	_	
449-7	67577-67585	symptoms	_	
449-8	67586-67588	of	_	
449-9	67589-67599	depression	_	
449-10	67600-67601	,	_	
449-11	67602-67605	and	_	
449-12	67606-67620	health-related	_	
449-13	67621-67628	quality	_	
449-14	67629-67631	of	_	
449-15	67632-67636	life	_	
449-16	67637-67638	.	1	

#Text=The first of these showed an 80-point improvement in pain for physical therapy strength training compared with an attention control ( 31 ) , and the second ( our pilot trial [ 12 ] ) found a 150-point improvement in pain for the Tai Chi group .
450-1	67639-67642	The	8	
450-2	67643-67648	first	_	
450-3	67649-67651	of	_	
450-4	67652-67657	these	_	
450-5	67658-67664	showed	1	
450-6	67665-67667	an	2	
450-7	67668-67670	80	_	
450-8	67670-67671	-	_	
450-9	67671-67676	point	_	
450-10	67677-67688	improvement	_	
450-11	67689-67691	in	_	
450-12	67692-67696	pain	_	
450-13	67697-67700	for	_	
450-14	67701-67709	physical	_	
450-15	67710-67717	therapy	_	
450-16	67718-67726	strength	_	
450-17	67727-67735	training	1	
450-18	67736-67744	compared	3	
450-19	67745-67749	with	1	
450-20	67750-67752	an	2	
450-21	67753-67762	attention	_	
450-22	67763-67770	control	_	
450-23	67771-67772	(	5	
450-24	67773-67775	31	_	
450-25	67776-67777	)	_	
450-26	67778-67779	,	1	
450-27	67780-67783	and	3	
450-28	67784-67787	the	_	
450-29	67788-67794	second	_	
450-30	67795-67796	(	5	
450-31	67797-67800	our	_	
450-32	67801-67806	pilot	_	
450-33	67807-67812	trial	_	
450-34	67813-67814	[	_	
450-35	67815-67817	12	_	
450-36	67818-67819	]	_	
450-37	67820-67821	)	1	
450-38	67822-67827	found	1	
450-39	67828-67829	a	2	
450-40	67830-67833	150	_	
450-41	67833-67834	-	_	
450-42	67834-67839	point	_	
450-43	67840-67851	improvement	_	
450-44	67852-67854	in	_	
450-45	67855-67859	pain	_	
450-46	67860-67863	for	_	
450-47	67864-67867	the	_	
450-48	67868-67871	Tai	_	
450-49	67872-67875	Chi	_	
450-50	67876-67881	group	_	
450-51	67882-67883	.	1	

#Text=A group-sequential adaptive design was chosen that allowed modifications , such as sample size re-estimation or planning of further analyses based on interim results .
451-1	67884-67885	A	9	
451-2	67886-67902	group-sequential	_	
451-3	67903-67911	adaptive	_	
451-4	67912-67918	design	1	
451-5	67919-67922	was	8	
451-6	67923-67929	chosen	1	
451-7	67930-67934	that	6	
451-8	67935-67942	allowed	3	
451-9	67943-67956	modifications	2	
451-10	67957-67958	,	_	
451-11	67959-67963	such	_	
451-12	67964-67966	as	_	
451-13	67967-67973	sample	_	
451-14	67974-67978	size	_	
451-15	67979-67992	re-estimation	_	
451-16	67993-67995	or	_	
451-17	67996-68004	planning	_	
451-18	68005-68007	of	_	
451-19	68008-68015	further	_	
451-20	68016-68024	analyses	_	
451-21	68025-68030	based	_	
451-22	68031-68033	on	_	
451-23	68034-68041	interim	_	
451-24	68042-68049	results	_	
451-25	68050-68051	.	1	

#Text=This was a prospective , randomized , investigator blind trial that included children ages 6 to 24 months with AOM enrolled from two sites .
452-1	68052-68056	This	8	
452-2	68057-68060	was	1	
452-3	68061-68062	a	2	
452-4	68063-68074	prospective	_	
452-5	68075-68076	,	_	
452-6	68077-68087	randomized	_	
452-7	68088-68089	,	_	
452-8	68090-68102	investigator	_	
452-9	68103-68108	blind	_	
452-10	68109-68114	trial	1	
452-11	68115-68119	that	6	
452-12	68120-68128	included	3	
452-13	68129-68137	children	2	
452-14	68138-68142	ages	_	
452-15	68143-68144	6	_	
452-16	68145-68147	to	_	
452-17	68148-68150	24	_	
452-18	68151-68157	months	_	
452-19	68158-68162	with	_	
452-20	68163-68166	AOM	_	
452-21	68167-68175	enrolled	_	
452-22	68176-68180	from	_	
452-23	68181-68184	two	_	
452-24	68185-68190	sites	_	
452-25	68191-68192	.	1	

#Text=The trial by Gagyor et al. was published in December 2015 [ 14 ] .
453-1	68193-68196	The	9	
453-2	68197-68202	trial	_	
453-3	68203-68205	by	_	
453-4	68206-68212	Gagyor	_	
453-5	68213-68215	et	_	
453-6	68216-68218	al	_	
453-7	68218-68219	.	1	
453-8	68220-68223	was	8	
453-9	68224-68233	published	_	
453-10	68234-68236	in	1	
453-11	68237-68245	December	2	
453-12	68246-68250	2015	1	
453-13	68251-68252	[	5	
453-14	68253-68255	14	_	
453-15	68256-68257	]	_	
453-16	68258-68259	.	1	

#Text=The use of general anesthesia was discouraged , and intraarterial tissue plasminogen activator ( t-PA ) was not allowed ( intravenous t-PA was allowed if begun within 4.5 hours after symptom onset ) .
454-1	68260-68263	The	9	
454-2	68264-68267	use	_	
454-3	68268-68270	of	_	
454-4	68271-68278	general	_	
454-5	68279-68289	anesthesia	1	
454-6	68290-68293	was	8	
454-7	68294-68305	discouraged	_	
454-8	68306-68307	,	1	
454-9	68308-68311	and	9	
454-10	68312-68325	intraarterial	_	
454-11	68326-68332	tissue	_	
454-12	68333-68344	plasminogen	_	
454-13	68345-68354	activator	1	
454-14	68355-68356	(	5	
454-15	68357-68361	t-PA	_	
454-16	68362-68363	)	1	
454-17	68364-68367	was	3	
454-18	68368-68371	not	_	
454-19	68372-68379	allowed	1	
454-20	68380-68381	(	5	
454-21	68382-68393	intravenous	_	
454-22	68394-68398	t-PA	_	
454-23	68399-68402	was	_	
454-24	68403-68410	allowed	_	
454-25	68411-68413	if	_	
454-26	68414-68419	begun	_	
454-27	68420-68426	within	_	
454-28	68427-68430	4.5	_	
454-29	68431-68436	hours	_	
454-30	68437-68442	after	_	
454-31	68443-68450	symptom	_	
454-32	68451-68456	onset	_	
454-33	68457-68458	)	_	
454-34	68459-68460	.	1	

#Text=A systematic review of yoga as a therapeutic intervention for adults with chronic pain concluded yoga is capable of reducing pain by a standard mean difference of -0.74 ( 95 % CI , -0.97 to -0.52 ; P < 0.0001 ) [ 19 ] .
455-1	68461-68462	A	9	
455-2	68463-68473	systematic	_	
455-3	68474-68480	review	_	
455-4	68481-68483	of	_	
455-5	68484-68488	yoga	_	
455-6	68489-68491	as	_	
455-7	68492-68493	a	_	
455-8	68494-68505	therapeutic	_	
455-9	68506-68518	intervention	_	
455-10	68519-68522	for	_	
455-11	68523-68529	adults	_	
455-12	68530-68534	with	_	
455-13	68535-68542	chronic	_	
455-14	68543-68547	pain	1	
455-15	68548-68557	concluded	8	
455-16	68558-68562	yoga	2	
455-17	68563-68565	is	3	
455-18	68566-68573	capable	_	
455-19	68574-68576	of	_	
455-20	68577-68585	reducing	1	
455-21	68586-68590	pain	2	
455-22	68591-68593	by	2	
455-23	68594-68595	a	_	
455-24	68596-68604	standard	_	
455-25	68605-68609	mean	_	
455-26	68610-68620	difference	_	
455-27	68621-68623	of	_	
455-28	68624-68625	-	_	
455-29	68625-68629	0.74	1	
455-30	68630-68631	(	5	
455-31	68632-68634	95	_	
455-32	68635-68636	%	_	
455-33	68637-68639	CI	_	
455-34	68640-68641	,	_	
455-35	68642-68643	-	_	
455-36	68643-68647	0.97	_	
455-37	68648-68650	to	_	
455-38	68651-68652	-	_	
455-39	68652-68656	0.52	_	
455-40	68657-68658	;	_	
455-41	68659-68660	P	_	
455-42	68661-68662	<	_	
455-43	68663-68669	0.0001	_	
455-44	68670-68671	)	1	
455-45	68672-68673	[	5	
455-46	68674-68676	19	_	
455-47	68677-68678	]	_	
455-48	68679-68680	.	1	

#Text=Data distribution was assessed visually and using Shapiro-Wilk tests ; homoscedasticity was assessed using Levene ’s test for equality of error variance ; independence of covariate and treatment effect was assessed using a one-way analysis of variance ( ANOVA ) ; and homogeneity of regression slopes of covariates versus dependent variables was assessed visually and by testing group allocation by baseline score interactions in an ANOVA .
456-1	68681-68685	Data	9	
456-2	68686-68698	distribution	1	
456-3	68699-68702	was	8	
456-4	68703-68711	assessed	_	
456-5	68712-68720	visually	_	
456-6	68721-68724	and	_	
456-7	68725-68730	using	1	
456-8	68731-68743	Shapiro-Wilk	2	
456-9	68744-68749	tests	1	
456-10	68750-68751	;	6	
456-11	68752-68768	homoscedasticity	2	
456-12	68769-68772	was	3	
456-13	68773-68781	assessed	_	
456-14	68782-68787	using	1	
456-15	68788-68794	Levene	2	
456-16	68795-68796	’	_	
456-17	68796-68797	s	_	
456-18	68798-68802	test	_	
456-19	68803-68806	for	_	
456-20	68807-68815	equality	_	
456-21	68816-68818	of	_	
456-22	68819-68824	error	_	
456-23	68825-68833	variance	1	
456-24	68834-68835	;	6	
456-25	68836-68848	independence	2	
456-26	68849-68851	of	_	
456-27	68852-68861	covariate	_	
456-28	68862-68865	and	_	
456-29	68866-68875	treatment	_	
456-30	68876-68882	effect	1	
456-31	68883-68886	was	3	
456-32	68887-68895	assessed	_	
456-33	68896-68901	using	1	
456-34	68902-68903	a	2	
456-35	68904-68911	one-way	_	
456-36	68912-68920	analysis	_	
456-37	68921-68923	of	_	
456-38	68924-68932	variance	1	
456-39	68933-68934	(	5	
456-40	68935-68940	ANOVA	_	
456-41	68941-68942	)	1	
456-42	68943-68944	;	6	
456-43	68945-68948	and	2	
456-44	68949-68960	homogeneity	_	
456-45	68961-68963	of	_	
456-46	68964-68974	regression	_	
456-47	68975-68981	slopes	_	
456-48	68982-68984	of	_	
456-49	68985-68995	covariates	_	
456-50	68996-69002	versus	_	
456-51	69003-69012	dependent	_	
456-52	69013-69022	variables	1	
456-53	69023-69026	was	9	
456-54	69027-69035	assessed	_	
456-55	69036-69044	visually	_	
456-56	69045-69048	and	_	
456-57	69049-69051	by	_	
456-58	69052-69059	testing	1	
456-59	69060-69065	group	2	
456-60	69066-69076	allocation	1	
456-61	69077-69079	by	2	
456-62	69080-69088	baseline	_	
456-63	69089-69094	score	_	
456-64	69095-69107	interactions	1	
456-65	69108-69110	in	2	
456-66	69111-69113	an	_	
456-67	69114-69119	ANOVA	_	
456-68	69120-69121	.	1	

#Text=The separation was performed by HILIC as described previously [ 15 ] .
457-1	69122-69125	The	9	
457-2	69126-69136	separation	1	
457-3	69137-69140	was	8	
457-4	69141-69150	performed	_	
457-5	69151-69153	by	1	
457-6	69154-69159	HILIC	2	
457-7	69160-69162	as	3	
457-8	69163-69172	described	_	
457-9	69173-69183	previously	1	
457-10	69184-69185	[	5	
457-11	69186-69188	15	_	
457-12	69189-69190	]	_	
457-13	69191-69192	.	1	

#Text=The quadriceps were targeted at every session .
458-1	69193-69196	The	9	
458-2	69197-69207	quadriceps	1	
458-3	69208-69212	were	8	
458-4	69213-69221	targeted	_	
458-5	69222-69224	at	1	
458-6	69225-69230	every	2	
458-7	69231-69238	session	_	
458-8	69239-69240	.	1	

#Text=This 52-week , single-blind , randomized , comparative effectiveness trial recruited participants with symptomatic and radiographic knee osteoarthritis .
459-1	69241-69245	This	9	
459-2	69246-69248	52	_	
459-3	69248-69249	-	_	
459-4	69249-69253	week	_	
459-5	69254-69255	,	_	
459-6	69256-69268	single-blind	_	
459-7	69269-69270	,	_	
459-8	69271-69281	randomized	_	
459-9	69282-69283	,	_	
459-10	69284-69295	comparative	_	
459-11	69296-69309	effectiveness	_	
459-12	69310-69315	trial	1	
459-13	69316-69325	recruited	8	
459-14	69326-69338	participants	2	
459-15	69339-69343	with	_	
459-16	69344-69355	symptomatic	_	
459-17	69356-69359	and	_	
459-18	69360-69372	radiographic	_	
459-19	69373-69377	knee	_	
459-20	69378-69392	osteoarthritis	_	
459-21	69393-69394	.	1	

#Text=Subgroup analyses compared the patients with positive baseline urine cultures to those with negative cultures within the 2 treatment groups , both with regards to symptom load and duration of symptoms .
460-1	69395-69403	Subgroup	9	
460-2	69404-69412	analyses	1	
460-3	69413-69421	compared	8	
460-4	69422-69425	the	2	
460-5	69426-69434	patients	_	
460-6	69435-69439	with	_	
460-7	69440-69448	positive	_	
460-8	69449-69457	baseline	_	
460-9	69458-69463	urine	_	
460-10	69464-69472	cultures	1	
460-11	69473-69475	to	2	
460-12	69476-69481	those	_	
460-13	69482-69486	with	_	
460-14	69487-69495	negative	_	
460-15	69496-69504	cultures	1	
460-16	69505-69511	within	2	
460-17	69512-69515	the	_	
460-18	69516-69517	2	_	
460-19	69518-69527	treatment	_	
460-20	69528-69534	groups	_	
460-21	69535-69536	,	1	
460-22	69537-69541	both	2	
460-23	69542-69546	with	_	
460-24	69547-69554	regards	_	
460-25	69555-69557	to	_	
460-26	69558-69565	symptom	_	
460-27	69566-69570	load	_	
460-28	69571-69574	and	_	
460-29	69575-69583	duration	_	
460-30	69584-69586	of	_	
460-31	69587-69595	symptoms	_	
460-32	69596-69597	.	1	

#Text=Follow-up took place at the outpatient clinic three weeks after discharge and subsequently by a phone call once every month for one year .
461-1	69598-69607	Follow-up	9	
461-2	69608-69612	took	8	
461-3	69613-69618	place	_	
461-4	69619-69621	at	1	
461-5	69622-69625	the	2	
461-6	69626-69636	outpatient	_	
461-7	69637-69643	clinic	1	
461-8	69644-69649	three	2	
461-9	69650-69655	weeks	_	
461-10	69656-69661	after	_	
461-11	69662-69671	discharge	1	
461-12	69672-69675	and	6	
461-13	69676-69688	subsequently	_	
461-14	69689-69691	by	1	
461-15	69692-69693	a	2	
461-16	69694-69699	phone	_	
461-17	69700-69704	call	1	
461-18	69705-69709	once	2	
461-19	69710-69715	every	_	
461-20	69716-69721	month	_	
461-21	69722-69725	for	_	
461-22	69726-69729	one	_	
461-23	69730-69734	year	_	
461-24	69735-69736	.	1	

#Text=Following the randomization list , Kragerø Tablettproduksjon distributed the study medicine to each study site , where it was kept in a locked facility .
462-1	69737-69746	Following	3	
462-2	69747-69750	the	2	
462-3	69751-69764	randomization	_	
462-4	69765-69769	list	_	
462-5	69770-69771	,	1	
462-6	69772-69779	Kragerø	9	
462-7	69780-69797	Tablettproduksjon	1	
462-8	69798-69809	distributed	8	
462-9	69810-69813	the	2	
462-10	69814-69819	study	_	
462-11	69820-69828	medicine	1	
462-12	69829-69831	to	2	
462-13	69832-69836	each	_	
462-14	69837-69842	study	_	
462-15	69843-69847	site	_	
462-16	69848-69849	,	1	
462-17	69850-69855	where	6	
462-18	69856-69858	it	2	
462-19	69859-69862	was	_	
462-20	69863-69867	kept	_	
462-21	69868-69870	in	1	
462-22	69871-69872	a	2	
462-23	69873-69879	locked	_	
462-24	69880-69888	facility	_	
462-25	69889-69890	.	1	

#Text=Both the KOOS and ICOAP produce valid and reliable data in adults with knee OA [ 32,33 ] .
463-1	69891-69895	Both	9	
463-2	69896-69899	the	_	
463-3	69900-69904	KOOS	_	
463-4	69905-69908	and	_	
463-5	69909-69914	ICOAP	1	
463-6	69915-69922	produce	8	
463-7	69923-69928	valid	2	
463-8	69929-69932	and	_	
463-9	69933-69941	reliable	_	
463-10	69942-69946	data	_	
463-11	69947-69949	in	_	
463-12	69950-69956	adults	_	
463-13	69957-69961	with	_	
463-14	69962-69966	knee	_	
463-15	69967-69969	OA	1	
463-16	69970-69971	[	5	
463-17	69972-69977	32,33	_	
463-18	69978-69979	]	_	
463-19	69980-69981	.	1	

#Text=These sessions included non-physically active somatic awareness exercises including breath and body-scan meditation practices performed in passive postures fully supported by the use of yoga props .
464-1	69982-69987	These	9	
464-2	69988-69996	sessions	1	
464-3	69997-70005	included	2	
464-4	70006-70020	non-physically	2	
464-5	70021-70027	active	_	
464-6	70028-70035	somatic	_	
464-7	70036-70045	awareness	_	
464-8	70046-70055	exercises	1	
464-9	70056-70065	including	3	
464-10	70066-70072	breath	2	
464-11	70073-70076	and	_	
464-12	70077-70086	body-scan	_	
464-13	70087-70097	meditation	_	
464-14	70098-70107	practices	1	
464-15	70108-70117	performed	3	
464-16	70118-70120	in	1	
464-17	70121-70128	passive	2	
464-18	70129-70137	postures	1	
464-19	70138-70143	fully	3	
464-20	70144-70153	supported	_	
464-21	70154-70156	by	1	
464-22	70157-70160	the	2	
464-23	70161-70164	use	_	
464-24	70165-70167	of	_	
464-25	70168-70172	yoga	_	
464-26	70173-70178	props	_	
464-27	70179-70180	.	1	

#Text=The blinded assessors did not have access to the data until data collection was complete .
465-1	70181-70184	The	9	
465-2	70185-70192	blinded	_	
465-3	70193-70202	assessors	1	
465-4	70203-70206	did	2	
465-5	70207-70210	not	_	
465-6	70211-70215	have	1	
465-7	70216-70222	access	2	
465-8	70223-70225	to	_	
465-9	70226-70229	the	_	
465-10	70230-70234	data	1	
465-11	70235-70240	until	6	
465-12	70241-70245	data	9	
465-13	70246-70256	collection	1	
465-14	70257-70260	was	8	
465-15	70261-70269	complete	7	
465-16	70270-70271	.	1	

#Text=The exclusion criteria were added when a patient with Crohn 's disease wanted to be enrolled in the study .
466-1	70272-70275	The	9	
466-2	70276-70285	exclusion	_	
466-3	70286-70294	criteria	1	
466-4	70295-70299	were	8	
466-5	70300-70305	added	1	
466-6	70306-70310	when	6	
466-7	70311-70312	a	9	
466-8	70313-70320	patient	_	
466-9	70321-70325	with	_	
466-10	70326-70331	Crohn	_	
466-11	70332-70333	'	_	
466-12	70333-70334	s	_	
466-13	70335-70342	disease	1	
466-14	70343-70349	wanted	3	
466-15	70350-70352	to	_	
466-16	70353-70355	be	_	
466-17	70356-70364	enrolled	_	
466-18	70365-70367	in	1	
466-19	70368-70371	the	2	
466-20	70372-70377	study	_	
466-21	70378-70379	.	1	

#Text=There was a progressive increase in the number of sets and resistance during strengthening exercises over the course of the intervention .
467-1	70380-70385	There	8	
467-2	70386-70389	was	_	
467-3	70390-70391	a	_	
467-4	70392-70403	progressive	_	
467-5	70404-70412	increase	_	
467-6	70413-70415	in	_	
467-7	70416-70419	the	_	
467-8	70420-70426	number	_	
467-9	70427-70429	of	_	
467-10	70430-70434	sets	_	
467-11	70435-70438	and	_	
467-12	70439-70449	resistance	1	
467-13	70450-70456	during	2	
467-14	70457-70470	strengthening	_	
467-15	70471-70480	exercises	1	
467-16	70481-70485	over	2	
467-17	70486-70489	the	_	
467-18	70490-70496	course	_	
467-19	70497-70499	of	_	
467-20	70500-70503	the	_	
467-21	70504-70516	intervention	_	
467-22	70517-70518	.	1	

#Text=Data management , oversight of site monitoring , and interim statistical analysis were performed by the NIH StrokeNet National Data Management Center at the Medical University of South Carolina .
468-1	70519-70523	Data	9	
468-2	70524-70534	management	_	
468-3	70535-70536	,	_	
468-4	70537-70546	oversight	_	
468-5	70547-70549	of	_	
468-6	70550-70554	site	_	
468-7	70555-70565	monitoring	_	
468-8	70566-70567	,	_	
468-9	70568-70571	and	_	
468-10	70572-70579	interim	_	
468-11	70580-70591	statistical	_	
468-12	70592-70600	analysis	1	
468-13	70601-70605	were	8	
468-14	70606-70615	performed	_	
468-15	70616-70618	by	1	
468-16	70619-70622	the	2	
468-17	70623-70626	NIH	_	
468-18	70627-70636	StrokeNet	_	
468-19	70637-70645	National	_	
468-20	70646-70650	Data	_	
468-21	70651-70661	Management	_	
468-22	70662-70668	Center	1	
468-23	70669-70671	at	2	
468-24	70672-70675	the	_	
468-25	70676-70683	Medical	_	
468-26	70684-70694	University	_	
468-27	70695-70697	of	_	
468-28	70698-70703	South	_	
468-29	70704-70712	Carolina	_	
468-30	70713-70714	.	1	

#Text=Quality of life was assessed using the four-item knee related quality of life ( QoL ) subscale of the KOOS .
469-1	70715-70722	Quality	9	
469-2	70723-70725	of	_	
469-3	70726-70730	life	1	
469-4	70731-70734	was	8	
469-5	70735-70743	assessed	_	
469-6	70744-70749	using	1	
469-7	70750-70753	the	2	
469-8	70754-70763	four-item	_	
469-9	70764-70768	knee	_	
469-10	70769-70776	related	_	
469-11	70777-70784	quality	_	
469-12	70785-70787	of	_	
469-13	70788-70792	life	_	
469-14	70793-70794	(	5	
469-15	70795-70798	QoL	_	
469-16	70799-70800	)	1	
469-17	70801-70809	subscale	_	
469-18	70810-70812	of	_	
469-19	70813-70816	the	_	
469-20	70817-70821	KOOS	_	
469-21	70822-70823	.	2	

#Text=The sample size calculation was based on an expected reduction in the primary endpoints from 28 % in the percutaneous drainage group to 15 % in the cholecystectomy group.
470-1	70824-70827	The	9	
470-2	70828-70834	sample	_	
470-3	70835-70839	size	_	
470-4	70840-70851	calculation	1	
470-5	70852-70855	was	8	
470-6	70856-70861	based	_	
470-7	70862-70864	on	1	
470-8	70865-70867	an	2	
470-9	70868-70876	expected	_	
470-10	70877-70886	reduction	_	
470-11	70887-70889	in	_	
470-12	70890-70893	the	_	
470-13	70894-70901	primary	_	
470-14	70902-70911	endpoints	_	
470-15	70912-70916	from	_	
470-16	70917-70919	28	_	
470-17	70920-70921	%	_	
470-18	70922-70924	in	_	
470-19	70925-70928	the	_	
470-20	70929-70941	percutaneous	_	
470-21	70942-70950	drainage	_	
470-22	70951-70956	group	_	
470-23	70957-70959	to	_	
470-24	70960-70962	15	_	
470-25	70963-70964	%	_	
470-26	70965-70967	in	_	
470-27	70968-70971	the	_	
470-28	70972-70987	cholecystectomy	_	
470-29	70988-70993	group	_	
470-30	70993-70994	.	1	

#Text=Four subsets were identified for use in the post hoc analyses : patients with baseline levels of ≥   70   mg/L CRP ( high CRP ) ,   ≤   0.8   g/L IgM ( low IgM ) , CRP   ≥   70   mg/L and   ≤   0.8   g/L IgM ( combined high CRP/low IgM ) , and   ≥   2   ng/mL procalcitonin ( high procalcitonin [ PCT ] ) .
471-1	70995-70999	Four	9	
471-2	71000-71007	subsets	1	
471-3	71008-71012	were	8	
471-4	71013-71023	identified	_	
471-5	71024-71027	for	1	
471-6	71028-71031	use	2	
471-7	71032-71034	in	_	
471-8	71035-71038	the	_	
471-9	71039-71043	post	_	
471-10	71044-71047	hoc	_	
471-11	71048-71056	analyses	1	
471-12	71057-71058	:	6	
471-13	71059-71067	patients	_	
471-14	71068-71072	with	_	
471-15	71073-71081	baseline	_	
471-16	71082-71088	levels	_	
471-17	71089-71091	of	_	
471-18	71092-71093	≥	_	
471-19	71096-71098	70	_	
471-20	71099-71100	 	_	
471-21	71101-71103	mg	_	
471-22	71103-71104	/	_	
471-23	71104-71105	L	_	
471-24	71106-71109	CRP	_	
471-25	71110-71111	(	5	
471-26	71112-71116	high	_	
471-27	71117-71120	CRP	_	
471-28	71121-71122	)	1	
471-29	71123-71124	,	_	
471-30	71127-71128	≤	_	
471-31	71131-71134	0.8	_	
471-32	71135-71136	 	_	
471-33	71137-71138	g	_	
471-34	71138-71139	/	_	
471-35	71139-71140	L	_	
471-36	71141-71144	IgM	_	
471-37	71145-71146	(	5	
471-38	71147-71150	low	_	
471-39	71151-71154	IgM	_	
471-40	71155-71156	)	1	
471-41	71157-71158	,	_	
471-42	71159-71162	CRP	_	
471-43	71165-71166	≥	_	
471-44	71169-71171	70	_	
471-45	71172-71173	 	_	
471-46	71174-71176	mg	_	
471-47	71176-71177	/	_	
471-48	71177-71178	L	_	
471-49	71179-71182	and	_	
471-50	71185-71186	≤	_	
471-51	71189-71192	0.8	_	
471-52	71193-71194	 	_	
471-53	71195-71196	g	_	
471-54	71196-71197	/	_	
471-55	71197-71198	L	_	
471-56	71199-71202	IgM	_	
471-57	71203-71204	(	5	
471-58	71205-71213	combined	_	
471-59	71214-71218	high	_	
471-60	71219-71222	CRP	_	
471-61	71222-71223	/	_	
471-62	71223-71226	low	_	
471-63	71227-71230	IgM	_	
471-64	71231-71232	)	1	
471-65	71233-71234	,	_	
471-66	71235-71238	and	_	
471-67	71241-71242	≥	_	
471-68	71245-71246	2	_	
471-69	71247-71248	 	_	
471-70	71249-71251	ng	_	
471-71	71251-71252	/	_	
471-72	71252-71254	mL	_	
471-73	71255-71268	procalcitonin	_	
471-74	71269-71270	(	5	
471-75	71271-71275	high	_	
471-76	71276-71289	procalcitonin	_	
471-77	71290-71291	[	_	
471-78	71292-71295	PCT	_	
471-79	71296-71297	]	_	
471-80	71298-71299	)	1	
471-81	71300-71301	.	1	

#Text=The monitors visited the study sites at the start of the pilot and after the pilot , and made 1 or 2 visits during the study and a final visit when all patient follow-up was done .
472-1	71302-71305	The	9	
472-2	71306-71314	monitors	1	
472-3	71315-71322	visited	8	
472-4	71323-71326	the	2	
472-5	71327-71332	study	_	
472-6	71333-71338	sites	1	
472-7	71339-71341	at	2	
472-8	71342-71345	the	_	
472-9	71346-71351	start	_	
472-10	71352-71354	of	_	
472-11	71355-71358	the	_	
472-12	71359-71364	pilot	_	
472-13	71365-71368	and	_	
472-14	71369-71374	after	_	
472-15	71375-71378	the	_	
472-16	71379-71384	pilot	_	
472-17	71385-71386	,	1	
472-18	71387-71390	and	3	
472-19	71391-71395	made	1	
472-20	71396-71397	1	2	
472-21	71398-71400	or	_	
472-22	71401-71402	2	_	
472-23	71403-71409	visits	_	
472-24	71410-71416	during	_	
472-25	71417-71420	the	_	
472-26	71421-71426	study	1	
472-27	71427-71430	and	2	
472-28	71431-71432	a	_	
472-29	71433-71438	final	_	
472-30	71439-71444	visit	1	
472-31	71445-71449	when	6	
472-32	71450-71453	all	9	
472-33	71454-71461	patient	_	
472-34	71462-71471	follow-up	1	
472-35	71472-71475	was	3	
472-36	71476-71480	done	_	
472-37	71481-71482	.	1	

#Text=The NE intervention consisted of group-based , guided meditative relaxation classes led by a certified yoga-instructor .
473-1	71483-71486	The	9	
473-2	71487-71489	NE	_	
473-3	71490-71502	intervention	1	
473-4	71503-71512	consisted	8	
473-5	71513-71515	of	1	
473-6	71516-71527	group-based	2	
473-7	71528-71529	,	_	
473-8	71530-71536	guided	_	
473-9	71537-71547	meditative	_	
473-10	71548-71558	relaxation	_	
473-11	71559-71566	classes	_	
473-12	71567-71570	led	_	
473-13	71571-71573	by	_	
473-14	71574-71575	a	_	
473-15	71576-71585	certified	_	
473-16	71586-71601	yoga-instructor	_	
473-17	71602-71603	.	1	

#Text=We chose this cut-off on the basis of systematic evaluation of several imaginary case scenarios by a multicentre , multidisciplinary expert panel of surgeons , gastroenterologists , and radiologists .
474-1	71604-71606	We	8	
474-2	71607-71612	chose	1	
474-3	71613-71617	this	2	
474-4	71618-71625	cut-off	1	
474-5	71626-71628	on	2	
474-6	71629-71632	the	_	
474-7	71633-71638	basis	_	
474-8	71639-71641	of	_	
474-9	71642-71652	systematic	_	
474-10	71653-71663	evaluation	_	
474-11	71664-71666	of	_	
474-12	71667-71674	several	_	
474-13	71675-71684	imaginary	_	
474-14	71685-71689	case	_	
474-15	71690-71699	scenarios	1	
474-16	71700-71702	by	2	
474-17	71703-71704	a	_	
474-18	71705-71716	multicentre	_	
474-19	71717-71718	,	_	
474-20	71719-71736	multidisciplinary	_	
474-21	71737-71743	expert	_	
474-22	71744-71749	panel	_	
474-23	71750-71752	of	_	
474-24	71753-71761	surgeons	_	
474-25	71762-71763	,	_	
474-26	71764-71783	gastroenterologists	_	
474-27	71784-71785	,	_	
474-28	71786-71789	and	_	
474-29	71790-71802	radiologists	_	
474-30	71803-71804	.	1	

#Text=All patients received oral and written information about the trial and signed an informed consent form .
475-1	71805-71808	All	9	
475-2	71809-71817	patients	1	
475-3	71818-71826	received	8	
475-4	71827-71831	oral	2	
475-5	71832-71835	and	_	
475-6	71836-71843	written	_	
475-7	71844-71855	information	_	
475-8	71856-71861	about	_	
475-9	71862-71865	the	_	
475-10	71866-71871	trial	1	
475-11	71872-71875	and	3	
475-12	71876-71882	signed	1	
475-13	71883-71885	an	2	
475-14	71886-71894	informed	_	
475-15	71895-71902	consent	_	
475-16	71903-71907	form	_	
475-17	71908-71909	.	1	

#Text=Statistical analyses were conducted using SPSS v. 23 ( IBM , IL , USA ) .
476-1	71910-71921	Statistical	9	
476-2	71922-71930	analyses	1	
476-3	71931-71935	were	8	
476-4	71936-71945	conducted	_	
476-5	71946-71951	using	1	
476-6	71952-71956	SPSS	2	
476-7	71957-71958	v	_	
476-8	71958-71959	.	_	
476-9	71960-71962	23	1	
476-10	71963-71964	(	5	
476-11	71965-71968	IBM	_	
476-12	71969-71970	,	_	
476-13	71971-71973	IL	_	
476-14	71974-71975	,	_	
476-15	71976-71979	USA	_	
476-16	71980-71981	)	_	
476-17	71982-71983	.	1	

#Text=One of the authors ( AJ ) with experience of patient diagnostics and care assigned a final diagnosis for each patient based on medical record information and routine laboratory results without knowledge of the results for phospholipid , cytokine , and autotaxin analyses .
477-1	71984-71987	One	9	
477-2	71988-71990	of	_	
477-3	71991-71994	the	_	
477-4	71995-72002	authors	_	
477-5	72003-72004	(	5	
477-6	72005-72007	AJ	_	
477-7	72008-72009	)	1	
477-8	72010-72014	with	_	
477-9	72015-72025	experience	_	
477-10	72026-72028	of	_	
477-11	72029-72036	patient	_	
477-12	72037-72048	diagnostics	_	
477-13	72049-72052	and	_	
477-14	72053-72057	care	1	
477-15	72058-72066	assigned	8	
477-16	72067-72068	a	2	
477-17	72069-72074	final	_	
477-18	72075-72084	diagnosis	_	
477-19	72085-72088	for	_	
477-20	72089-72093	each	_	
477-21	72094-72101	patient	1	
477-22	72102-72107	based	2	
477-23	72108-72110	on	_	
477-24	72111-72118	medical	_	
477-25	72119-72125	record	_	
477-26	72126-72137	information	_	
477-27	72138-72141	and	_	
477-28	72142-72149	routine	_	
477-29	72150-72160	laboratory	_	
477-30	72161-72168	results	_	
477-31	72169-72176	without	_	
477-32	72177-72186	knowledge	_	
477-33	72187-72189	of	_	
477-34	72190-72193	the	_	
477-35	72194-72201	results	_	
477-36	72202-72205	for	_	
477-37	72206-72218	phospholipid	_	
477-38	72219-72220	,	_	
477-39	72221-72229	cytokine	_	
477-40	72230-72231	,	_	
477-41	72232-72235	and	_	
477-42	72236-72245	autotaxin	_	
477-43	72246-72254	analyses	_	
477-44	72255-72256	.	1	

#Text=We recruited non-pregnant women aged 18–60 years with symptoms of an uncomplicated UTI .
478-1	72257-72259	We	8	
478-2	72260-72269	recruited	1	
478-3	72270-72282	non-pregnant	2	
478-4	72283-72288	women	_	
478-5	72289-72293	aged	_	
478-6	72294-72296	18	_	
478-7	72296-72297	–	_	
478-8	72297-72299	60	_	
478-9	72300-72305	years	_	
478-10	72306-72310	with	_	
478-11	72311-72319	symptoms	_	
478-12	72320-72322	of	_	
478-13	72323-72325	an	_	
478-14	72326-72339	uncomplicated	_	
478-15	72340-72343	UTI	_	
478-16	72344-72345	.	1	

#Text=The intervention arms included a yoga exercise ( YE ) experimental group , a traditional exercise ( TE ) active treatment comparison group , and a no exercise ( NE ) attention-equivalent control group .
479-1	72346-72349	The	9	
479-2	72350-72362	intervention	_	
479-3	72363-72367	arms	1	
479-4	72368-72376	included	8	
479-5	72377-72378	a	2	
479-6	72379-72383	yoga	_	
479-7	72384-72392	exercise	_	
479-8	72393-72394	(	5	
479-9	72395-72397	YE	_	
479-10	72398-72399	)	1	
479-11	72400-72412	experimental	_	
479-12	72413-72418	group	_	
479-13	72419-72420	,	_	
479-14	72421-72422	a	_	
479-15	72423-72434	traditional	_	
479-16	72435-72443	exercise	_	
479-17	72444-72445	(	5	
479-18	72446-72448	TE	_	
479-19	72449-72450	)	1	
479-20	72451-72457	active	_	
479-21	72458-72467	treatment	_	
479-22	72468-72478	comparison	_	
479-23	72479-72484	group	_	
479-24	72485-72486	,	_	
479-25	72487-72490	and	_	
479-26	72491-72492	a	_	
479-27	72493-72495	no	_	
479-28	72496-72504	exercise	_	
479-29	72505-72506	(	5	
479-30	72507-72509	NE	_	
479-31	72510-72511	)	1	
479-32	72512-72532	attention-equivalent	_	
479-33	72533-72540	control	_	
479-34	72541-72546	group	_	
479-35	72547-72548	.	1	

#Text=We calculated a daily symptom sum score for each patient from the patient diary .
480-1	72549-72551	We	8	
480-2	72552-72562	calculated	1	
480-3	72563-72564	a	2	
480-4	72565-72570	daily	_	
480-5	72571-72578	symptom	_	
480-6	72579-72582	sum	_	
480-7	72583-72588	score	_	
480-8	72589-72592	for	_	
480-9	72593-72597	each	_	
480-10	72598-72605	patient	1	
480-11	72606-72610	from	2	
480-12	72611-72614	the	_	
480-13	72615-72622	patient	_	
480-14	72623-72628	diary	_	
480-15	72629-72630	.	1	

#Text=A Bonferroni correction was used to adjust for multiple within-group comparisons ; an alpha value of 0.0167 was used .
481-1	72631-72632	A	9	
481-2	72633-72643	Bonferroni	_	
481-3	72644-72654	correction	1	
481-4	72655-72658	was	8	
481-5	72659-72663	used	_	
481-6	72664-72666	to	_	
481-7	72667-72673	adjust	_	
481-8	72674-72677	for	1	
481-9	72678-72686	multiple	2	
481-10	72687-72699	within-group	_	
481-11	72700-72711	comparisons	1	
481-12	72712-72713	;	6	
481-13	72714-72716	an	9	
481-14	72717-72722	alpha	_	
481-15	72723-72728	value	_	
481-16	72729-72731	of	_	
481-17	72732-72738	0.0167	1	
481-18	72739-72742	was	3	
481-19	72743-72747	used	_	
481-20	72748-72749	.	1	

#Text=The TI determined injection volumes based on clinical experience , with the total volume not to exceed 4 mL in each NLF for the initial and touch-up treatments combined .
482-1	72750-72753	The	9	
482-2	72754-72756	TI	1	
482-3	72757-72767	determined	8	
482-4	72768-72777	injection	2	
482-5	72778-72785	volumes	1	
482-6	72786-72791	based	2	
482-7	72792-72794	on	_	
482-8	72795-72803	clinical	_	
482-9	72804-72814	experience	_	
482-10	72815-72816	,	1	
482-11	72817-72821	with	2	
482-12	72822-72825	the	_	
482-13	72826-72831	total	_	
482-14	72832-72838	volume	1	
482-15	72839-72842	not	2	
482-16	72843-72845	to	_	
482-17	72846-72852	exceed	1	
482-18	72853-72854	4	2	
482-19	72855-72857	mL	1	
482-20	72858-72860	in	2	
482-21	72861-72865	each	_	
482-22	72866-72869	NLF	1	
482-23	72870-72873	for	2	
482-24	72874-72877	the	_	
482-25	72878-72885	initial	_	
482-26	72886-72889	and	_	
482-27	72890-72898	touch-up	_	
482-28	72899-72909	treatments	_	
482-29	72910-72918	combined	_	
482-30	72919-72920	.	1	

#Text=The study was conducted in compliance with Good Clinical Practice guidelines and was registered at Clinicaltrials.gov ( identifier : { " type":"clinical-trial","attrs":{"text":"NCT01976663","term_id":"NCT01976663"}}NCT01976663 ) .
483-1	72921-72924	The	9	
483-2	72925-72930	study	1	
483-3	72931-72934	was	8	
483-4	72935-72944	conducted	_	
483-5	72945-72947	in	_	
483-6	72948-72958	compliance	_	
483-7	72959-72963	with	1	
483-8	72964-72968	Good	2	
483-9	72969-72977	Clinical	_	
483-10	72978-72986	Practice	_	
483-11	72987-72997	guidelines	1	
483-12	72998-73001	and	3	
483-13	73002-73005	was	_	
483-14	73006-73016	registered	_	
483-15	73017-73019	at	1	
483-16	73020-73038	Clinicaltrials.gov	2	
483-17	73039-73040	(	5	
483-18	73041-73051	identifier	_	
483-19	73052-73053	:	_	
483-20	73054-73055	{	_	
483-21	73056-73057	"	_	
483-22	73058-73062	type	_	
483-23	73062-73063	"	_	
483-24	73063-73064	:	_	
483-25	73064-73065	"	_	
483-26	73065-73079	clinical-trial	_	
483-27	73079-73080	"	_	
483-28	73080-73081	,	_	
483-29	73081-73082	"	_	
483-30	73082-73087	attrs	_	
483-31	73087-73088	"	_	
483-32	73088-73089	:	_	
483-33	73089-73090	{	_	
483-34	73090-73091	"	_	
483-35	73091-73095	text	_	
483-36	73095-73096	"	_	
483-37	73096-73097	:	_	
483-38	73097-73098	"	_	
483-39	73098-73109	NCT01976663	_	
483-40	73109-73110	"	_	
483-41	73110-73111	,	_	
483-42	73111-73112	"	_	
483-43	73112-73119	term_id	_	
483-44	73119-73120	"	_	
483-45	73120-73121	:	_	
483-46	73121-73122	"	_	
483-47	73122-73133	NCT01976663	_	
483-48	73133-73134	"	_	
483-49	73134-73135	}	_	
483-50	73135-73136	}	_	
483-51	73136-73147	NCT01976663	_	
483-52	73148-73149	)	_	
483-53	73150-73151	.	1	

#Text=She observed evaluations and interventions during each treatment cycle to ensure consistency in documentation and provided feedback for program progression ( 17 ) .
484-1	73152-73155	She	8	
484-2	73156-73164	observed	1	
484-3	73165-73176	evaluations	2	
484-4	73177-73180	and	_	
484-5	73181-73194	interventions	1	
484-6	73195-73201	during	2	
484-7	73202-73206	each	_	
484-8	73207-73216	treatment	_	
484-9	73217-73222	cycle	1	
484-10	73223-73225	to	3	
484-11	73226-73232	ensure	1	
484-12	73233-73244	consistency	2	
484-13	73245-73247	in	_	
484-14	73248-73261	documentation	1	
484-15	73262-73265	and	3	
484-16	73266-73274	provided	1	
484-17	73275-73283	feedback	2	
484-18	73284-73287	for	_	
484-19	73288-73295	program	_	
484-20	73296-73307	progression	1	
484-21	73308-73309	(	5	
484-22	73310-73312	17	_	
484-23	73313-73314	)	_	
484-24	73315-73316	.	1	

#Text=Fifty patients ( females   =   18 ; males   =   32 ; body mass index   =   18.5–24.9 ) aged between 6 and 87   years [ 50.2   ±   2.3 , mean ± standard error of the mean ( SEM ) ] who had appealed to our “ Second Opinion Medical Network ” ( Modena , Italy ) between 2016 and 2017 due to gastritis symptoms were included in this study .
485-1	73317-73322	Fifty	9	
485-2	73323-73331	patients	_	
485-3	73332-73333	(	5	
485-4	73334-73341	females	_	
485-5	73344-73345	=	_	
485-6	73348-73350	18	_	
485-7	73351-73352	;	_	
485-8	73353-73358	males	_	
485-9	73361-73362	=	_	
485-10	73365-73367	32	_	
485-11	73368-73369	;	_	
485-12	73370-73374	body	_	
485-13	73375-73379	mass	_	
485-14	73380-73385	index	_	
485-15	73388-73389	=	_	
485-16	73392-73396	18.5	_	
485-17	73396-73397	–	_	
485-18	73397-73401	24.9	_	
485-19	73402-73403	)	1	
485-20	73404-73408	aged	3	
485-21	73409-73416	between	2	
485-22	73417-73418	6	_	
485-23	73419-73422	and	_	
485-24	73423-73425	87	_	
485-25	73426-73427	 	_	
485-26	73428-73433	years	1	
485-27	73434-73435	[	5	
485-28	73436-73440	50.2	_	
485-29	73443-73444	±	_	
485-30	73447-73450	2.3	_	
485-31	73451-73452	,	_	
485-32	73453-73457	mean	_	
485-33	73458-73459	±	_	
485-34	73460-73468	standard	_	
485-35	73469-73474	error	_	
485-36	73475-73477	of	_	
485-37	73478-73481	the	_	
485-38	73482-73486	mean	_	
485-39	73487-73488	(	_	
485-40	73489-73492	SEM	_	
485-41	73493-73494	)	_	
485-42	73495-73496	]	1	
485-43	73497-73500	who	6	
485-44	73501-73504	had	3	
485-45	73505-73513	appealed	_	
485-46	73514-73516	to	1	
485-47	73517-73520	our	2	
485-48	73521-73522	“	_	
485-49	73523-73529	Second	_	
485-50	73530-73537	Opinion	_	
485-51	73538-73545	Medical	_	
485-52	73546-73553	Network	_	
485-53	73554-73555	”	1	
485-54	73556-73557	(	5	
485-55	73558-73564	Modena	_	
485-56	73565-73566	,	_	
485-57	73567-73572	Italy	_	
485-58	73573-73574	)	1	
485-59	73575-73582	between	2	
485-60	73583-73587	2016	_	
485-61	73588-73591	and	_	
485-62	73592-73596	2017	1	
485-63	73597-73600	due	2	
485-64	73601-73603	to	_	
485-65	73604-73613	gastritis	_	
485-66	73614-73622	symptoms	1	
485-67	73623-73627	were	8	
485-68	73628-73636	included	_	
485-69	73637-73639	in	1	
485-70	73640-73644	this	2	
485-71	73645-73650	study	_	
485-72	73651-73652	.	1	

#Text=The main outcome measure of this trial was the proportion of patients who felt cured by day 4 as recorded in the patient diary .
486-1	73653-73656	The	9	
486-2	73657-73661	main	_	
486-3	73662-73669	outcome	_	
486-4	73670-73677	measure	_	
486-5	73678-73680	of	_	
486-6	73681-73685	this	_	
486-7	73686-73691	trial	1	
486-8	73692-73695	was	8	
486-9	73696-73699	the	2	
486-10	73700-73710	proportion	_	
486-11	73711-73713	of	_	
486-12	73714-73722	patients	_	
486-13	73723-73726	who	_	
486-14	73727-73731	felt	_	
486-15	73732-73737	cured	_	
486-16	73738-73740	by	_	
486-17	73741-73744	day	_	
486-18	73745-73746	4	2	
486-19	73747-73749	as	3	
486-20	73750-73758	recorded	_	
486-21	73759-73761	in	1	
486-22	73762-73765	the	2	
486-23	73766-73773	patient	_	
486-24	73774-73779	diary	_	
486-25	73780-73781	.	1	

#Text=The 2-week treatment was followed by a week without any medication .
487-1	73782-73785	The	9	
487-2	73786-73787	2	_	
487-3	73787-73788	-	_	
487-4	73788-73792	week	_	
487-5	73793-73802	treatment	1	
487-6	73803-73806	was	8	
487-7	73807-73815	followed	_	
487-8	73816-73818	by	1	
487-9	73819-73820	a	2	
487-10	73821-73825	week	_	
487-11	73826-73833	without	_	
487-12	73834-73837	any	_	
487-13	73838-73848	medication	_	
487-14	73849-73850	.	1	

#Text=The dipstick results were not part of the inclusion criteria , but were recorded to provide baseline information for later predictor analysis .
488-1	73851-73854	The	9	
488-2	73855-73863	dipstick	_	
488-3	73864-73871	results	1	
488-4	73872-73876	were	8	
488-5	73877-73880	not	_	
488-6	73881-73885	part	_	
488-7	73886-73888	of	1	
488-8	73889-73892	the	2	
488-9	73893-73902	inclusion	_	
488-10	73903-73911	criteria	_	
488-11	73912-73913	,	1	
488-12	73914-73917	but	3	
488-13	73918-73922	were	_	
488-14	73923-73931	recorded	_	
488-15	73932-73934	to	_	
488-16	73935-73942	provide	1	
488-17	73943-73951	baseline	2	
488-18	73952-73963	information	_	
488-19	73964-73967	for	_	
488-20	73968-73973	later	_	
488-21	73974-73983	predictor	_	
488-22	73984-73992	analysis	_	
488-23	73993-73994	.	1	

#Text=All data are presented as the means ± SEM .
489-1	73995-73998	All	9	
489-2	73999-74003	data	1	
489-3	74004-74007	are	8	
489-4	74008-74017	presented	_	
489-5	74018-74020	as	1	
489-6	74021-74024	the	2	
489-7	74025-74030	means	_	
489-8	74031-74032	±	_	
489-9	74033-74036	SEM	_	
489-10	74037-74038	.	1	

#Text=At each session , the physical therapist examined the participant for adverse signs and symptoms before proceeding with manual therapy or exercise .
490-1	74039-74041	At	2	
490-2	74042-74046	each	_	
490-3	74047-74054	session	_	
490-4	74055-74056	,	1	
490-5	74057-74060	the	9	
490-6	74061-74069	physical	_	
490-7	74070-74079	therapist	1	
490-8	74080-74088	examined	8	
490-9	74089-74092	the	2	
490-10	74093-74104	participant	1	
490-11	74105-74108	for	2	
490-12	74109-74116	adverse	_	
490-13	74117-74122	signs	_	
490-14	74123-74126	and	_	
490-15	74127-74135	symptoms	1	
490-16	74136-74142	before	3	
490-17	74143-74153	proceeding	_	
490-18	74154-74158	with	1	
490-19	74159-74165	manual	2	
490-20	74166-74173	therapy	_	
490-21	74174-74176	or	_	
490-22	74177-74185	exercise	_	
490-23	74186-74187	.	1	

#Text=Assessments of subject satisfaction and NLF preference were repeated if optional touch-up treatment was administered on Day 30 .
491-1	74188-74199	Assessments	9	
491-2	74200-74202	of	_	
491-3	74203-74210	subject	_	
491-4	74211-74223	satisfaction	_	
491-5	74224-74227	and	_	
491-6	74228-74231	NLF	_	
491-7	74232-74242	preference	1	
491-8	74243-74247	were	8	
491-9	74248-74256	repeated	1	
491-10	74257-74259	if	6	
491-11	74260-74268	optional	9	
491-12	74269-74277	touch-up	_	
491-13	74278-74287	treatment	1	
491-14	74288-74291	was	8	
491-15	74292-74304	administered	_	
491-16	74305-74307	on	1	
491-17	74308-74311	Day	2	
491-18	74312-74314	30	_	
491-19	74315-74316	.	1	

#Text=A month after the end of the study , a phone interview was used to determine if the patients ’ improvement in gastritis-related upper abdominal pain/discomfort was still persisting .
492-1	74317-74318	A	2	
492-2	74319-74324	month	_	
492-3	74325-74330	after	_	
492-4	74331-74334	the	_	
492-5	74335-74338	end	_	
492-6	74339-74341	of	_	
492-7	74342-74345	the	_	
492-8	74346-74351	study	_	
492-9	74352-74353	,	1	
492-10	74354-74355	a	9	
492-11	74356-74361	phone	_	
492-12	74362-74371	interview	1	
492-13	74372-74375	was	8	
492-14	74376-74380	used	_	
492-15	74381-74383	to	_	
492-16	74384-74393	determine	1	
492-17	74394-74396	if	6	
492-18	74397-74400	the	9	
492-19	74401-74409	patients	_	
492-20	74410-74411	’	_	
492-21	74412-74423	improvement	_	
492-22	74424-74426	in	_	
492-23	74427-74444	gastritis-related	_	
492-24	74445-74450	upper	_	
492-25	74451-74460	abdominal	_	
492-26	74461-74465	pain	_	
492-27	74465-74466	/	_	
492-28	74466-74476	discomfort	1	
492-29	74477-74480	was	3	
492-30	74481-74486	still	_	
492-31	74487-74497	persisting	_	
492-32	74498-74499	.	1	

#Text=The sum score consisted of the symptoms dysuria , urinary urgency , and urinary frequency .
493-1	74500-74503	The	9	
493-2	74504-74507	sum	_	
493-3	74508-74513	score	1	
493-4	74514-74523	consisted	8	
493-5	74524-74526	of	1	
493-6	74527-74530	the	2	
493-7	74531-74539	symptoms	_	
493-8	74540-74547	dysuria	_	
493-9	74548-74549	,	_	
493-10	74550-74557	urinary	_	
493-11	74558-74565	urgency	_	
493-12	74566-74567	,	_	
493-13	74568-74571	and	_	
493-14	74572-74579	urinary	_	
493-15	74580-74589	frequency	_	
493-16	74590-74591	.	1	

#Text=These were monitored weekly by telephone by using standardized forms to ascertain frequency , exercises completed , adverse events , and adherence .
494-1	74592-74597	These	8	
494-2	74598-74602	were	_	
494-3	74603-74612	monitored	_	
494-4	74613-74619	weekly	_	
494-5	74620-74622	by	1	
494-6	74623-74632	telephone	2	
494-7	74633-74635	by	3	
494-8	74636-74641	using	1	
494-9	74642-74654	standardized	2	
494-10	74655-74660	forms	1	
494-11	74661-74663	to	3	
494-12	74664-74673	ascertain	1	
494-13	74674-74683	frequency	2	
494-14	74684-74685	,	_	
494-15	74686-74695	exercises	_	
494-16	74696-74705	completed	_	
494-17	74706-74707	,	_	
494-18	74708-74715	adverse	_	
494-19	74716-74722	events	_	
494-20	74723-74724	,	_	
494-21	74725-74728	and	_	
494-22	74729-74738	adherence	_	
494-23	74739-74740	.	1	

#Text=Randomisation was stratified according to treatment centre .
495-1	74741-74754	Randomisation	9	
495-2	74755-74758	was	8	
495-3	74759-74769	stratified	_	
495-4	74770-74779	according	_	
495-5	74780-74782	to	1	
495-6	74783-74792	treatment	2	
495-7	74793-74799	centre	_	
495-8	74800-74801	.	1	

#Text=Briefly , an amount between 10 pmole and 6 nmole of the LPC calibration standards were added with the IS to the extraction vial before evaporation to dryness in a vacuum concentrator .
496-1	74802-74809	Briefly	6	
496-2	74810-74811	,	1	
496-3	74812-74814	an	9	
496-4	74815-74821	amount	_	
496-5	74822-74829	between	_	
496-6	74830-74832	10	_	
496-7	74833-74838	pmole	_	
496-8	74839-74842	and	_	
496-9	74843-74844	6	_	
496-10	74845-74850	nmole	_	
496-11	74851-74853	of	_	
496-12	74854-74857	the	_	
496-13	74858-74861	LPC	_	
496-14	74862-74873	calibration	_	
496-15	74874-74883	standards	1	
496-16	74884-74888	were	8	
496-17	74889-74894	added	_	
496-18	74895-74899	with	1	
496-19	74900-74903	the	2	
496-20	74904-74906	IS	_	
496-21	74907-74909	to	_	
496-22	74910-74913	the	_	
496-23	74914-74924	extraction	_	
496-24	74925-74929	vial	1	
496-25	74930-74936	before	2	
496-26	74937-74948	evaporation	_	
496-27	74949-74951	to	_	
496-28	74952-74959	dryness	_	
496-29	74960-74962	in	_	
496-30	74963-74964	a	_	
496-31	74965-74971	vacuum	_	
496-32	74972-74984	concentrator	_	
496-33	74985-74986	.	1	

#Text=A p value ˂   0.05 was considered significant .
497-1	74987-74988	A	9	
497-2	74989-74990	p	_	
497-3	74991-74996	value	_	
497-4	74997-74998	˂	_	
497-5	74999-75000	 	_	
497-6	75001-75005	0.05	1	
497-7	75006-75009	was	8	
497-8	75010-75020	considered	_	
497-9	75021-75032	significant	_	
497-10	75033-75034	.	1	

#Text=Clinical breakpoints for susceptibility were assessed according to the European Committee on Antimicrobial Susceptibility Testing ( EUCAST ) [ 20 ] .
498-1	75035-75043	Clinical	9	
498-2	75044-75055	breakpoints	_	
498-3	75056-75059	for	_	
498-4	75060-75074	susceptibility	1	
498-5	75075-75079	were	8	
498-6	75080-75088	assessed	_	
498-7	75089-75098	according	_	
498-8	75099-75101	to	1	
498-9	75102-75105	the	2	
498-10	75106-75114	European	_	
498-11	75115-75124	Committee	_	
498-12	75125-75127	on	_	
498-13	75128-75141	Antimicrobial	_	
498-14	75142-75156	Susceptibility	_	
498-15	75157-75164	Testing	1	
498-16	75165-75166	(	5	
498-17	75167-75173	EUCAST	_	
498-18	75174-75175	)	1	
498-19	75176-75177	[	5	
498-20	75178-75180	20	_	
498-21	75181-75182	]	_	
498-22	75183-75184	.	1	

#Text=The exclusion criteria were duration of symptoms for more than 7 days ; allergies/adverse reactions to penicillin or ibuprofen ; breastfeeding a child under 1 month of age ; any sign of an upper UTI ( fever , upper back pain , reduced general condition ) ; vaginal irritation/discharge ; severe abdominal pain ; diabetes ; kidney disease ; genetic aciduria ; severe gastritis ; ulcerative colitis ; Crohn 's disease ; low platelets ; use of probenecid , steroids , immunosuppressant drugs , or blood-thinning drugs ; previous pyelonephritis ; use of urinary catheter or symptoms of a UTI within the last 4 weeks ; or use of antibiotics within the last 2 weeks ( S1 Fig ) .
499-1	75185-75188	The	9	
499-2	75189-75198	exclusion	1	
499-3	75199-75207	criteria	_	
499-4	75208-75212	were	8	
499-5	75213-75221	duration	2	
499-6	75222-75224	of	_	
499-7	75225-75233	symptoms	_	
499-8	75234-75237	for	_	
499-9	75238-75242	more	_	
499-10	75243-75247	than	_	
499-11	75248-75249	7	_	
499-12	75250-75254	days	_	
499-13	75255-75256	;	_	
499-14	75257-75266	allergies	_	
499-15	75266-75267	/	_	
499-16	75267-75274	adverse	_	
499-17	75275-75284	reactions	_	
499-18	75285-75287	to	_	
499-19	75288-75298	penicillin	_	
499-20	75299-75301	or	_	
499-21	75302-75311	ibuprofen	_	
499-22	75312-75313	;	_	
499-23	75314-75327	breastfeeding	_	
499-24	75328-75329	a	_	
499-25	75330-75335	child	_	
499-26	75336-75341	under	_	
499-27	75342-75343	1	_	
499-28	75344-75349	month	_	
499-29	75350-75352	of	_	
499-30	75353-75356	age	_	
499-31	75357-75358	;	_	
499-32	75359-75362	any	_	
499-33	75363-75367	sign	_	
499-34	75368-75370	of	_	
499-35	75371-75373	an	_	
499-36	75374-75379	upper	_	
499-37	75380-75383	UTI	_	
499-38	75384-75385	(	_	
499-39	75386-75391	fever	_	
499-40	75392-75393	,	_	
499-41	75394-75399	upper	_	
499-42	75400-75404	back	_	
499-43	75405-75409	pain	_	
499-44	75410-75411	,	_	
499-45	75412-75419	reduced	_	
499-46	75420-75427	general	_	
499-47	75428-75437	condition	_	
499-48	75438-75439	)	_	
499-49	75440-75441	;	_	
499-50	75442-75449	vaginal	_	
499-51	75450-75460	irritation	_	
499-52	75460-75461	/	_	
499-53	75461-75470	discharge	_	
499-54	75471-75472	;	_	
499-55	75473-75479	severe	_	
499-56	75480-75489	abdominal	_	
499-57	75490-75494	pain	_	
499-58	75495-75496	;	_	
499-59	75497-75505	diabetes	_	
499-60	75506-75507	;	_	
499-61	75508-75514	kidney	_	
499-62	75515-75522	disease	_	
499-63	75523-75524	;	_	
499-64	75525-75532	genetic	_	
499-65	75533-75541	aciduria	_	
499-66	75542-75543	;	_	
499-67	75544-75550	severe	_	
499-68	75551-75560	gastritis	_	
499-69	75561-75562	;	_	
499-70	75563-75573	ulcerative	_	
499-71	75574-75581	colitis	_	
499-72	75582-75583	;	_	
499-73	75584-75589	Crohn	_	
499-74	75590-75591	'	_	
499-75	75591-75592	s	_	
499-76	75593-75600	disease	_	
499-77	75601-75602	;	_	
499-78	75603-75606	low	_	
499-79	75607-75616	platelets	_	
499-80	75617-75618	;	_	
499-81	75619-75622	use	_	
499-82	75623-75625	of	_	
499-83	75626-75636	probenecid	_	
499-84	75637-75638	,	_	
499-85	75639-75647	steroids	_	
499-86	75648-75649	,	_	
499-87	75650-75667	immunosuppressant	_	
499-88	75668-75673	drugs	_	
499-89	75674-75675	,	_	
499-90	75676-75678	or	_	
499-91	75679-75693	blood-thinning	_	
499-92	75694-75699	drugs	_	
499-93	75700-75701	;	_	
499-94	75702-75710	previous	_	
499-95	75711-75725	pyelonephritis	_	
499-96	75726-75727	;	_	
499-97	75728-75731	use	_	
499-98	75732-75734	of	_	
499-99	75735-75742	urinary	_	
499-100	75743-75751	catheter	_	
499-101	75752-75754	or	_	
499-102	75755-75763	symptoms	_	
499-103	75764-75766	of	_	
499-104	75767-75768	a	_	
499-105	75769-75772	UTI	_	
499-106	75773-75779	within	_	
499-107	75780-75783	the	_	
499-108	75784-75788	last	_	
499-109	75789-75790	4	_	
499-110	75791-75796	weeks	_	
499-111	75797-75798	;	_	
499-112	75799-75801	or	_	
499-113	75802-75805	use	_	
499-114	75806-75808	of	_	
499-115	75809-75820	antibiotics	_	
499-116	75821-75827	within	_	
499-117	75828-75831	the	_	
499-118	75832-75836	last	_	
499-119	75837-75838	2	_	
499-120	75839-75844	weeks	_	
499-121	75845-75846	(	5	
499-122	75847-75849	S1	_	
499-123	75850-75853	Fig	_	
499-124	75854-75855	)	1	
499-125	75856-75857	.	1	

#Text=The procedures were performed by , or under direct supervision of , qualified radiologists .
500-1	75858-75861	The	9	
500-2	75862-75872	procedures	1	
500-3	75873-75877	were	8	
500-4	75878-75887	performed	_	
500-5	75888-75890	by	_	
500-6	75891-75892	,	_	
500-7	75893-75895	or	_	
500-8	75896-75901	under	1	
500-9	75902-75908	direct	2	
500-10	75909-75920	supervision	_	
500-11	75921-75923	of	_	
500-12	75924-75925	,	_	
500-13	75926-75935	qualified	_	
500-14	75936-75948	radiologists	_	
500-15	75949-75950	.	1	

#Text=The study subjects were adults and provided their written informed consent .
501-1	75951-75954	The	9	
501-2	75955-75960	study	_	
501-3	75961-75969	subjects	1	
501-4	75970-75974	were	8	
501-5	75975-75981	adults	2	
501-6	75982-75985	and	3	
501-7	75986-75994	provided	1	
501-8	75995-76000	their	2	
501-9	76001-76008	written	_	
501-10	76009-76017	informed	_	
501-11	76018-76025	consent	_	
501-12	76026-76027	.	1	

#Text=The classes began with a body-awareness exercise performed in supine followed by the strengthening postures and concluded with a closing deliberate relaxation exercise performed in supine .
502-1	76028-76031	The	9	
502-2	76032-76039	classes	1	
502-3	76040-76045	began	8	
502-4	76046-76050	with	1	
502-5	76051-76052	a	2	
502-6	76053-76067	body-awareness	_	
502-7	76068-76076	exercise	1	
502-8	76077-76086	performed	3	
502-9	76087-76089	in	1	
502-10	76090-76096	supine	2	
502-11	76097-76105	followed	3	
502-12	76106-76108	by	1	
502-13	76109-76112	the	2	
502-14	76113-76126	strengthening	_	
502-15	76127-76135	postures	1	
502-16	76136-76139	and	3	
502-17	76140-76149	concluded	_	
502-18	76150-76154	with	1	
502-19	76155-76156	a	2	
502-20	76157-76164	closing	_	
502-21	76165-76175	deliberate	_	
502-22	76176-76186	relaxation	_	
502-23	76187-76195	exercise	1	
502-24	76196-76205	performed	3	
502-25	76206-76208	in	1	
502-26	76209-76215	supine	2	
502-27	76216-76217	.	1	

#Text=The questionnaire consisted of the inclusion and exclusion criteria and was based on the diagnostic algorithm already in use at the AEOC in Oslo [ 6 ] .
503-1	76218-76221	The	9	
503-2	76222-76235	questionnaire	1	
503-3	76236-76245	consisted	3	
503-4	76246-76248	of	1	
503-5	76249-76252	the	2	
503-6	76253-76262	inclusion	_	
503-7	76263-76266	and	_	
503-8	76267-76276	exclusion	_	
503-9	76277-76285	criteria	1	
503-10	76286-76289	and	3	
503-11	76290-76293	was	_	
503-12	76294-76299	based	_	
503-13	76300-76302	on	1	
503-14	76303-76306	the	2	
503-15	76307-76317	diagnostic	_	
503-16	76318-76327	algorithm	_	
503-17	76328-76335	already	_	
503-18	76336-76338	in	_	
503-19	76339-76342	use	_	
503-20	76343-76345	at	_	
503-21	76346-76349	the	_	
503-22	76350-76354	AEOC	_	
503-23	76355-76357	in	_	
503-24	76358-76362	Oslo	1	
503-25	76363-76364	[	5	
503-26	76365-76366	6	_	
503-27	76367-76368	]	_	
503-28	76369-76370	.	1	

#Text=This tool is scored out of 80 , where higher scores indicate better function .
504-1	76371-76375	This	9	
504-2	76376-76380	tool	1	
504-3	76381-76383	is	8	
504-4	76384-76390	scored	_	
504-5	76391-76394	out	_	
504-6	76395-76397	of	1	
504-7	76398-76400	80	2	
504-8	76401-76402	,	1	
504-9	76403-76408	where	6	
504-10	76409-76415	higher	9	
504-11	76416-76422	scores	1	
504-12	76423-76431	indicate	3	
504-13	76432-76438	better	2	
504-14	76439-76447	function	_	
504-15	76448-76449	.	1	

#Text=In Sweden , study personnel used plastic containers without any added chemicals ; this was due to short delivery time to the laboratory ( < 6 hours ) .
505-1	76450-76452	In	2	
505-2	76453-76459	Sweden	_	
505-3	76460-76461	,	1	
505-4	76462-76467	study	9	
505-5	76468-76477	personnel	1	
505-6	76478-76482	used	8	
505-7	76483-76490	plastic	2	
505-8	76491-76501	containers	_	
505-9	76502-76509	without	_	
505-10	76510-76513	any	_	
505-11	76514-76519	added	_	
505-12	76520-76529	chemicals	1	
505-13	76530-76531	;	6	
505-14	76532-76536	this	3	
505-15	76537-76540	was	_	
505-16	76541-76544	due	_	
505-17	76545-76547	to	1	
505-18	76548-76553	short	2	
505-19	76554-76562	delivery	_	
505-20	76563-76567	time	_	
505-21	76568-76570	to	_	
505-22	76571-76574	the	_	
505-23	76575-76585	laboratory	1	
505-24	76586-76587	(	5	
505-25	76588-76589	<	_	
505-26	76590-76591	6	_	
505-27	76592-76597	hours	_	
505-28	76598-76599	)	_	
505-29	76600-76601	.	1	

#Text=They were instructed to collect a midstream urine sample after spreading of the labia , preferably morning urine .
506-1	76602-76606	They	8	
506-2	76607-76611	were	_	
506-3	76612-76622	instructed	_	
506-4	76623-76625	to	_	
506-5	76626-76633	collect	1	
506-6	76634-76635	a	2	
506-7	76636-76645	midstream	_	
506-8	76646-76651	urine	_	
506-9	76652-76658	sample	1	
506-10	76659-76664	after	2	
506-11	76665-76674	spreading	_	
506-12	76675-76677	of	_	
506-13	76678-76681	the	_	
506-14	76682-76687	labia	_	
506-15	76688-76689	,	1	
506-16	76690-76700	preferably	2	
506-17	76701-76708	morning	_	
506-18	76709-76714	urine	_	
506-19	76715-76716	.	1	

#Text=The list was retrieved only at the end of the study , when all data had been collected and entered into the study database , and the SAP was completed and signed .
507-1	76717-76720	The	9	
507-2	76721-76725	list	1	
507-3	76726-76729	was	8	
507-4	76730-76739	retrieved	_	
507-5	76740-76744	only	_	
507-6	76745-76747	at	1	
507-7	76748-76751	the	2	
507-8	76752-76755	end	_	
507-9	76756-76758	of	_	
507-10	76759-76762	the	_	
507-11	76763-76768	study	_	
507-12	76769-76770	,	1	
507-13	76771-76775	when	6	
507-14	76776-76779	all	9	
507-15	76780-76784	data	1	
507-16	76785-76788	had	3	
507-17	76789-76793	been	_	
507-18	76794-76803	collected	_	
507-19	76804-76807	and	_	
507-20	76808-76815	entered	_	
507-21	76816-76820	into	_	
507-22	76821-76824	the	1	
507-23	76825-76830	study	2	
507-24	76831-76839	database	_	
507-25	76840-76841	,	1	
507-26	76842-76845	and	2	
507-27	76846-76849	the	_	
507-28	76850-76853	SAP	1	
507-29	76854-76857	was	3	
507-30	76858-76867	completed	_	
507-31	76868-76871	and	_	
507-32	76872-76878	signed	_	
507-33	76879-76880	.	1	

#Text=Patients were discharged with the percutaneous drain .
508-1	76881-76889	Patients	9	
508-2	76890-76894	were	8	
508-3	76895-76905	discharged	_	
508-4	76906-76910	with	1	
508-5	76911-76914	the	2	
508-6	76915-76927	percutaneous	_	
508-7	76928-76933	drain	_	
508-8	76934-76935	.	1	

#Text=TE was designed and supervised by kinesiologists and physical therapists and took place at a physical activity center .
509-1	76936-76938	TE	9	
509-2	76939-76942	was	8	
509-3	76943-76951	designed	_	
509-4	76952-76955	and	_	
509-5	76956-76966	supervised	_	
509-6	76967-76969	by	1	
509-7	76970-76984	kinesiologists	2	
509-8	76985-76988	and	_	
509-9	76989-76997	physical	_	
509-10	76998-77008	therapists	1	
509-11	77009-77012	and	3	
509-12	77013-77017	took	_	
509-13	77018-77023	place	_	
509-14	77024-77026	at	1	
509-15	77027-77028	a	2	
509-16	77029-77037	physical	_	
509-17	77038-77046	activity	_	
509-18	77047-77053	center	_	
509-19	77054-77055	.	1	

#Text=Time to event endpoints were analyzed using a Cox regression model adjusted for randomization stratum and are presented using Kaplan – Meier plots .
510-1	77056-77060	Time	9	
510-2	77061-77063	to	_	
510-3	77064-77069	event	_	
510-4	77070-77079	endpoints	1	
510-5	77080-77084	were	8	
510-6	77085-77093	analyzed	_	
510-7	77094-77099	using	1	
510-8	77100-77101	a	2	
510-9	77102-77105	Cox	_	
510-10	77106-77116	regression	_	
510-11	77117-77122	model	_	
510-12	77123-77131	adjusted	_	
510-13	77132-77135	for	_	
510-14	77136-77149	randomization	_	
510-15	77150-77157	stratum	1	
510-16	77158-77161	and	3	
510-17	77162-77165	are	_	
510-18	77166-77175	presented	_	
510-19	77176-77181	using	1	
510-20	77182-77188	Kaplan	2	
510-21	77189-77190	–	_	
510-22	77191-77196	Meier	_	
510-23	77197-77202	plots	_	
510-24	77203-77204	.	1	

#Text=If it turned out that significantly more patients in the ibuprofen group were hospitalized , we would consider terminating the study .
511-1	77205-77207	If	6	
511-2	77208-77210	it	3	
511-3	77211-77217	turned	_	
511-4	77218-77221	out	1	
511-5	77222-77226	that	6	
511-6	77227-77240	significantly	9	
511-7	77241-77245	more	_	
511-8	77246-77254	patients	_	
511-9	77255-77257	in	_	
511-10	77258-77261	the	_	
511-11	77262-77271	ibuprofen	_	
511-12	77272-77277	group	1	
511-13	77278-77282	were	3	
511-14	77283-77295	hospitalized	_	
511-15	77296-77297	,	1	
511-16	77298-77300	we	8	
511-17	77301-77306	would	_	
511-18	77307-77315	consider	_	
511-19	77316-77327	terminating	1	
511-20	77328-77331	the	2	
511-21	77332-77337	study	_	
511-22	77338-77339	.	1	

#Text=Within the patients with positive urine cultures , we also compared those with cultures susceptible to pivmecillinam to those with cultures resistant to pivmecillinam with regards to symptom burden .
512-1	77340-77346	Within	2	
512-2	77347-77350	the	_	
512-3	77351-77359	patients	_	
512-4	77360-77364	with	_	
512-5	77365-77373	positive	_	
512-6	77374-77379	urine	_	
512-7	77380-77388	cultures	_	
512-8	77389-77390	,	1	
512-9	77391-77393	we	8	
512-10	77394-77398	also	_	
512-11	77399-77407	compared	1	
512-12	77408-77413	those	2	
512-13	77414-77418	with	_	
512-14	77419-77427	cultures	_	
512-15	77428-77439	susceptible	_	
512-16	77440-77442	to	_	
512-17	77443-77456	pivmecillinam	1	
512-18	77457-77459	to	2	
512-19	77460-77465	those	_	
512-20	77466-77470	with	_	
512-21	77471-77479	cultures	_	
512-22	77480-77489	resistant	_	
512-23	77490-77492	to	_	
512-24	77493-77506	pivmecillinam	1	
512-25	77507-77511	with	2	
512-26	77512-77519	regards	_	
512-27	77520-77522	to	_	
512-28	77523-77530	symptom	_	
512-29	77531-77537	burden	_	
512-30	77538-77539	.	1	

#Text=Subjects returned at 3 and 14 days after treatment to undergo facial digital photography , to rate satisfaction and NLF preference , and to complete safety assessments .
513-1	77540-77548	Subjects	9	
513-2	77549-77557	returned	8	
513-3	77558-77560	at	2	
513-4	77561-77562	3	_	
513-5	77563-77566	and	_	
513-6	77567-77569	14	_	
513-7	77570-77574	days	_	
513-8	77575-77580	after	_	
513-9	77581-77590	treatment	1	
513-10	77591-77593	to	3	
513-11	77594-77601	undergo	1	
513-12	77602-77608	facial	2	
513-13	77609-77616	digital	_	
513-14	77617-77628	photography	_	
513-15	77629-77630	,	1	
513-16	77631-77633	to	3	
513-17	77634-77638	rate	_	
513-18	77639-77651	satisfaction	2	
513-19	77652-77655	and	_	
513-20	77656-77659	NLF	_	
513-21	77660-77670	preference	_	
513-22	77671-77672	,	1	
513-23	77673-77676	and	3	
513-24	77677-77679	to	_	
513-25	77680-77688	complete	1	
513-26	77689-77695	safety	2	
513-27	77696-77707	assessments	_	
513-28	77708-77709	.	1	

#Text=The software Matlab R2014a ( MathWorks , Natick , MA ) was used for performing statistical analyses in the validation and evaluation process of setting up the laboratory methods for phospholipid analysis .
514-1	77710-77713	The	9	
514-2	77714-77722	software	_	
514-3	77723-77729	Matlab	_	
514-4	77730-77736	R2014a	1	
514-5	77737-77738	(	5	
514-6	77739-77748	MathWorks	_	
514-7	77749-77750	,	_	
514-8	77751-77757	Natick	_	
514-9	77758-77759	,	_	
514-10	77760-77762	MA	_	
514-11	77763-77764	)	1	
514-12	77765-77768	was	8	
514-13	77769-77773	used	_	
514-14	77774-77777	for	_	
514-15	77778-77788	performing	1	
514-16	77789-77800	statistical	2	
514-17	77801-77809	analyses	_	
514-18	77810-77812	in	_	
514-19	77813-77816	the	_	
514-20	77817-77827	validation	_	
514-21	77828-77831	and	_	
514-22	77832-77842	evaluation	_	
514-23	77843-77850	process	_	
514-24	77851-77853	of	_	
514-25	77854-77861	setting	_	
514-26	77862-77864	up	_	
514-27	77865-77868	the	_	
514-28	77869-77879	laboratory	_	
514-29	77880-77887	methods	_	
514-30	77888-77891	for	_	
514-31	77892-77904	phospholipid	_	
514-32	77905-77913	analysis	_	
514-33	77914-77915	.	1	

#Text=Markers were selected taking into account the possible targeting of the inflammatory response or immunomodulatory capacity of trimodulin [ 23 ] .
515-1	77916-77923	Markers	9	
515-2	77924-77928	were	8	
515-3	77929-77937	selected	_	
515-4	77938-77944	taking	_	
515-5	77945-77949	into	_	
515-6	77950-77957	account	1	
515-7	77958-77961	the	2	
515-8	77962-77970	possible	_	
515-9	77971-77980	targeting	_	
515-10	77981-77983	of	_	
515-11	77984-77987	the	_	
515-12	77988-78000	inflammatory	_	
515-13	78001-78009	response	_	
515-14	78010-78012	or	_	
515-15	78013-78029	immunomodulatory	_	
515-16	78030-78038	capacity	_	
515-17	78039-78041	of	_	
515-18	78042-78052	trimodulin	1	
515-19	78053-78054	[	5	
515-20	78055-78057	23	_	
515-21	78058-78059	]	_	
515-22	78060-78061	.	1	

#Text=Participants were positioned on a dynamometer ( Biodex System 2 , Biodex Medical Systems , Shirley , NY , USA ) with the knee joint center aligned with the device axis of rotation and in 65 ° of flexion relative to full extension .
516-1	78062-78074	Participants	9	
516-2	78075-78079	were	8	
516-3	78080-78090	positioned	_	
516-4	78091-78093	on	1	
516-5	78094-78095	a	2	
516-6	78096-78107	dynamometer	1	
516-7	78108-78109	(	5	
516-8	78110-78116	Biodex	_	
516-9	78117-78123	System	_	
516-10	78124-78125	2	_	
516-11	78126-78127	,	_	
516-12	78128-78134	Biodex	_	
516-13	78135-78142	Medical	_	
516-14	78143-78150	Systems	_	
516-15	78151-78152	,	_	
516-16	78153-78160	Shirley	_	
516-17	78161-78162	,	_	
516-18	78163-78165	NY	_	
516-19	78166-78167	,	_	
516-20	78168-78171	USA	_	
516-21	78172-78173	)	1	
516-22	78174-78178	with	2	
516-23	78179-78182	the	_	
516-24	78183-78187	knee	_	
516-25	78188-78193	joint	_	
516-26	78194-78200	center	_	
516-27	78201-78208	aligned	_	
516-28	78209-78213	with	_	
516-29	78214-78217	the	_	
516-30	78218-78224	device	_	
516-31	78225-78229	axis	_	
516-32	78230-78232	of	_	
516-33	78233-78241	rotation	1	
516-34	78242-78245	and	2	
516-35	78246-78248	in	_	
516-36	78249-78251	65	_	
516-37	78252-78253	°	_	
516-38	78254-78256	of	_	
516-39	78257-78264	flexion	_	
516-40	78265-78273	relative	_	
516-41	78274-78276	to	_	
516-42	78277-78281	full	_	
516-43	78282-78291	extension	_	
516-44	78292-78293	.	1	

#Text=Efficacy measures were adjusted risk difference and adjusted relative risk using the delta method .
517-1	78294-78302	Efficacy	8	
517-2	78303-78311	measures	9	
517-3	78312-78316	were	8	
517-4	78317-78325	adjusted	1	
517-5	78326-78330	risk	2	
517-6	78331-78341	difference	_	
517-7	78342-78345	and	_	
517-8	78346-78354	adjusted	_	
517-9	78355-78363	relative	_	
517-10	78364-78368	risk	1	
517-11	78369-78374	using	3	
517-12	78375-78378	the	2	
517-13	78379-78384	delta	_	
517-14	78385-78391	method	_	
517-15	78392-78393	.	1	

#Text=Assignments were concealed in sealed , opaque envelopes with date and signature labels .
518-1	78394-78405	Assignments	9	
518-2	78406-78410	were	8	
518-3	78411-78420	concealed	_	
518-4	78421-78423	in	1	
518-5	78424-78430	sealed	2	
518-6	78431-78432	,	_	
518-7	78433-78439	opaque	_	
518-8	78440-78449	envelopes	_	
518-9	78450-78454	with	_	
518-10	78455-78459	date	_	
518-11	78460-78463	and	_	
518-12	78464-78473	signature	_	
518-13	78474-78480	labels	_	
518-14	78481-78482	.	1	

#Text=Further secondary outcomes were the proportion of patients ( i ) with positive second urine culture ( significant bacteriuria ) , ( ii ) in need of a medical consultation within the 4 weeks of follow-up , and ( iii ) who received antibiotic treatment during this period .
519-1	78483-78490	Further	9	
519-2	78491-78500	secondary	_	
519-3	78501-78509	outcomes	1	
519-4	78510-78514	were	8	
519-5	78515-78518	the	2	
519-6	78519-78529	proportion	_	
519-7	78530-78532	of	_	
519-8	78533-78541	patients	_	
519-9	78542-78543	(	5	
519-10	78544-78545	i	_	
519-11	78546-78547	)	1	
519-12	78548-78552	with	_	
519-13	78553-78561	positive	_	
519-14	78562-78568	second	_	
519-15	78569-78574	urine	_	
519-16	78575-78582	culture	_	
519-17	78583-78584	(	5	
519-18	78585-78596	significant	_	
519-19	78597-78608	bacteriuria	_	
519-20	78609-78610	)	1	
519-21	78611-78612	,	_	
519-22	78613-78614	(	5	
519-23	78615-78617	ii	_	
519-24	78618-78619	)	1	
519-25	78620-78622	in	_	
519-26	78623-78627	need	_	
519-27	78628-78630	of	_	
519-28	78631-78632	a	_	
519-29	78633-78640	medical	_	
519-30	78641-78653	consultation	_	
519-31	78654-78660	within	_	
519-32	78661-78664	the	_	
519-33	78665-78666	4	_	
519-34	78667-78672	weeks	_	
519-35	78673-78675	of	_	
519-36	78676-78685	follow-up	_	
519-37	78686-78687	,	_	
519-38	78688-78691	and	_	
519-39	78692-78693	(	5	
519-40	78694-78697	iii	_	
519-41	78698-78699	)	1	
519-42	78700-78703	who	_	
519-43	78704-78712	received	_	
519-44	78713-78723	antibiotic	_	
519-45	78724-78733	treatment	_	
519-46	78734-78740	during	_	
519-47	78741-78745	this	_	
519-48	78746-78752	period	_	
519-49	78753-78754	.	1	

#Text=Enrollment in the DEFUSE 3 trial was placed on hold , and an early interim analysis , including subgroup analysis of the primary and secondary efficacy outcomes in patients who would have been eligible for the DAWN trial , was requested by the sponsor ( the NIH ) .
520-1	78755-78765	Enrollment	9	
520-2	78766-78768	in	_	
520-3	78769-78772	the	_	
520-4	78773-78779	DEFUSE	_	
520-5	78780-78781	3	_	
520-6	78782-78787	trial	1	
520-7	78788-78791	was	8	
520-8	78792-78798	placed	_	
520-9	78799-78801	on	_	
520-10	78802-78806	hold	_	
520-11	78807-78808	,	1	
520-12	78809-78812	and	9	
520-13	78813-78815	an	_	
520-14	78816-78821	early	_	
520-15	78822-78829	interim	_	
520-16	78830-78838	analysis	_	
520-17	78839-78840	,	_	
520-18	78841-78850	including	_	
520-19	78851-78859	subgroup	_	
520-20	78860-78868	analysis	_	
520-21	78869-78871	of	_	
520-22	78872-78875	the	_	
520-23	78876-78883	primary	_	
520-24	78884-78887	and	_	
520-25	78888-78897	secondary	_	
520-26	78898-78906	efficacy	_	
520-27	78907-78915	outcomes	_	
520-28	78916-78918	in	_	
520-29	78919-78927	patients	_	
520-30	78928-78931	who	_	
520-31	78932-78937	would	_	
520-32	78938-78942	have	_	
520-33	78943-78947	been	_	
520-34	78948-78956	eligible	_	
520-35	78957-78960	for	_	
520-36	78961-78964	the	_	
520-37	78965-78969	DAWN	_	
520-38	78970-78975	trial	_	
520-39	78976-78977	,	1	
520-40	78978-78981	was	3	
520-41	78982-78991	requested	_	
520-42	78992-78994	by	1	
520-43	78995-78998	the	2	
520-44	78999-79006	sponsor	1	
520-45	79007-79008	(	5	
520-46	79009-79012	the	_	
520-47	79013-79016	NIH	_	
520-48	79017-79018	)	_	
520-49	79019-79020	.	1	

#Text=Samples were independently prepared and analyzed on five subsequent days .
521-1	79021-79028	Samples	9	
521-2	79029-79033	were	8	
521-3	79034-79047	independently	_	
521-4	79048-79056	prepared	_	
521-5	79057-79060	and	_	
521-6	79061-79069	analyzed	_	
521-7	79070-79072	on	1	
521-8	79073-79077	five	2	
521-9	79078-79088	subsequent	_	
521-10	79089-79093	days	_	
521-11	79094-79095	.	1	

#Text=Then , lower extremity strengthening was performed on pneumatically-resisted exercise machines ( HUR USA , Inc. , Northbrook , IL , USA ) .
522-1	79096-79100	Then	6	
522-2	79101-79102	,	1	
522-3	79103-79108	lower	9	
522-4	79109-79118	extremity	_	
522-5	79119-79132	strengthening	1	
522-6	79133-79136	was	8	
522-7	79137-79146	performed	_	
522-8	79147-79149	on	1	
522-9	79150-79172	pneumatically-resisted	2	
522-10	79173-79181	exercise	_	
522-11	79182-79190	machines	1	
522-12	79191-79192	(	5	
522-13	79193-79196	HUR	_	
522-14	79197-79200	USA	_	
522-15	79201-79202	,	_	
522-16	79203-79206	Inc	_	
522-17	79206-79207	.	_	
522-18	79208-79209	,	_	
522-19	79210-79220	Northbrook	_	
522-20	79221-79222	,	_	
522-21	79223-79225	IL	_	
522-22	79226-79227	,	_	
522-23	79228-79231	USA	_	
522-24	79232-79233	)	_	
522-25	79234-79235	.	1	

#Text=Participants also completed balancing activities and static stretching .
523-1	79236-79248	Participants	9	
523-2	79249-79253	also	8	
523-3	79254-79263	completed	1	
523-4	79264-79273	balancing	2	
523-5	79274-79284	activities	_	
523-6	79285-79288	and	_	
523-7	79289-79295	static	_	
523-8	79296-79306	stretching	_	
523-9	79307-79308	.	1	

#Text=The AEOCs in Norway are part of the primary healthcare system and are mainly staffed with GPs or doctors training to become GPs ; we therefore consider them to be a general practice setting .
524-1	79309-79312	The	9	
524-2	79313-79318	AEOCs	_	
524-3	79319-79321	in	_	
524-4	79322-79328	Norway	1	
524-5	79329-79332	are	8	
524-6	79333-79337	part	2	
524-7	79338-79340	of	_	
524-8	79341-79344	the	_	
524-9	79345-79352	primary	_	
524-10	79353-79363	healthcare	_	
524-11	79364-79370	system	1	
524-12	79371-79374	and	3	
524-13	79375-79378	are	_	
524-14	79379-79385	mainly	_	
524-15	79386-79393	staffed	_	
524-16	79394-79398	with	1	
524-17	79399-79402	GPs	2	
524-18	79403-79405	or	_	
524-19	79406-79413	doctors	_	
524-20	79414-79422	training	_	
524-21	79423-79425	to	_	
524-22	79426-79432	become	_	
524-23	79433-79436	GPs	1	
524-24	79437-79438	;	6	
524-25	79439-79441	we	3	
524-26	79442-79451	therefore	_	
524-27	79452-79460	consider	_	
524-28	79461-79465	them	_	
524-29	79466-79468	to	_	
524-30	79469-79471	be	1	
524-31	79472-79473	a	2	
524-32	79474-79481	general	_	
524-33	79482-79490	practice	_	
524-34	79491-79498	setting	_	
524-35	79499-79500	.	1	

#Text=In regard to the two children involved in this investigation , their parents were allowed to stay to give their support in relation to the VAS pain scoring .
525-1	79501-79503	In	6	
525-2	79504-79510	regard	_	
525-3	79511-79513	to	1	
525-4	79514-79517	the	2	
525-5	79518-79521	two	_	
525-6	79522-79530	children	1	
525-7	79531-79539	involved	3	
525-8	79540-79542	in	1	
525-9	79543-79547	this	2	
525-10	79548-79561	investigation	_	
525-11	79562-79563	,	1	
525-12	79564-79569	their	9	
525-13	79570-79577	parents	1	
525-14	79578-79582	were	8	
525-15	79583-79590	allowed	_	
525-16	79591-79593	to	_	
525-17	79594-79598	stay	_	
525-18	79599-79601	to	_	
525-19	79602-79606	give	1	
525-20	79607-79612	their	2	
525-21	79613-79620	support	1	
525-22	79621-79623	in	6	
525-23	79624-79632	relation	_	
525-24	79633-79635	to	1	
525-25	79636-79639	the	2	
525-26	79640-79643	VAS	_	
525-27	79644-79648	pain	_	
525-28	79649-79656	scoring	_	
525-29	79657-79658	.	1	

#Text=An outlier is defined to be any value more than 1.5 times the interquartile range ( the height of the box ) from the median .
526-1	79659-79661	An	9	
526-2	79662-79669	outlier	1	
526-3	79670-79672	is	8	
526-4	79673-79680	defined	_	
526-5	79681-79683	to	_	
526-6	79684-79686	be	1	
526-7	79687-79690	any	2	
526-8	79691-79696	value	_	
526-9	79697-79701	more	_	
526-10	79702-79706	than	_	
526-11	79707-79710	1.5	_	
526-12	79711-79716	times	_	
526-13	79717-79720	the	_	
526-14	79721-79734	interquartile	_	
526-15	79735-79740	range	_	
526-16	79741-79742	(	5	
526-17	79743-79746	the	_	
526-18	79747-79753	height	_	
526-19	79754-79756	of	_	
526-20	79757-79760	the	_	
526-21	79761-79764	box	_	
526-22	79765-79766	)	1	
526-23	79767-79771	from	_	
526-24	79772-79775	the	_	
526-25	79776-79782	median	_	
526-26	79783-79784	.	1	

#Text=In the original study protocol,11 an interim analysis for efficacy was specified after the first year of inclusion because it was anticipated that half the number of required patients would have been randomised at that time .
527-1	79785-79787	In	2	
527-2	79788-79791	the	_	
527-3	79792-79800	original	_	
527-4	79801-79806	study	_	
527-5	79807-79815	protocol	_	
527-6	79815-79816	,	1	
527-7	79816-79818	11	9	
527-8	79819-79821	an	_	
527-9	79822-79829	interim	_	
527-10	79830-79838	analysis	_	
527-11	79839-79842	for	_	
527-12	79843-79851	efficacy	1	
527-13	79852-79855	was	8	
527-14	79856-79865	specified	_	
527-15	79866-79871	after	1	
527-16	79872-79875	the	2	
527-17	79876-79881	first	_	
527-18	79882-79886	year	_	
527-19	79887-79889	of	_	
527-20	79890-79899	inclusion	1	
527-21	79900-79907	because	6	
527-22	79908-79910	it	3	
527-23	79911-79914	was	_	
527-24	79915-79926	anticipated	1	
527-25	79927-79931	that	6	
527-26	79932-79936	half	9	
527-27	79937-79940	the	_	
527-28	79941-79947	number	_	
527-29	79948-79950	of	_	
527-30	79951-79959	required	_	
527-31	79960-79968	patients	1	
527-32	79969-79974	would	3	
527-33	79975-79979	have	_	
527-34	79980-79984	been	_	
527-35	79985-79995	randomised	_	
527-36	79996-79998	at	1	
527-37	79999-80003	that	2	
527-38	80004-80008	time	_	
527-39	80009-80010	.	1	

#Text=Subsets with a high mortality delta ( defined as the difference between the percentage of patients who received trimodulin and died , and the percentage of patients who received placebo and died ) were considered for further analyses ( if the subsets were of sufficient size ) .
528-1	80011-80018	Subsets	9	
528-2	80019-80023	with	_	
528-3	80024-80025	a	_	
528-4	80026-80030	high	_	
528-5	80031-80040	mortality	_	
528-6	80041-80046	delta	_	
528-7	80047-80048	(	5	
528-8	80049-80056	defined	_	
528-9	80057-80059	as	_	
528-10	80060-80063	the	_	
528-11	80064-80074	difference	_	
528-12	80075-80082	between	_	
528-13	80083-80086	the	_	
528-14	80087-80097	percentage	_	
528-15	80098-80100	of	_	
528-16	80101-80109	patients	_	
528-17	80110-80113	who	_	
528-18	80114-80122	received	_	
528-19	80123-80133	trimodulin	_	
528-20	80134-80137	and	_	
528-21	80138-80142	died	_	
528-22	80143-80144	,	_	
528-23	80145-80148	and	_	
528-24	80149-80152	the	_	
528-25	80153-80163	percentage	_	
528-26	80164-80166	of	_	
528-27	80167-80175	patients	_	
528-28	80176-80179	who	_	
528-29	80180-80188	received	_	
528-30	80189-80196	placebo	_	
528-31	80197-80200	and	_	
528-32	80201-80205	died	_	
528-33	80206-80207	)	1	
528-34	80208-80212	were	8	
528-35	80213-80223	considered	_	
528-36	80224-80227	for	1	
528-37	80228-80235	further	2	
528-38	80236-80244	analyses	1	
528-39	80245-80246	(	5	
528-40	80247-80249	if	_	
528-41	80250-80253	the	_	
528-42	80254-80261	subsets	_	
528-43	80262-80266	were	_	
528-44	80267-80269	of	_	
528-45	80270-80280	sufficient	_	
528-46	80281-80285	size	_	
528-47	80286-80287	)	_	
528-48	80288-80289	.	1	

#Text=The final product was tested before the trial started to ensure that the capsules had the same look , feel , weight , and taste .
529-1	80290-80293	The	9	
529-2	80294-80299	final	_	
529-3	80300-80307	product	1	
529-4	80308-80311	was	8	
529-5	80312-80318	tested	_	
529-6	80319-80325	before	1	
529-7	80326-80329	the	9	
529-8	80330-80335	trial	1	
529-9	80336-80343	started	3	
529-10	80344-80346	to	_	
529-11	80347-80353	ensure	1	
529-12	80354-80358	that	6	
529-13	80359-80362	the	9	
529-14	80363-80371	capsules	1	
529-15	80372-80375	had	3	
529-16	80376-80379	the	2	
529-17	80380-80384	same	_	
529-18	80385-80389	look	_	
529-19	80390-80391	,	_	
529-20	80392-80396	feel	_	
529-21	80397-80398	,	_	
529-22	80399-80405	weight	_	
529-23	80406-80407	,	_	
529-24	80408-80411	and	_	
529-25	80412-80417	taste	_	
529-26	80418-80419	.	1	

#Text=We also assessed participants ’ expectations of their respective interventions by using the Outcome Expectations for Exercise Scale ( 29 ) .
530-1	80420-80422	We	8	
530-2	80423-80427	also	_	
530-3	80428-80436	assessed	1	
530-4	80437-80449	participants	2	
530-5	80450-80451	’	_	
530-6	80452-80464	expectations	_	
530-7	80465-80467	of	_	
530-8	80468-80473	their	_	
530-9	80474-80484	respective	_	
530-10	80485-80498	interventions	1	
530-11	80499-80501	by	3	
530-12	80502-80507	using	1	
530-13	80508-80511	the	2	
530-14	80512-80519	Outcome	_	
530-15	80520-80532	Expectations	_	
530-16	80533-80536	for	_	
530-17	80537-80545	Exercise	_	
530-18	80546-80551	Scale	1	
530-19	80552-80553	(	5	
530-20	80554-80556	29	_	
530-21	80557-80558	)	_	
530-22	80559-80560	.	1	

#Text=The MCID represents the smallest increment of change that a patient would identify as important .
531-1	80561-80564	The	9	
531-2	80565-80569	MCID	1	
531-3	80570-80580	represents	8	
531-4	80581-80584	the	2	
531-5	80585-80593	smallest	_	
531-6	80594-80603	increment	_	
531-7	80604-80606	of	_	
531-8	80607-80613	change	1	
531-9	80614-80618	that	6	
531-10	80619-80620	a	2	
531-11	80621-80628	patient	1	
531-12	80629-80634	would	3	
531-13	80635-80643	identify	_	
531-14	80644-80646	as	1	
531-15	80647-80656	important	7	
531-16	80657-80658	.	1	

#Text=This study was a single-blind , three-arm , parallel , randomized controlled trial .
532-1	80659-80663	This	9	
532-2	80664-80669	study	1	
532-3	80670-80673	was	8	
532-4	80674-80675	a	2	
532-5	80676-80688	single-blind	_	
532-6	80689-80690	,	_	
532-7	80691-80700	three-arm	_	
532-8	80701-80702	,	_	
532-9	80703-80711	parallel	_	
532-10	80712-80713	,	_	
532-11	80714-80724	randomized	_	
532-12	80725-80735	controlled	_	
532-13	80736-80741	trial	_	
532-14	80742-80743	.	1	

#Text=For the exploratory interactions , we used a significance level of 0.01 to protect against false-positive interactions .
533-1	80744-80747	For	2	
533-2	80748-80751	the	_	
533-3	80752-80763	exploratory	_	
533-4	80764-80776	interactions	_	
533-5	80777-80778	,	1	
533-6	80779-80781	we	8	
533-7	80782-80786	used	1	
533-8	80787-80788	a	2	
533-9	80789-80801	significance	_	
533-10	80802-80807	level	_	
533-11	80808-80810	of	_	
533-12	80811-80815	0.01	1	
533-13	80816-80818	to	3	
533-14	80819-80826	protect	_	
533-15	80827-80834	against	1	
533-16	80835-80849	false-positive	2	
533-17	80850-80862	interactions	_	
533-18	80863-80864	.	1	

#Text=Randomization numbers were grouped in blocks of four to facilitate equal distribution into the two groups .
534-1	80865-80878	Randomization	9	
534-2	80879-80886	numbers	1	
534-3	80887-80891	were	8	
534-4	80892-80899	grouped	_	
534-5	80900-80902	in	1	
534-6	80903-80909	blocks	2	
534-7	80910-80912	of	_	
534-8	80913-80917	four	1	
534-9	80918-80920	to	3	
534-10	80921-80931	facilitate	1	
534-11	80932-80937	equal	2	
534-12	80938-80950	distribution	_	
534-13	80951-80955	into	_	
534-14	80956-80959	the	_	
534-15	80960-80963	two	_	
534-16	80964-80970	groups	_	
534-17	80971-80972	.	1	

#Text=Descriptive statistics were calculated .
535-1	80973-80984	Descriptive	9	
535-2	80985-80995	statistics	1	
535-3	80996-81000	were	8	
535-4	81001-81011	calculated	_	
535-5	81012-81013	.	1	

#Text=Therefore , we conducted the interim analysis at a later stage , when half the sample size had been reached .
536-1	81014-81023	Therefore	6	
536-2	81024-81025	,	1	
536-3	81026-81028	we	8	
536-4	81029-81038	conducted	1	
536-5	81039-81042	the	2	
536-6	81043-81050	interim	_	
536-7	81051-81059	analysis	1	
536-8	81060-81062	at	2	
536-9	81063-81064	a	_	
536-10	81065-81070	later	_	
536-11	81071-81076	stage	_	
536-12	81077-81078	,	1	
536-13	81079-81083	when	6	
536-14	81084-81088	half	3	
536-15	81089-81092	the	_	
536-16	81093-81099	sample	_	
536-17	81100-81104	size	_	
536-18	81105-81108	had	_	
536-19	81109-81113	been	_	
536-20	81114-81121	reached	_	
536-21	81122-81123	.	1	

#Text=For patients with stenosis or occlusion of the cervical internal carotid artery due to atherosclerosis , carotid angioplasty with or without stenting was permitted as part of the intervention .
537-1	81124-81127	For	2	
537-2	81128-81136	patients	_	
537-3	81137-81141	with	_	
537-4	81142-81150	stenosis	_	
537-5	81151-81153	or	_	
537-6	81154-81163	occlusion	_	
537-7	81164-81166	of	_	
537-8	81167-81170	the	_	
537-9	81171-81179	cervical	_	
537-10	81180-81188	internal	_	
537-11	81189-81196	carotid	_	
537-12	81197-81203	artery	_	
537-13	81204-81207	due	_	
537-14	81208-81210	to	_	
537-15	81211-81226	atherosclerosis	_	
537-16	81227-81228	,	1	
537-17	81229-81236	carotid	9	
537-18	81237-81248	angioplasty	_	
537-19	81249-81253	with	_	
537-20	81254-81256	or	_	
537-21	81257-81264	without	_	
537-22	81265-81273	stenting	1	
537-23	81274-81277	was	8	
537-24	81278-81287	permitted	_	
537-25	81288-81290	as	1	
537-26	81291-81295	part	2	
537-27	81296-81298	of	_	
537-28	81299-81302	the	_	
537-29	81303-81315	intervention	_	
537-30	81316-81317	.	1	

#Text=Secondary outcomes were measured at baseline and 12 , 24 , and 52 weeks and included WOMAC physical function and stiffness scores , Patient Global Assessment score , Beck Depression Inventory-II score ( 24 ) , scores on the physical and mental components of the 36-item Short Form Health Survey ( SF-36 ) ( 25 ) , Arthritis Self-Efficacy Scale score ( 26 ) , and results of the 6-minute walk test ( 27 ) and the 20-meter walk test ( 28 ) .
538-1	81318-81327	Secondary	9	
538-2	81328-81336	outcomes	1	
538-3	81337-81341	were	8	
538-4	81342-81350	measured	_	
538-5	81351-81353	at	1	
538-6	81354-81362	baseline	2	
538-7	81363-81366	and	_	
538-8	81367-81369	12	_	
538-9	81370-81371	,	_	
538-10	81372-81374	24	_	
538-11	81375-81376	,	_	
538-12	81377-81380	and	_	
538-13	81381-81383	52	_	
538-14	81384-81389	weeks	1	
538-15	81390-81393	and	3	
538-16	81394-81402	included	1	
538-17	81403-81408	WOMAC	2	
538-18	81409-81417	physical	_	
538-19	81418-81426	function	_	
538-20	81427-81430	and	_	
538-21	81431-81440	stiffness	_	
538-22	81441-81447	scores	_	
538-23	81448-81449	,	_	
538-24	81450-81457	Patient	_	
538-25	81458-81464	Global	_	
538-26	81465-81475	Assessment	_	
538-27	81476-81481	score	_	
538-28	81482-81483	,	_	
538-29	81484-81488	Beck	_	
538-30	81489-81499	Depression	_	
538-31	81500-81512	Inventory-II	_	
538-32	81513-81518	score	_	
538-33	81519-81520	(	5	
538-34	81521-81523	24	_	
538-35	81524-81525	)	1	
538-36	81526-81527	,	_	
538-37	81528-81534	scores	_	
538-38	81535-81537	on	_	
538-39	81538-81541	the	_	
538-40	81542-81550	physical	_	
538-41	81551-81554	and	_	
538-42	81555-81561	mental	_	
538-43	81562-81572	components	_	
538-44	81573-81575	of	_	
538-45	81576-81579	the	_	
538-46	81580-81582	36	_	
538-47	81582-81583	-	_	
538-48	81583-81587	item	_	
538-49	81588-81593	Short	_	
538-50	81594-81598	Form	_	
538-51	81599-81605	Health	_	
538-52	81606-81612	Survey	_	
538-53	81613-81614	(	5	
538-54	81615-81617	SF	_	
538-55	81617-81618	-	_	
538-56	81618-81620	36	_	
538-57	81621-81622	)	1	
538-58	81623-81624	(	5	
538-59	81625-81627	25	_	
538-60	81628-81629	)	1	
538-61	81630-81631	,	_	
538-62	81632-81641	Arthritis	_	
538-63	81642-81655	Self-Efficacy	_	
538-64	81656-81661	Scale	_	
538-65	81662-81667	score	_	
538-66	81668-81669	(	5	
538-67	81670-81672	26	_	
538-68	81673-81674	)	1	
538-69	81675-81676	,	_	
538-70	81677-81680	and	_	
538-71	81681-81688	results	_	
538-72	81689-81691	of	_	
538-73	81692-81695	the	_	
538-74	81696-81697	6	_	
538-75	81697-81698	-	_	
538-76	81698-81704	minute	_	
538-77	81705-81709	walk	_	
538-78	81710-81714	test	_	
538-79	81715-81716	(	5	
538-80	81717-81719	27	_	
538-81	81720-81721	)	1	
538-82	81722-81725	and	_	
538-83	81726-81729	the	_	
538-84	81730-81732	20	_	
538-85	81732-81733	-	_	
538-86	81733-81738	meter	_	
538-87	81739-81743	walk	_	
538-88	81744-81748	test	_	
538-89	81749-81750	(	5	
538-90	81751-81753	28	_	
538-91	81754-81755	)	_	
538-92	81756-81757	.	1	

#Text=Exclusion criteria consisted of other forms of arthritis , history of osteoporotic fracture , patellofemoral pain , non-arthritic knee disease , knee surgery , unstable heart condition , neurological conditions , physician-advised physical activity restrictions , skin allergy to medical tape , lower limb trauma in past three months , ipsilateral hip or ankle conditions , undergoing cancer treatment , and pregnancy .
539-1	81758-81767	Exclusion	9	
539-2	81768-81776	criteria	1	
539-3	81777-81786	consisted	8	
539-4	81787-81789	of	1	
539-5	81790-81795	other	2	
539-6	81796-81801	forms	_	
539-7	81802-81804	of	_	
539-8	81805-81814	arthritis	_	
539-9	81815-81816	,	_	
539-10	81817-81824	history	_	
539-11	81825-81827	of	_	
539-12	81828-81840	osteoporotic	_	
539-13	81841-81849	fracture	_	
539-14	81850-81851	,	_	
539-15	81852-81866	patellofemoral	_	
539-16	81867-81871	pain	_	
539-17	81872-81873	,	_	
539-18	81874-81887	non-arthritic	_	
539-19	81888-81892	knee	_	
539-20	81893-81900	disease	_	
539-21	81901-81902	,	_	
539-22	81903-81907	knee	_	
539-23	81908-81915	surgery	_	
539-24	81916-81917	,	_	
539-25	81918-81926	unstable	_	
539-26	81927-81932	heart	_	
539-27	81933-81942	condition	_	
539-28	81943-81944	,	_	
539-29	81945-81957	neurological	_	
539-30	81958-81968	conditions	_	
539-31	81969-81970	,	_	
539-32	81971-81988	physician-advised	_	
539-33	81989-81997	physical	_	
539-34	81998-82006	activity	_	
539-35	82007-82019	restrictions	_	
539-36	82020-82021	,	_	
539-37	82022-82026	skin	_	
539-38	82027-82034	allergy	_	
539-39	82035-82037	to	_	
539-40	82038-82045	medical	_	
539-41	82046-82050	tape	_	
539-42	82051-82052	,	_	
539-43	82053-82058	lower	_	
539-44	82059-82063	limb	_	
539-45	82064-82070	trauma	_	
539-46	82071-82073	in	_	
539-47	82074-82078	past	_	
539-48	82079-82084	three	_	
539-49	82085-82091	months	_	
539-50	82092-82093	,	_	
539-51	82094-82105	ipsilateral	_	
539-52	82106-82109	hip	_	
539-53	82110-82112	or	_	
539-54	82113-82118	ankle	_	
539-55	82119-82129	conditions	_	
539-56	82130-82131	,	_	
539-57	82132-82142	undergoing	_	
539-58	82143-82149	cancer	_	
539-59	82150-82159	treatment	_	
539-60	82160-82161	,	_	
539-61	82162-82165	and	_	
539-62	82166-82175	pregnancy	_	
539-63	82176-82177	.	1	

#Text=Except for the drugs listed in the exclusion criteria , there are no known significant drug interactions for the study medications .
540-1	82178-82184	Except	6	
540-2	82185-82188	for	1	
540-3	82189-82192	the	2	
540-4	82193-82198	drugs	_	
540-5	82199-82205	listed	_	
540-6	82206-82208	in	_	
540-7	82209-82212	the	_	
540-8	82213-82222	exclusion	_	
540-9	82223-82231	criteria	_	
540-10	82232-82233	,	1	
540-11	82234-82239	there	8	
540-12	82240-82243	are	_	
540-13	82244-82246	no	_	
540-14	82247-82252	known	_	
540-15	82253-82264	significant	_	
540-16	82265-82269	drug	_	
540-17	82270-82282	interactions	_	
540-18	82283-82286	for	_	
540-19	82287-82290	the	_	
540-20	82291-82296	study	_	
540-21	82297-82308	medications	_	
540-22	82309-82310	.	1	

#Text=All the authors attest to the trial integrity and the completeness and accuracy of the reported data and adverse events .
541-1	82311-82314	All	9	
541-2	82315-82318	the	_	
541-3	82319-82326	authors	1	
541-4	82327-82333	attest	8	
541-5	82334-82336	to	1	
541-6	82337-82340	the	2	
541-7	82341-82346	trial	_	
541-8	82347-82356	integrity	_	
541-9	82357-82360	and	_	
541-10	82361-82364	the	_	
541-11	82365-82377	completeness	1	
541-12	82378-82381	and	2	
541-13	82382-82390	accuracy	_	
541-14	82391-82393	of	_	
541-15	82394-82397	the	_	
541-16	82398-82406	reported	_	
541-17	82407-82411	data	1	
541-18	82412-82415	and	2	
541-19	82416-82423	adverse	_	
541-20	82424-82430	events	_	
541-21	82431-82432	.	1	

#Text=Clinical assessments were performed at baseline , 24 hours after randomization , at hospital discharge , and at 30 and 90 days ; assessments included the score on the modified Rankin scale and the NIHSS score , both determined by certified assessors who were unaware of the trial group assignments at 30 and 90 days .
542-1	82433-82441	Clinical	9	
542-2	82442-82453	assessments	1	
542-3	82454-82458	were	8	
542-4	82459-82468	performed	_	
542-5	82469-82471	at	1	
542-6	82472-82480	baseline	2	
542-7	82481-82482	,	_	
542-8	82483-82485	24	_	
542-9	82486-82491	hours	_	
542-10	82492-82497	after	_	
542-11	82498-82511	randomization	_	
542-12	82512-82513	,	_	
542-13	82514-82516	at	_	
542-14	82517-82525	hospital	_	
542-15	82526-82535	discharge	_	
542-16	82536-82537	,	_	
542-17	82538-82541	and	_	
542-18	82542-82544	at	_	
542-19	82545-82547	30	_	
542-20	82548-82551	and	_	
542-21	82552-82554	90	_	
542-22	82555-82559	days	1	
542-23	82560-82561	;	6	
542-24	82562-82573	assessments	9	
542-25	82574-82582	included	8	
542-26	82583-82586	the	2	
542-27	82587-82592	score	_	
542-28	82593-82595	on	_	
542-29	82596-82599	the	_	
542-30	82600-82608	modified	_	
542-31	82609-82615	Rankin	_	
542-32	82616-82621	scale	_	
542-33	82622-82625	and	_	
542-34	82626-82629	the	_	
542-35	82630-82635	NIHSS	_	
542-36	82636-82641	score	_	
542-37	82642-82643	,	1	
542-38	82644-82648	both	3	
542-39	82649-82659	determined	_	
542-40	82660-82662	by	1	
542-41	82663-82672	certified	2	
542-42	82673-82682	assessors	_	
542-43	82683-82686	who	_	
542-44	82687-82691	were	_	
542-45	82692-82699	unaware	_	
542-46	82700-82702	of	_	
542-47	82703-82706	the	_	
542-48	82707-82712	trial	_	
542-49	82713-82718	group	_	
542-50	82719-82730	assignments	1	
542-51	82731-82733	at	2	
542-52	82734-82736	30	_	
542-53	82737-82740	and	_	
542-54	82741-82743	90	_	
542-55	82744-82748	days	_	
542-56	82749-82750	.	1	

#Text=The concentrations calculated using the calibration curves were within ± 20 % of the theoretical levels .
543-1	82751-82754	The	9	
543-2	82755-82769	concentrations	1	
543-3	82770-82780	calculated	3	
543-4	82781-82786	using	1	
543-5	82787-82790	the	2	
543-6	82791-82802	calibration	_	
543-7	82803-82809	curves	1	
543-8	82810-82814	were	8	
543-9	82815-82821	within	1	
543-10	82822-82823	±	2	
543-11	82824-82826	20	_	
543-12	82827-82828	%	_	
543-13	82829-82831	of	_	
543-14	82832-82835	the	_	
543-15	82836-82847	theoretical	_	
543-16	82848-82854	levels	_	
543-17	82855-82856	.	1	

#Text=Safety was assessed throughout the trial , with events classified using the Medical Dictionary for Regulatory Activities ( MedDRA ) version 17.1.
544-1	82857-82863	Safety	9	
544-2	82864-82867	was	8	
544-3	82868-82876	assessed	_	
544-4	82877-82887	throughout	1	
544-5	82888-82891	the	2	
544-6	82892-82897	trial	_	
544-7	82898-82899	,	1	
544-8	82900-82904	with	2	
544-9	82905-82911	events	_	
544-10	82912-82922	classified	1	
544-11	82923-82928	using	3	
544-12	82929-82932	the	2	
544-13	82933-82940	Medical	_	
544-14	82941-82951	Dictionary	_	
544-15	82952-82955	for	_	
544-16	82956-82966	Regulatory	_	
544-17	82967-82977	Activities	_	
544-18	82978-82979	(	5	
544-19	82980-82986	MedDRA	_	
544-20	82987-82988	)	1	
544-21	82989-82996	version	_	
544-22	82997-83001	17.1	_	
544-23	83001-83002	.	1	

#Text=LPC 17:0 was used for LPC containing > 16 C and < 18 carbons in the FA side chain , and LPC 18:1 was used for quantification of all LPCs containing a FA with > 17 carbons .
545-1	83003-83006	LPC	9	
545-2	83007-83009	17	_	
545-3	83009-83010	:	_	
545-4	83010-83011	0	1	
545-5	83012-83015	was	8	
545-6	83016-83020	used	_	
545-7	83021-83024	for	1	
545-8	83025-83028	LPC	2	
545-9	83029-83039	containing	3	
545-10	83040-83041	>	2	
545-11	83042-83044	16	_	
545-12	83045-83046	C	_	
545-13	83047-83050	and	_	
545-14	83051-83052	<	_	
545-15	83053-83055	18	_	
545-16	83056-83063	carbons	_	
545-17	83064-83066	in	_	
545-18	83067-83070	the	_	
545-19	83071-83073	FA	_	
545-20	83074-83078	side	_	
545-21	83079-83084	chain	_	
545-22	83085-83086	,	1	
545-23	83087-83090	and	9	
545-24	83091-83094	LPC	_	
545-25	83095-83097	18	_	
545-26	83097-83098	:	_	
545-27	83098-83099	1	1	
545-28	83100-83103	was	3	
545-29	83104-83108	used	_	
545-30	83109-83112	for	1	
545-31	83113-83127	quantification	2	
545-32	83128-83130	of	_	
545-33	83131-83134	all	_	
545-34	83135-83139	LPCs	1	
545-35	83140-83150	containing	3	
545-36	83151-83152	a	1	
545-37	83153-83155	FA	_	
545-38	83156-83160	with	_	
545-39	83161-83162	>	_	
545-40	83163-83165	17	_	
545-41	83166-83173	carbons	_	
545-42	83174-83175	.	1	

#Text=For each of the three interventions , participants were asked to attend three of four available one-hour classes/sessions each week .
546-1	83176-83179	For	2	
546-2	83180-83184	each	_	
546-3	83185-83187	of	_	
546-4	83188-83191	the	_	
546-5	83192-83197	three	_	
546-6	83198-83211	interventions	_	
546-7	83212-83213	,	1	
546-8	83214-83226	participants	9	
546-9	83227-83231	were	8	
546-10	83232-83237	asked	_	
546-11	83238-83240	to	_	
546-12	83241-83247	attend	1	
546-13	83248-83253	three	2	
546-14	83254-83256	of	_	
546-15	83257-83261	four	_	
546-16	83262-83271	available	_	
546-17	83272-83280	one-hour	_	
546-18	83281-83288	classes	_	
546-19	83288-83289	/	_	
546-20	83289-83297	sessions	1	
546-21	83298-83302	each	2	
546-22	83303-83307	week	_	
546-23	83308-83309	.	1	

#Text=The primary safety outcomes were death within 90 days and the occurrence of symptomatic intracranial hemorrhage within 36 hours , defined as an increase of at least 4 points in the NIHSS score that was associated with brain hemorrhage on imaging within 36 hours after symptom onset .
547-1	83310-83313	The	9	
547-2	83314-83321	primary	_	
547-3	83322-83328	safety	_	
547-4	83329-83337	outcomes	1	
547-5	83338-83342	were	8	
547-6	83343-83348	death	2	
547-7	83349-83355	within	_	
547-8	83356-83358	90	_	
547-9	83359-83363	days	1	
547-10	83364-83367	and	2	
547-11	83368-83371	the	_	
547-12	83372-83382	occurrence	_	
547-13	83383-83385	of	_	
547-14	83386-83397	symptomatic	_	
547-15	83398-83410	intracranial	_	
547-16	83411-83421	hemorrhage	_	
547-17	83422-83428	within	_	
547-18	83429-83431	36	_	
547-19	83432-83437	hours	_	
547-20	83438-83439	,	1	
547-21	83440-83447	defined	3	
547-22	83448-83450	as	1	
547-23	83451-83453	an	2	
547-24	83454-83462	increase	_	
547-25	83463-83465	of	_	
547-26	83466-83468	at	_	
547-27	83469-83474	least	_	
547-28	83475-83476	4	_	
547-29	83477-83483	points	_	
547-30	83484-83486	in	_	
547-31	83487-83490	the	_	
547-32	83491-83496	NIHSS	_	
547-33	83497-83502	score	1	
547-34	83503-83507	that	6	
547-35	83508-83511	was	3	
547-36	83512-83522	associated	_	
547-37	83523-83527	with	1	
547-38	83528-83533	brain	2	
547-39	83534-83544	hemorrhage	_	
547-40	83545-83547	on	_	
547-41	83548-83555	imaging	_	
547-42	83556-83562	within	_	
547-43	83563-83565	36	_	
547-44	83566-83571	hours	_	
547-45	83572-83577	after	_	
547-46	83578-83585	symptom	_	
547-47	83586-83591	onset	_	
547-48	83592-83593	.	1	

#Text=The lower and upper sides of the box represent the 25th and 75th percentile .
548-1	83594-83597	The	9	
548-2	83598-83603	lower	_	
548-3	83604-83607	and	_	
548-4	83608-83613	upper	_	
548-5	83614-83619	sides	_	
548-6	83620-83622	of	_	
548-7	83623-83626	the	_	
548-8	83627-83630	box	1	
548-9	83631-83640	represent	8	
548-10	83641-83644	the	2	
548-11	83645-83649	25th	_	
548-12	83650-83653	and	_	
548-13	83654-83658	75th	_	
548-14	83659-83669	percentile	_	
548-15	83670-83671	.	1	

#Text=Infusion was initiated ≥   1 and ≤   12   h following commencement of IMV at a rate of 0.1   mL/min , increasing by 0.1 mL every 10   min to a maximum of 0.5   mL/min ( target infusion rate ) .
549-1	83672-83680	Infusion	9	
549-2	83681-83684	was	8	
549-3	83685-83694	initiated	1	
549-4	83695-83696	≥	2	
549-5	83699-83700	1	_	
549-6	83701-83704	and	_	
549-7	83705-83706	≤	_	
549-8	83709-83711	12	_	
549-9	83712-83713	 	_	
549-10	83714-83715	h	1	
549-11	83716-83725	following	3	
549-12	83726-83738	commencement	2	
549-13	83739-83741	of	_	
549-14	83742-83745	IMV	_	
549-15	83746-83748	at	_	
549-16	83749-83750	a	_	
549-17	83751-83755	rate	_	
549-18	83756-83758	of	_	
549-19	83759-83762	0.1	_	
549-20	83763-83764	 	_	
549-21	83765-83767	mL	_	
549-22	83767-83768	/	_	
549-23	83768-83771	min	_	
549-24	83772-83773	,	1	
549-25	83774-83784	increasing	3	
549-26	83785-83787	by	1	
549-27	83788-83791	0.1	2	
549-28	83792-83794	mL	_	
549-29	83795-83800	every	_	
549-30	83801-83803	10	_	
549-31	83804-83805	 	_	
549-32	83806-83809	min	1	
549-33	83810-83812	to	2	
549-34	83813-83814	a	_	
549-35	83815-83822	maximum	_	
549-36	83823-83825	of	_	
549-37	83826-83829	0.5	_	
549-38	83830-83831	 	_	
549-39	83832-83834	mL	_	
549-40	83834-83835	/	_	
549-41	83835-83838	min	1	
549-42	83839-83840	(	5	
549-43	83841-83847	target	_	
549-44	83848-83856	infusion	_	
549-45	83857-83861	rate	_	
549-46	83862-83863	)	_	
549-47	83864-83865	.	1	

#Text=We had not thought of this patient group when writing the protocol , but when the issue emerged , we decided to exclude patents with inflammatory bowel disease .
550-1	83866-83868	We	9	
550-2	83869-83872	had	_	
550-3	83873-83876	not	_	
550-4	83877-83884	thought	_	
550-5	83885-83887	of	1	
550-6	83888-83892	this	2	
550-7	83893-83900	patient	_	
550-8	83901-83906	group	1	
550-9	83907-83911	when	6	
550-10	83912-83919	writing	3	
550-11	83920-83923	the	2	
550-12	83924-83932	protocol	_	
550-13	83933-83934	,	1	
550-14	83935-83938	but	6	
550-15	83939-83943	when	1	
550-16	83944-83947	the	9	
550-17	83948-83953	issue	1	
550-18	83954-83961	emerged	3	
550-19	83962-83963	,	1	
550-20	83964-83966	we	3	
550-21	83967-83974	decided	_	
550-22	83975-83977	to	_	
550-23	83978-83985	exclude	1	
550-24	83986-83993	patents	2	
550-25	83994-83998	with	_	
550-26	83999-84011	inflammatory	_	
550-27	84012-84017	bowel	_	
550-28	84018-84025	disease	_	
550-29	84026-84027	.	1	

#Text=The technical efficacy of the endovascular procedure in establishing reperfusion was defined in the endovascular-therapy group by a modified Thrombolysis in Cerebral Infarction ( TICI ) score of 2b ( 50 to 99 % reperfusion ) or 3 ( complete reperfusion).
551-1	84028-84031	The	9	
551-2	84032-84041	technical	_	
551-3	84042-84050	efficacy	_	
551-4	84051-84053	of	_	
551-5	84054-84057	the	_	
551-6	84058-84070	endovascular	_	
551-7	84071-84080	procedure	1	
551-8	84081-84083	in	3	
551-9	84084-84096	establishing	1	
551-10	84097-84108	reperfusion	2	
551-11	84109-84112	was	1	
551-12	84113-84120	defined	_	
551-13	84121-84123	in	1	
551-14	84124-84127	the	2	
551-15	84128-84148	endovascular-therapy	_	
551-16	84149-84154	group	1	
551-17	84155-84157	by	2	
551-18	84158-84159	a	_	
551-19	84160-84168	modified	_	
551-20	84169-84181	Thrombolysis	_	
551-21	84182-84184	in	_	
551-22	84185-84193	Cerebral	_	
551-23	84194-84204	Infarction	_	
551-24	84205-84206	(	5	
551-25	84207-84211	TICI	_	
551-26	84212-84213	)	1	
551-27	84214-84219	score	_	
551-28	84220-84222	of	_	
551-29	84223-84225	2b	_	
551-30	84226-84227	(	5	
551-31	84228-84230	50	_	
551-32	84231-84233	to	_	
551-33	84234-84236	99	_	
551-34	84237-84238	%	_	
551-35	84239-84250	reperfusion	_	
551-36	84251-84252	)	1	
551-37	84253-84255	or	_	
551-38	84256-84257	3	1	
551-39	84258-84259	(	5	
551-40	84260-84268	complete	_	
551-41	84269-84280	reperfusion	_	
551-42	84280-84281	)	_	
551-43	84281-84282	.	1	

#Text=Treatment-emergent adverse events ( TEAEs ; defined as an adverse event [ AE ] that occurred from the time of first dose of study medication until the final follow-up visit , independent of relation to study drug ) , infusion-related reactions ( defined as TEAEs that occurred during or within 24   h after infusion of study medication ) , vital signs , electrocardiograms , and laboratory parameters including clinical chemistry , hematology , and coagulation were recorded .
552-1	84283-84301	Treatment-emergent	9	
552-2	84302-84309	adverse	_	
552-3	84310-84316	events	_	
552-4	84317-84318	(	5	
552-5	84319-84324	TEAEs	_	
552-6	84325-84326	;	_	
552-7	84327-84334	defined	_	
552-8	84335-84337	as	_	
552-9	84338-84340	an	_	
552-10	84341-84348	adverse	_	
552-11	84349-84354	event	_	
552-12	84355-84356	[	_	
552-13	84357-84359	AE	_	
552-14	84360-84361	]	_	
552-15	84362-84366	that	_	
552-16	84367-84375	occurred	_	
552-17	84376-84380	from	_	
552-18	84381-84384	the	_	
552-19	84385-84389	time	_	
552-20	84390-84392	of	_	
552-21	84393-84398	first	_	
552-22	84399-84403	dose	_	
552-23	84404-84406	of	_	
552-24	84407-84412	study	_	
552-25	84413-84423	medication	_	
552-26	84424-84429	until	_	
552-27	84430-84433	the	_	
552-28	84434-84439	final	_	
552-29	84440-84449	follow-up	_	
552-30	84450-84455	visit	_	
552-31	84456-84457	,	_	
552-32	84458-84469	independent	_	
552-33	84470-84472	of	_	
552-34	84473-84481	relation	_	
552-35	84482-84484	to	_	
552-36	84485-84490	study	_	
552-37	84491-84495	drug	_	
552-38	84496-84497	)	1	
552-39	84498-84499	,	_	
552-40	84500-84516	infusion-related	_	
552-41	84517-84526	reactions	_	
552-42	84527-84528	(	5	
552-43	84529-84536	defined	_	
552-44	84537-84539	as	_	
552-45	84540-84545	TEAEs	_	
552-46	84546-84550	that	_	
552-47	84551-84559	occurred	_	
552-48	84560-84566	during	_	
552-49	84567-84569	or	_	
552-50	84570-84576	within	_	
552-51	84577-84579	24	_	
552-52	84580-84581	 	_	
552-53	84582-84583	h	_	
552-54	84584-84589	after	_	
552-55	84590-84598	infusion	_	
552-56	84599-84601	of	_	
552-57	84602-84607	study	_	
552-58	84608-84618	medication	_	
552-59	84619-84620	)	1	
552-60	84621-84622	,	_	
552-61	84623-84628	vital	_	
552-62	84629-84634	signs	_	
552-63	84635-84636	,	_	
552-64	84637-84655	electrocardiograms	_	
552-65	84656-84657	,	_	
552-66	84658-84661	and	_	
552-67	84662-84672	laboratory	_	
552-68	84673-84683	parameters	_	
552-69	84684-84693	including	_	
552-70	84694-84702	clinical	_	
552-71	84703-84712	chemistry	_	
552-72	84713-84714	,	_	
552-73	84715-84725	hematology	_	
552-74	84726-84727	,	_	
552-75	84728-84731	and	_	
552-76	84732-84743	coagulation	1	
552-77	84744-84748	were	8	
552-78	84749-84757	recorded	_	
552-79	84758-84759	.	1	

#Text=Different study numbers were assigned to each study site : Oslo , 1000–1299 ; Bergen , 1300–1399 ; Denmark , 1400–1499 ; and Sweden , 1500–1599 .
553-1	84760-84769	Different	9	
553-2	84770-84775	study	_	
553-3	84776-84783	numbers	1	
553-4	84784-84788	were	8	
553-5	84789-84797	assigned	_	
553-6	84798-84800	to	1	
553-7	84801-84805	each	2	
553-8	84806-84811	study	_	
553-9	84812-84816	site	1	
553-10	84817-84818	:	6	
553-11	84819-84823	Oslo	2	
553-12	84824-84825	,	_	
553-13	84826-84830	1000	_	
553-14	84830-84831	–	_	
553-15	84831-84835	1299	_	
553-16	84836-84837	;	6	
553-17	84838-84844	Bergen	_	
553-18	84845-84846	,	_	
553-19	84847-84851	1300	_	
553-20	84851-84852	–	_	
553-21	84852-84856	1399	_	
553-22	84857-84858	;	_	
553-23	84859-84866	Denmark	_	
553-24	84867-84868	,	_	
553-25	84869-84873	1400	_	
553-26	84873-84874	–	_	
553-27	84874-84878	1499	_	
553-28	84879-84880	;	6	
553-29	84881-84884	and	_	
553-30	84885-84891	Sweden	_	
553-31	84892-84893	,	_	
553-32	84894-84898	1500	_	
553-33	84898-84899	–	_	
553-34	84899-84903	1599	_	
553-35	84904-84905	.	1	

#Text=The primary endpoints were death within one year and the occurrence of major complications , defined as infectious and cardiopulmonary complications within one month , the need for reintervention within one year , or recurrent biliary disease within one year .
554-1	84906-84909	The	9	
554-2	84910-84917	primary	_	
554-3	84918-84927	endpoints	1	
554-4	84928-84932	were	8	
554-5	84933-84938	death	2	
554-6	84939-84945	within	_	
554-7	84946-84949	one	_	
554-8	84950-84954	year	_	
554-9	84955-84958	and	_	
554-10	84959-84962	the	_	
554-11	84963-84973	occurrence	_	
554-12	84974-84976	of	_	
554-13	84977-84982	major	_	
554-14	84983-84996	complications	_	
554-15	84997-84998	,	1	
554-16	84999-85006	defined	3	
554-17	85007-85009	as	1	
554-18	85010-85020	infectious	2	
554-19	85021-85024	and	_	
554-20	85025-85040	cardiopulmonary	_	
554-21	85041-85054	complications	_	
554-22	85055-85061	within	_	
554-23	85062-85065	one	_	
554-24	85066-85071	month	_	
554-25	85072-85073	,	_	
554-26	85074-85077	the	_	
554-27	85078-85082	need	_	
554-28	85083-85086	for	_	
554-29	85087-85101	reintervention	_	
554-30	85102-85108	within	_	
554-31	85109-85112	one	_	
554-32	85113-85117	year	_	
554-33	85118-85119	,	_	
554-34	85120-85122	or	_	
554-35	85123-85132	recurrent	_	
554-36	85133-85140	biliary	_	
554-37	85141-85148	disease	_	
554-38	85149-85155	within	_	
554-39	85156-85159	one	_	
554-40	85160-85164	year	_	
554-41	85165-85166	.	1	

#Text=The study was investigator initiated and conducted in accordance with the principles of the Declaration of Helsinki .
555-1	85167-85170	The	9	
555-2	85171-85176	study	1	
555-3	85177-85180	was	8	
555-4	85181-85193	investigator	_	
555-5	85194-85203	initiated	_	
555-6	85204-85207	and	_	
555-7	85208-85217	conducted	_	
555-8	85218-85220	in	_	
555-9	85221-85231	accordance	_	
555-10	85232-85236	with	1	
555-11	85237-85240	the	2	
555-12	85241-85251	principles	_	
555-13	85252-85254	of	_	
555-14	85255-85258	the	_	
555-15	85259-85270	Declaration	_	
555-16	85271-85273	of	_	
555-17	85274-85282	Helsinki	_	
555-18	85283-85284	.	1	

#Text=The patients included in this study also had dyspepsia .
556-1	85285-85288	The	9	
556-2	85289-85297	patients	_	
556-3	85298-85306	included	_	
556-4	85307-85309	in	_	
556-5	85310-85314	this	_	
556-6	85315-85320	study	1	
556-7	85321-85325	also	8	
556-8	85326-85329	had	1	
556-9	85330-85339	dyspepsia	2	
556-10	85340-85341	.	1	

#Text=The KOOS pain subscale yields a score of pain intensity during a variety of movements and activities .
557-1	85342-85345	The	9	
557-2	85346-85350	KOOS	_	
557-3	85351-85355	pain	_	
557-4	85356-85364	subscale	1	
557-5	85365-85371	yields	8	
557-6	85372-85373	a	2	
557-7	85374-85379	score	_	
557-8	85380-85382	of	_	
557-9	85383-85387	pain	_	
557-10	85388-85397	intensity	_	
557-11	85398-85404	during	_	
557-12	85405-85406	a	_	
557-13	85407-85414	variety	_	
557-14	85415-85417	of	_	
557-15	85418-85427	movements	_	
557-16	85428-85431	and	_	
557-17	85432-85442	activities	_	
557-18	85443-85444	.	1	

#Text=Efficacy estimates of secondary endpoints are presented with 95 % confidence intervals .
558-1	85445-85453	Efficacy	9	
558-2	85454-85463	estimates	_	
558-3	85464-85466	of	_	
558-4	85467-85476	secondary	_	
558-5	85477-85486	endpoints	1	
558-6	85487-85490	are	8	
558-7	85491-85500	presented	_	
558-8	85501-85505	with	1	
558-9	85506-85508	95	2	
558-10	85509-85510	%	_	
558-11	85511-85521	confidence	_	
558-12	85522-85531	intervals	_	
558-13	85532-85533	.	1	

#Text=The trial by Kronenberg et al. was published after all our analyses were finalized and did not have any impact on the conduct of our trial [ 15 ] .
559-1	85534-85537	The	9	
559-2	85538-85543	trial	_	
559-3	85544-85546	by	_	
559-4	85547-85557	Kronenberg	_	
559-5	85558-85560	et	_	
559-6	85561-85563	al	_	
559-7	85563-85564	.	1	
559-8	85565-85568	was	8	
559-9	85569-85578	published	_	
559-10	85579-85584	after	1	
559-11	85585-85588	all	9	
559-12	85589-85592	our	_	
559-13	85593-85601	analyses	1	
559-14	85602-85606	were	_	
559-15	85607-85616	finalized	_	
559-16	85617-85620	and	_	
559-17	85621-85624	did	_	
559-18	85625-85628	not	_	
559-19	85629-85633	have	1	
559-20	85634-85637	any	2	
559-21	85638-85644	impact	_	
559-22	85645-85647	on	_	
559-23	85648-85651	the	_	
559-24	85652-85659	conduct	_	
559-25	85660-85662	of	_	
559-26	85663-85666	our	_	
559-27	85667-85672	trial	1	
559-28	85673-85674	[	5	
559-29	85675-85677	15	_	
559-30	85678-85679	]	_	
559-31	85680-85681	.	1	

#Text=In the trial by Gagyor et al. , they left this classification to the discretion of the GP .
560-1	85682-85684	In	2	
560-2	85685-85688	the	_	
560-3	85689-85694	trial	_	
560-4	85695-85697	by	_	
560-5	85698-85704	Gagyor	_	
560-6	85705-85707	et	_	
560-7	85708-85710	al	_	
560-8	85710-85711	.	_	
560-9	85712-85713	,	1	
560-10	85714-85718	they	9	
560-11	85719-85723	left	8	
560-12	85724-85728	this	2	
560-13	85729-85743	classification	1	
560-14	85744-85746	to	2	
560-15	85747-85750	the	_	
560-16	85751-85761	discretion	_	
560-17	85762-85764	of	_	
560-18	85765-85768	the	_	
560-19	85769-85771	GP	_	
560-20	85772-85773	.	1	

#Text=Risk assessment was based on the APACHE II ( acute physiology assessment and chronic health evaluation II ) severity of disease classification system.
561-1	85774-85778	Risk	9	
561-2	85779-85789	assessment	1	
561-3	85790-85793	was	8	
561-4	85794-85799	based	_	
561-5	85800-85802	on	1	
561-6	85803-85806	the	2	
561-7	85807-85813	APACHE	_	
561-8	85814-85816	II	_	
561-9	85817-85818	(	5	
561-10	85819-85824	acute	_	
561-11	85825-85835	physiology	_	
561-12	85836-85846	assessment	_	
561-13	85847-85850	and	_	
561-14	85851-85858	chronic	_	
561-15	85859-85865	health	_	
561-16	85866-85876	evaluation	_	
561-17	85877-85879	II	_	
561-18	85880-85881	)	1	
561-19	85882-85890	severity	_	
561-20	85891-85893	of	_	
561-21	85894-85901	disease	_	
561-22	85902-85916	classification	_	
561-23	85917-85923	system	_	
561-24	85923-85924	.	1	

#Text=Further , mobility performance was assessed using the set of tools that is recommended for interventional studies of knee OA [ 30 ] .
562-1	85925-85932	Further	6	
562-2	85933-85934	,	1	
562-3	85935-85943	mobility	9	
562-4	85944-85955	performance	1	
562-5	85956-85959	was	8	
562-6	85960-85968	assessed	_	
562-7	85969-85974	using	1	
562-8	85975-85978	the	2	
562-9	85979-85982	set	_	
562-10	85983-85985	of	_	
562-11	85986-85991	tools	1	
562-12	85992-85996	that	6	
562-13	85997-85999	is	3	
562-14	86000-86011	recommended	_	
562-15	86012-86015	for	1	
562-16	86016-86030	interventional	2	
562-17	86031-86038	studies	_	
562-18	86039-86041	of	_	
562-19	86042-86046	knee	_	
562-20	86047-86049	OA	1	
562-21	86050-86051	[	5	
562-22	86052-86054	30	_	
562-23	86055-86056	]	_	
562-24	86057-86058	.	1	

#Text=Secondary outcome measures included duration of symptoms and the patients ’ symptom load for specific symptoms .
563-1	86059-86068	Secondary	9	
563-2	86069-86076	outcome	_	
563-3	86077-86085	measures	1	
563-4	86086-86094	included	8	
563-5	86095-86103	duration	2	
563-6	86104-86106	of	_	
563-7	86107-86115	symptoms	1	
563-8	86116-86119	and	2	
563-9	86120-86123	the	_	
563-10	86124-86132	patients	_	
563-11	86133-86134	’	_	
563-12	86135-86142	symptom	_	
563-13	86143-86147	load	_	
563-14	86148-86151	for	_	
563-15	86152-86160	specific	_	
563-16	86161-86169	symptoms	_	
563-17	86170-86171	.	1	

#Text=It is a nine-item tool answered on a five-point Likert scale .
564-1	86172-86174	It	8	
564-2	86175-86177	is	1	
564-3	86178-86179	a	2	
564-4	86180-86189	nine-item	_	
564-5	86190-86194	tool	_	
564-6	86195-86203	answered	_	
564-7	86204-86206	on	_	
564-8	86207-86208	a	_	
564-9	86209-86219	five-point	_	
564-10	86220-86226	Likert	_	
564-11	86227-86232	scale	_	
564-12	86233-86234	.	1	

#Text=Eighteen patients presented non-atrophic gastritis ( possibly due to unbalanced diet and lifestyle ) , 8 patients were affected by atrophic gastritis and 24 by chemical gastritis ( bile reflux observed by endoscopy ) based on the classification by Dixon and coworkers [ 32 ] .
565-1	86235-86243	Eighteen	9	
565-2	86244-86252	patients	1	
565-3	86253-86262	presented	8	
565-4	86263-86275	non-atrophic	2	
565-5	86276-86285	gastritis	1	
565-6	86286-86287	(	5	
565-7	86288-86296	possibly	_	
565-8	86297-86300	due	_	
565-9	86301-86303	to	_	
565-10	86304-86314	unbalanced	_	
565-11	86315-86319	diet	_	
565-12	86320-86323	and	_	
565-13	86324-86333	lifestyle	_	
565-14	86334-86335	)	_	
565-15	86336-86337	,	1	
565-16	86338-86339	8	9	
565-17	86340-86348	patients	1	
565-18	86349-86353	were	3	
565-19	86354-86362	affected	_	
565-20	86363-86365	by	1	
565-21	86366-86374	atrophic	2	
565-22	86375-86384	gastritis	1	
565-23	86385-86388	and	2	
565-24	86389-86391	24	_	
565-25	86392-86394	by	_	
565-26	86395-86403	chemical	_	
565-27	86404-86413	gastritis	1	
565-28	86414-86415	(	5	
565-29	86416-86420	bile	_	
565-30	86421-86427	reflux	_	
565-31	86428-86436	observed	_	
565-32	86437-86439	by	_	
565-33	86440-86449	endoscopy	_	
565-34	86450-86451	)	1	
565-35	86452-86457	based	3	
565-36	86458-86460	on	1	
565-37	86461-86464	the	2	
565-38	86465-86479	classification	_	
565-39	86480-86482	by	_	
565-40	86483-86488	Dixon	_	
565-41	86489-86492	and	_	
565-42	86493-86502	coworkers	1	
565-43	86503-86504	[	5	
565-44	86505-86507	32	_	
565-45	86508-86509	]	_	
565-46	86510-86511	.	1	

#Text=The statistical analysis plan specified one-sided hypothesis testing for the Wilcoxon rank-sum test and a P value of less than 0.025 as a measure of statistical significance , but we report two-sided results and use a P value of less than 0.05 as a measure of statistical significance .
566-1	86512-86515	The	9	
566-2	86516-86527	statistical	_	
566-3	86528-86536	analysis	_	
566-4	86537-86541	plan	1	
566-5	86542-86551	specified	8	
566-6	86552-86561	one-sided	2	
566-7	86562-86572	hypothesis	_	
566-8	86573-86580	testing	_	
566-9	86581-86584	for	_	
566-10	86585-86588	the	_	
566-11	86589-86597	Wilcoxon	_	
566-12	86598-86606	rank-sum	_	
566-13	86607-86611	test	1	
566-14	86612-86615	and	_	
566-15	86616-86617	a	2	
566-16	86618-86619	P	_	
566-17	86620-86625	value	_	
566-18	86626-86628	of	_	
566-19	86629-86633	less	_	
566-20	86634-86638	than	_	
566-21	86639-86644	0.025	1	
566-22	86645-86647	as	2	
566-23	86648-86649	a	_	
566-24	86650-86657	measure	_	
566-25	86658-86660	of	_	
566-26	86661-86672	statistical	_	
566-27	86673-86685	significance	_	
566-28	86686-86687	,	1	
566-29	86688-86691	but	3	
566-30	86692-86694	we	_	
566-31	86695-86701	report	1	
566-32	86702-86711	two-sided	2	
566-33	86712-86719	results	_	
566-34	86720-86723	and	_	
566-35	86724-86727	use	_	
566-36	86728-86729	a	_	
566-37	86730-86731	P	_	
566-38	86732-86737	value	_	
566-39	86738-86740	of	_	
566-40	86741-86745	less	_	
566-41	86746-86750	than	_	
566-42	86751-86755	0.05	1	
566-43	86756-86758	as	2	
566-44	86759-86760	a	_	
566-45	86761-86768	measure	_	
566-46	86769-86771	of	_	
566-47	86772-86783	statistical	_	
566-48	86784-86796	significance	_	
566-49	86797-86798	.	1	

#Text=The socio-demographics of the patient populations of the 2 sites differ .
567-1	86799-86802	The	9	
567-2	86803-86821	socio-demographics	_	
567-3	86822-86824	of	_	
567-4	86825-86828	the	_	
567-5	86829-86836	patient	_	
567-6	86837-86848	populations	_	
567-7	86849-86851	of	_	
567-8	86852-86855	the	_	
567-9	86856-86857	2	_	
567-10	86858-86863	sites	1	
567-11	86864-86870	differ	2	
567-12	86871-86872	.	1	

#Text=Subjects were excluded if they had undergone facial tissue augmentation in the lower two-thirds of the face with dermal fillers within the previous 12 months or with fat or botulinum toxin injections within the previous 6 months ; had undergone cosmetic facial procedures in the face or neck within the previous 6 months ; or had received semipermanent fillers or permanent facial implants in the lower face .
568-1	86873-86881	Subjects	9	
568-2	86882-86886	were	8	
568-3	86887-86895	excluded	1	
568-4	86896-86898	if	6	
568-5	86899-86903	they	3	
568-6	86904-86907	had	_	
568-7	86908-86917	undergone	1	
568-8	86918-86924	facial	2	
568-9	86925-86931	tissue	_	
568-10	86932-86944	augmentation	_	
568-11	86945-86947	in	_	
568-12	86948-86951	the	_	
568-13	86952-86957	lower	_	
568-14	86958-86968	two-thirds	_	
568-15	86969-86971	of	_	
568-16	86972-86975	the	_	
568-17	86976-86980	face	_	
568-18	86981-86985	with	_	
568-19	86986-86992	dermal	_	
568-20	86993-87000	fillers	_	
568-21	87001-87007	within	_	
568-22	87008-87011	the	_	
568-23	87012-87020	previous	_	
568-24	87021-87023	12	_	
568-25	87024-87030	months	1	
568-26	87031-87033	or	2	
568-27	87034-87038	with	_	
568-28	87039-87042	fat	_	
568-29	87043-87045	or	_	
568-30	87046-87055	botulinum	_	
568-31	87056-87061	toxin	_	
568-32	87062-87072	injections	_	
568-33	87073-87079	within	_	
568-34	87080-87083	the	_	
568-35	87084-87092	previous	_	
568-36	87093-87094	6	_	
568-37	87095-87101	months	1	
568-38	87102-87103	;	6	
568-39	87104-87107	had	3	
568-40	87108-87117	undergone	1	
568-41	87118-87126	cosmetic	2	
568-42	87127-87133	facial	_	
568-43	87134-87144	procedures	_	
568-44	87145-87147	in	_	
568-45	87148-87151	the	_	
568-46	87152-87156	face	_	
568-47	87157-87159	or	_	
568-48	87160-87164	neck	_	
568-49	87165-87171	within	_	
568-50	87172-87175	the	_	
568-51	87176-87184	previous	_	
568-52	87185-87186	6	_	
568-53	87187-87193	months	1	
568-54	87194-87195	;	6	
568-55	87196-87198	or	3	
568-56	87199-87202	had	_	
568-57	87203-87211	received	1	
568-58	87212-87225	semipermanent	2	
568-59	87226-87233	fillers	_	
568-60	87234-87236	or	_	
568-61	87237-87246	permanent	_	
568-62	87247-87253	facial	_	
568-63	87254-87262	implants	_	
568-64	87263-87265	in	_	
568-65	87266-87269	the	_	
568-66	87270-87275	lower	_	
568-67	87276-87280	face	_	
568-68	87281-87282	.	1	

#Text=Within each block of patients randomly assigned in each cycle , those assigned to Tai Chi were further randomly assigned to 1 of 3 instructors so that each instructor treated 1 group every 3 blocks .
569-1	87283-87289	Within	2	
569-2	87290-87294	each	_	
569-3	87295-87300	block	_	
569-4	87301-87303	of	_	
569-5	87304-87312	patients	_	
569-6	87313-87321	randomly	_	
569-7	87322-87330	assigned	_	
569-8	87331-87333	in	_	
569-9	87334-87338	each	_	
569-10	87339-87344	cycle	_	
569-11	87345-87346	,	1	
569-12	87347-87352	those	9	
569-13	87353-87361	assigned	_	
569-14	87362-87364	to	_	
569-15	87365-87368	Tai	_	
569-16	87369-87372	Chi	9	
569-17	87373-87377	were	8	
569-18	87378-87385	further	_	
569-19	87386-87394	randomly	_	
569-20	87395-87403	assigned	_	
569-21	87404-87406	to	1	
569-22	87407-87408	1	2	
569-23	87409-87411	of	_	
569-24	87412-87413	3	_	
569-25	87414-87425	instructors	1	
569-26	87426-87428	so	6	
569-27	87429-87433	that	1	
569-28	87434-87438	each	9	
569-29	87439-87449	instructor	1	
569-30	87450-87457	treated	8	
569-31	87458-87459	1	2	
569-32	87460-87465	group	_	
569-33	87466-87471	every	_	
569-34	87472-87473	3	_	
569-35	87474-87480	blocks	_	
569-36	87481-87482	.	1	

#Text=Correction for [M+Na]+ adducts and isobaric [M+H]+ ions was performed to avoid errors in overlapping areas , e.g. , LPC 16:0 Na+ adducts were determined and subtracted from the isobaric LPC 18:3 H+ adducts .
570-1	87483-87493	Correction	9	
570-2	87494-87497	for	_	
570-3	87498-87499	[	5	
570-4	87499-87500	M	_	
570-5	87500-87501	+	_	
570-6	87501-87503	Na	_	
570-7	87503-87504	]	1	
570-8	87504-87505	+	_	
570-9	87506-87513	adducts	_	
570-10	87514-87517	and	_	
570-11	87518-87526	isobaric	_	
570-12	87527-87528	[	5	
570-13	87528-87529	M	_	
570-14	87529-87530	+	_	
570-15	87530-87531	H	_	
570-16	87531-87532	]	1	
570-17	87532-87533	+	_	
570-18	87534-87538	ions	1	
570-19	87539-87542	was	8	
570-20	87543-87552	performed	_	
570-21	87553-87555	to	_	
570-22	87556-87561	avoid	1	
570-23	87562-87568	errors	2	
570-24	87569-87571	in	_	
570-25	87572-87583	overlapping	_	
570-26	87584-87589	areas	_	
570-27	87590-87591	,	1	
570-28	87592-87595	e.g	6	
570-29	87595-87596	.	_	
570-30	87597-87598	,	1	
570-31	87599-87602	LPC	9	
570-32	87603-87605	16	_	
570-33	87605-87606	:	_	
570-34	87606-87607	0	_	
570-35	87608-87610	Na	_	
570-36	87610-87611	+	_	
570-37	87612-87619	adducts	1	
570-38	87620-87624	were	3	
570-39	87625-87635	determined	_	
570-40	87636-87639	and	_	
570-41	87640-87650	subtracted	_	
570-42	87651-87655	from	3	
570-43	87656-87659	the	2	
570-44	87660-87668	isobaric	_	
570-45	87669-87672	LPC	_	
570-46	87673-87675	18	_	
570-47	87675-87676	:	_	
570-48	87676-87677	3	_	
570-49	87678-87679	H	_	
570-50	87679-87680	+	_	
570-51	87681-87688	adducts	_	
570-52	87689-87690	.	1	

#Text=The study coordinator verified all completed forms in accordance with onsite source data .
571-1	87691-87694	The	9	
571-2	87695-87700	study	_	
571-3	87701-87712	coordinator	1	
571-4	87713-87721	verified	8	
571-5	87722-87725	all	2	
571-6	87726-87735	completed	_	
571-7	87736-87741	forms	1	
571-8	87742-87744	in	2	
571-9	87745-87755	accordance	_	
571-10	87756-87760	with	_	
571-11	87761-87767	onsite	_	
571-12	87768-87774	source	_	
571-13	87775-87779	data	_	
571-14	87780-87781	.	1	

#Text=The primary endpoint was ventilator-free days ( VFDs ) , defined as the number of days between extubation from IMV to day   28 after enrollment .
572-1	87782-87785	The	9	
572-2	87786-87793	primary	_	
572-3	87794-87802	endpoint	1	
572-4	87803-87806	was	8	
572-5	87807-87822	ventilator-free	2	
572-6	87823-87827	days	1	
572-7	87828-87829	(	5	
572-8	87830-87834	VFDs	_	
572-9	87835-87836	)	_	
572-10	87837-87838	,	1	
572-11	87839-87846	defined	3	
572-12	87847-87849	as	1	
572-13	87850-87853	the	2	
572-14	87854-87860	number	_	
572-15	87861-87863	of	_	
572-16	87864-87868	days	_	
572-17	87869-87876	between	_	
572-18	87877-87887	extubation	_	
572-19	87888-87892	from	_	
572-20	87893-87896	IMV	_	
572-21	87897-87899	to	_	
572-22	87900-87903	day	_	
572-23	87904-87905	 	_	
572-24	87906-87908	28	_	
572-25	87909-87914	after	_	
572-26	87915-87925	enrollment	_	
572-27	87926-87927	.	1	

#Text=We did not change or recommend changes in medical therapy .
573-1	87928-87930	We	9	
573-2	87931-87934	did	_	
573-3	87935-87938	not	_	
573-4	87939-87945	change	_	
573-5	87946-87948	or	_	
573-6	87949-87958	recommend	1	
573-7	87959-87966	changes	2	
573-8	87967-87969	in	_	
573-9	87970-87977	medical	_	
573-10	87978-87985	therapy	_	
573-11	87986-87987	.	1	

#Text=A 1-sided 95 % Wald confidence interval ( CI ) for the mean difference in improvement in NLFSS scores between VYC-17.5L versus control was constructed to test for noninferiority ; a p-value was determined using the Wilcoxon signed-rank test .
574-1	87988-87989	A	9	
574-2	87990-87991	1	_	
574-3	87991-87992	-	_	
574-4	87992-87997	sided	_	
574-5	87998-88000	95	_	
574-6	88001-88002	%	_	
574-7	88003-88007	Wald	_	
574-8	88008-88018	confidence	_	
574-9	88019-88027	interval	_	
574-10	88028-88029	(	5	
574-11	88030-88032	CI	_	
574-12	88033-88034	)	1	
574-13	88035-88038	for	_	
574-14	88039-88042	the	_	
574-15	88043-88047	mean	_	
574-16	88048-88058	difference	_	
574-17	88059-88061	in	_	
574-18	88062-88073	improvement	_	
574-19	88074-88076	in	_	
574-20	88077-88082	NLFSS	_	
574-21	88083-88089	scores	_	
574-22	88090-88097	between	_	
574-23	88098-88101	VYC	_	
574-24	88101-88102	-	_	
574-25	88102-88107	17.5L	_	
574-26	88108-88114	versus	_	
574-27	88115-88122	control	1	
574-28	88123-88126	was	8	
574-29	88127-88138	constructed	_	
574-30	88139-88141	to	_	
574-31	88142-88146	test	_	
574-32	88147-88150	for	1	
574-33	88151-88165	noninferiority	2	
574-34	88166-88167	;	6	
574-35	88168-88169	a	9	
574-36	88170-88177	p-value	1	
574-37	88178-88181	was	3	
574-38	88182-88192	determined	_	
574-39	88193-88198	using	1	
574-40	88199-88202	the	2	
574-41	88203-88211	Wilcoxon	_	
574-42	88212-88223	signed-rank	_	
574-43	88224-88228	test	_	
574-44	88229-88230	.	1	

#Text=Symptoms of depression were evaluated using the Center for Epidemiological Studies Depression Scale ( CESD ) .
575-1	88231-88239	Symptoms	9	
575-2	88240-88242	of	_	
575-3	88243-88253	depression	1	
575-4	88254-88258	were	8	
575-5	88259-88268	evaluated	_	
575-6	88269-88274	using	1	
575-7	88275-88278	the	2	
575-8	88279-88285	Center	_	
575-9	88286-88289	for	_	
575-10	88290-88305	Epidemiological	_	
575-11	88306-88313	Studies	_	
575-12	88314-88324	Depression	_	
575-13	88325-88330	Scale	1	
575-14	88331-88332	(	5	
575-15	88333-88337	CESD	_	
575-16	88338-88339	)	_	
575-17	88340-88341	.	1	

#Text=Safety analyses were performed using the safety set , which comprised all patients who received at least one dose of study drug according to medication received , regardless of randomization .
576-1	88342-88348	Safety	9	
576-2	88349-88357	analyses	1	
576-3	88358-88362	were	8	
576-4	88363-88372	performed	_	
576-5	88373-88378	using	1	
576-6	88379-88382	the	2	
576-7	88383-88389	safety	_	
576-8	88390-88393	set	_	
576-9	88394-88395	,	1	
576-10	88396-88401	which	6	
576-11	88402-88411	comprised	3	
576-12	88412-88415	all	2	
576-13	88416-88424	patients	_	
576-14	88425-88428	who	_	
576-15	88429-88437	received	_	
576-16	88438-88440	at	_	
576-17	88441-88446	least	_	
576-18	88447-88450	one	_	
576-19	88451-88455	dose	_	
576-20	88456-88458	of	_	
576-21	88459-88464	study	_	
576-22	88465-88469	drug	_	
576-23	88470-88479	according	_	
576-24	88480-88482	to	_	
576-25	88483-88493	medication	_	
576-26	88494-88502	received	_	
576-27	88503-88504	,	_	
576-28	88505-88515	regardless	_	
576-29	88516-88518	of	_	
576-30	88519-88532	randomization	_	
576-31	88533-88534	.	1	

#Text=The classification was done after the trial by Gagyor et al. was published ( December 2015 ) and was clearly defined in the SAP and implemented in the database prior to allocation unblinding .
577-1	88535-88538	The	9	
577-2	88539-88553	classification	1	
577-3	88554-88557	was	8	
577-4	88558-88562	done	_	
577-5	88563-88568	after	1	
577-6	88569-88572	the	9	
577-7	88573-88578	trial	_	
577-8	88579-88581	by	_	
577-9	88582-88588	Gagyor	_	
577-10	88589-88591	et	_	
577-11	88592-88594	al	_	
577-12	88594-88595	.	1	
577-13	88596-88599	was	3	
577-14	88600-88609	published	2	
577-15	88610-88611	(	5	
577-16	88612-88620	December	_	
577-17	88621-88625	2015	_	
577-18	88626-88627	)	1	
577-19	88628-88631	and	3	
577-20	88632-88635	was	_	
577-21	88636-88643	clearly	_	
577-22	88644-88651	defined	_	
577-23	88652-88654	in	1	
577-24	88655-88658	the	2	
577-25	88659-88662	SAP	1	
577-26	88663-88666	and	3	
577-27	88667-88678	implemented	_	
577-28	88679-88681	in	1	
577-29	88682-88685	the	2	
577-30	88686-88694	database	1	
577-31	88695-88700	prior	2	
577-32	88701-88703	to	_	
577-33	88704-88714	allocation	_	
577-34	88715-88725	unblinding	_	
577-35	88726-88727	.	1	

#Text=Angiographic studies from the endovascular procedure were assessed for reperfusion by two independent raters , who were unaware of any other imaging and clinical data , and a consensus was reached in cases of disagreement .
578-1	88728-88740	Angiographic	9	
578-2	88741-88748	studies	_	
578-3	88749-88753	from	_	
578-4	88754-88757	the	_	
578-5	88758-88770	endovascular	_	
578-6	88771-88780	procedure	1	
578-7	88781-88785	were	8	
578-8	88786-88794	assessed	_	
578-9	88795-88798	for	1	
578-10	88799-88810	reperfusion	2	
578-11	88811-88813	by	2	
578-12	88814-88817	two	_	
578-13	88818-88829	independent	_	
578-14	88830-88836	raters	_	
578-15	88837-88838	,	_	
578-16	88839-88842	who	_	
578-17	88843-88847	were	_	
578-18	88848-88855	unaware	_	
578-19	88856-88858	of	_	
578-20	88859-88862	any	_	
578-21	88863-88868	other	_	
578-22	88869-88876	imaging	_	
578-23	88877-88880	and	_	
578-24	88881-88889	clinical	_	
578-25	88890-88894	data	_	
578-26	88895-88896	,	1	
578-27	88897-88900	and	9	
578-28	88901-88902	a	_	
578-29	88903-88912	consensus	1	
578-30	88913-88916	was	3	
578-31	88917-88924	reached	_	
578-32	88925-88927	in	_	
578-33	88928-88933	cases	_	
578-34	88934-88936	of	1	
578-35	88937-88949	disagreement	2	
578-36	88950-88951	.	1	

#Text=Twenty-eight-day all-cause mortality was evaluated using the Kaplan – Meier method and analyzed using a Mantel – Haenszel test .
579-1	88952-88968	Twenty-eight-day	9	
579-2	88969-88978	all-cause	_	
579-3	88979-88988	mortality	1	
579-4	88989-88992	was	8	
579-5	88993-89002	evaluated	_	
579-6	89003-89008	using	1	
579-7	89009-89012	the	2	
579-8	89013-89019	Kaplan	_	
579-9	89020-89021	–	_	
579-10	89022-89027	Meier	_	
579-11	89028-89034	method	1	
579-12	89035-89038	and	3	
579-13	89039-89047	analyzed	_	
579-14	89048-89053	using	1	
579-15	89054-89055	a	2	
579-16	89056-89062	Mantel	_	
579-17	89063-89064	–	_	
579-18	89065-89073	Haenszel	_	
579-19	89074-89078	test	_	
579-20	89079-89080	.	1	

#Text=Results of the trial will be made available to all participants by email .
580-1	89081-89088	Results	9	
580-2	89089-89091	of	_	
580-3	89092-89095	the	_	
580-4	89096-89101	trial	1	
580-5	89102-89106	will	8	
580-6	89107-89109	be	_	
580-7	89110-89114	made	1	
580-8	89115-89124	available	7	
580-9	89125-89127	to	2	
580-10	89128-89131	all	_	
580-11	89132-89144	participants	1	
580-12	89145-89147	by	2	
580-13	89148-89153	email	_	
580-14	89154-89155	.	1	

#Text=Scores are normalized out of 100 ; lower scores indicate more extreme and troublesome symptoms .
581-1	89156-89162	Scores	9	
581-2	89163-89166	are	8	
581-3	89167-89177	normalized	_	
581-4	89178-89181	out	_	
581-5	89182-89184	of	1	
581-6	89185-89188	100	2	
581-7	89189-89190	;	6	
581-8	89191-89196	lower	9	
581-9	89197-89203	scores	1	
581-10	89204-89212	indicate	3	
581-11	89213-89217	more	2	
581-12	89218-89225	extreme	_	
581-13	89226-89229	and	_	
581-14	89230-89241	troublesome	_	
581-15	89242-89250	symptoms	_	
581-16	89251-89252	.	1	

#Text=All patients ( or their representatives ) provided written informed consent .
582-1	89253-89256	All	9	
582-2	89257-89265	patients	1	
582-3	89266-89267	(	5	
582-4	89268-89270	or	_	
582-5	89271-89276	their	_	
582-6	89277-89292	representatives	_	
582-7	89293-89294	)	1	
582-8	89295-89303	provided	8	
582-9	89304-89311	written	2	
582-10	89312-89320	informed	_	
582-11	89321-89328	consent	_	
582-12	89329-89330	.	1	

#Text=Pyelonephritis was defined as symptoms of UTI with flank pain , self-reported fever , and C-reactive protein ( CRP ) ≥ 40 mg/l .
583-1	89331-89345	Pyelonephritis	9	
583-2	89346-89349	was	8	
583-3	89350-89357	defined	_	
583-4	89358-89360	as	1	
583-5	89361-89369	symptoms	2	
583-6	89370-89372	of	_	
583-7	89373-89376	UTI	_	
583-8	89377-89381	with	_	
583-9	89382-89387	flank	_	
583-10	89388-89392	pain	_	
583-11	89393-89394	,	_	
583-12	89395-89408	self-reported	_	
583-13	89409-89414	fever	_	
583-14	89415-89416	,	_	
583-15	89417-89420	and	_	
583-16	89421-89431	C-reactive	_	
583-17	89432-89439	protein	_	
583-18	89440-89441	(	5	
583-19	89442-89445	CRP	_	
583-20	89446-89447	)	1	
583-21	89448-89449	≥	_	
583-22	89450-89452	40	_	
583-23	89453-89455	mg	_	
583-24	89455-89456	/	_	
583-25	89456-89457	l	_	
583-26	89458-89459	.	1	

#Text=The interventions took place between June and September 2015 in Hamilton , Ontario , Canada .
584-1	89460-89463	The	9	
584-2	89464-89477	interventions	9	
584-3	89478-89482	took	8	
584-4	89483-89488	place	_	
584-5	89489-89496	between	1	
584-6	89497-89501	June	2	
584-7	89502-89505	and	_	
584-8	89506-89515	September	_	
584-9	89516-89520	2015	1	
584-10	89521-89523	in	2	
584-11	89524-89532	Hamilton	_	
584-12	89533-89534	,	_	
584-13	89535-89542	Ontario	_	
584-14	89543-89544	,	_	
584-15	89545-89551	Canada	_	
584-16	89552-89553	.	1	

#Text=The study was approved by an investigational review board ( Western IRB , Seattle WA ) and written informed consent was obtained .
585-1	89554-89557	The	9	
585-2	89558-89563	study	1	
585-3	89564-89567	was	8	
585-4	89568-89576	approved	_	
585-5	89577-89579	by	1	
585-6	89580-89582	an	2	
585-7	89583-89598	investigational	_	
585-8	89599-89605	review	_	
585-9	89606-89611	board	1	
585-10	89612-89613	(	5	
585-11	89614-89621	Western	_	
585-12	89622-89625	IRB	_	
585-13	89626-89627	,	_	
585-14	89628-89635	Seattle	_	
585-15	89636-89638	WA	_	
585-16	89639-89640	)	1	
585-17	89641-89644	and	9	
585-18	89645-89652	written	_	
585-19	89653-89661	informed	_	
585-20	89662-89669	consent	1	
585-21	89670-89673	was	3	
585-22	89674-89682	obtained	_	
585-23	89683-89684	.	1	

#Text=A central institutional review board covering all investigational sites approved the protocol before any subjects were enrolled , and all subjects provided written informed consent before participation .
586-1	89685-89686	A	9	
586-2	89687-89694	central	_	
586-3	89695-89708	institutional	_	
586-4	89709-89715	review	_	
586-5	89716-89721	board	1	
586-6	89722-89730	covering	3	
586-7	89731-89734	all	2	
586-8	89735-89750	investigational	_	
586-9	89751-89756	sites	1	
586-10	89757-89765	approved	8	
586-11	89766-89769	the	2	
586-12	89770-89778	protocol	1	
586-13	89779-89785	before	6	
586-14	89786-89789	any	9	
586-15	89790-89798	subjects	1	
586-16	89799-89803	were	8	
586-17	89804-89812	enrolled	_	
586-18	89813-89814	,	1	
586-19	89815-89818	and	9	
586-20	89819-89822	all	_	
586-21	89823-89831	subjects	1	
586-22	89832-89840	provided	3	
586-23	89841-89848	written	2	
586-24	89849-89857	informed	_	
586-25	89858-89865	consent	1	
586-26	89866-89872	before	2	
586-27	89873-89886	participation	_	
586-28	89887-89888	.	1	

#Text=The peak torque value obtained during these five efforts was expressed relative to body mass ( Nm/kg ) .
587-1	89889-89892	The	9	
587-2	89893-89897	peak	_	
587-3	89898-89904	torque	_	
587-4	89905-89910	value	1	
587-5	89911-89919	obtained	3	
587-6	89920-89926	during	1	
587-7	89927-89932	these	2	
587-8	89933-89937	five	_	
587-9	89938-89945	efforts	1	
587-10	89946-89949	was	8	
587-11	89950-89959	expressed	_	
587-12	89960-89968	relative	_	
587-13	89969-89971	to	1	
587-14	89972-89976	body	2	
587-15	89977-89981	mass	1	
587-16	89982-89983	(	5	
587-17	89984-89986	Nm	_	
587-18	89986-89987	/	_	
587-19	89987-89989	kg	_	
587-20	89990-89991	)	_	
587-21	89992-89993	.	1	

#Text=The WOMAC pain and function subscores were converted to scales of 0 to 100 by dividing by 5 and 17 , respectively .
588-1	89994-89997	The	9	
588-2	89998-90003	WOMAC	_	
588-3	90004-90008	pain	_	
588-4	90009-90012	and	_	
588-5	90013-90021	function	_	
588-6	90022-90031	subscores	1	
588-7	90032-90036	were	8	
588-8	90037-90046	converted	_	
588-9	90047-90049	to	1	
588-10	90050-90056	scales	2	
588-11	90057-90059	of	_	
588-12	90060-90061	0	_	
588-13	90062-90064	to	_	
588-14	90065-90068	100	1	
588-15	90069-90071	by	3	
588-16	90072-90080	dividing	_	
588-17	90081-90083	by	1	
588-18	90084-90085	5	2	
588-19	90086-90089	and	_	
588-20	90090-90092	17	_	
588-21	90093-90094	,	1	
588-22	90095-90107	respectively	6	
588-23	90108-90109	.	1	

#Text=The CESD is a 20-item tool inquiring about affect ( mood , guilt , worthlessness , helplessness , appetite , and sleep ) that produces valid and reliable data in the general population and individuals with rheumatoid arthritis [ 39,40 ] .
589-1	90110-90113	The	9	
589-2	90114-90118	CESD	1	
589-3	90119-90121	is	8	
589-4	90122-90123	a	2	
589-5	90124-90126	20	_	
589-6	90126-90127	-	_	
589-7	90127-90131	item	_	
589-8	90132-90136	tool	_	
589-9	90137-90146	inquiring	_	
589-10	90147-90152	about	_	
589-11	90153-90159	affect	1	
589-12	90160-90161	(	5	
589-13	90162-90166	mood	_	
589-14	90167-90168	,	_	
589-15	90169-90174	guilt	_	
589-16	90175-90176	,	_	
589-17	90177-90190	worthlessness	_	
589-18	90191-90192	,	_	
589-19	90193-90205	helplessness	_	
589-20	90206-90207	,	_	
589-21	90208-90216	appetite	_	
589-22	90217-90218	,	_	
589-23	90219-90222	and	_	
589-24	90223-90228	sleep	_	
589-25	90229-90230	)	1	
589-26	90231-90235	that	6	
589-27	90236-90244	produces	3	
589-28	90245-90250	valid	2	
589-29	90251-90254	and	_	
589-30	90255-90263	reliable	_	
589-31	90264-90268	data	_	
589-32	90269-90271	in	_	
589-33	90272-90275	the	_	
589-34	90276-90283	general	_	
589-35	90284-90294	population	_	
589-36	90295-90298	and	_	
589-37	90299-90310	individuals	_	
589-38	90311-90315	with	_	
589-39	90316-90326	rheumatoid	_	
589-40	90327-90336	arthritis	1	
589-41	90337-90338	[	5	
589-42	90339-90344	39,40	_	
589-43	90345-90346	]	_	
589-44	90347-90348	.	1	

#Text=The patients were also asked to rate their compliance/tolerability related to viscosity , taste , and difficulty to swallow the treatments as “ poor , ” “ fair , ” “ good , ” or “ very good .
590-1	90349-90352	The	9	
590-2	90353-90361	patients	1	
590-3	90362-90366	were	8	
590-4	90367-90371	also	_	
590-5	90372-90377	asked	_	
590-6	90378-90380	to	_	
590-7	90381-90385	rate	1	
590-8	90386-90391	their	2	
590-9	90392-90402	compliance	_	
590-10	90402-90403	/	_	
590-11	90403-90415	tolerability	_	
590-12	90416-90423	related	_	
590-13	90424-90426	to	_	
590-14	90427-90436	viscosity	_	
590-15	90437-90438	,	_	
590-16	90439-90444	taste	_	
590-17	90445-90446	,	_	
590-18	90447-90450	and	_	
590-19	90451-90461	difficulty	_	
590-20	90462-90464	to	_	
590-21	90465-90472	swallow	_	
590-22	90473-90476	the	_	
590-23	90477-90487	treatments	1	
590-24	90488-90490	as	7	
590-25	90491-90492	“	_	
590-26	90493-90497	poor	_	
590-27	90498-90499	,	_	
590-28	90500-90501	”	_	
590-29	90502-90503	“	_	
590-30	90504-90508	fair	_	
590-31	90509-90510	,	_	
590-32	90511-90512	”	_	
590-33	90513-90514	“	_	
590-34	90515-90519	good	_	
590-35	90520-90521	,	_	
590-36	90522-90523	”	_	
590-37	90524-90526	or	_	
590-38	90527-90528	“	_	
590-39	90529-90533	very	_	
590-40	90534-90538	good	_	
590-41	90539-90540	.	1	

#Text=The above analyses were performed in Excel 2010 ( Microsoft , Albuquerque , NM ) .
591-1	90541-90544	The	9	
591-2	90545-90550	above	_	
591-3	90551-90559	analyses	1	
591-4	90560-90564	were	8	
591-5	90565-90574	performed	_	
591-6	90575-90577	in	1	
591-7	90578-90583	Excel	2	
591-8	90584-90588	2010	1	
591-9	90589-90590	(	5	
591-10	90591-90600	Microsoft	_	
591-11	90601-90602	,	_	
591-12	90603-90614	Albuquerque	_	
591-13	90615-90616	,	_	
591-14	90617-90619	NM	_	
591-15	90620-90621	)	_	
591-16	90622-90623	.	1	

#Text=The placebo composition was as follows : 10 % Vaseline oil/water emulsion , viscosity enhancer , preservatives , aroma , and water .
592-1	90624-90627	The	9	
592-2	90628-90635	placebo	_	
592-3	90636-90647	composition	1	
592-4	90648-90651	was	8	
592-5	90652-90654	as	_	
592-6	90655-90662	follows	1	
592-7	90663-90664	:	6	
592-8	90665-90667	10	2	
592-9	90668-90669	%	_	
592-10	90670-90678	Vaseline	_	
592-11	90679-90682	oil	_	
592-12	90682-90683	/	_	
592-13	90683-90688	water	_	
592-14	90689-90697	emulsion	_	
592-15	90698-90699	,	_	
592-16	90700-90709	viscosity	_	
592-17	90710-90718	enhancer	_	
592-18	90719-90720	,	_	
592-19	90721-90734	preservatives	_	
592-20	90735-90736	,	_	
592-21	90737-90742	aroma	_	
592-22	90743-90744	,	_	
592-23	90745-90748	and	_	
592-24	90749-90754	water	_	
592-25	90755-90756	.	1	

#Text=At inclusion , each patient received a kit labeled only with the study number .
593-1	90757-90759	At	2	
593-2	90760-90769	inclusion	_	
593-3	90770-90771	,	1	
593-4	90772-90776	each	9	
593-5	90777-90784	patient	1	
593-6	90785-90793	received	8	
593-7	90794-90795	a	2	
593-8	90796-90799	kit	_	
593-9	90800-90807	labeled	_	
593-10	90808-90812	only	_	
593-11	90813-90817	with	_	
593-12	90818-90821	the	_	
593-13	90822-90827	study	_	
593-14	90828-90834	number	_	
593-15	90835-90836	.	1	

#Text=We considered a two tailed P value < 0.05 to be significant .
594-1	90837-90839	We	8	
594-2	90840-90850	considered	1	
594-3	90851-90852	a	2	
594-4	90853-90856	two	_	
594-5	90857-90863	tailed	_	
594-6	90864-90865	P	_	
594-7	90866-90871	value	_	
594-8	90872-90873	<	_	
594-9	90874-90878	0.05	1	
594-10	90879-90881	to	3	
594-11	90882-90884	be	1	
594-12	90885-90896	significant	7	
594-13	90897-90898	.	1	

#Text=Both groups received educational information about the importance of physical activity and home practice .
595-1	90899-90903	Both	9	
595-2	90904-90910	groups	1	
595-3	90911-90919	received	8	
595-4	90920-90931	educational	2	
595-5	90932-90943	information	_	
595-6	90944-90949	about	_	
595-7	90950-90953	the	_	
595-8	90954-90964	importance	_	
595-9	90965-90967	of	_	
595-10	90968-90976	physical	_	
595-11	90977-90985	activity	_	
595-12	90986-90989	and	_	
595-13	90990-90994	home	_	
595-14	90995-91003	practice	_	
595-15	91004-91005	.	1	

#Text=Estimated glomerular filtration rate was calculated post hoc using the Chronic Kidney Disease Epidemiology Collaboration equation considering serum creatinine , age , gender , and race [ 22 ] .
596-1	91006-91015	Estimated	9	
596-2	91016-91026	glomerular	_	
596-3	91027-91037	filtration	_	
596-4	91038-91042	rate	1	
596-5	91043-91046	was	8	
596-6	91047-91057	calculated	_	
596-7	91058-91062	post	_	
596-8	91063-91066	hoc	_	
596-9	91067-91072	using	1	
596-10	91073-91076	the	2	
596-11	91077-91084	Chronic	_	
596-12	91085-91091	Kidney	_	
596-13	91092-91099	Disease	_	
596-14	91100-91112	Epidemiology	_	
596-15	91113-91126	Collaboration	_	
596-16	91127-91135	equation	1	
596-17	91136-91147	considering	3	
596-18	91148-91153	serum	2	
596-19	91154-91164	creatinine	_	
596-20	91165-91166	,	_	
596-21	91167-91170	age	_	
596-22	91171-91172	,	_	
596-23	91173-91179	gender	_	
596-24	91180-91181	,	_	
596-25	91182-91185	and	_	
596-26	91186-91190	race	1	
596-27	91191-91192	[	5	
596-28	91193-91195	22	_	
596-29	91196-91197	]	_	
596-30	91198-91199	.	1	

#Text=Strategies to enhance participant adherence included a gift bag after the initial data collection visit , rewards for best attendance halfway through intervention , and a $ 50 stipend upon study completion .
597-1	91200-91210	Strategies	9	
597-2	91211-91213	to	3	
597-3	91214-91221	enhance	1	
597-4	91222-91233	participant	2	
597-5	91234-91243	adherence	1	
597-6	91244-91252	included	8	
597-7	91253-91254	a	2	
597-8	91255-91259	gift	_	
597-9	91260-91263	bag	_	
597-10	91264-91269	after	_	
597-11	91270-91273	the	_	
597-12	91274-91281	initial	_	
597-13	91282-91286	data	_	
597-14	91287-91297	collection	_	
597-15	91298-91303	visit	_	
597-16	91304-91305	,	1	
597-17	91306-91313	rewards	2	
597-18	91314-91317	for	_	
597-19	91318-91322	best	_	
597-20	91323-91333	attendance	_	
597-21	91334-91341	halfway	_	
597-22	91342-91349	through	_	
597-23	91350-91362	intervention	_	
597-24	91363-91364	,	1	
597-25	91365-91368	and	2	
597-26	91369-91370	a	_	
597-27	91371-91372	$	_	
597-28	91373-91375	50	_	
597-29	91376-91383	stipend	_	
597-30	91384-91388	upon	_	
597-31	91389-91394	study	_	
597-32	91395-91405	completion	_	
597-33	91406-91407	.	1	

#Text=This report presents data from a preplanned interim analysis , with results through 6 months for all subjects .
598-1	91408-91412	This	9	
598-2	91413-91419	report	1	
598-3	91420-91428	presents	8	
598-4	91429-91433	data	2	
598-5	91434-91438	from	_	
598-6	91439-91440	a	_	
598-7	91441-91451	preplanned	_	
598-8	91452-91459	interim	_	
598-9	91460-91468	analysis	_	
598-10	91469-91470	,	1	
598-11	91471-91475	with	2	
598-12	91476-91483	results	_	
598-13	91484-91491	through	_	
598-14	91492-91493	6	_	
598-15	91494-91500	months	_	
598-16	91501-91504	for	_	
598-17	91505-91508	all	_	
598-18	91509-91517	subjects	_	
598-19	91518-91519	.	1	

#Text=Imaging outcomes were infarct volume measured at 24 hours ( with a window of ±6 hours ) after randomization ; lesion growth ( increase in volume of the infarct ) between baseline imaging and 24 hours ; reperfusion , defined as a greater than 90 % reduction in the region of perfusion delay ( Tmax of > 6 seconds ) between baseline and 24 hours ; and complete recanalization of the primary arterial occlusive lesion at 24 hours on CTA or MRA .
599-1	91520-91527	Imaging	9	
599-2	91528-91536	outcomes	1	
599-3	91537-91541	were	8	
599-4	91542-91549	infarct	9	
599-5	91550-91556	volume	1	
599-6	91557-91565	measured	3	
599-7	91566-91568	at	2	
599-8	91569-91571	24	_	
599-9	91572-91577	hours	_	
599-10	91578-91579	(	5	
599-11	91580-91584	with	_	
599-12	91585-91586	a	_	
599-13	91587-91593	window	_	
599-14	91594-91596	of	_	
599-15	91597-91598	±	_	
599-16	91598-91599	6	_	
599-17	91600-91605	hours	_	
599-18	91606-91607	)	1	
599-19	91608-91613	after	_	
599-20	91614-91627	randomization	1	
599-21	91628-91629	;	6	
599-22	91630-91636	lesion	2	
599-23	91637-91643	growth	_	
599-24	91644-91645	(	5	
599-25	91646-91654	increase	_	
599-26	91655-91657	in	_	
599-27	91658-91664	volume	_	
599-28	91665-91667	of	_	
599-29	91668-91671	the	_	
599-30	91672-91679	infarct	_	
599-31	91680-91681	)	1	
599-32	91682-91689	between	_	
599-33	91690-91698	baseline	_	
599-34	91699-91706	imaging	_	
599-35	91707-91710	and	_	
599-36	91711-91713	24	_	
599-37	91714-91719	hours	1	
599-38	91720-91721	;	6	
599-39	91722-91733	reperfusion	9	
599-40	91734-91735	,	1	
599-41	91736-91743	defined	3	
599-42	91744-91746	as	1	
599-43	91747-91748	a	2	
599-44	91749-91756	greater	_	
599-45	91757-91761	than	_	
599-46	91762-91764	90	_	
599-47	91765-91766	%	_	
599-48	91767-91776	reduction	_	
599-49	91777-91779	in	_	
599-50	91780-91783	the	_	
599-51	91784-91790	region	_	
599-52	91791-91793	of	_	
599-53	91794-91803	perfusion	_	
599-54	91804-91809	delay	_	
599-55	91810-91811	(	5	
599-56	91812-91816	Tmax	_	
599-57	91817-91819	of	_	
599-58	91820-91821	>	_	
599-59	91822-91823	6	_	
599-60	91824-91831	seconds	_	
599-61	91832-91833	)	1	
599-62	91834-91841	between	_	
599-63	91842-91850	baseline	_	
599-64	91851-91854	and	_	
599-65	91855-91857	24	_	
599-66	91858-91863	hours	1	
599-67	91864-91865	;	6	
599-68	91866-91869	and	2	
599-69	91870-91878	complete	_	
599-70	91879-91893	recanalization	_	
599-71	91894-91896	of	_	
599-72	91897-91900	the	_	
599-73	91901-91908	primary	_	
599-74	91909-91917	arterial	_	
599-75	91918-91927	occlusive	_	
599-76	91928-91934	lesion	_	
599-77	91935-91937	at	_	
599-78	91938-91940	24	_	
599-79	91941-91946	hours	_	
599-80	91947-91949	on	_	
599-81	91950-91953	CTA	_	
599-82	91954-91956	or	_	
599-83	91957-91960	MRA	_	
599-84	91961-91962	.	1	

#Text=To obtain the calibration slopes , the area/IS ratios were plotted versus the concentrations using least square analysis .
600-1	91963-91965	To	3	
600-2	91966-91972	obtain	1	
600-3	91973-91976	the	2	
600-4	91977-91988	calibration	_	
600-5	91989-91995	slopes	_	
600-6	91996-91997	,	1	
600-7	91998-92001	the	9	
600-8	92002-92006	area	_	
600-9	92006-92007	/	_	
600-10	92007-92009	IS	_	
600-11	92010-92016	ratios	1	
600-12	92017-92021	were	8	
600-13	92022-92029	plotted	1	
600-14	92030-92036	versus	2	
600-15	92037-92040	the	_	
600-16	92041-92055	concentrations	1	
600-17	92056-92061	using	3	
600-18	92062-92067	least	2	
600-19	92068-92074	square	_	
600-20	92075-92083	analysis	_	
600-21	92084-92085	.	1	

#Text=Muscle strength was represented by peak torque of the knee extensor and flexor muscle groups of participants ’ most symptomatic knee during maximal voluntary efforts .
601-1	92086-92092	Muscle	9	
601-2	92093-92101	strength	1	
601-3	92102-92105	was	8	
601-4	92106-92117	represented	_	
601-5	92118-92120	by	1	
601-6	92121-92125	peak	2	
601-7	92126-92132	torque	_	
601-8	92133-92135	of	_	
601-9	92136-92139	the	_	
601-10	92140-92144	knee	_	
601-11	92145-92153	extensor	_	
601-12	92154-92157	and	_	
601-13	92158-92164	flexor	_	
601-14	92165-92171	muscle	_	
601-15	92172-92178	groups	_	
601-16	92179-92181	of	_	
601-17	92182-92194	participants	_	
601-18	92195-92196	’	_	
601-19	92197-92201	most	_	
601-20	92202-92213	symptomatic	_	
601-21	92214-92218	knee	_	
601-22	92219-92225	during	_	
601-23	92226-92233	maximal	_	
601-24	92234-92243	voluntary	_	
601-25	92244-92251	efforts	_	
601-26	92252-92253	.	1	

#Text=A gastrointestinal endoscopy ( criteria for diagnosis of gastritis were bleeding , vascular pattern [ congestion ] , and excess mucous secretion ) and gastric biopsy ( from antrum or pyloric areas in all forms of gastritis and mainly from the gastric body for chemical gastritis ) were carried out to confirm the diagnosis of gastritis .
602-1	92254-92255	A	9	
602-2	92256-92272	gastrointestinal	_	
602-3	92273-92282	endoscopy	_	
602-4	92283-92284	(	5	
602-5	92285-92293	criteria	_	
602-6	92294-92297	for	_	
602-7	92298-92307	diagnosis	_	
602-8	92308-92310	of	_	
602-9	92311-92320	gastritis	_	
602-10	92321-92325	were	_	
602-11	92326-92334	bleeding	_	
602-12	92335-92336	,	_	
602-13	92337-92345	vascular	_	
602-14	92346-92353	pattern	_	
602-15	92354-92355	[	_	
602-16	92356-92366	congestion	_	
602-17	92367-92368	]	_	
602-18	92369-92370	,	_	
602-19	92371-92374	and	_	
602-20	92375-92381	excess	_	
602-21	92382-92388	mucous	_	
602-22	92389-92398	secretion	_	
602-23	92399-92400	)	1	
602-24	92401-92404	and	_	
602-25	92405-92412	gastric	_	
602-26	92413-92419	biopsy	1	
602-27	92420-92421	(	5	
602-28	92422-92426	from	_	
602-29	92427-92433	antrum	_	
602-30	92434-92436	or	_	
602-31	92437-92444	pyloric	_	
602-32	92445-92450	areas	_	
602-33	92451-92453	in	_	
602-34	92454-92457	all	_	
602-35	92458-92463	forms	_	
602-36	92464-92466	of	_	
602-37	92467-92476	gastritis	_	
602-38	92477-92480	and	_	
602-39	92481-92487	mainly	_	
602-40	92488-92492	from	_	
602-41	92493-92496	the	_	
602-42	92497-92504	gastric	_	
602-43	92505-92509	body	_	
602-44	92510-92513	for	_	
602-45	92514-92522	chemical	_	
602-46	92523-92532	gastritis	_	
602-47	92533-92534	)	1	
602-48	92535-92539	were	8	
602-49	92540-92547	carried	_	
602-50	92548-92551	out	_	
602-51	92552-92554	to	_	
602-52	92555-92562	confirm	1	
602-53	92563-92566	the	2	
602-54	92567-92576	diagnosis	_	
602-55	92577-92579	of	_	
602-56	92580-92589	gastritis	_	
602-57	92590-92591	.	1	

#Text=The trial design has been published,9 and the protocol and statistical analysis plan are available at NEJM.org .
603-1	92592-92595	The	9	
603-2	92596-92601	trial	_	
603-3	92602-92608	design	1	
603-4	92609-92612	has	8	
603-5	92613-92617	been	_	
603-6	92618-92627	published	_	
603-7	92627-92628	,	_	
603-8	92628-92629	9	1	
603-9	92630-92633	and	9	
603-10	92634-92637	the	_	
603-11	92638-92646	protocol	_	
603-12	92647-92650	and	_	
603-13	92651-92662	statistical	_	
603-14	92663-92671	analysis	_	
603-15	92672-92676	plan	1	
603-16	92677-92680	are	3	
603-17	92681-92690	available	7	
603-18	92691-92693	at	_	
603-19	92694-92702	NEJM.org	_	
603-20	92703-92704	.	1	

#Text=The two-tailed Student 's t-test was used to determine if the means of clinical parameters differed by gender given that the data fulfilled normal distribution criteria .
604-1	92705-92708	The	9	
604-2	92709-92719	two-tailed	_	
604-3	92720-92727	Student	_	
604-4	92728-92729	'	_	
604-5	92729-92730	s	_	
604-6	92731-92737	t-test	1	
604-7	92738-92741	was	8	
604-8	92742-92746	used	_	
604-9	92747-92749	to	_	
604-10	92750-92759	determine	1	
604-11	92760-92762	if	6	
604-12	92763-92766	the	9	
604-13	92767-92772	means	_	
604-14	92773-92775	of	_	
604-15	92776-92784	clinical	_	
604-16	92785-92795	parameters	1	
604-17	92796-92804	differed	3	
604-18	92805-92807	by	1	
604-19	92808-92814	gender	2	
604-20	92815-92820	given	6	
604-21	92821-92825	that	1	
604-22	92826-92829	the	9	
604-23	92830-92834	data	1	
604-24	92835-92844	fulfilled	8	
604-25	92845-92851	normal	2	
604-26	92852-92864	distribution	_	
604-27	92865-92873	criteria	_	
604-28	92874-92875	.	1	

#Text=LPC 12:0 was used for LPCs containing FAs with ≤ 14:0 carbons .
605-1	92876-92879	LPC	9	
605-2	92880-92882	12	_	
605-3	92882-92883	:	_	
605-4	92883-92884	0	1	
605-5	92885-92888	was	8	
605-6	92889-92893	used	_	
605-7	92894-92897	for	1	
605-8	92898-92902	LPCs	2	
605-9	92903-92913	containing	_	
605-10	92914-92917	FAs	_	
605-11	92918-92922	with	_	
605-12	92923-92924	≤	_	
605-13	92925-92927	14	_	
605-14	92927-92928	:	_	
605-15	92928-92929	0	_	
605-16	92930-92937	carbons	_	
605-17	92938-92939	.	1	

#Text=Ten milliliters of the placebo or medical device was administered four times a day ( prior to breakfast , lunch , dinner , and bedtime ) for 2   weeks .
606-1	92940-92943	Ten	9	
606-2	92944-92955	milliliters	_	
606-3	92956-92958	of	_	
606-4	92959-92962	the	_	
606-5	92963-92970	placebo	_	
606-6	92971-92973	or	_	
606-7	92974-92981	medical	_	
606-8	92982-92988	device	1	
606-9	92989-92992	was	8	
606-10	92993-93005	administered	1	
606-11	93006-93010	four	2	
606-12	93011-93016	times	_	
606-13	93017-93018	a	_	
606-14	93019-93022	day	_	
606-15	93023-93024	(	5	
606-16	93025-93030	prior	_	
606-17	93031-93033	to	_	
606-18	93034-93043	breakfast	_	
606-19	93044-93045	,	_	
606-20	93046-93051	lunch	_	
606-21	93052-93053	,	_	
606-22	93054-93060	dinner	_	
606-23	93061-93062	,	_	
606-24	93063-93066	and	_	
606-25	93067-93074	bedtime	_	
606-26	93075-93076	)	1	
606-27	93077-93080	for	_	
606-28	93081-93082	2	_	
606-29	93083-93084	 	_	
606-30	93085-93090	weeks	_	
606-31	93091-93092	.	1	

#Text=Results are presented as between-group differences with 95 % CIs based on estimates from the longitudinal models .
607-1	93093-93100	Results	9	
607-2	93101-93104	are	8	
607-3	93105-93114	presented	_	
607-4	93115-93117	as	1	
607-5	93118-93131	between-group	2	
607-6	93132-93143	differences	_	
607-7	93144-93148	with	_	
607-8	93149-93151	95	_	
607-9	93152-93153	%	_	
607-10	93154-93157	CIs	1	
607-11	93158-93163	based	3	
607-12	93164-93166	on	1	
607-13	93167-93176	estimates	2	
607-14	93177-93181	from	_	
607-15	93182-93185	the	_	
607-16	93186-93198	longitudinal	_	
607-17	93199-93205	models	_	
607-18	93206-93207	.	1	

#Text=We kept a written record of changes in use of analgesics and NSAIDs throughout the entire intervention and evaluation period .
608-1	93208-93210	We	8	
608-2	93211-93215	kept	1	
608-3	93216-93217	a	2	
608-4	93218-93225	written	_	
608-5	93226-93232	record	_	
608-6	93233-93235	of	_	
608-7	93236-93243	changes	_	
608-8	93244-93246	in	_	
608-9	93247-93250	use	_	
608-10	93251-93253	of	_	
608-11	93254-93264	analgesics	_	
608-12	93265-93268	and	_	
608-13	93269-93275	NSAIDs	1	
608-14	93276-93286	throughout	2	
608-15	93287-93290	the	_	
608-16	93291-93297	entire	_	
608-17	93298-93310	intervention	_	
608-18	93311-93314	and	_	
608-19	93315-93325	evaluation	_	
608-20	93326-93332	period	_	
608-21	93333-93334	.	1	

#Text=As a result of that interim analysis , the trial was halted because the prespecified efficacy boundary ( P<0.0025 ) had been exceeded .
609-1	93335-93337	As	2	
609-2	93338-93339	a	_	
609-3	93340-93346	result	_	
609-4	93347-93349	of	_	
609-5	93350-93354	that	_	
609-6	93355-93362	interim	_	
609-7	93363-93371	analysis	_	
609-8	93372-93373	,	1	
609-9	93374-93377	the	9	
609-10	93378-93383	trial	1	
609-11	93384-93387	was	8	
609-12	93388-93394	halted	1	
609-13	93395-93402	because	6	
609-14	93403-93406	the	9	
609-15	93407-93419	prespecified	_	
609-16	93420-93428	efficacy	_	
609-17	93429-93437	boundary	9	
609-18	93438-93439	(	5	
609-19	93440-93441	P	_	
609-20	93441-93442	<	_	
609-21	93442-93448	0.0025	_	
609-22	93449-93450	)	1	
609-23	93451-93454	had	3	
609-24	93455-93459	been	_	
609-25	93460-93468	exceeded	_	
609-26	93469-93470	.	1	

#Text=A one-way ANOVA was used to detect whether differences in age , BMI and LEFS score existed between groups baseline .
610-1	93471-93472	A	9	
610-2	93473-93480	one-way	_	
610-3	93481-93486	ANOVA	1	
610-4	93487-93490	was	8	
610-5	93491-93495	used	_	
610-6	93496-93498	to	_	
610-7	93499-93505	detect	1	
610-8	93506-93513	whether	6	
610-9	93514-93525	differences	9	
610-10	93526-93528	in	_	
610-11	93529-93532	age	_	
610-12	93533-93534	,	_	
610-13	93535-93538	BMI	_	
610-14	93539-93542	and	_	
610-15	93543-93547	LEFS	_	
610-16	93548-93553	score	1	
610-17	93554-93561	existed	3	
610-18	93562-93569	between	1	
610-19	93570-93576	groups	9	
610-20	93577-93585	baseline	_	
610-21	93586-93587	.	1	

#Text=The Bardstown Pediatric Group cares for a predominantly rural , lower SES population .
611-1	93588-93591	The	9	
611-2	93592-93601	Bardstown	_	
611-3	93602-93611	Pediatric	_	
611-4	93612-93617	Group	1	
611-5	93618-93623	cares	8	
611-6	93624-93627	for	1	
611-7	93628-93629	a	2	
611-8	93630-93643	predominantly	_	
611-9	93644-93649	rural	_	
611-10	93650-93651	,	_	
611-11	93652-93657	lower	_	
611-12	93658-93661	SES	_	
611-13	93662-93672	population	_	
611-14	93673-93674	.	1	

#Text=The ESI settings were as follows : Ion spray voltage = 4.0 kV ; gas temperature = 300 ° C ; drying gas = 8 L/min ; nebulizer = 40 psig ; sheath gas temperature = 350 ° C ; and sheath gas flow = 11 L/min .
612-1	93675-93678	The	9	
612-2	93679-93682	ESI	_	
612-3	93683-93691	settings	1	
612-4	93692-93696	were	1	
612-5	93697-93699	as	_	
612-6	93700-93707	follows	1	
612-7	93708-93709	:	6	
612-8	93710-93713	Ion	2	
612-9	93714-93719	spray	_	
612-10	93720-93727	voltage	_	
612-11	93728-93729	=	_	
612-12	93730-93733	4.0	_	
612-13	93734-93736	kV	_	
612-14	93737-93738	;	6	
612-15	93739-93742	gas	_	
612-16	93743-93754	temperature	_	
612-17	93755-93756	=	_	
612-18	93757-93760	300	_	
612-19	93761-93762	°	_	
612-20	93763-93764	C	_	
612-21	93765-93766	;	6	
612-22	93767-93773	drying	_	
612-23	93774-93777	gas	_	
612-24	93778-93779	=	_	
612-25	93780-93781	8	_	
612-26	93782-93783	L	_	
612-27	93783-93784	/	_	
612-28	93784-93787	min	_	
612-29	93788-93789	;	6	
612-30	93790-93799	nebulizer	_	
612-31	93800-93801	=	_	
612-32	93802-93804	40	_	
612-33	93805-93809	psig	_	
612-34	93810-93811	;	_	
612-35	93812-93818	sheath	_	
612-36	93819-93822	gas	_	
612-37	93823-93834	temperature	_	
612-38	93835-93836	=	_	
612-39	93837-93840	350	_	
612-40	93841-93842	°	_	
612-41	93843-93844	C	_	
612-42	93845-93846	;	1	
612-43	93847-93850	and	_	
612-44	93851-93857	sheath	_	
612-45	93858-93861	gas	_	
612-46	93862-93866	flow	_	
612-47	93867-93868	=	_	
612-48	93869-93871	11	_	
612-49	93872-93873	L	_	
612-50	93873-93874	/	_	
612-51	93874-93877	min	_	
612-52	93878-93879	.	1	

#Text=For correcting Na+ adducts of LPC 20:3 and LPC 20:4 overlapping with isobaric H+ adducts of LPC 21:0 and LPC 22:6 , a polynomic fit function determined for LPC 18:0 and LPC 18:1 was used .
613-1	93880-93883	For	3	
613-2	93884-93894	correcting	1	
613-3	93895-93897	Na	2	
613-4	93897-93898	+	_	
613-5	93899-93906	adducts	_	
613-6	93907-93909	of	_	
613-7	93910-93913	LPC	_	
613-8	93914-93916	20	_	
613-9	93916-93917	:	_	
613-10	93917-93918	3	_	
613-11	93919-93922	and	_	
613-12	93923-93926	LPC	_	
613-13	93927-93929	20	_	
613-14	93929-93930	:	_	
613-15	93930-93931	4	1	
613-16	93932-93943	overlapping	3	
613-17	93944-93948	with	1	
613-18	93949-93957	isobaric	2	
613-19	93958-93959	H	_	
613-20	93959-93960	+	_	
613-21	93961-93968	adducts	_	
613-22	93969-93971	of	_	
613-23	93972-93975	LPC	_	
613-24	93976-93978	21	_	
613-25	93978-93979	:	_	
613-26	93979-93980	0	_	
613-27	93981-93984	and	_	
613-28	93985-93988	LPC	_	
613-29	93989-93991	22	_	
613-30	93991-93992	:	_	
613-31	93992-93993	6	_	
613-32	93994-93995	,	1	
613-33	93996-93997	a	9	
613-34	93998-94007	polynomic	_	
613-35	94008-94011	fit	_	
613-36	94012-94020	function	1	
613-37	94021-94031	determined	3	
613-38	94032-94035	for	1	
613-39	94036-94039	LPC	2	
613-40	94040-94042	18	_	
613-41	94042-94043	:	_	
613-42	94043-94044	0	_	
613-43	94045-94048	and	_	
613-44	94049-94052	LPC	_	
613-45	94053-94055	18	_	
613-46	94055-94056	:	_	
613-47	94056-94057	1	1	
613-48	94058-94061	was	8	
613-49	94062-94066	used	_	
613-50	94067-94068	.	1	

#Text=Each effort lasted five seconds , with five seconds of rest between bouts .
614-1	94069-94073	Each	9	
614-2	94074-94080	effort	1	
614-3	94081-94087	lasted	8	
614-4	94088-94092	five	2	
614-5	94093-94100	seconds	_	
614-6	94101-94102	,	1	
614-7	94103-94107	with	2	
614-8	94108-94112	five	_	
614-9	94113-94120	seconds	_	
614-10	94121-94123	of	_	
614-11	94124-94128	rest	_	
614-12	94129-94136	between	_	
614-13	94137-94142	bouts	_	
614-14	94143-94144	.	1	

#Text=The sessions involved a ten-minute warm-up performed on a treadmill or cycle ergometer .
615-1	94145-94148	The	9	
615-2	94149-94157	sessions	1	
615-3	94158-94166	involved	8	
615-4	94167-94168	a	2	
615-5	94169-94179	ten-minute	_	
615-6	94180-94187	warm-up	1	
615-7	94188-94197	performed	3	
615-8	94198-94200	on	1	
615-9	94201-94202	a	2	
615-10	94203-94212	treadmill	_	
615-11	94213-94215	or	_	
615-12	94216-94221	cycle	_	
615-13	94222-94231	ergometer	_	
615-14	94232-94233	.	1	

#Text=All patients or their legal representatives provided written informed consent .
616-1	94234-94237	All	9	
616-2	94238-94246	patients	_	
616-3	94247-94249	or	_	
616-4	94250-94255	their	_	
616-5	94256-94261	legal	_	
616-6	94262-94277	representatives	1	
616-7	94278-94286	provided	8	
616-8	94287-94294	written	2	
616-9	94295-94303	informed	_	
616-10	94304-94311	consent	_	
616-11	94312-94313	.	1	

#Text=Secondary endpoints included 28-day all-cause mortality , 28-day investigator-determined pneumonia-related mortality , time from admission to discharge from the ICU , time from hospital admission to discharge , change in Sequential Organ Failure Assessment ( SOFA ) score ( measured on days 1 and 28 ) , and days free from inotrope/vasopressor ( dobutamine , epinephrine , dopamine , or norepinephrine ) .
617-1	94314-94323	Secondary	9	
617-2	94324-94333	endpoints	1	
617-3	94334-94342	included	8	
617-4	94343-94345	28	2	
617-5	94345-94346	-	_	
617-6	94346-94349	day	_	
617-7	94350-94359	all-cause	_	
617-8	94360-94369	mortality	_	
617-9	94370-94371	,	_	
617-10	94372-94374	28	_	
617-11	94374-94375	-	_	
617-12	94375-94378	day	_	
617-13	94379-94402	investigator-determined	_	
617-14	94403-94420	pneumonia-related	_	
617-15	94421-94430	mortality	_	
617-16	94431-94432	,	_	
617-17	94433-94437	time	_	
617-18	94438-94442	from	_	
617-19	94443-94452	admission	_	
617-20	94453-94455	to	_	
617-21	94456-94465	discharge	_	
617-22	94466-94470	from	_	
617-23	94471-94474	the	_	
617-24	94475-94478	ICU	_	
617-25	94479-94480	,	_	
617-26	94481-94485	time	_	
617-27	94486-94490	from	_	
617-28	94491-94499	hospital	_	
617-29	94500-94509	admission	_	
617-30	94510-94512	to	_	
617-31	94513-94522	discharge	_	
617-32	94523-94524	,	_	
617-33	94525-94531	change	_	
617-34	94532-94534	in	_	
617-35	94535-94545	Sequential	_	
617-36	94546-94551	Organ	_	
617-37	94552-94559	Failure	_	
617-38	94560-94570	Assessment	_	
617-39	94571-94572	(	5	
617-40	94573-94577	SOFA	_	
617-41	94578-94579	)	1	
617-42	94580-94585	score	_	
617-43	94586-94587	(	5	
617-44	94588-94596	measured	_	
617-45	94597-94599	on	_	
617-46	94600-94604	days	_	
617-47	94605-94606	1	_	
617-48	94607-94610	and	_	
617-49	94611-94613	28	_	
617-50	94614-94615	)	1	
617-51	94616-94617	,	_	
617-52	94618-94621	and	_	
617-53	94622-94626	days	_	
617-54	94627-94631	free	_	
617-55	94632-94636	from	_	
617-56	94637-94645	inotrope	_	
617-57	94645-94646	/	_	
617-58	94646-94657	vasopressor	1	
617-59	94658-94659	(	5	
617-60	94660-94670	dobutamine	_	
617-61	94671-94672	,	_	
617-62	94673-94684	epinephrine	_	
617-63	94685-94686	,	_	
617-64	94687-94695	dopamine	_	
617-65	94696-94697	,	_	
617-66	94698-94700	or	_	
617-67	94701-94715	norepinephrine	_	
617-68	94716-94717	)	_	
617-69	94718-94719	.	1	

#Text=YE consisted of alignment-based postures that activate the lower limb musculature while maintaining a low KAM [ 10,11 ] .
618-1	94720-94722	YE	9	
618-2	94723-94732	consisted	3	
618-3	94733-94735	of	1	
618-4	94736-94751	alignment-based	2	
618-5	94752-94760	postures	1	
618-6	94761-94765	that	6	
618-7	94766-94774	activate	3	
618-8	94775-94778	the	2	
618-9	94779-94784	lower	_	
618-10	94785-94789	limb	_	
618-11	94790-94801	musculature	1	
618-12	94802-94807	while	3	
618-13	94808-94819	maintaining	1	
618-14	94820-94821	a	2	
618-15	94822-94825	low	_	
618-16	94826-94829	KAM	1	
618-17	94830-94831	[	5	
618-18	94832-94837	10,11	_	
618-19	94838-94839	]	_	
618-20	94840-94841	.	1	

#Text=Differences between groups were expressed as risk ratios with corresponding 95 % confidence interval .
619-1	94842-94853	Differences	9	
619-2	94854-94861	between	_	
619-3	94862-94868	groups	1	
619-4	94869-94873	were	8	
619-5	94874-94883	expressed	_	
619-6	94884-94886	as	1	
619-7	94887-94891	risk	2	
619-8	94892-94898	ratios	_	
619-9	94899-94903	with	_	
619-10	94904-94917	corresponding	_	
619-11	94918-94920	95	_	
619-12	94921-94922	%	_	
619-13	94923-94933	confidence	_	
619-14	94934-94942	interval	_	
619-15	94943-94944	.	1	

#Text=The WOMAC is a validated , self-administered visual analogue scale designed specifically to evaluate osteoarthritis symptoms ( 23 ) .
620-1	94945-94948	The	9	
620-2	94949-94954	WOMAC	1	
620-3	94955-94957	is	8	
620-4	94958-94959	a	2	
620-5	94960-94969	validated	_	
620-6	94970-94971	,	_	
620-7	94972-94989	self-administered	_	
620-8	94990-94996	visual	_	
620-9	94997-95005	analogue	_	
620-10	95006-95011	scale	1	
620-11	95012-95020	designed	3	
620-12	95021-95033	specifically	_	
620-13	95034-95036	to	_	
620-14	95037-95045	evaluate	1	
620-15	95046-95060	osteoarthritis	2	
620-16	95061-95069	symptoms	1	
620-17	95070-95071	(	5	
620-18	95072-95074	23	_	
620-19	95075-95076	)	_	
620-20	95077-95078	.	1	

#Text=Each envelope contained the name of the active substance given to the patient with the corresponding study number .
621-1	95079-95083	Each	9	
621-2	95084-95092	envelope	1	
621-3	95093-95102	contained	8	
621-4	95103-95106	the	2	
621-5	95107-95111	name	_	
621-6	95112-95114	of	_	
621-7	95115-95118	the	_	
621-8	95119-95125	active	_	
621-9	95126-95135	substance	_	
621-10	95136-95141	given	_	
621-11	95142-95144	to	_	
621-12	95145-95148	the	_	
621-13	95149-95156	patient	_	
621-14	95157-95161	with	_	
621-15	95162-95165	the	_	
621-16	95166-95179	corresponding	_	
621-17	95180-95185	study	_	
621-18	95186-95192	number	_	
621-19	95193-95194	.	1	
